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ABSTRACT 
 
The aim of this thesis was to establish the extent, impact and stability of cognitive functioning 
in Adult Congenital Heart Disease (ACHD) patients. A cross-sectional and a follow-up study 
were conducted to address these objectives. The aims of the cross-sectional study were to i) 
identify the extent of cognitive impairments ii) compare cognitive performance across structural 
complexity groups, iii) identify factors associated with cognition in ACHD. The follow-up 
study aimed to evaluate the stability of cognitive functioning over time and identify predictors 
of change. 
 
Three hundred and ten ACHD patients from the Heart Hospital, London were recruited. 
Participants were divided into four structural complexity groups: Tetralogy of Fallot (ToF), 
Transposition of the Great Arteries (TGA), Single Ventricle (SV) and Simple. Each participant 
completed a neuropsychological (NP) test battery and psychosocial self-report questionnaires.  
 
The results showed ACHD patients with IQ below the normative mean score. Impairment in 
executive function, attention and motor function were noted. The TGA group had the worst 
overall cognitive functioning. The Simple group performed significantly better than the TGA 
and SV groups on attention. Demographic, clinical and mood factors were associated with 
cognitive function. No association between cognitive functioning and Quality of Life was 
found. 
 
In the follow-up study 153 participants were followed-up (over 4 years). The NP test battery 
was re-administered to assess change over time. Mood, demographic and clinical factors were 
assessed to identify predictors of change in cognitive functioning. 
   
The results indicated both a decline and an improvement in performance on tests assessing 
attention, memory, executive functioning and motor functioning. Education and oxygen 
saturation levels predicted change in memory. 
  
The results of this study address a gap in the literature and highlight the extent of cognitive 
impairments in ACHD. It also indicates a range of intrinsic and modifiable factors that are 
associated with and predict change in cognitive outcomes. The clinical implications of the 
findings are discussed. Recommendations for clinical practice include regular, ongoing 
assessment of cognition in ACHD patients. 
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THESIS STRUCTURE 
 
This thesis aims to identify the level of cognitive functioning in ACHD, while also comparing 
functioning across different types of ACHD, and examining the stability of cognitive 
functioning over time. The thesis used both a cross sectional and a longitudinal study design to 
address these objectives. For ease of interpretation, the background and findings of this thesis 
are presented in two parts: the cross-sectional and the follow-up (longitudinal).    
 
Chapter 1 discusses the nature, prevalence and incidence rates of ACHD and also describes the 
most common forms of Congenital Heart Disease (CHD), pertinent to this study. A brief 
description of each condition and its associated treatments and prognosis is presented.   
Chapter 2 examines the concept of cognitive functioning, and introduces the domains of 
cognitive functions assessed in this thesis. It also presents a brief discussion of some of the 
challenges associated with the measurement of cognitive functioning.  
Chapter 3 discusses the relationship between the brain and the heart, and explains how these 
two organs can impact each other in patients with CHD. It also presents an overview of the 
existing evidence on cognitive outcomes in children with CHD.  
Chapter 4 presents the findings of the systematic review that examines the existing evidence on 
the extent of cognitive impairment in the ACHD population. 
Chapter 5: discusses the association between cognitive functioning and Quality of Life (QoL) 
in ACHD patients. It presents a brief overview of the literature on QoL in ACHD.  
 Chapter 6 presents an introduction to the cross-sectional study and details its aims and 
objectives.  
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Chapter 7 provides a detailed description of the study design, measures and methodology 
adopted. It also describes the statistical strategy adopted to answer the research questions and 
objectives of this study.   
Chapter 8 reports the results of the cross-sectional analysis.  
Chapter 9 discusses the results of the cross-sectional study pertinent to each of the research 
aims and objectives in the context of the existing literature. It also makes recommendations for 
future research and discusses implications of the study findings.  
 
The follow-up study is presented in Chapters 10-14.  
Chapter 10 introduces the concept of longitudinal neuropsychological (cognitive) assessment. 
It discusses the different techniques available in the literature to measure change in cognitive 
functioning reliably over time. It also presents the available longitudinal evidence on change in 
cognitive functioning in the ACHD population.  
Chapter 11 presents the rationale, aims and objective of the follow-up study.  
Chapter 12 details the study design, methodology, and the statistical strategy adopted to 
address each of the research objectives in the follow-up study.  
Chapter 13 reports the results of the follow-up study.    
Chapter 14 presents and discusses the outcomes of the follow-up study in the context of the 
existing literature.  
Chapter 15 presents an overall discussion of the thesis. It synthesizes the results of both sets of 
analyses (cross-sectional and follow-up) and presents a discussion on the contributions of this 
study to the existing literature. It also highlights the strengths and weaknesses of this thesis 
along with making suggestions for future research, and recommendations for clinical practice.       
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1 BACKGROUND TO CONGENITAL HEART DISEASE 
 
1.1 Prologue  
The aim of this chapter is to present a detailed overview of Congenital Heart Disease (CHD) 
and its associated treatments. It presents a description of the normal heart and its morphology, 
followed by a description of CHD and its prevalence, incidence and mortality rates. Lastly, the 
long-term complications of CHD are also discussed.   
 
1.2  The structure and function of a normal heart  
In order to understand the different types of CHD, it is important to first understand the 
structure and function of a normal heart. The heart is a hollow and cone shaped muscular 
structure located between the lungs in an area referred to as the thoracic cavity (See Figure 1.1: 
The thoracic cavity below). By adulthood, it is normally 10cm long, 255-350gms in weight, and 
roughly the size of its owner’s fist; and its main function is to pump blood throughout the body.  
 
 
Figure 1.1: The thoracic cavity 
© Medical Dictionary, (2009) Farlex & Partners 
 
Figure 1.2: The normal heart 
©Texas Heart Institute [texasheart.org] 
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A normal heart consists of four chambers (two left, two right) that are separated by a muscular 
wall called the septum. The Atria (upper chambers) receive blood; the right atrium receives 
deoxygenated blood from the superior vena cava, inferior vena cava and the coronary sinus, 
while the left atrium receives oxygenated blood from the pulmonary veins. The Ventricles 
(lower chambers) are responsible for pumping blood into the pulmonary and systemic 
circulation (as seen in Figure 1.2 above) (Katz, 2010).  
 
The flow of blood within the heart is controlled by the opening and closing of four valves, 
which are in turn controlled by the body’s blood pressure (See Figure 1.2 above). The circulatory 
cycle of the heart consists of deoxygenated blood from the superior and inferior vena cava and 
the coronary sinus being drained into the right atrium, which then passes through the valve and 
into the right ventricle (See in Figure 1.1 above). Blood then travels through the pulmonary valve 
into pulmonary arteries and into the lungs where the oxygen is absorbed and carbon dioxide 
released. The oxygenated blood then returns to the heart via the pulmonary veins which empty 
out into the left atrium. The blood then goes through the valve into the left ventricle from where 
it enters the aorta through the aortic valve and begins its journey of systemic circulation (See 
Figure 1.2 above) (Katz, 2010). The average heart pumps 5.25 litres of blood per minute (range 
4.0–8.0 litres per minute). 
 
1.3 Congenital Heart Disease (CHD) 
CHD is a heterogeneous group of conditions that are present from birth and are characterised by 
structural and functional abnormalities of the heart with varying levels of complexity (Karsdorp 
et al, 2007). This can vary from a hole in the septum to a more serious condition like the 
deformity or even the absence of a ventricle or valve.  
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1.3.1 The Aetiology of CHD  
The aetiology of most CHD is unknown, with only 10 % to 20% of cases with an identifiable 
cause (Buskens et al, 1995). It is thought to be multifactorial in origin with evidence of genetic 
and environmental factors being responsible. Some evidence suggests the role of genetic 
factors, with a higher incidence of CHD in cases where the parent (usually the mother) is 
diagnosed with CHD (Deanfield et al, 2003).  
 
With regards to environmental and external factors, it is reported that the presence of certain 
maternal diseases including German measles, maternal diabetes, and autoimmune conditions 
like Systemic Lupus Erythromatous can predispose an offspring to CHD (Nass and Frank, 
2010). Along with maternal diseases, other factors such as smoking or excessive alcohol intake 
during pregnancy are also thought to contribute to CHD (Nass and Frank, 2010). Furthermore, 
there is evidence of an association between CHD and chromosomal abnormalities, for instance 
higher rates of CHD are reported in patients with chromosomal abnormalities such as Down’s 
syndrome (Vis el al, 2009). However, there is a paucity of evidence on the interacting and 
cumulative effects of these factors in causing CHD, which prevents firm conclusions from being 
drawn about the aetiology of CHD.  
 
1.3.2  Symptoms and diagnosis of CHD 
There are usually no outwardly observable signs and symptoms in most forms of CHD. 
However, some commonly found characteristics include: shortness of breath, dizziness, 
fainting, arrhythmias (irregular heart beat), cyanosis (present in cyanotic conditions, 
characterised by lack of oxygen in the blood leading to blueness of skin), palpitations (heartbeat 
abnormalities) and fatigue (Harrox, 2002). The characteristic symptomology and the structural 
malformations of different forms of CHD are discussed below in more detail.  
 
CHD can be diagnosed as early as the antenatal period, using ultrasound (foetal 
echocardiography) during early pregnancy (Brown and Sullivan, 2014). Initial physical 
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examination and diagnostic tests such as chest radiography, magnetic resonance imagining 
(MRI), computerised tomography (CT scan) and transthoracic or transesophageal 
echocardiography (TOE) are used for the purpose of diagnosis (Popelova et al, 2008). 
 
1.3.3 Incidence and Prevalence  
Estimating the incidence and prevalence rates of CHD is challenging, due to the large variation 
in the classifications used by authors to define different forms of CHD (Garne et al, 2012). As a 
result, the prevalence and incidence rates of CHD vary greatly across the existing literature. 
 
1.3.3.1 Incidence of CHD 
Defining the incidence rates of CHD is complex, given that the conventional meaning of 
incidence: “the occurrence of a new case of a certain disease” does not apply to CHD due to its 
congenital nature (Van Der Bom et al, 2011). In CHD the number of new cases is generally 
stated as the number of cases per 1000 births. This term is referred to as the 'birth prevalence’, 
which technically differs from the concept of incidence (Van Der Bom et al, 2011). The 
ambiguity in defining the nature and types of CHD leads to a wide range of birth prevalence 
estimates in the literature ranging from 4 to 50 per 1000 births (Hoffman, and Kaplan 2002; 
Bernier et al, 2010). The UK birth prevalence is reported as 6.4 per 1000 births for all forms of 
CHD, and 1 per 1000 births for severe forms of CHD (Wren, Reinhardt and Khawaja, 2008).  
 
A systematic review and meta-analysis of the literature on the worldwide birth prevalence of 
CHD reported that the overall total CHD birth prevalence has increased substantially from 0.6 
per 1,000 births in 1930-1934, to 9.1 per 1,000 births in 1997-2011 (See Van Der Linde et al, 
2011 for more details). One potential reason for the increase in the birth prevalence rates could 
be the improvements in the diagnostic techniques over time, which enables identification of new 
cases. This review and meta-analysis also reported significant geographical differences in the 
birth prevalence rates, with Asia having the highest (9.3 per 1000 births), followed by Europe 
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(8.2 per 1000 births), and the lowest birth prevalence being reported in Africa (1.9 per 1000 
births) (Van Der Linde et al, 2011).  
 
1.3.3.2 Prevalence of CHD 
Prevalence rate is defined as the number of people living with the condition at a particular point 
in time. The prevalence rate of CHD is calculated by deriving the difference between the 
number of people born with CHD and those that are deceased or have had a spontaneous closure 
(i.e. when the heart defect spontaneously corrects itself without the need for surgical 
intervention) (Van Der Bom et al, 2011). Similar to the estimation of birth prevalence, 
calculating the prevalence rate of CHD is difficult with different studies using different figures 
and rationale for estimating prevalence.  
 
In a systematic review of the literature, the overall prevalence rate of CHD was reported as 
being 3,000 per million adults (Van Der Bom et al, 2011). The prevalence of Adult Congenital 
Heart Disease (ACHD) patients is rapidly increasing, with more recent reports suggesting an 
increase in numbers by a 2:1 ratio (Avila et al, 2014). This increase in the prevalence rates of 
ACHD could be attributed to the improvement in the treatment techniques that have led to an 
increasing number of children with CHD surviving into adulthood.  
 
1.3.4 Mortality and trends of survival  
The survival rate of CHD patients has increased over time. The median age of patients with 
severe CHD has increased from 11 years (in 1985) to 17 years (in 2000); similarly their median 
age at death has increased from 37 years (in 2002) to 57 years (in 2007) (Boneva, 2001; Van 
Der Bom et al, 2011). A 50-70% decline (from 1980-2005) in the mortality rate among patients 
with CHD has been reported, depending on the diagnosis (Pillutla, Shetty and Foster, 2009). 
This has led to a 70% increase in adult survivors since the 1950’s, leading to a larger ACHD 
population in comparison to the paediatric population (Van Der Bom et al, 2011). 
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1.4  Nomenclature and classification of CHD 
Given the inherent diversity of CHD, several ways of categorizing the different CHD conditions 
into groups have been developed. A comprehensive system of nomenclature called the 
International Paediatric and Congenital Cardiac Code (IPCCC) has been developed by the 
Society for Nomenclature of Paediatrics and Congenital Heart Disease (Franklin et al, 2008). 
Specialists in the field of cardiology created the IPCCC in order to name and classify the 
different forms of paediatric and congenital heart disease and their treatments, for the purpose of 
improving patient outcomes, risk stratification and comparing outcomes internationally between 
different specialist centres. This classification is increasingly being used in clinical practice by 
cardiologists but its value in research is yet to be established. 
    
A common categorization often used in the field of research is that of cyanotic and acyanotic 
forms of CHD; cyanotic conditions are those characterised by poor blood oxygen saturation 
levels while acyanotic conditions have normal oxygen saturation levels. However, such a broad 
classification fails to take into account the range of complexity of the different conditions 
included within these two groups. For instance, one could classify a range of conditions as 
“cyanotic” however the prognosis, incidence rates and long-term outcomes of different cyanotic 
conditions may vary considerably. This variation is overlooked when assessing these distinct 
conditions as a group. Given the large amount of variability in the different forms of CHD and 
their associated treatments and prognosis, the outcomes of each condition could be expected to 
vary. Therefore, merging together a range of conditions does not allow a clear understanding of 
the impact of the different conditions on long-term outcomes such as quality of life, prognosis 
and recovery over time. 
  
Alternatively, a potentially useful way to classify and evaluate the wide range of conditions in 
CHD could be based on the varying levels of structural complexity of these different conditions. 
Such a classification takes into account the variability in the anatomy, prognosis, treatments and 
symptomologies of the different forms of CHD and allows the assessment of different long-term 
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outcomes (e.g. quality of life, cognitive functioning) in patient groups with different levels of 
structural complexity. Furthermore, it enables both independent and comparative analysis of the 
different conditions.   
 
The patient group categorization adopted within this thesis was based on the idea of assessing 
different levels of structural complexity both independently and among themselves, and is 
presented within Chapter 7 (Section 7.2.1.2). For the purposes of this thesis some of the most 
common forms of CHD were divided, based on the level of the anatomical complexity of the 
structural heart defect, into four groups i) “Simple” group, ii) Tetralogy of Fallot (ToF), iii) 
Single Ventricle (SV), and iv) Transposition of the Great Arteries (TGA). A detailed description 
of each of these groups is presented later in the chapter (see Table 1.1 for a summary of the 
complexity classification used within this thesis).  
 
The label used to describe and differentiate these four groups is “structural complexity groups”. 
Although TGA and SV groups are structurally different they are considered ‘complex’ in their 
level of anatomical complexity. The ToF group, while considered complex can also be referred 
to as ‘moderately complex’ in the absence of cyanosis when compared to SV and TGA. The 
‘Simple’ group is the least anatomically complex group of conditions in comparison to the other 
three groups and hence labelled ‘Simple’.  
 
Within the thesis, the term ‘structural complexity groups’ is used when referring to the four 
independent groups collectively. When making comparisons between SV, TGA and ToF groups 
with the ‘Simple’ group, these three conditions will collectively be referred to as ‘more 
structurally complex’ conditions and the Simple group as ‘Simple’/ ‘less structurally complex’ 
conditions, unless individual complexity groups are specified (i.e. labelled as TGA, ToF, SV). 
When making comparisons between SV and TGA group with the ToF group these conditions 
will be referred to as ‘more structurally complex’ conditions and ToF as a ‘moderately 
complex’ condition. Evidence presented within this thesis is discussed using this classification 
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and terminology irrespective of the classification adopted by the authors in the existing 
literature. This is done to maintain consistency of terminology across the thesis, and to enable 
comparison of existing evidence in the context of the classification used in this study.   
 
1.4.1 “Simple” group  
1.4.1.1 Atrial Septal Defect (ASD) 
ASD is defined as one or more communications or openings across the atrial septum that allows 
the flow of blood between the left and right atria of the heart (See Figure 1.3 below) (Geva, 
Martin and Wald, 2014). There are different forms of ASD based on the specific location of the 
defect along the septum, for an overview of the different type see Geva, Martin and Wald, 
(2014). ASD accounts for approximately 9-11% of all CHD in childhood and about 22-30% in 
adulthood, and is more common in females than males (2:1) (Harrox, 2002).  
 
ASD is generally asymptomatic in childhood and is usually diagnosed well into adulthood 
(Baumgartner et al, 2010). Although smaller ASDs do not cause many symptoms, larger ASDs 
may lead to some symptomology including palpitations (heart beats faster and becomes more 
noticeable), shortness of breath, arrhythmias and heart failure later in life when the patients are 
in their forties (Silversides et al, 2010).  
 
Operative treatment for CHD can be classified as palliative or total/complete surgical repair or 
correction, depending on the objective of the treatment. Palliative procedures do not correct the 
defect, they help manage the symptoms and improve an abnormal heart function, while the 
total/complete repair refers to procedures that are aimed at correcting the defect and obtaining 
normal heart function (Yuan and Jing, 2009).  
 
Treatment for ASD can involve palliative procedures such as transcatheter closures and/or 
surgical correction. Transcatheter closure involves inserting a closure device through a catheter 
(tube) that is usually inserted through the groin up to the heart where the device is placed in 
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order to close the opening (ASD). The use of a transcatheter closure is considered safe and less 
invasive than surgical correction for most forms of ASD (Shen, Zhou and Gao, 2003), and is 
considered to provide similar results to those obtained by surgery (Silversides et al, 2010). 
However, open-heart surgery (complete repair) involving sewing a patch over the opening may 
be required in some cases depending on the size of the ASD. Repair surgery has a low mortality 
rate (1%) and patients have good long-term outcomes (Baumgartner et al, 2010). The 
morphology of the defect is an important factor in determining which procedure is appropriate.  
 
 
 
Figure 1.3 Normal heart and heart with ASD 
© National Heart, Lung, and Blood Institute (NHLBI) [www.nhlbi.nih.gov] 
 
 
Most patients that undergo an ASD closure in the first two decades of life lead regular lives 
with excellent outlooks and normal survival (Gatzoulis, Webb, and Daubeney, 2010). However 
older age at repair has been reported as a risk factor for long-term complications (Attie et al, 
2001). Most patients that have undergone correction for ASD do not require frequent follow-up, 
unless patients who have undergone late repair experience additional complications such as 
progressive pulmonary vascular disease, which warrants regular follow-up (Gatzoulis, Webb, 
and Daubeney, 2010) 
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Table 1.1 Details of the structural complexity group classification used in the present study 
The Groups  Anatomical 
complexity 
of the heart 
defect 
Cyanosis Specific diagnosis and surgical procedures included in each structural 
complexity group within this study  
Need for 
repeated 
surgical 
interventions 
“Simple” group Less complex 
(Simple)  
× Atrial Septal 
Defect (ASD) 
(surgical or 
percutaneous) 
Ventricular Septal 
Defect (VSD) 
Coarctation of the 
Aorta (early/late 
repair, re-COA) 
 
Pulmonary 
stenosis,  
Valvular 
Aortic 
Stenosis  
 
× 
 
“ToF” group Complex  to 
Moderately 
complex 
 Tetralogy of 
Fallot (TOF) 
Pulmonary atresia 
(PA) 
Major 
Aortopulmonary 
collateral arteries 
(MAPCAS) 
Pulmonary 
valve 
replacement 
 
“SV” group Complex   Fontan operation 
 
Total 
Cavopulmonary 
Connection 
(TCPC) 
Cyanotic patients 
under single 
ventricle 
diagnosis 
  
“TGA” group Complex   Mustard 
procedure 
 
Senning procedure Senning patients 
(including 
pacemakers & 
Implantable 
Cardioverter 
Defibrillators) 
  
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1.4.1.2 Ventricular Septal Defect (VSD) 
VSD is the presence of one or more communications or openings along the ventricular septum, 
leading to an increased blood flow to the lungs (See Figure 1.4 below). It can occur in several 
places along the ventricular septum and may vary in size; it may also present as a secondary 
defect to other conditions such as ToF and atrioventricular septal defect (King and de Moor, 
1999). VSD is one of the most common forms of CHD accounting for approximately 33% of all 
CHD (Harrox, 2002). VSD is the most common heart defect in childhood and is present in 3-3.5 
per 1000 births, while in adults it is estimated to be much lower (0.3 per 1000 births) due to the 
high incidence of spontaneous closures (Hoffman and Kaplan, 2002; Warnes et al, 2001).  
 
Symptom presentation in VSD is determined by the size of the defect; small VSD usually 
present no symptoms but they may be at an increased risk of endocarditis (infection of the inner 
lining of the heart) and paradoxical embolism (blockage of a systemic artery by a blood clot) 
(Findlow and Doyle, 1997). 
 
Patients with medium VSD may present symptoms like heart failure, chest infections, and 
normal or moderately high blood pressure in the pulmonary artery; while those with large VSD 
may present with congestive cardiac failure, chest infections and failure to thrive (King and de 
Moor, 1999). Spontaneous closure of the VSD may occur in about 35%-40% of patients mostly 
in the first 2 years of their lives with a 10% chance of closure in adolescence and adulthood 
(Neumayer, Stone and Somerville, 1998). 
 
Patients with a small VSD tend to remain asymptomatic and do not require treatment, however 
those with a larger VSD require timely closure of the defect as they are at an increased risk of 
developing congestive heart failure and irreversible pulmonary vascular disease (a condition 
affecting blood vessels that connect the heart and lungs) (Gatzoulis, Webb, and Daubeney, 
2010). The aim of surgery is to correct the defect by closing the hole using a patch under open-
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heart surgery (Harrox, 2002). Transcatheter closure may be performed as an alternative to 
surgery for those who cannot undergo surgery or those who have undergone previous surgical 
interventions (Aleem et al, 2006).  
 
 
 
Figure 1.4: Normal heart and heart with VSD 
© National Heart, Lung, and Blood Institute (NHLBI) [www.nhlbi.nih.gov] 
 
 
Surgical repair greatly improves the long-term morbidity and mortality outcomes of VSD 
patients (Meijboom et al, 1994; Roos-Hesselink et al, 2004). The operative mortality rate for 
surgical repair is quite low (1%-2%) and offers good long-term outcomes (Baumgartner et al, 
2010). The prognosis for VSD patients is good, with no restriction in activity necessary unless 
there are complications from surgery (Gatzoulis, Webb, and Daubeney, 2010).  
 
1.4.1.3 Left Ventricular Outflow Track Obstructions (LVOTO)  
LVOTO are a group of conditions that are characterized by an obstruction or blockage in the 
blood flow through the left ventricle. A number of conditions can be classified as LVOTO; the 
common forms include Coarctation of the Aorta (CoA) and Valvular Aortic Stenosis (VAS).   
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Coarctation of the aorta (CoA) 
CoA is characterized by the constriction (narrowing) of the aorta, which is the main artery 
leading out of the heart (See Figure 1.5 below). CoA constitutes about 5%-8% of all CHD and 
is more common in males than in females (2:1) (Park, 1997; Gatzoulis, Webb, and Daubeney, 
2010). CoA may occur as an isolated defect (simple CoA) or in conjunction with other cardiac 
defects (complex CoA) mainly bicuspid aortic valve (up to 85%), VSD, and mitral valve 
abnormalities; the prevalence of isolated CoA is approximately 0.33 per 1000 births (Gatzoulis, 
Webb, and Daubeney, 2010).  
 
The symptoms of CoA can be present in several systems including the respiratory, 
gastrointestinal and renal; some of the signs and symptoms include congestive heart failure 
usually seen in patients with a coexisting VSD, shortness of breath, nosebleeds, dizziness, 
hypertension and headaches (Harrox, 2002; Gatzoulis, Webb, and Daubeney, 2010). Depending 
on the severity of the condition some patients may remain asymptomatic and only be diagnosed 
upon examination in adulthood. 
 
Treatment for CoA can include transcatheter and/or surgical correction, dependent on the time 
of diagnosis, degree of constriction and the presence of other associated cardiac defects. The use 
of transcatheter interventions in CoA is less common, and surgery is generally conducted at the 
time of diagnosis, in order to prevent later morbidity and mortality (Gatzoulis, Webb, and 
Daubeney, 2010). The primary aim of surgery is to relieve the constriction and reduce the strain 
to the aorta, before hypertension causes irreversible consequences (Harrox, 2002). 
 
There are several surgical techniques that are used to treat CoA, such as subclavian flap repair 
(the Subclavian artery is opened and used to widen the aorta), end-to-end anastomosis (involves 
removal of the narrowing and sewing the two ends together), and interposition graft (involving 
the use of synthetic material to bypass or remove the narrowing) (See Gatzoulis, Webb, and 
Daubeney, 2010 for more details on the surgical procedures). Long-term complications are 
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associated with all forms of treatment; some of the main complications may include aneurysm 
(excessive swelling) of the aorta and/or site of intervention and recoarctation (reoccurrence of 
the constriction after correction) (Gatzoulis, Webb, and Daubeney, 2010). 
 
 
 
Figure 1.5: Image of a heart with CoA 
© Texas Heart Institute [www.texasheart.org] 
 
 
Depending on the degree of constriction, 90% of untreated complex CoA patients can die in the 
first year of their lives; those that survive into adulthood without treatment usually only 
experience mild CoA, often delaying diagnosis until later in life (Gatzoulis, Webb, and 
Daubeney, 2010). The prognosis for CoA is better if surgery is performed in childhood; survival 
rates of 24 and 44 years after surgery are reported as 81% and 73% respectively (Popelova et al, 
2008). However, some complex forms of CoA may not necessarily be cured by surgical 
intervention; while surgical treatment can improve symptomology, the long-term survival is 
reportedly lower than that of the general population, making life-long follow-up of COA 
patients important (Gatzoulis, Webb, and Daubeney, 2010). 
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Valvular Aortic Stenosis (AS) 
Valvular Aortic Stenosis (AS) is one of the most common forms of LVOTO, accounting for 
approximately 8% of all CHD (Gatzoulis, Webb, and Daubeney, 2010; Popelova et al, 2008).  
AS is the narrowing of the aortic valve opening, causing a restriction in the blood flow from the 
left ventricle to the aorta (See Figure 1.6 below).  
 
AS can be classified as Sub-Aortic (SAS) or Supravalvular (SVAS) depending on the exact 
location of the narrowing (stenosis) (Aboulhosn & Child, 2006). Symptoms of AS develop 
gradually over a period of 10 to 20 years, and can include chest pains, syncope (temporary loss 
of consciousness) and heart failure (Brickner, Hillis and Lange, 2000) 
 
Treatment for AS is determined by the severity of the defect and the symptoms. Patients may 
undergo transcatheter interventions as a palliative procedure to manage symptomology. 
However in order to correct the defect, the definitive treatment for AS involves undergoing an 
aortic valve replacement, whereby an artificial heart valve replaces the patient’s aortic valve, by 
means of surgery (Brickner, Hillis and Lange, 2000).  
 
The 25-year mortality rate of AS patients is reported as 25% (Hoffman, Kaplan and Liberthson, 
2004). Patients that remain asymptomatic have a normal life expectancy; however for those that 
develop symptoms in adulthood the life expectancy is considered low (Brickner, Hillis and 
Lange, 2000). The median survival rate after experiencing chest pain, syncope and heart failure 
is reported as five, three and two years respectively (Brickner, Hillis and Lange, 2000). Given 
the progressive nature of AS, regular follow-up is recommended for both symptomatic and 
asymptomatic patients alike (Gatzoulis, Webb, and Daubeney, 2010).  
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Figure 1.6: Image of a heart with AS 
© Texas Heart Institute [www.texasheart.org] 
 
 
1.4.1.4 Right Ventricular Outflow Track Obstructions (RVOTO)  
RVOTO are a group of conditions that are characterized by an obstruction or blockage in the 
blood flow through the right ventricle. The most common form is Valvular Pulmonary Stenosis 
(PS) occurring in 80%-90% of all cases (Popelova et al, 2008).  
 
PS is the narrowing of the pulmonary valve leading to an obstruction in the ejection of blood 
from the right ventricle into the lungs (Gatzoulis, Webb, and Daubeney, 2010) (See Figure 1.7 
below). PS can occur both as an isolated defect and associated with other forms of CHD 
including ASD, VSD and ToF. As an isolated defect PS occurs in 6%-10% of all CHD, with an 
equal male to female ratio (Popelova et al, 2008).  
 
Symptoms of PS depend on the severity of the stenosis; some children may remain 
asymptomatic and only be diagnosed upon physical examination, not requiring treatment until 
adulthood (Popelova et al, 2008; Gatzoulis, Webb, and Daubeney, 2010). Some of the common 
symptoms in more severe forms of PS may include fatigue, syncope, chest pains and 
palpitations (Popelova et al, 2008).  
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Treatment for PS generally involves the use of transcatheter interventions, which involves 
relieving the obstruction by dilating the pulmonary valve (Gatzoulis, Webb, and Daubeney, 
2010). Surgical treatment may be required in cases where the use of transcatheter intervention is 
not possible, and there is a coexistence of other associated defects (Baumgartner et al, 2010).  
 
Long-term outcomes for patients with an isolated PS that has been treated using transcatheter 
intervention and/or surgery is generally considered to be good, and comparable to a healthy 
normal population with a 97% survival rate at 25 years (Popelova et al, 2008). Mortality rates 
are higher in patients that have severe PS that has been left untreated into adulthood (Connelly 
et al, 1998). Some long-term complication in patients with PS may include arrhythmias, heart 
failure and pulmonary regurgitation (a leaking pulmonary valve) (Gatzoulis, Webb, and 
Daubeney, 2010). 
 
 
Figure 1.7: Image of a heart with PS 
© Texas Heart Institute [www.texasheart.org] 
 
 
1.4.2 Tetralogy of Fallot (ToF) 
Tetralogy of Fallot (ToF) is one of the most common cyanotic forms of CHD, accounting for 
approximately 10% of all CHD, with a slight male to female predominance (Gatzoulis, Webb, 
and Daubeney, 2010). ToF is characterised by the coexistence of four individual defects (See 
Figure 1.8 below): 
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 RVOTO (Pulmonary Stenosis-PS): A narrowing in the way out of the right side of the 
heart to the lungs 
 Ventricular Septal Defect (VSD): A hole in the septum that separates the left and right 
ventricles  
 Over-riding Aorta: The aorta rides over the VSD allowing blood from both ventricles to 
enter into circulation 
 Right Ventricular Hypertrophy: Thickening of the muscle in the right ventricle caused 
by overworking due to the PS. 
 
The signs and symptoms of ToF can occur across several systems including: cardiovascular, 
respiratory, neurological and haematological systems (Harrox, 2002). One of the most common 
symptoms is cyanosis, characterised by blue or purple coloration of the skin due to lack of 
oxygen supply caused by deoxygenated blood bypassing the lungs and being shunted directly 
into arterial circulation (Harrox, 2002).  
 
The presentation and severity of cyanosis depends on the degree of RVOTO obstruction. Most 
ToF patients present with cyanosis in infancy and others with milder RVOTO may have 
minimal cyanosis (so-called pink Tetralogy or acyanotic Fallot) and present well into adulthood 
(Gatzoulis, Webb, and Daubeney, 2010). If left untreated, it may lead to complications such as 
stroke, arrhythmias (irregular heart beat), exercise intolerance and endocarditis (an infection of 
the inner lining of the heart) in adult patients (Gatzoulis, Webb, and Daubeney, 2010). 
 
The choice of treatment for ToF depends upon the complexity of the condition and the urgency 
to conduct complete repair. In the past most children underwent staged treatment with palliative 
procedures before complete repair. The general aim of the palliative procedures is to delay the 
complete repair and this is achieved using a systemic-to-pulmonary artery shunt (i.e. creating a 
hole or passage) to enable pulmonary blood flow. However, due to the resultant side effects (e.g. 
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hypertension), these staged procedures are largely being abandoned for complete repair early on 
in the baby’s life (Harrox, 2002).  
 
 
 
Figure 1.8: Normal heart and heart with ToF 
© National Heart, Lung, and Blood Institute (NHLBI) [www.nhlbi.nih.gov/] 
 
 
Repair surgery for ToF involves two main steps; i) closing the VSD by sewing a patch of fabric 
or pericardium (the normal lining around the outside of the heart) over the hole to close it 
completely, and ii) relieving the RVOTO through the right atrium and the pulmonary artery 
(Gatzoulis, Webb, and Daubeney, 2010). Repair surgery carries approximately 1% risk of 
mortality in patients with ToF (Baumgartner et al, 2010).  
 
The survival rate for untreated ToF is very low with only 3% of patients reaching over 30 years 
of age (Brickner, Hills and Lange, 2000). The use of palliative procedures has led to an 
improvement in early and mid-term outcomes for ToF, however long-term outcomes are limited 
compared to those undergoing complete repair (Bailliard, 2009; Gatzoulis, Webb, and 
Daubeney, 2010). The survival rate for patients that had complete repair is approximately 85% 
after 36 years (Warnes et al., 2008). Long-term complications in patients with ToF are common 
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and approximately 10% of repaired patients will need to undergo re-intervention over a 20-year 
follow-up period (Oechslin et al, 1999; Gatzoulis, Webb, and Daubeney, 2010). 
 
1.4.3 Transposition of the Great Arteries (TGA) 
TGA accounts for 4-5% of all CHD, and is more prevalent in males than females with a 2:1 
ratio (Gatzoulis, Webb, and Daubeney, 2010). TGA is characterised by a ventriculo-arterial 
discordance which involves an anatomic arrangement whereby the aorta arises from the right 
ventricle and pulmonary artery from the left ventricle in a fashion that is opposite to that seen in 
a normal heart (See Figure 1.2 (page 23) for a representation of the normal heart) (Martins and 
Castela, 2008). Therefore in patients with TGA, the aorta and the pulmonary artery run parallel 
to each other as opposed to the normal cross over (See Figure 1.9 below). Associated 
abnormalities are very common in TGA with the most common ones being VSD (40%-45%), 
LVOTO (25%) and CoA (5%) (Gatzoulis, Webb, and Daubeney, 2010).  
  
With regards to the symptomology, cyanosis is the most common symptom often seen within 
the first few hours from birth. Other signs and symptoms include shortness of breath, rapid 
breathing, hyperpnoea (deep breathing using abdominal muscles) and heart failure (Harrox, 
2002). 
 
Treatment for TGA usually involves at least one operation in childhood; patients may undergo a 
palliative procedure to delay the complete repair, as palliative procedures are usually less 
invasive. This may include balloon atrial septostomy (creating a small hole between the two 
atria) to increase the blood flow and improve the mixing of the blood, however most patients 
ultimately require total surgical repair (Popelova et al, 2008). Until recently the most common 
forms of surgical repair for TGA included Senning and Mustard operations (atrial switch 
operations) (Gatzoulis, Webb, and Daubeney, 2010). Both these procedures correct the 
transposed arteries by creating a baffle (tunnel) within the atria to switch the flow of blood 
thereby correcting the defect, leading to a normal blood flow.  
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Figure 1.9: Image of a heart with TGA 
© Texas Heart Institute [www.texasheart.org] 
 
 
These procedures were then replaced by the Jatene procedure (arterial switch operation) in the 
1990’s. It’s performed within the first few weeks of a patient’s life, and involves switching the 
main arteries, which are then sutured into the correct position, providing better outcomes than 
the Mustard and Senning procedures (Gatzoulis, Webb, and Daubeney, 2010). The surgical 
mortality rate for the arterial switch operation is low (2-7%) for patients without associated 
defects (Sarris et al, 2006). In TGA patients with coexisting conditions such as VSD or 
pulmonary outflow track obstruction, the Rastelli procedure (involves the use of tubes to 
redirect the blood flow) is most frequently used (Rastelli, 1969; Gatzoulis, Webb, and 
Daubeney, 2010).  
 
The outcomes for TGA patients without surgery are considered quite poor with most patients 
not surviving beyond the first few months (Gatzoulis, Webb, and Daubeney, 2010). A 90% 10-
year survival rate and an 80% 20-year survival rate are reported for those who undergo the atrial 
switch operation (Wilson et al, 1998).  The long-term survival rate for the arterial switch 
operation is 88% at 10 and 15 years with no deaths reported after 5 years of the operation 
(Losay et al, 2001). Long-term complications for those undergoing arterial switch operations 
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and Rastelli procedures may include ventricular dysfunction, arrhythmias, PS and hypertension 
(Popelova et al, 2008).  
 
1.4.4 Single Ventricle (SV) 
SV conditions account for 1%-4% of all CHD (Harrox, 2002). Single ventricle circulation is an 
umbrella term referring to a group of conditions that are characterized by the absence or poor 
development of one of the ventricles (hypoplastic left or right ventricle), or inlet valves of the 
heart (tricuspid and mitral atresia). They are a serious group of conditions that cannot be 
corrected, as a biventricular repair (restoring a two ventricle circulation) is not possible in 
patients with SV (Popelova et al, 2008). Some of the most common SV conditions include: 
 Tricuspid Atresia (TA): characterized by the absence of a tricuspid valve, and a 
resultant lack of communication between the right atrium and ventricle 
 Double-inlet left ventricle (DILV): characterized by both the left and right atrium 
draining into one ventricle, which is usually very small in size and has a hole in the 
ventricular septum  
 Hypoplastic Left Heart Syndrome (HLHS): is characterized by the presence of a 
severely underdeveloped left ventricle (See Figure 1.10 below). 
 
Common co-existing conditions include CoA, interrupted aortic arch, and patent ductus 
arteriosus (Gatzoulis et al, 2008). Symptoms in patients with SV conditions depend on the level 
of pulmonary blood flow and the mixing of systemic and pulmonary blood circulation; some of 
the signs and symptoms include severe congestive heart failure, cyanosis, pulmonary 
hypertension and chest infections (Harrox, 2002).  
 
Most children diagnosed with SV are treated in childhood. Depending on the level of 
pulmonary flow, patients may initially undergo a range of palliative procedures such as 
pulmonary artery banding (to reduce excessive pulmonary blood flow) and systemic-to-
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pulmonary artery shunts (a surgically created connection between the systemic and pulmonary 
artery) to increase the blood flow and relieve pulmonary stenosis (Gatzoulis and Swan, 2009).  
Treatment for SV is generally staged leading up to a Fontan procedure (Talwar et al, 2014). The 
Fontan procedure involves three stages leading up to the final Fontan. The aim and outcome of 
a Fontan operation is near normal arterial oxygen saturation and minimising cyanosis (Jaquiss 
and Imamura, 2009). For an overview of the different types and variations of the Fontan 
procedure see McRae, (2013). 
 
 
 
Figure 1.10: Image of a heart with with SV (HLHS) 
© Stanford Children’s Health [www.forms.stanfordchildrens.org] 
 
 
The prognosis for untreated SV patients is extremely poor (Silversides et al, 2010).  Survival 
rates after a Fontan procedure are reported as 86%-94% at ten years and 82%-87% at 15-20 
years (Silversides et al, 2010). The complex and multi-systemic nature of SV conditions can 
have further complications for patients (operated and un-operated) including congestive heart 
failure, arrhythmias, chronic cyanosis, and stroke amongst others (Warnes et al., 2008). SV 
patients generally require frequent follow-ups and constant surveillance to manage their 
condition.   
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1.5 Long-term complications of Adult Congenital Heart Disease  
Having discussed some of the most common forms of CHD and their associated treatments, this 
section addresses some of the most common long-term complications affecting patients with 
ACHD. Long-term complications in ACHD are inevitable; as the heart ages, many forms of 
ACHD may require re-intervention and further treatment due to recurring problems. A recent 
review of the ACHD literature reported the most common long-term complications being 
arrhythmias, endocarditis, hypertension and heart failure (Ministeri et al, 2016).  
 
Some patients with ACHD experience arrhythmias (an irregular heart beat) in the long-term due 
to several factors, including their underlying cardiac defect and post-operative scarring 
(Deanfield et al, 2003). When experiencing an arrhythmia patients may have symptoms such as 
shortness of breath, dizziness, chest pains, loss of consciousness or sudden cardiac death. 
Arrhythmias are reported to be one of the main factors responsible for hospitalization in ACHD, 
and are a frequent cause of increased morbidity and mortality (Somerville, 1997).  
 
Another common complication in ACHD is the risk of an infection leading to an inflammation 
of the inner wall of the heart (endocardium) i.e. infective endocarditis (IE). Patients may 
experience a range of symptoms including fever, weight loss, joint pains and shortness of breath 
(Cabell, Abrutyn and Karchmer, 2003). Factors both external (tattooing, piercing and dental 
treatment/infection) and treatment related (surgical interventions) can be implicated in causing 
IE in patients with ACHD (Perloff and Warnes, 2001; Deanfield et al, 2003). Antibiotic 
prophylaxis is usually warranted to manage symptomology, with guidelines varying based on 
the underlying condition. Untreated IE can lead to damage of the heart valves and reduced 
pumping capability, which can result in death (Thuny et al, 2005).  
 
Pulmonary Hypertension (PH) refers to a rise in blood pressure within the pulmonary arteries, 
and is a common complication of ACHD (Ministeri et al, 2016). PH in patients with ACHD is 
associated with increased morbidity and mortality (Rodriguez-Lopez, 2014). Furthermore Heart 
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Failure (HF) is another common complication of ACHD and is a known cause of morbidity and 
mortality in this patient group. HF includes a range of symptoms including difficult and 
laboured breathing, peripheral edema (accumulation of fluid in tissue) and increased central 
venous pressure (Ministeri et al, 2016). HF occurs due to the inability of the heart to efficiently 
deliver blood to other organs and tissues in the body (Mcmurray et al, 2012).  
 
Another potential complication of ACHD is brain injury leading to impairment of neurological 
and cognitive functioning. Some of the most common causes for these injuries are hypoxic-
ischemic/reperfusion injury, referring to the damage and injury caused to the brain, due to 
changes in cerebral perfusion i.e. cerebral blood flow and metabolism when undergoing cardiac 
surgery (Busl and Greer 2010). Furthermore, a characteristic symptom of some forms of CHD is 
cyanosis; the reduced blood oxygen saturation levels in cyanotic conditions may have 
neurological implications. Evidence related to the relationship between the heart and the brain, 
and the different types of brain injury and their causes in CHD is presented in Chapter 3. One 
potential complication of these injuries is cognitive impairment i.e. a decline in cognitive 
abilities such as memory and attention. Cognitive impairment can have a range of implications 
for patients, including difficulty and challenges with education and employment and the ability 
to conduct independent day-to-day activities such as self-care. Despite the growing literature in 
children with CHD this area of research has remained under explored in adult CHD patients. 
The aim of this thesis was to explore this area of research and investigate the extent of cognitive 
impairment and its potential mechanisms in ACHD patients.  
 
1.6 Conclusions  
Overall the improvements in treatment techniques have led to an increase in the survival rates of 
CHD, with an increasing number of patients reaching adulthood. Despite the improvements, this 
group of patients are often faced with long-term complications. These complications can have 
widespread implications for patients, including their physical, emotional and functional 
outcomes. One such complication is cognitive impairment, which can have widespread and 
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long-term implications for patients with ACHD. Assessing cognitive functioning in ACHD 
patients is the main focus of this thesis. The following chapter introduces and elaborates the 
concept of cognitive functioning.  
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2 COGNITION AND COGNITIVE FUNCTIONING 
 
2.1 Prologue 
As discussed in Chapter 1, cognitive impairment is a potential complication affecting some 
patients with CHD. This chapter provides an introduction to cognitive functioning and an 
overview of the key cognitive domains that pertain to this thesis. The chapter then discusses 
some of the challenges associated with cognitive testing.   
 
2.2 Cognitive functioning    
Cognitive functioning is an umbrella term encompassing a number of mental processes and 
abilities. Broadly speaking, cognitive functions can be classified into four areas; i) receptive 
functions involving the ability to acquire and integrate information, ii) memory and learning 
referring to the ability to store and retrieve information, iii) thinking which involves the ability 
to gather and organize information, and iv) expressive functions which refer to the ability to 
communicate and execute information (Lezak et al, 2012).  
 
Each of these broad areas of cognitive function include a wide range of mental processes and 
abilities that are often referred to as ‘domains’ of cognitive functioning, such as attention, 
executive functioning, and motor function (Sections 2.2.2 - 2.2.5 provide a description of the 
different domains). While these mental processes and abilities can be classified conceptually 
into different domains, they are often intrinsically co-dependent, for instance attention and 
memory; whereby an individual must pay attention to a task in order to be able to acquire the 
relevant information for storing in memory.  
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2.2.1 Intelligence quotient (IQ) 
Interest in assessing different domains of cognitive functioning is a recent development in the 
cognitive literature, as historically cognition was assessed as a single function, under the 
umbrella term ’intelligence’ which refers to a general cognitive ability. Intelligence Quotient 
(IQ) is the unit of measurement used to describe this hypothesized general ability (Lezak et al, 
2012). IQ tests generally consist of a number of tasks with varying levels of difficulty, that 
assess different cognitive abilities such as verbal comprehension, processing speed, working 
memory and perceptual organization. These tasks are then scored individually and cumulated to 
provide a single score for an individual’s overall functional abilities i.e. IQ. IQ scores can range 
from low to high, with scores below 69 considered very low and score over 130 considered very 
high. A score of 100 is usually considered as the mean score on most tests of intelligence, 
representing an average IQ level.  
 
In addition to this overall IQ score, the different subtests of an IQ test battery can also be 
utilized independently to assess specific areas of cognitive function such as the working 
memory and verbal abilities. Majority of IQ tests categorize these subtest scores into two broad 
areas: verbal IQ (VIQ) and performance IQ (PIQ). Verbal IQ is a measure of the individual’s 
ability to apply verbal skills (e.g. language expression, comprehension) to analyze information 
and solve problems, for example answering questions orally or naming words. Performance IQ 
is a measure of the individual’s ability to solve problems and analyze information using non-
verbal skills (e.g. perceptual, visuo-spatial, and organizational) for example solving a puzzle or 
building a design (Wechsler, 1997).  
  
There are a number of IQ test batteries used in the cognitive literature, for instance the Stanford-
Binet Intelligence Scale (Terman and Merril, 1960), Raven’s Progressive Matrices (Raven and 
Court, 1998), the Wechsler Adult Intelligence Scale-Revised (WAIS-R) (Wechsler, 1981), the 
Wechsler Adult Intelligence Scale – III (WAIS-III) (Wechsler, 1997), and the more recent 
version the Wechsler Adult Intelligence Scale- IV (WAIS-IV) (Wechsler, 2008). The WAIS 
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predominates the IQ literature and is one of the most widely used tests of intelligence. The 
WAIS is also considered ‘the gold standard’ in intelligence testing (Ivnik et al, 1992). The 
WAIS measures a range of cognitive abilities such as mental arithmetic, general knowledge and 
vocabulary; it provides both the PIQ and VIQ scores (Strauss, Sherman and Spreen, 2006). 
 
Despite being widely used the concept of intelligence and measurement of IQ have been 
criticized as inadequate in the assessment and identification of specific cognitive impairment. 
IQ scores are cumulative in nature and are derived from assessment of a number of different 
functions. The use of a cumulative score may obscure the nature of specific impairments 
preventing the identification of the impaired cognitive domains. Furthermore, some researchers 
consider IQ scores to be unreliable; such that impairment of specific cognitive functions may 
lead to an erroneous representation of the overall intellectual ability of an individual (Lezak et 
al, 2012). For instance if an individual has impaired working memory, a low score on the 
memory task may pull down the overall average IQ when the individual scores are cumulated to 
derive a full-scale IQ score.  
 
Critiques of the approach using a single cumulative measure like IQ have led to the 
development and use of more sophisticated measures aimed at assessing individual domains of 
cognitive functioning. Despite these criticisms, IQ remains one of the most widely used 
measures of cognitive functioning. IQ tests may be useful in situations requiring a general 
measure of an individual’s functional abilities, for instance as part of a job or educational 
placement. IQ has been found in some studies to be predictive of certain forms of achievement 
including academic, occupational, and financial outcomes (Neisser et al, 1996).   
 
Despite the critique presented above IQ was measured in the present study for two reasons: 
firstly to gain an insight into the overall functional abilities of this patient group, and secondly 
for the purposes of comparison to the existing literature.    
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2.2.2 Executive functioning  
Executive function refers to a set of mental processes and abilities, which are thought to be 
higher order cognitive functions that govern in the overall hierarchy of brain processing (Baron, 
2004; Gilbert and Burgess 2008). Executive function includes abilities such as problem solving 
which is the ability to identify a strategy in a complex situation; cognitive flexibility which is 
the ability to switch between different concepts; and response inhibition which is the ability to 
suppress actions that may interfere with a goal driven behaviour (Diamond, 2013).   
 
Executive functions are an essential component of cognitive functioning, which enable an 
individual to initiate and monitor actions, deal with novel situations, engage in independent self-
directed behaviours such as self-care, maintaining social and work relationships, and achieving 
goal directed behaviour (Strauss, Sherman and Spreen, 2006).  
 
There is a wide range of measures used to assess executive functioning in the cognitive 
literature. A study surveying the cognitive assessment practices and test usage patterns among 
clinical psychologists reported the three most common measures used to assess executive 
functioning as the Wisconsin card sorting test (WCST- Kongs et al, 2000), Rey–Osterrieth 
complex figure test (Rey, 1941; Osterrieth, 1944), and the Halstead category test (Reitan and 
Wolfson, 1985) (Rabin, Barr and Burton, 2005). Within the present study executive function 
was assessed using a range of tests (See Chapter 7 for details). 
 
2.2.3 Attention 
Attention refers to the ability of an individual to be receptive to incoming information and 
stimuli, and to be able to identify and filter the relevant information to the brain for further 
processing (Cohen, Sparling-Cohen and O’Donnell, 1993). It is comprised of several processes 
including response selection which is the ability to select an appropriate response in a given 
situation; sensory selection which involves selecting a sensory modality such as visual, auditory 
and tactile; attentional capacity which is the extent to which one can focus and process 
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information; and sustained performance which is the ability to focus on a task for an extended 
period for time (Strauss, Sherman and Spreen, 2006).  
 
The measurement of attention is complicated, in that impairments in attention may occur due to 
one or more of the above mentioned processes making it difficult to identify where the 
impairment lies. Furthermore in order for an individual to pay attention to “a task” one needs to 
attend to the incoming information that could be visual, verbal or spatial in nature. Similarly the 
response to this “task” may be in a similar or a different modality, requiring the individual to 
exercise multiple faculties’ simultaneously. Tests of attention often require other additional 
cognitive skills such as motor speed and verbal abilities to be used (Strauss, Sherman and 
Spreen, 2006). A good example of this is the Trail Making Test B (TMT) of divided attention 
which requires the test taker to switch between sequences of numbers and letters (joining the 
numbers and letters as quickly as possible), and assesses divided attention along with perceptuo-
motor skills and motor speed. Given the multiple modalities the nature of the test may involve 
and the different domains of cognitive functioning that need to be exercised, assessing attention 
can be a difficult task. Within the present study a range of tests was used to assess different 
aspects of attention e.g. divided attention and complex visual scanning. A detailed description 
of the tests utilized in this study is presented in Chapter 7.   
 
2.2.4 Memory   
Memory refers to the complex process of encoding, storing and retrieving information (Lezak et 
al, 2012). Broadly speaking memory can be divided into i) Sensory memory, ii) Working 
memory (previously referred to as short-term memory), and iii) Long-term memory (Strauss, 
Sherman and Spreen, 2006). Sensory memory holds information perceived for less than one 
second; a memory of any information observed only for a split second refers to the concept of 
sensory memory. Information is then transferred into the working memory, which retains 
information for a small period of time (1-2 minutes) (Strauss, Sherman and Spreen, 2006). 
Working memory is considered to include two subsystems; one that is responsible for 
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processing language (phonological loop) and the other for processing visuospatial data 
(visuospatial sketch pad) (Baddeley, Kopelman and Wilson, 2004).  
 
Lastly, the information is transferred from working memory to the long-term memory, which is 
considered a more permanent store for information that can be retrieved at a later date, and can 
be stored indefinitely. Information transferred from working memory to long-term memory is 
more likely to be stored if it is rehearsed and/or repeated. Long-term memory is generally 
divided into i) implicit memory (procedural) which is used at an unconscious level to perform a 
task without conscious recollection of previous experiences; and ii) explicit memory which on 
the contrary is used at a conscious level with intentional recollection of past experiences and 
information (declarative and conscious) (See Strauss, Sherman and Spreen, 2006 for a detailed 
overview on the sub-types of long-term memory).  
 
There are many types of memory used to store and retrieve different types of information, for 
instance episodic memory refers to the memory of specific events and experiences in time, 
which allows one to reconstruct an event that occurred. On the other hand semantic memory is a 
more structured record of facts, meanings, theories and concepts acquired. 
 
A cognitive skill closely linked to memory is that of ‘learning’; which refers to the ability of an 
individual to acquire new information (Lezak et al, 2012). Memory and learning are two closely 
related constructs, as learning is a process used to acquire memories and in turn memory is the 
process used to retrieve and expresses acquired or learnt information that has been stored 
(Okano, Hirano and Balaban, 2000). The present study includes a measure of verbal learning 
and memory (See Chapter 7, for details).     
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2.2.5 Motor functioning and dexterity 
Motor functions are physical actions and movements that require the use of muscles. There are 
two types of motor function: gross motor function and fine motor function. Gross motor 
function involves actions that use larger muscles, which are responsible for movements such as 
walking, rolling over and balancing. Fine motor function involves the use of smaller muscles 
that enable one to do activities such as writing and picking up small objects using fingers 
(Cuffaro, 2011).  
 
Motor functioning is an essential component of a comprehensive Neuropsychological (NP) 
assessment. Most tests of motor functioning involve tasks requiring the test taker to use their 
hands (Strauss, Sherman and Spreen, 2006). These tests assess different aspects of motor 
functioning including strength, speed, and dexterity, and are usually conducted for both hands.  
 
 Generally the performance of test takers is reported to be better with the preferred or dominant 
hand, however some studies have shown considerable variability in the normal population, with 
the dominant hand not always being more dexterous or proficient (Benton, Meyers and Polder, 
1962, Strauss, Sherman and Spreen, 2006). It may therefore be important to assess both hands 
independently when testing motor function. The present study includes a measure of motor 
function that assesses fine motor functioning, visuo-motor co-ordination and dexterity for both 
hands (See Chapter 7, for more details).   
 
2.3 A note on the specificity of cognitive assessments 
As discussed above in Section 2.2, the multifaceted nature of cognition implies that cognitive 
tests are rarely unitary in nature and in any task are likely to interact with each other (Lezak et 
al, 2012). While conceptually understandable, it complicates the task of identifying which 
specific domains are responsible for the performance on any particular test. 
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Within the present study the NP tests utilized are discussed within four broad domains 
(executive function, attention, memory and motor function) that these tests fall under, along 
with IQ (See Chapter 7, for details). Given the complex nature of cognition, and the nature of 
cognitive tests, it is acknowledged that some of the cognitive tests used in this study may 
require one or more domains of cognitive functioning to be exercised. Therefore based on the 
recommendation of the published literature any patterns in the results of tests assessing a similar 
function are discussed where applicable, to identify specific areas of impairment (Lezak et al, 
2012). 
 
2.4  Factors commonly associated with cognitive functioning 
When assessing cognitive functioning it is important to consider the range of potential factors 
that may have the ability to influence cognitive outcomes. These factors could play the role of 
confounders when assessing the level of cognitive impairment, which may lead to false positive 
conclusions and/or incorrect diagnosis. Some of the most common demographic factors that are 
known to influence cognitive functioning are age, gender and level of education.  
 
The association of age and cognitive functioning is well established with changes in cognitive 
functioning reported with increasing age (Lezak et al, 2012), therefore comparing cognitive 
functioning in a group of people with different age groups is challenging and incorrect. Another 
factor that has the ability to influence cognitive functioning and test performance is the level of 
education achieved. Higher education is generally associated with better cognitive functioning 
across different domains and IQ and therefore must be taken into consideration (Lezak et al, 
2012). Lastly gender differences in cognitive functioning have also been reported with males 
being better than females on certain domains of cognition and vice versa (Hill, Laird and 
Robinson, 2014), therefore when assessing cognitive functioning these factors must be taken 
into consideration and preferably controlled for. 
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Along with demographic factors some psychosocial factors have also been reported as having 
an influence on cognitive functioning. Mood related variables such as anxiety, affect and 
depression have been reported as being potential confounders when assessing cognitive 
functioning. Poorer cognitive performance has been reported in people experiencing negative 
moods such as increased anxiety or negative affect (Bartolic et al., 1999). On the contrary 
positive mood has also been associated with better cognitive performances (Bartolic et al., 
1999); therefore making it important to control for factors like mood when assessing cognitive 
functioning.  
 
Lastly, some extraneous factors that need to be considered when conducting cognitive 
assessments are the consistency of testing environment and the reliability of the cognitive tests 
used. The reliability of a test refers to its ability to measure the construct consistently. Therefore 
when using a cognitive test, good reliability is important to ensure that the test measures the 
same construct each time it is administered. If the reliability of the measure is poor, it would 
result in different scores each time it is administered (Mitrushina et al, 2005), making it difficult 
to drawing inferences about the cognitive ability being assessed. Therefore these factors must be 
considered when choosing the NP test battery.  
 
2.5  Evaluating cognitive test performance  
When evaluating the performance of an individual or group on tests of cognitive functioning, 
one needs to establish what constitutes a normal score and/or performance. In order to evaluate 
a test performance an empirical frame of reference is needed, generally normative data provide 
this frame of reference (Mitrushina et al, 2005). Normative data refers to a set of data (cognitive 
scores) on different tests gathered from a group of healthy individuals, with similar 
demographic characteristics. Normative data is generally considered the gold standard for 
comparing cognitive performance in the cognitive literature (Mitrushina et al, 2005). 
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An alternative to normative data is the use of control groups that independent studies can 
recruit. Similar to normative data, control groups include a healthy group of individuals with 
homogeneous demographic characteristics that match the subject/sample in question. Matching 
the characteristics of the study sample to that of the normative or control group are essential, as 
discussed above in Section 2.4 these factors can have the potential to influence cognitive 
functioning and therefore must be accounted for when drawing comparisons. 
  
Lastly, in order to compare the performance of the patient with a normative/control group an 
impairment criterion needs to be established in order to assess the relative performance of the 
participant in comparison to the normal population. There is a wide range of impairment criteria 
used in the literature to define a cognitive impairment. A detailed description on the subject is 
presented in Chapter 7 (section 7.7.1).  
 
2.6 Conclusions  
This chapter introduced the concept of cognitive functioning, and its measurement. It presented 
the key domains of cognitive functioning that are fundamental to an individual’s ability to 
function independently on a day-to-day basis. It also highlighted the complexities associated 
with the measurement and interpretation of cognitive assessments.  The current evidence on 
cognitive functioning within the CHD population will be discussed in the next two chapters.  
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3 BRAIN DAMAGE, NEURODEVELOPMENTAL AND 
COGNITIVE IMPAIRMENT IN CHILDREN WITH CHD 
– AN OVERVIEW 
 
3.1 Prologue  
This chapter begins by considering the relationship between the brain and the heart. It then goes 
on to discuss evidence on both the structural (structural brain damage) and functional 
(neurodevelopmental and cognitive impairment) outcomes in children with CHD. This is 
followed by a brief discussion of the findings.  
 
3.2 The brain and the heart 
The relationship between the brain and the heart has been subject to much investigation, so 
much so that the last few decades have seen the emergence of a new medical subspecialty- 
‘Neurocardiology’ (Samuels, 2007). As the heart and the brain develop in tandem in the human 
fetus, through a complex genetic process, the development of both organs is codependent. The 
brain depends on the heart for delivery of oxygen and nutrients; in turn the heart is governed by 
the autonomic nervous system both during organ development and normal bodily function. 
Therefore it is not surprising that disruption in the development of one organ could have 
implications for the other (McQuillen and Miller, 2010). 
 
Evidence in relation to the brain structure and its functioning in children with CHD is reviewed 
here, as it provides an important background to compare with the adult CHD literature. It helps 
identify the key areas of impairment in this patient group and enables comparing the outcomes 
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in childhood with those in adulthood to gain better understanding of whether the impairments 
identified in childhood persist into adulthood.  
 
As children are not the primary focus of this thesis only a brief overview of key findings, from 
recent literature reviews and meta-analyses on children are presented. Evidence is discussed 
under two broad areas i) brain development and brain injury in children with CHD - addressing 
pathophysiological evidence regarding structural brain damage and ii) functional outcomes in 
children with CHD - addressing outcomes such as neurodevelopmental and cognitive 
impairment. 
 
3.3 Brain development and brain injury in children with CHD 
Improved imaging techniques such as Magnetic Resonance Imagining (MRI) have increased 
understanding of structural differences in the brains of children with CHD when compared to 
healthy controls. These differences can be classified into two categories: i) reduced brain 
development (referring to an impaired development of the brain in comparison to age matched 
controls) and ii) acquired brain injury (injury or damage caused to the brain after birth as a 
result of both internal (e.g. reduced cerebral blood flow) and/or external (e.g. pharmacological 
agents/surgical procedures such as cardio pulmonary bypass) factors (Martinez-Biarge et al, 
2013; McQuillen and Miller, 2010).  
 
3.3.1 Reduced brain development in CHD  
Reduced brain development, indicated by reduced brain volume, retarded neuroaxonal 
development, and reduced cerebral blood flow, has been identified as early as in utero (i.e. 
foetal stages) in CHD patients, when compared to normal healthy foetuses (Donofrio et al, 
2003). Advanced imaging techniques like MRI have enabled clinicians to gain an insight into 
the timing and nature of these developments. A three-dimensional volumetric MRI study of 
foetuses with CHD (primarily those with SV and TGA), reported smaller gestational-age-
adjusted brain volume and altered brain metabolism relative to healthy foetuses 
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(Limperopoulous et al, 2010). Furthermore the results showed a slow rise in the level of N-
acetylaspartate choline (NAA- an acetylated amino acid fluid that increases with cerebral/brain 
maturity) in CHD patients particularly in those diagnosed with TGA and HLHS when compared 
to healthy controls suggesting impairment in brain growth for CHD patients (Limperopoulous et 
al, 2010).  
 
Reduced brain development in infants and children has been reported across different forms of 
CHD including SV, PS and TGA; with smaller brain volumes, brain immaturity, and reduced 
cerebral blood flow observed in these patient groups (Glauser et al, 1990; Tavani et al, 2003; 
Beca et al, 2009 and Donofrio et al, 2003). Brain growth and development largely depends on 
the level of oxygen supply, which is determined by the level of cerebral blood flow. One of the 
factors that may predispose patients with CHD to abnormal brain development is the alteration 
and disturbance in the blood flow, as a result of certain cardiac defects such as cyanotic 
conditions (Donofrio et al, 2003). 
 
3.3.2 Acquired brain injury in CHD  
3.3.2.1 Acquired brain injury in CHD prior to surgery  
Beyond reduced brain development; infants with CHD are also at risk of brain injuries such as 
white matter injury (WMI), stroke, and haemorrhage, even prior to having any form of cardiac 
surgery. Some authors suggest the role of reduced brain development in causing this brain 
injury (Andropoulous et al, 2010). For example, factors such as brain immaturity and reduced 
cerebral blood flow may lead to lack of oxygen supply to the brain tissue causing it to 
deteriorate and/or eventually die, in turn causing injuries such as stroke and Periventricular 
Leukomalacia (PVL) which is a type of a WMI characterized by the death of brain tissue due to 
the lack of oxygen (Licht et al, 2004; Tabbutt, Gaynor and Newburger 2012).   
 
MRI studies have highlighted the magnitude of brain injury in this patient group, indicating that 
28-59% of infants experience some degree of brain injury prior to cardiac surgery. More 
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specifically the review reports the presence of WMI in 7%-27%, haemorrhage in up to 54% and 
stroke in up to 30% of CHD patients (Owen et al, 2011).  
 
A more recent systematic review and meta-analysis of the literature (13 studies, N=425) showed 
a high incidence of brain injury in patients with CHD before cardiac surgery, with studies 
reporting the presence of WMI (PVL), stroke and cerebral atrophy (loss of neurons and 
connections between them) (Khalil et al, 2014).  The overall prevalence of brain injury prior to 
congenital cardiac surgery is reported as 43% in the meta-analysis conducted by Khalil and 
colleagues, however the prevalence rates varied with the type of cardiac defect, ranging from 
34% in TGA to 49% in left-sided heart defects such as HLHS, aortic stenosis (AS) and CoA 
(Khalil et al, 2014).  
 
3.3.2.2 Acquired brain injury in CHD associated with cardiac surgery 
Evidence shows that cardiac surgery in CHD patients can increase the risk of brain injury due to 
the risk of reduced cerebral perfusion (oxygen supply to the brain), microemboli (a blood 
clot/fat globule causing a blockage) and the body’s inflammatory response to surgery (Kinney 
et al, 2005). 
 
Cardiac surgery in patients with CHD can lead to an occurrence or increase in brain damage 
and/or worsening of existing brain lesions. In a study of 24-neonates with CHD (e.g. TGA, 
VSD, and HLHS) the presence of PVL and infarcts (a localized area of dead tissue due to lack 
of blood supply) was reported as 16% and 8% respectively prior to open-heart cardiac surgery 
(Mahle et al, 2002). Upon re-assessment after cardiac surgery a new PVL, infarct and 
haemorrhage was reported in 48%, 19% and 33% of the sample respectively; a total of 67% of 
the cohort presented a new or worsened brain injury after undergoing cardiac surgery (Mahle et 
al, 2002).  
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Another study assessing CHD patients both before and after cardiac surgery reported the 
presence of WMI in 20% of the infants in their study prior to any form of cardiac surgery. A 
new WMI was reported in 44% of the sample after undergoing cardiac surgery (Beca et al, 
2013). These results showed that cardiac surgery in CHD patients may either cause or 
exacerbate brain damage and/or injury. However in contrast some research in children with 
CHD (TGA, SV) reports no worsening of preoperative brain injury after undergoing cardiac 
surgery (Block et al, 2010). 
 
Reduced brain development and brain injury are common complications of both CHD and its 
related treatments (Snookes et al, 2010). Studies report that brain injuries such as diminished 
white matter can contribute to impaired cognitive function in domains such as visuo-spatial 
skills, learning, executive function, and IQ in children and adolescents with CHD (Rollins et al, 
2014; Panigrahy et al, 2015). It is important to consider the evidence on the extent to which this 
reduced brain development and acquired brain injury are associated with functional outcomes in 
CHD patients, as these can have long lasting implications in the form of neurodevelopmental or 
cognitive impairment which may affect different areas of the patient’s life, such as educational 
attainment, quality of life and social adaptation. The developmental and cognitive outcomes of 
patients with CHD are reviewed in the next section.  
 
3.4 Developmental and cognitive outcomes in patients with CHD  
There are two key concepts to be considered in the paediatric literature when discussing brain 
related developmental and functional outcomes in CHD; these are neurodevelopment outcomes 
and cognitive outcomes. In this thesis we will consider ‘Neurodevelopment’ to refer to the early 
stages of development and meeting developmental milestones in the areas of learning, speech, 
motor function, social adaptation and behavioural functioning; impairments in 
neurodevelopment are presumed to reflect a lack of time-appropriate development (Marino et al, 
2012). 
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As discussed in Chapter two ‘Cognitive functioning’ is an umbrella term referring to a set of 
mental processes and abilities such as problem solving, higher order language skills, attention, 
executive functioning, motor function, dexterity and memory. In the CHD literature cognitive 
assessments overlap with neurodevelopment measures, but do not address specific 
developmental milestones. 
 
Cognition and neurodevelopment have a conceptual overlap, for instance while the term 
neurodevelopment refers to a wide range of outcomes including behavioural (e.g. hyperactivity) 
and social (e.g. social adjustment and adaptation), it also includes the assessment of some 
cognitive functions such as motor function, attention and some elements of language and 
arithmetic abilities. As the focus of this thesis is on cognitive functioning as opposed to the 
broader field of neurodevelopment; only the key findings in the neurodevelopment literature 
relevant to cognition are discussed under the appropriate cognitive domains.   
 
A note on terminology  
Interpreting the literature on neurodevelopment and cognitive functioning is challenging owing 
to the variety of terms used by authors to describe the findings in the paediatric literature. For 
instance the terms neurodevelopmental or developmental delay and/or deficit are frequently 
used to describe the performance of those with CHD on traditional developmental measures 
(e.g. Bayley Scales of Infant and Toddler Development (Bayley, 1993)). This term ‘delay’ 
implies that the individuals will at some time in the future recover their performance to the 
normal level; while the term ‘deficit’ implies a more permanent impairment that may not 
recover to within the normal level. However, usually this empirical question is not addressed 
within these studies, as it requires long-term follow up and therefore there is no consensus on 
whether the impairments seen in children are delays or deficits. Therefore a more neutral term – 
‘impairment’ was used in this thesis, regardless of the term used in the studies reported. Thus 
when referring to traditional developmental measures such as language or motor development, 
the term “neurodevelopment impairment" is used.  
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Similarly when discussing the evidence on cognitive assessments in this patient group the term 
used to describe performance below the ‘normal’ range is “cognitive impairment” as opposed to 
the commonly used ‘cognitive deficit’ and ‘cognitive defect’, as it carries no implication of 
the potential of the individual to recover (or not) but is descriptive of the findings in the 
literature and the present study.  
 
A brief summary of the prevalence rates and most common forms of neurodevelopmental 
impairment in CHD is presented below in Section 3.4.1, before discussing some of the evidence 
pertinent to each of the cognitive domains assessed in this study (see Section 3.4.2).  
 
3.4.1 Neurodevelopmental impairment in CHD 
Several reviews of the literature have summarized the evidence on neurodevelopmental 
impairments in infants and children with CHD (Martinez-Biarge et al 2013; Tabbutt, Gaynor 
and Newburger, 2012). The systematic review and meta-analysis conducted by Khalil and 
colleagues reported a high risk of neurodevelopmental impairment in CHD patients (9 studies, 
N=512, age range= 4 days to 10 months), with a prevalence rate of 206/512 cases (~40%). 
Some of the most commonly reported neurodevelopmental impairments include altered muscle 
tone, reduced consciousness and retardation in motor development (Khalil et al, 2014).  
 
Many studies using neurodevelopmental measures showed the presence of motor and cognitive 
impairment in patients with CHD within the first 2-3 years, with motor impairment being more 
pronounced in the first year (Tabbutt, Gaynor and Newburger, 2012). As children grow older a 
wider range of neurodevelopmental impairments, including poorer visual-motor skills, 
language, fine motor function and social maladjustment, are reported in school aged children 
and adolescents (Wray, 2006; Snookes et al, 2010). These findings could be explained by the 
fact that, with increasing age children may be confronted with more complex demands requiring 
a wider range of functions to be exercised. These more complex cognitive functions may not be 
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assessed in the formative years, making long-term follow up of these children critical 
(Martinez-Biarge et al, 2013). Evidence related to specific cognitive functions is discussed 
below in more detail.  
 
3.4.2 Cognitive impairment in CHD 
There is extensive evidence regarding cognition and possible cognitive impairments in children 
with different forms of CHD. A number of systematic reviews and meta-analyses have 
attempted to synthesize this evidence (Karsdorp et al, 2007; Bellinger and Newburger, 2010; 
Miatton et al, 2006; Sterken et al, 2015; Latal, 2016). Evidence relating to IQ and some of the 
key domains of cognitive functioning affected in children with CHD are discussed below.  
 
3.4.2.1 Intelligence Quotient (IQ) 
The literature on IQ in children with CHD is inconsistent; some studies report IQ in CHD 
patients to be lower than a healthy normative or control group (Miatton et al, 2007; Wernovsky 
et al, 2000) while other studies report IQ in CHD patients as comparable to normative groups 
(Goldberg et al, 2000). Generally the literature on cognitive functioning in CHD patients reports 
IQ levels within the average IQ range, even when the scores are lower in comparison to the age 
matched normative/control group data (Bellinger et al, 2003; Krueger et al, 2015).  
 
3.4.2.2  Motor functioning  
Studies report motor impairment in children with CHD across a range of conditions, including 
SV, ToF and TGA (Marinez-Biarge et al, 2013; Sarajuuri et al, 2012). In a study assessing 
children with SV 21.4% of the sample exhibited impairment in visual-motor integration, which 
is the ability of the hands and eyes to function simultaneously in co-ordination (Uzark et al, 
1998). Similar findings were reported in another study, which reported 25% of children with 
different forms of CHD exhibiting impairment in motor function when compared to normative 
data, particularly in the areas of visual-motor integration and motor speed (Miatton et al, 
2007b).  
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Impairment of both gross and fine motor function have been observed in children with CHD 
when compared to normative data, with one study reporting 42% of children with CHD 
exhibiting gross motor impairment and 42% fine motor impairment (Limperopoulos et al, 
2002). The odds of motor impairment in children with CHD are reported as being three times 
higher for more structurally complex forms of CHD and two times higher for less structurally 
complex/Simple forms when compared to healthy controls (Brandlistuen et al, 2011).  
 
3.4.2.3 Attention  
Studies of children with CHD report impairments in some aspects of attention when compared 
to age matched normative data (Miatton et al, 2007a). A study assessing attention in school-
aged TGA patients reported impairments (using a measure of inattention), in comparison to age 
matched normative data, with response times (measure of how fast /slow information is 
processed and responded to) being 1Standard Deviation (SD) slower in TGA patients when 
compared to the normative group  (Bellinger et al, 2003).  
 
Hovels-Gurich et al, (2007) assessed children with VSD and ToF using the computerized 
Attention Network Test (Adólfsdóttir, Sorensen and Lundervold, 2008) which provided 
performance measures on three functions of attention; alerting (continuous performance and 
vigilance tasks that require different levels of alertness), orienting (tasks requiring directing 
attention to a cued location) and executive control (tasks involving cognitive conflict i.e. two 
simultaneously competing tasks).  ToF patients performed worse on the function of executive 
control in comparison to children with VSD and a healthy control group; the other two 
functions, including alerting and orienting, were reported to be normal in comparison to the 
control group, and performance did not differ between the groups (Hovels-Gurich et al, 2007). 
These results showed impaired attention (executive control) in patients with more complex 
forms of CHD in comparison to less complex conditions and control groups.  
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3.4.2.4 Memory  
Evidence with regards to memory in CHD patients is inconclusive, as some studies of children 
with CHD show impairments in memory when compared to normal healthy controls, while 
others do not show any differences. A study investigating cognitive functioning in school-aged 
children with surgically corrected CHD, reported impairment in memory when compared to 
healthy controls, particularly with regards to memory for names i.e. recalling correct name 
associated with faces and learning (Miatton et al, 2007a).  
 
On the contrary other studies have reported memory function in children with CHD (TGA, and 
ToF) to be within the normal range when compared to healthy controls (Miatton et al, 2006). A 
study assessing memory in children with different forms of CHD (such as SV, TGA, ToF, ASD, 
CoA) who have undergone cardiac surgery, reported memory function in the areas of picture 
memory, design memory, verbal memory and story memory as being within the normal range 
(Forbess et al, 2002). However the only exception reported in the study conducted by Forbess 
and colleagues was that patients with SV conditions performed below average on the picture 
memory test (Forbess et al, 2002).  
 
3.4.2.5 Executive functioning  
Relatively few studies have focused on assessing executive functioning in patients with CHD 
(Bellinger and Newburger, 2010). Amongst the studies that have, executive function is reported 
as being impaired in children with CHD. The Boston Circulatory Arrest Trial reported cognitive 
impairments in children with TGA that are collectively indicative of problems in executive 
functioning, which may affect the ability to organize and implement strategies and plans 
(Bellinger et al, 2003). School aged children diagnosed with ToF have been reported to perform 
lower on executive functioning tasks, in comparison to healthy peers (Miatton et al, 2007b).  
 
More recently the occurrence of impaired executive functioning in a group of CHD patients 
with structurally complex forms of CHD (SV, TGA, & ToF) was found to be approximately 
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twice as high (75-81%) as healthy controls (43%) (Cassidy et al, 2015). All CHD groups in the 
Cassidy study showed impairment in the areas of cognitive flexibility, problem solving and 
verbally mediated executive functioning, while the SV and ToF groups also demonstrated 
impairment in visuo-spatially mediated executive functioning skills (Cassidy et al, 2015).   
 
3.5 Cognitive impairment and the structural complexity of CHD  
Literature on cognitive functioning in CHD generally reports that patients with more 
structurally complex forms of CHD exhibit greater cognitive impairment, in comparison to less 
structurally complex forms of CHD (Bellinger et al, 2003) (See Table 1.1 for the structural 
complexity classification used within this thesis). A meta-analysis of the literature on cognitive 
functioning in children and adolescents with CHD reported that patients with structurally 
complex conditions such as SV (HLHS), and TGA demonstrated impaired cognitive functioning 
when compared to normative data and control groups (Karsdorp et al, 2007); while those with 
less structurally complex conditions such as ASD and VSD demonstrated cognitive functioning 
within the normative range (Karsdorp et al, 2007). Similarly, with regards to IQ, more 
structurally complex forms of CHD exhibited both, impaired verbal and performance IQ when 
compared to normative data (Karsdorp et al, 2007).  
 
A possible explanation for these findings is that complex forms of CHD are generally cyanotic 
in nature; and those with cyanotic conditions are at an increased risk of cognitive impairment 
compared to those with acyanotic conditions (Nass and Frank, 2010). Cyanotic conditions are 
characterized by low levels of oxygen in the blood, and this lack of oxygen supply may have 
detrimental effects for the brain causing impairments in cognitive functioning (Bass et al, 2004). 
Furthermore as seen in Section 3.3.2, the treatment techniques such as surgery associated with 
structurally complex forms of CHD may cause brain damage, which may in turn cause 
cognitive impairment (Kinney et al, 2005). Additionally patients with structurally complex 
forms of CHD are more likely to undergo multiple surgical procedures to correct their heart 
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defect, which increases their risk for brain damage and cognitive impairment in comparison to 
less complex forms of CHD.  
 
3.6 Discussion    
Both structural and functional impairments of the brain occur in children with CHD, with brain 
damage and cognitive impairment being common long-term complications (Newburger and 
Bellinger, 2006). While there is extensive empirical evidence regarding cognitive impairment in 
children with CHD, some caution is warranted when drawing conclusions. There is a large 
amount of variability in the findings across the literature with inconclusive results regarding the 
presence of impairment in some domains such as executive function and IQ; with studies 
reporting both poorer and similar performance in CHD patients when compared to the 
normative data and control groups. This variability could be attributed to the different measures 
used to assess these domains across the studies. Furthermore there are considerable differences 
in sampling across studies with some studies focusing on a single diagnosis while others include 
a more heterogeneous group of CHD patients.  
 
Furthermore drawing comparisons between studies is challenging as the majority of the 
paediatric literature involves samples ranging from 4-18 years of age. This wide age-range 
makes drawing comparisons and inferences across studies challenging, given the difference in 
measures used to assess cognitive functioning in the different age groups.  
 
There is also variability in the studies discussed with regards to the comparator group used to 
compare performance with the normal population; with some studies using established 
normative data and others a study control group. Each of these factors could potentially explain 
the differences in the results. Future studies may benefit from establishing a gold standard with 
regards to the assessment and measurement of cognitive functioning in patients with CHD, to 
enable drawing comparisons across the literature.  
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Lastly, the extrapolation from studies of cognitive impairment in children with CHD to the 
current era of CHD patients is challenging and perhaps inaccurate, due to the on-going advent 
and improvements in anesthetics, prenatal diagnosis, treatment techniques, and post-operative 
care; as the outcomes of patients born in the current era are likely to be very different from, and 
perhaps better than, the previous generation.  
 
3.7 Conclusions  
Despite the extensive evidence of cognitive impairment amongst infants and children with 
CHD; drawing conclusions regarding the long-term trajectory of these impairments is 
challenging in the absence of longitudinal data. The cross-sectional nature of these studies limits 
the ability to determine whether the performances observed persist over time and development, 
or whether children with CHD do at some time point catch up with their peers, albeit somewhat 
later in their development. Studies assessing adult CHD patients could help determine if these 
impairments indicate a delay in the development of functional abilities that will eventually 
develop to their full capacity, or are they in fact deficits that will not improve and persist well 
into adulthood. In order to address this issue the next chapter reviews the available evidence on 
cognitive functioning in the adult CHD population. 
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4 EXTENT OF COGNITIVE IMPAIRMENT IN ADULT 
CONGENITAL HEART DISEASE (ACHD) – A 
SYSTEMATIC REVIEW  
 
4.1 Prologue  
In Chapter 3 the relationship between the brain and the heart was introduced and evidence 
regarding neurodevelopmental and cognitive impairment in infants and children with CHD was 
presented. This chapter presents the findings of a systematic review of studies that have 
examined cognitive functioning specifically in ACHD patients, which is the main focus of this 
thesis. The chapter begins by detailing the focus, aims and objectives of the review followed by 
the methodology adopted. Thereafter the main findings of the review are presented and 
discussed.  
 
4.2 Background  
Given the increase in survival rates of CHD patients, there has been a shift in the focus from 
morbidity and mortality onto long-term functional abilities and outcomes such as their 
emotional health and wellbeing, cognitive functioning and Quality of Life (QoL). While there 
are a number of systematic reviews and meta-analyses that have aimed to synthesise the 
evidence on cognitive functioning in the paediatric CHD population (Sterken et al, 2015; 
Karsdorp et al, 2007), the literature on cognitive functioning in ACHD patients has not had such 
an extensive examination.  
 
As discussed in Chapter 3, children with CHD exhibit a wide range of cognitive impairments in 
domains such as executive function, attention and motor function. However, given the lack of 
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longitudinal data the child literature does not allow any conclusions to be drawn regarding the 
persistence or not of these impairments. Therefore, it is difficult to determine whether the 
impairments seen in childhood, are delays in development that will eventually recover to within 
the normal range or if they are more permanent cognitive deficits that persist into adulthood. In 
order to address this question, cognitive functioning in the ACHD population needs to be 
assessed.  
 
This systematic literature review aims to summarize and synthesize the existing empirical 
evidence on cognitive functioning in ACHD patients. 
 
4.3 Aims of the systematic review   
The primary focus of this review was on cognitive functioning in ACHD patients; therefore 
studies assessing only the paediatric CHD population were not included. The specific aims of 
the review were:   
i) To examine the evidence on the extent and nature of cognitive impairment in 
ACHD, including the areas of cognitive functioning most affected.  
ii) To identify factors which may influence and/or impact cognitive functioning in 
ACHD patients  
 
4.4 Methodology  
In accordance with the reporting guidelines for systematic reviews, a Preferred Reporting Items 
for Systematic reviews and Meta- Analyses (PRISMA) checklist was used and can be found in 
Appendix-A (Moher et al, 2009). According to the PRISMA checklist a systematic review of 
the literature must consist of certain methodological aspects such as a literature search strategy, 
information sources, eligibility inclusion and exclusion criteria, literature selection processes, a 
flow chart, study quality assessment and the analysis and synthesis of the evidence.  
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4.4.1 Literature search strategy 
The electronic databases listed below were searched in 2011 and a literature review was 
published (Tyagi et al, 2013- See Appendix-B). In 2016 an updated systematic review was 
conducted for the purpose of this thesis. All databases were searched from inception through to 
August 2016. Furthermore a bibliographic search of the relevant articles was conducted to 
identify any additional articles for inclusion.  
 
Databases searched via the OVID interface  
 Embase (1974 – August 2016) 
 Amed (1985 – August 2016) 
 Cochrane database for systematic reviews (2005 – August 2016)  
Databases searched via the EBSCOHost interface  
 Psychinfo (1806 – August 2016) 
 Medline (1948 – August 2016) 
 Cinhal (1937 – August 2016) 
Databases searched from other Sources  
 Web of Science (1970 – August 2016) 
 Google scholar (2004 – August 2016) 
 
The literature searches were conducted using both key word and subject heading searches (e.g. 
MESH terms). The key words used to search all databases were (“Cogniti* “ OR 
“neuropsycholog*” OR “neurocogniti*” OR “intelligence” OR “IQ”) AND (“adult” OR 
“grown-up”) AND (“congenital heart*” OR “congenital heart disease” OR “congenital heart 
defect”). The subject headings identified varied based on the database being reviewed; the 
detailed search strategy for each database is presented in Appendix-C and an example of the full 
electronic search for one database is presented in Appendix-D.  
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4.4.2 Inclusion and exclusion criteria for articles included in the systematic review 
Given the limited number of studies assessing cognitive functioning in ACHD patients, the 
inclusion and exclusion criteria for the systematic review were deliberately not stringent, with 
the aim of being as inclusive as possible. The specific criteria applied within the review are 
discussed below. 
 
4.4.2.1 Publication type  
Articles were included only if they were written in English language, and published in an 
academic peer reviewed journal.  
 
4.4.2.2 Study design and purpose  
Articles were only included if they utilized a quantitative methodology to assess cognitive 
functioning in ACHD; including both cross-sectional and longitudinal study designs. 
Qualitative studies, literature reviews, meta-analyses and commentaries were excluded. Studies 
were included if their purpose was to i) assess the extent of cognitive impairment in ACHD 
patients, ii) assess the association of disease complexity with cognitive functioning in ACHD 
iii) identify predictors of cognitive functioning in ACHD.  
 
4.4.2.3 Measures and outcomes  
Only articles that assessed cognitive functioning as a primary outcome variable were included. 
Studies that only considered cognitive function, as a confounding variable and/or predictor 
variable were not included. Studies that included an objective assessment of cognitive 
functioning using an established and validated neuropsychological assessment tool were 
included. Articles were excluded if they assessed cognitive function using observational ratings 
and/or only recorded the participant’s subjective reports of cognitive functioning in the absence 
of an objective evaluation of their cognitive abilities. 
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4.4.2.4 Participants   
Only articles with an adult congenital heart disease sample were included, ACHD patients were 
defined as those ≥18 of age for the purpose of this review. Articles that only included patients 
≤18 years of age were considered to be paediatric literature and were therefore not included. 
However articles that had both children (≤18 yrs) and adults (≥18 yrs) were included and 
reviewed with the aim of being as inclusive as possible.  
 
Articles that only assessed patients with chromosomal abnormalities such as Williams’s 
syndrome, Noonan syndrome and 22q11 syndrome, where CHD could be considered a 
secondary diagnosis were excluded. The presence of such chromosomal abnormalities has been 
associated with impaired cognitive functioning (Lott and Dierssen, 2010), which may obscure 
the association between congenital heart disease and the cognitive outcomes, which was the 
primary focus of this review. Therefore only studies that include a sample with CHD as a 
primary diagnosis were included in this review. 
 
4.4.3 Systematic review procedure  
4.4.3.1 Initial assessment of article relevance  
The titles of all identified articles were assessed for relevance to the systematic review. Those 
that were not related to the research question and/or did not meet the inclusion and exclusion 
criteria were rejected at this stage and the reasons for exclusion were recorded. In instances 
where the article relevance was unclear based on the title alone, the article abstracts were 
reviewed. Abstracts of articles with relevant titles were then reviewed and assessed using the 
review inclusion and exclusion criteria. Any uncertainties regarding the inclusion of an article 
based on the abstract were resolved in liaison with a member of the supervisory team. Reasons 
for exclusion after reviewing article abstracts were recorded and are presented in Figure 4.1 
(below). Full texts of all articles with relevant abstracts were then reviewed. Lastly a 
bibliographic search of relevant articles was also conducted, in order to identify potential 
articles for inclusion in the systematic review. 
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4.4.3.2 Analysis of selected articles  
This review did not include a quantitative meta-analysis of the evidence. A narrative synthesis 
of the data was planned and considered more appropriate given the small number of studies, and 
the heterogeneity of the measures and samples used across the studies. To enable a systematic 
synthesis of the data the characteristics and results of the studies included were tabulated in 
Table 4.1. 
  
4.4.3.3 Data extraction and synthesis  
A data extraction form was designed to extract key information from the articles included in the 
systematic review. The data extraction form recorded general article information (title, authors 
and source of article), sample characteristics (sample size, inclusion and exclusion criteria, 
control/normative group, structural complexity groups), study characteristics (aims, design, 
measures used, cognitive impairment criteria used, analysis conducted) and the main findings 
and conclusions for each study (See Appendix-E).  
 
The findings of the included studies are discussed under three broad areas, with aim of 
synthesising the literature: i) measurement of cognitive functioning, detailing the range of 
measures used across the studies included, ii) the extent of cognitive impairment in ACHD, 
detailing the results of the cognitive tests and the performance of ACHD patients in comparison 
to normative/control group data and iii) factors that may influence and/or impact cognitive 
functioning in ACHD, detailing any evidence on factors that may have an association with 
cognitive functioning. 
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Figure 4.1 The study selection process for the systematic review search (2016) 
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4.4.3.4 Quality assessment 
A quality assessment tool developed by Downs and Black (1998) was chosen to evaluate the 
methodological quality of the studies included in this systematic review. This quality 
assessment tool was chosen as it is designed for use with both randomized control trials (RCT) 
and observational studies. Furthermore it provides a total cumulative score for study quality, 
which enables comparison across studies. It includes 4 areas of assessment including: i) 
reporting, ii) external validity, iii) internal validity (both control of bias and confounding), and 
iv) power. 
 
Given the nature of the research question, no RCT’s were included in the review, consequently 
some of the items in the measure were not considered relevant. Following other studies that 
amended the measure to better fit their research (Hignett, Otter and Keen, 2016) the items 
pertinent to RCT’s were excluded from the measure (e.g. was an attempt made to blind study 
subjects to the intervention they received?) and some items were adapted to better fit this area of 
research (e.g. “are interventions of interest clearly defined?” was replaced with “was the criteria 
for cognitive impairment clearly defined?”). The method for scoring was kept consistent to the 
original measure. All items on the scale were given a score of 2 (yes), 1 (partially) or 0 
(no/unable to determine).  The highest score possible for the quality assessment was 38, with a 
higher score representing better quality (Appendix-F). 
  
4.5 Results of the systematic review 
4.5.1 Identified papers  
Using the search strategy detailed in Appendix-C a total of 552 articles were retrieved. Figure 
4.1 illustrates the number of articles identified at each stage. The titles of each one of these 
articles was assessed and after rejecting papers based on title relevance a total of 87 articles 
remained. The abstracts of these remaining 87 articles were assessed and after exclusion a total 
80 
 
of 19 articles remained. The full-texts of the remaining articles were examined in detail for 
inclusion in the systematic review.  
 
A total of 8 articles were finally included in the systematic review. Seven articles were 
identified from the literature searches, and one from the bibliography search. Two of the studies 
included were based on the same sample (Utens et al 1994; 1998). Utens et al (1998) only 
included a subset (19-25 year olds) of the original participants. Within the systematic review 
both these studies were included and treated separately with the aim of being as inclusive as 
possible, given the dearth of literature assessing cognitive functioning in ACHD.   
 
4.5.2 Characteristics of the studies included in the systematic review 
The characteristics of all the studies included in the systematic review are presented in Table 4.1 
(page no. 82). All included studies (8/8) were cross-sectional in design and assessed cognitive 
functioning as a main outcome measure. Across the 8 studies a total of 1023 patients with CHD 
were assessed. The majority of the patients included across the studies were male (N=645 
63.05%). Seven out of the eight studies included both males and females, with the exception of 
Eide et al, (2006), which included only male participants. The articles included were published 
between the years 1994 and 2015. Majority of the studies (6/8) were conducted in Europe, and 
the other two in the United States of America (2/8).  
 
4.5.3 Quality assessment of studies included in the systematic review  
The results of the quality assessment undertaken (Downs and Blacks, 1998) showed that the 
reviewed studies varied considerable with regards to the methodological quality (mean score 
=27/38; range of scores= 21-32), with higher scores indicating superior quality.  
 
The most common issues related to study quality were the exclusion of critical information 
about recruitment procedures. Details about the recruitment procedures and how patients were 
invited and why certain patients declined were not presented (Utens et al, 1994). Further, some 
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studies did not report the sample size calculations and discuss the statistical power of the study 
(Utens et al, 1994; Heinrichs et al, 2014). Some studies did not describe the patient 
characteristics clearly (e.g. gender), which made it challenging to evaluate the 
representativeness of their study sample (Wernovsky et al, 2000).  
 
With regards to the reporting of results, some studies failed to include the exact values and 
proportions and only provided approximations of the results for instance up to 10% of the 
patients experienced impairment in the domain of memory (Daliento et al, 2005). The lack of 
exact results made it difficult to draw conclusions regarding the magnitude of the problem 
observed within these studies. Furthermore, some studies included both children and adults in 
their study sample but combined the results of the different age groups and did not provide 
specific results for each age groups, which did not enable any conclusions to be drawn with 
regards to the adult population included in the study (Wernovsky et al, 2000). It also made it 
difficult to determine whether it was the performance of the child, adult or both groups of 
patients that led to the impaired scores. Overall given the lack of critical information and 
fundamental results and statistics, the majority of the identified studies scored low on the 
quality assessment measure with most studies ranging from poor to moderate quality.  
 
4.5.4 Measures of cognitive functioning 
The studies reviewed showed the most common form of cognitive assessment (7/8 studies) was 
the use of IQ tests, although there was considerable variability with regards to the measures 
utilized to assess IQ across the studies. Six out of the eight studies assessed IQ as the only 
measure of cognitive functioning. Two studies assessed domains of cognitive functioning 
beyond IQ and included the assessment of cognitive speed, executive functioning, memory, 
attention and language (Idorn et al, 2013; Daliento et al, 2005). Specific measures used in each 
study are detailed in Table 4.1 below.  
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Table 4.1 Details of studies included in the systematic review 
Study author Sample size and 
sample 
characteristics 
Study 
design 
Normative 
data used 
for NP 
comparison 
Structural 
complexity 
groups 
included (N) 
NP Measures used to 
assess cognitive function 
Key findings Quality 
score  
Utens et al, 
(1994)* 
N: 288 
Mean age: 22.7 (18-
35)     
Gender: M=147, 
F=141 
 
Cross-
sectional 
Normed 
population 
data 
Simple 
(ASD=91, 
VSD=67), 
TOF=52, 
TGA=15,PS=2
9, Other 
unspecified= 
35  
Groninger Intelligence Test 
(GIT) short form 
Subtests:: 
i)Visualisation 
ii)Verbal 
induction/deduction 
iii)Numbers 
Patients had higher IQ 
than normative data 
(Mean IQ=105.5 vs. 
100.0)  
17% scored <86 
indicating borderline 
mental functioning 
24 
 
Utens et al, 
(1998)* 
 
 
Total N: 166, final 
included in 
analysis=146 
Mean age: 21.7 (19-
25)  
Gender: M=84, 
F=82 
 
 
Cross-
sectional 
(Sample 
from 
Utens et 
al, 1994) 
 
Not available 
 
Simple 
(ASD=50, 
VSD=40, 
PS=15), 
TOF=28, 
TGA=13  
 
GIT short form 
 
 
Patients had higher IQ 
than normative data 
(Mean IQ=105 vs. 100.0)  
12.7% scored <86 
indicating borderline 
mental functioning 
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Study author Sample size and 
sample 
characteristics 
Study 
design 
Normative 
data used 
for NP 
comparison 
Structural 
complexity 
groups 
included  
NP Measures used Key findings Quality 
score 
 
Wernovsky et 
al, (2000) 
 
N: 133 
Mean age: 14.1 ±8.8 
(3.7-41.0) 
Gender: M=73, 
F=60 
 
Cross-
sectional 
 
Normed 
population 
data 
 
LV-TGA, SV 
(HLHS, 
Fontan LV- 
NRGA, 
Heterotaxy)
a
  
 
Age appropriate IQ test: 
Wechsler Preschool and 
Primary Scale of 
Intelligence Revised. 
Wechsler Intelligence Scale 
for Children – Third 
Edition 
Wechsler Adult 
Intelligence 
 
 
Patients had lower IQ 
than normative data 
(Mean IQ=95.7 ±17.4) 
7.8% participants scored 
>2SD below normative 
data  
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Daliento et al, 
(2005) 
N: 54 
Mean age: 32 
Gender: M=24, 
F=30 
 
Cross-
sectional 
Control group TOF= 54 Cognitive measures: 
i) Tower of London 
ii) Raven Progressive iii) 
Matrices 
iv) Trail making test A and 
B 
v) Calculation 
vi) Verbal fluency 
vii) Attentive Matrices 
viii) Digit Span 
ix) Logical story 
x) Corsi Blocks 
xi) Paired Associate 
learning 
More than 2/3 of the 
sample had IQ scores in 
the normal range.  
Small proportion had 
impaired memory (0-
10%)attention (10-20%) 
and learning (0-10%) and 
a larger proportion had 
impaired executive 
functioning (up to 53% on 
tower of London test) 
22 
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Study author Sample size and 
sample 
characteristics 
Study 
design 
Normative 
data used for 
NP 
comparison 
Structural 
complexity 
groups 
included (N) 
NP Measures used Key findings Quality 
score 
 
Eide et al, 
(2006) 
 
N: 166 (heart 
defect patients) 
Mean age: 18.7 
Gender: M=166 
(only males 
included) 
 
 
Cross-
sectional 
 
384 healthy 
army recruits 
 
 
 
TGA=2, Simple 
(dextrocardia=6, 
VSD/ASD =17) 
Unspecified 
cyanotic 
patients=141 
 
Validated IQ test designed 
for the Norwegian draft 
board in 1953. 
Sub scales: 
i) Verbal analogues 
ii) Number series 
(calculation) 
iii) Geometrical figures 
(abbreviated version) 
 
 
 
Patients had lower IQ  
scores in comparison to 
normative data  
(Mean ‘stanine’ IQ score 
(i.e. 1-9)= 5.30) 
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Idorn et al, 
(2013) 
N=158 
Median age = 13.9 
(IQR=10.2-19.3) 
Gender: M=93, 
F=65 
Cross-
sectional 
Control group AVSD=15 
DILV=39 
HLHS=12 
PA-IVS=12 
TA=43 
Other 
unspecified 
Fontan 
patients=37  
A quick test of cognitive 
speed (AQT)  
Subtests  
i) Colour  
ii) Form  
iii) Colour-form  
 
The adult patients 
included in the study 
performed lower in 
comparison to the control 
group on all three tests 
included in the AQT: 
colour (p<0.001), form 
(p<0.001) and colour-
form (p<0.001).  
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Study author Sample size and 
sample 
characteristics 
Study 
design 
Normative 
data used for 
NP 
comparison 
Structural 
complexity 
groups 
included  
NP Measures used Key findings Quality 
score 
Heinrichs et al, 
(2014) 
N: 60  
Mean age: 16.9 ± 
1.7 (14- 21.1) 
Gender: M=47,  
F= 13 
 
Cross-
sectional  
Normed 
population 
data 
TGA=74%, 
Simple 
(VSD=18%, 
VSD closed 
during Atrial 
switch 
operation=5%)C
oA corrected in 
infancy=3% 
Hamburg-Wechsler 
intelligence test (German 
version of the Wechsler 
Adult Intelligence Scale, 
revised) 
Subscales (6/11)  
i) Information 
ii) Arithmetic 
iii) Similarities 
iv) Vocabulary 
v) Picture completion 
vi) Block design 
vii) Leistungsprufsytem 
nach Horn test 
Patients had higher IQ 
scores than normative 
data (FSIQ=106.7 vs. 
100.0). 
9% and 5% scored 1 and 
2 SD below the mean on 
FSIQ 
28 
Murphy et al, 
(2015) 
N= 18 (case and 
sibling pairs) 
Mean age: 
16.1(SD=3.5) 
Gender: M=11, F=7  
Cross-
sectional 
Sibling 
controls and 
normed 
population 
data  
ToF=12, 
TGA=6  
Wechsler Intelligence Scale 
for Children – Fourth 
Edition 
Wechsler Adult 
Intelligence Scale – Fourth 
Edition 
Patients scored lower than 
their siblings and 
normative data on the 
FSIQ (p<0.05), and 
Processing Speed Index 
(p<0.05) and Perceptual 
Reasoning Index (p<0.05)  
 
32 
Note- *Studies using the same sample,  a= exact proportion of patients in each structural complexity group unspecified, AVSD-Atrioventriclar Septal Defect, DILV- Double Inlet Left Ventricle, PA-
IVS-pulmonary atresia with intact ventricular septum, TA- tricuspid atresia 
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Two of the articles included in the systematic review (Utens et al, 1994, 1998) examined IQ 
using the Groninger Intelligence Test (Luteijn and Van der Ploeg, 1983), a standardized Dutch 
measure of IQ; the short version of the test assessed three sub-tests; verbal induction/deduction, 
numbers and visualization. Normative reference group scores were used for the purpose of 
comparison with the general population.  
 
In total 4/8 studies included both children and adults in their study cohort. Two of the four 
studies used age specific measures to assess IQ in the different age groups (See Table 4.1 above 
for details of measures used). The Wechsler Adult Intelligence scale –Revised (WAIS-R) was 
used for those >17 years of age (Wechsler, 1981) in the study conducted by Wernovsky et al, 
(2000) and the Wechsler Adult Intelligence scale – Fourth Edition (Weschsler, 2008) was used 
to assess IQ by Murphy et al, (2015). The other two studies utilized a single measure to assess 
all age groups. One study used the Hamburg-Wechsler intelligence test (Tewes, 1994) (German 
version of the Wechsler Adult Intelligence Scale, revised) (Heinrichs et al, 2014) and another 
used A Quick Test of cognitive speed (AQT) (Wiig et al, 2002) to assess cognitive speed (Idorn 
et al, 2013). The AQT involves three subtests: colour, form and colour form. The colour and 
form subtests assess perceptual speed and the colour-form test assesses cognitive speed, along 
with some aspects of executive functioning including the ability to shift sets (i.e. shift attention 
from one task to the other) and working memory.  All four studies utilized normative data or 
control groups for the purposes of comparison to the normal population. 
 
Eide et al, (2006) utilized a measure of general IQ performance that was designed and 
developed in 1953 for the Norwegian military draft board and was revised in 1962. It is a timed 
test involving categories of items; verbal analogue, number series (calculation) and geometrical 
figures (an abbreviated version of the Ravens Progressive Matrices) (Sundet et al, 1988; Raven, 
Raven and De Lemos, 1990). The test comprises 120 questions with increasing levels of 
difficulty. The measure is highly correlated with the well-established Wechsler Adult 
Intelligence Scale (r=0.73) (Sundet et al, 1988). This study utilized a group of healthy army 
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recruits as a control group to compare the performance of the patient group to the normal 
population.  
 
In contrast to the studies discussed above, Daliento et al, (2005) utilized a range of measures to 
assess different domains of cognitive functioning using specific neuropsychological tests; Trail 
Making Tests (Reitan, 1958) to evaluate motor speed, attention and switching ability, the digit 
span subtest of the Wechsler Memory Scale to measure the span of immediate verbal recall 
(Wechsler, 1974). Verbal memory and learning was assessed using the verbal paired associates 
test (Wechsler, 1987) (from the revised edition of the Wechsler memory scale). The Corsi block 
test (Milner, 1971) was used to assess orientation and spatial attention, while the Attentive 
matrices test (Spinnler and Tognoni, 1987) was used to assess selective and sustained attention. 
Lastly, the Calculation test (arithmetic abilities) (Basso, 1979), the Tower of London test 
(Shallice, 1982) and the Ravens progressive matrices test (Raven, 1978) were used to assess 
executive function. The Ravens progressive matrices test also provided a measure of the 
patients’ IQ. The patient data was compared to the scores of a reference control group to enable 
comparison with the general population.  
 
Overall a wide range of measures was used across the different studies to assess cognitive 
functioning. This variability in choice of measures increases the difficulty in drawing 
comparisons across studies. The specific results and impairments identified within these studies 
are discussed in the following section and a summary is presented in Table 4.1 (page no. 82). 
 
4.5.5 The extent of cognitive impairment in ACHD 
The results of the reviewed studies showed mixed findings with regards to IQ in adults with 
CHD. Some studies reported IQ in ACHD patients as being higher in comparison to the 
normative/control group data. Utens et al, (1994) reported the level of IQ in their cohort as 
being higher (IQ= 105.5) than that of the normative group (Normative data mean IQ on the GIT; 
IQ=100), however the exact proportion of participants scoring above the normative mean was 
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not reported. Of the total sample the authors reported 17% of patients with borderline mental 
functioning classified by a score lower than 86 on the IQ test. The authors also reported 
including some patients with chromosomal anomalies such as Down’s syndrome (N=1), 
Marfan's syndrome (N=1), and Reifenstein's syndrome (N=1). The interpretation of the findings 
in this study is complicated by the large amount of missing data (> 15%) and the inclusion of 
patients with intellectual disability (i.e. IQ<86) and chromosomal abnormalities. 
 
Utens et al, (1998) utilized the same sample as Utens et al, (1994) but only included the 19-25 
year olds from the sample (N=166, mean age=21.7 yrs). The mean IQ score of the sample was 
105 (SD=15). As with the full sample a similar proportion of participants (12.7%) showed 
borderline mental functioning with low IQ levels (<70-85). The authors reported that normative 
data for the IQ scores were not available for comparison within their study, although no reasons 
were reported (Utens et al, 1998). However, they presumed that since a normative group would 
consist of the general normal population its scores should be normally distributed (i.e. IQ=100, 
SD=15). Based on this assumption the authors concluded that the results of their ACHD sample 
(IQ=105) were more ‘favourable’ (as stated by the author) as compared to a healthy normative 
group.  
 
With regards to the level of cognitive performance in the different structural complexity groups, 
a significant difference in IQ (p=<0.01) was reported (Utens et al, 1998). The authors concluded 
that patients with more structurally complex conditions such as TGA (IQ=96) and ToF (IQ=96) 
exhibited the lowest level of IQ in comparison to the less structurally complex conditions such 
as ASD (IQ=107), VSD (IQ=106) and Pulmonary Stenosis (IQ=113). However when 
interpreting the results of both studies conducted by Utens and colleagues some caution is 
warranted, due to the poor methodological quality of these studies, including problems such as 
the high level of missing data and small cell sizes, inclusion of participants with intellectual 
disability and chromosomal anomalies, and the lack of established normative data for the 
purpose of comparison. Although the higher IQ reported in this study seems contrary to 
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expectation, given the inclusion of patients with intellectual disability chromosomal anomalies, 
it could perhaps be explained by the fact that a very small number of these patients were 
included in this study, which may not have been enough to affect the overall results. 
 
Similar findings were reported more recently in the study conducted by Heinrichs et al, (2014), 
which found the average full-scale (106.7 ± 23.1), verbal (104.2 ± 22.6) and performance (105.4 
± 27.5) IQ in adolescent and adult TGA patients as being higher in comparison to the normative 
data (100 ± 15) (Heinrichs et al, 2014). With regards to the proportion of patients scoring 1 and 
2 SD below the mean, the authors reported 9% and 5% for full scale IQ, 9% and 2% for verbal 
IQ and 14% and 11% for performance IQ respectively (Heinrichs et al, 2014). It must be noted 
that the study conducted by Heinrichs et al, (2014) did not have the same methodological 
problems reported by Utens and colleagues, such as large amounts of missing data and lack of 
normative data for comparison.  
 
Contrary to the findings of Utens et al, (1994; 1998) and Heinrichs et al, (2014), other studies 
reported IQ scores in ACHD patients as being lower in comparison to normative data. 
Wernovsky et al, (2000) assessed cognitive functioning specifically in patients who underwent 
the Fontan operation. They assessed cognitive functioning in their cohort based on different age 
groups (<6yrs, 6-16yrs, >17yrs). Patients >17 years of age scored 95.7± 17.4 on the full scale 
IQ, 94.3± 14.2 on the verbal IQ, and 99.7± 16.0 on performance IQ respectively. However, the 
findings showed no significant differences in the IQ scores of the different age groups (Full-
scale p=0.7, verbal p=0.2, and performance p= 0.2). In the absence of any significant 
differences in the mean full scale IQ, the authors combined the scores of the different age 
groups to achieve a single score. This combined score was then used for all further analyses.  
 
The mean IQ of the combined age groups was 95.7±17.4, which was significantly lower than 
that of the published normative data for the WAIS test used (p=0.006). Of the total sample 7.8% 
scored <70 (i.e. more than 2 standard deviations (SD) below the normative mean of 100) on the 
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full scale IQ. Furthermore 6.3% and 8.5% of participants scored <70 on the verbal and 
performance IQ scores respectively. While the majority of the patients scored within the normal 
range, the cohort performed lower in comparison to the normative data (Wernovsky et al, 2000). 
However, the author’s treatment of the data by combining scores for the different age groups 
makes it difficult to independently assess the performance of the adult patients in their cohort 
without the influence of the other age groups. This makes drawing specific conclusions 
difficult; as it remains unclear as to whether it is the scores of the children or the adults that are 
below the normative mean, in turn pulling down the average of the entire study sample.   
 
Similar to the findings of Wernovsky and colleagues, Eide et al, (2006) also reported that 
patients CHD had lower IQ compared to a healthy control group. Eide et al, (2006) recruited 
only male participants in their study with a range of birth defects such as cleft pallet, cleft lip 
and CHD. Only the results of the CHD subgroup from this study are discussed in this systematic 
review. The authors reported significantly lower levels of IQ (p=0.007) in CHD patients when 
compared to the control group even after controlling for confounding factors such as birth order, 
maternal age, maternal education and marital status. Furthermore, the authors reported that 
patients with multiple heart defects did not exhibit any additional cognitive impairments in 
comparison to those with a single heart defect (p=0.7); to some extent these findings could be 
considered contrary to those of Utens et al, (1998) as having multiple heart defects could be 
considered more complex in comparison to a single heart defect.  
 
Another study reported similar findings in adolescent and adult patients with TGA and ToF, 
with lower IQ in the areas of Verbal Comprehension (VCI), Working Memory (WMI), 
Processing Speed (PSI), Perceptual Reasoning (PRI) and Full Scale IQ (FSIQ) as measured by 
the WAIS- 4
th
 edition; when compared to their sibling controls (matched by age and gender) and 
normative data (Murphy et al, 2015). Patients with CHD consistently scored lower than their 
siblings on all indexes, with scores being significantly lower on the FSIQ (p<0.05), and PSI 
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(p<0.05). Similarly, when compared to normative data CHD patients scored lower on all IQ 
indexes with significant differences on PRI (p<0.05).  
 
In contrast to the other studies Daliento et al, (2005) conducted a more comprehensive cognitive 
assessment, examining several cognitive domains using neuropsychological tests, in a group of 
ToF patients. The authors report IQ scores within the normal range for majority (> ⅔) their 
study sample; however other specific domains of cognitive functioning showed impairment. A 
small proportion of patients showed impairment in memory (between 0-10%), attention 
(between 10-20%) and learning (between 0-10%); however, the authors do not report the exact 
proportion of patients scoring below the normative data on these tests. A larger proportion of 
patients exhibited problems in executive function, problem solving, and planning strategies 
(Verbal fluency test, Ravens test, Trail making test A and B, Tower of London test). In 
particular 53% of patients were reported as experiencing difficulties in the Tower of London 
test, which requires planning abilities. These results suggest that ToF patients experienced more 
difficulty in dealing with complex situations and finding solutions to them when compared to a 
normative sample. The lack of information regarding the exact proportion (%) of participants 
with impairments on the domains of attention and memory restricts conclusions being drawn 
about the magnitude of the problem in these domains. 
 
Another study that assessed individual domains of cognitive functioning, reported impairment 
in cognitive and perceptual speed and executive functioning in patients with SV conditions 
(Idorn et al, 2013). ACHD patients performed poorer than the control group in all three subtests 
of the AQT, including the colour, form and colour-form. However, when interpreting the 
findings of this study some caution is warranted as the authors report severe cognitive 
impairment as one of the exclusion criteria within their study; which may have potentially 
resulted in a selection bias (i.e. not randomly selected) and suppressed the actual extent of 
impairment within this patient group.  
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Overall the results do not show a consistent pattern of impairment in IQ across the studies 
reviewed. While there is some indication of impairment in specific domains of cognitive 
functioning it is difficult to draw any conclusions based on a limited number of studies. 
Furthermore, given that the studies conducted by Daliento et al, (2005) and Idorn et al, (2013) 
only included patients diagnosed with ToF and SV respectively the findings may not be 
generalizable to ACHD patients as a group.  
 
4.5.6 Factors that may influence and/or impact cognitive functioning in ACHD 
Some of the studies examined in this systematic review showed the presence of cognitive 
impairment in ACHD patients. Five of the eight studies also examined possible factors that may 
influence and/or impact cognitive functioning. Of those, three studies reported an association 
between demographic factors and cognitive functioning. One study reported higher socio-
economic status (SES) as a strong predictor of higher IQ (p<0.001), with SES explaining 16.1% 
of the total variance in IQ (Wernovsky et al, 2000). Two studies reported that lower levels of 
education were associated with poor performance on the Trail Making Test (TMT A and B) of 
attention, and IQ respectively (Daliento et al, 2005; Eide et al, 2006). Furthermore, another 
study reported a positive association between maternal age and IQ, which implies that higher 
the maternal age at the time of birth the higher the IQ; and a negative association between 
marital status and IQ, with an unmarried status being associated with lower IQ (p<0.0005) (Eide 
et al, 2006). 
 
Three of the studies reviewed, reported an association between clinical variables and cognitive 
functioning. Wernovsky et al, (2000) reported a significant association between lower full scale 
IQ and the use of circulatory arrest before a Fontan operation (p=0.002), the use of circulatory 
arrest explained 6.1% of the variance in IQ. When the different structural complexity groups 
included in the study (TGA, SV, HLHS and “other complex conditions”) was added to the 
model, the condition Hypoplastic left heart syndrome (p <0.001) and the variable ‘other 
complex conditions’ were reported to be associated with full-scale IQ (p=0.05) (Wernovsky et 
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al, 2000). Further, the addition of the structural complexity groups to the model rendered 
circulatory arrest not significant in the analysis. These results could be explained by an overlap 
between the variables given that hypothermic arrest is often used as a support strategy in the 
treatment of HLHS and complex forms of CHD.  
 
A significant association between preoperative clinical factors (cyanosis), and cognitive 
functioning (executive functioning) has also been reported (Daliento et al, 2005). In particular 
ToF patients with a history of cyanosis in infancy performed poorly on the Trail Making Test 
(A and B) of attention and the Tower of London test of executive function (U = 104.00, p < 
0.005, and U = 184.00, p < 0.05, respectively).  
 
In another study neurological dysfunction (in patients with abnormal cranial nerves, motor 
dyspraxia, ataxia, sensory dysfunction, palsy, clinical seizures) was reported as being correlated 
with poor full scale (p=0.001), performance (p<0.0001) and verbal (p=0.15) IQ in patients with 
ACHD (Heinrichs et al, 2014). Furthermore, the authors also reported a significant correlation 
between reduced brain volume (measured through an MRI examination) and poor average full 
scale IQ in ACHD (p=0.009) (Heinrichs et al, 2014).  
 
The third study reported a significant correlation between cognitive functioning and 
psychosocial outcomes, reporting a medium but significant negative correlation between 
cognitive speed and QoL; suggesting that poorer cognitive speed was associated with poorer 
QoL in patients with ACHD (Idorn et al, 2013).  
 
These findings collectively suggest the role of both demographic and patient related clinical 
factors in influencing cognitive functioning in ACHD patients and the impact cognitive function 
may have on long-term outcomes such as QoL. However, the cross-sectional nature of these 3 
studies only suggests correlations between these variables, but do not allow determining 
causality. Further work is needed in order to explore a wider range of clinical, psychosocial, and 
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demographic factors and their impact on cognitive functioning, for instance the impact of 
different, surgical procedures, implications of hospitalization, anesthetics and gender. 
Longitudinal assessment of these factors would allow examination of the stability of cognitive 
functions and the underlying causality of these impairments to be established.  
 
4.6 Discussion  
Given the only recent increase in survival rate of CHD patients, the majority of the literature 
and research in CHD has focused on the paediatric population. Consequently, there is an 
understandable lack of evidence regarding cognitive functioning in ACHD. The literature 
review published in 2013 was the first to assess and synthesize the literature on cognitive 
functioning in ACHD (Tyagi et al, 2013). Both the published review and this updated 
systematic review found a limited number of studies in this area of research.  
 
The existing literature shows the presence of some cognitive impairment in patients with 
different forms of ACHD. The evidence with regards to IQ is inconclusive with some studies 
reporting IQ in the ACHD sample being lower than the normative data (Wernovsky et al, 2000; 
Murphy et al, 2015), while other studies reported IQ comparable to or better than the normative 
data (Utens et al, 1998; Heinrichs et al, 2014). Two studies investigated and reported 
impairments in specific domains of cognition such as cognitive speed, executive functioning, 
attention and memory (Daliento et al, 2005; Idorn et al, 2013). However the samples utilized 
within these two studies were limited to ToF (Daliento et al, 2005) and SV patients (Idorn et al, 
2013), thereby limiting the generalizability of the findings. Collectively, the findings of the 
adult literature helps address the delay versus deficit argument discussed earlier in Section 4.2, 
showing that the cognitive impairments seen in childhood may in fact be deficits as opposed to 
delays, which persist well into adulthood (A fuller discussion on the subject is presented in 
Chapter 15). 
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Overall when interpreting the adult literature, there are some methodological challenges that 
limit the conclusions that can be drawn about the level of cognitive functioning in ACHD. 
There is considerable variability in the methodology adopted across the studies, both with 
regards to the assessment and measurement of cognitive functioning and sample selection.  
 
With regards to the assessment of cognition, the systematic review showed an overreliance on 
the measures of IQ, as a global or cumulative measure of cognitive functioning in the ACHD 
literature. Furthermore, when interpreting the findings with regards to IQ it is difficult to draw 
comparisons across studies owing to the variety of instruments used to assess IQ. As discussed 
in Chapter 2, while IQ scores can be useful and informative, they are limited in the assessment 
and identification of specific cognitive impairments. As a result of this some of the subtle 
cognitive impairments in the ACHD population may not be identified. For instance, in the study 
conducted by Daliento and colleagues, the IQ scores of most patients (two-thirds) were within 
the normal range, however a considerable proportion of patients (>50%) showed impairments in 
specific domains such a executive functioning and problem solving, thus indicating the need to 
assess each domain of cognitive functioning independently.  
 
Given that different forms of CHD show impairments in different areas of cognitive 
functioning, for instance more structurally complex and cyanotic conditions (ToF, SV) show 
more impairment in domains such as executive functioning and attention as compared to the 
less structurally complex conditions (ASD, VSD) (Utens et al, 1998; Daliento et al 2005, Idorn 
et al, 2013), and that the use of a cumulative measure such as IQ may obscure specific 
impairments in different domains, it is considered essential to undertake a more exploratory 
approach to investigate each domain independently, as opposed to a cumulative score.  
 
Furthermore, there is considerable variability in the normative data used to compare the 
performance of the ACHD patients with the normal healthy population. Some studies utilized 
established normative data, while others recruited an independent control groups. This 
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variability makes it difficult to draw conclusive judgments as some groups were matched to the 
normative data by age, while others were matched by age and gender. Therefore, there is lack of 
standardization in the process of evaluation, which makes the interpretation and comparison 
between studies challenging. Furthermore, this variability in the source of the normative data 
may also help explain the contrary findings observed within the studies reviewed.  
 
Another distinction between the reviewed studies is the variability in the complexity of the heart 
disease within the sample. While some studies include and assess a range of different forms of 
ACHD both structurally complex and simple (Utens et al, 1998), others included patients from a 
single structural complexity group, for instance ToF (Daliento et al, 2005) and SV (Idorn et al, 
2013). The heterogeneity of the different levels of structural complexity amongst the study 
samples makes comparison across studies difficult, as there is some evidence to suggest that 
different types of ACHD show a different likelihood of demonstrating cognitive impairments. 
For instance, one of the studies in the systematic review reported more structurally complex 
forms of CHD exhibiting more cognitive impairment in comparison to those with less 
structurally complex forms (Utens et al, 1998), however no differences were noted between 
patients that were diagnosed with a single versus multiple forms of CHD (Eide et al, 2006). 
Although no inferences can be drawn with regards to the increase in structural complexity of 
those with multiple conditions, the fact that the different diagnosis may each be accompanied by 
their own associated treatments and complications, they could be considered more complex in 
comparison those with a single defect.  
 
Similarly, in a meta-analysis of the literature it was reported that children and adolescents with 
more structurally complex forms of CHD exhibit more cognitive impairment as compared to 
their counterparts (Karsdorp et al, 2007). The authors attribute these differences to the fact that 
more complex forms of CHD are associated with specific risk factors such as the number and 
complexity of surgeries undergone and the pre and post operative cerebral perfusion that may 
have a cumulative adverse effect on cognition (Karsdorp et al, 2007).  
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This heterogeneity of sample selection further raises an interesting question regarding the value 
of assessing each complexity group independently versus assessing a heterogeneous group with 
a range of ACHD conditions together. Assessment of independent structural complexity groups 
would allow specific analysis of the issues and challenges faced by the different conditions, 
which would enable a clearer understanding of the impact of these different forms of CHD. This 
may also enable more specific provision of care and support. Although the single condition 
approach does allow more specific assessment of the group in question it does restrict 
generalizability to ACHD patients as a group. Although assessing a heterogeneous group of 
patients collectively may allow wider generalizability, it may lead to dilution of specific effects 
if differential impairment exists.  
 
In light of the evidence discussed above and the presence of more cognitive impairments in 
structurally complex forms of CHD in comparison to those less complex, the former approach 
may have more merit and allow a better understanding of the level of impairment across 
different complexity levels. Therefore, future studies may benfit from undertaking a more 
exploratory approach to investigating cognitive functioning in ACHD by investigating different 
types of CHD independently while also conducting a comparative analysis to identify 
differences in cognitive functioning across different forms of CHD, which may get obscured if 
different conditions are grouped together.  
 
Another important question relates to sample selection. Critical here is whether to include or 
exclude patients with co-morbidities and other chromosomal anomalies inherent in some forms 
of CHD; including Down’s syndrome, and Di Georges syndrome. Within the systematic review 
most studies did not report including patients with chromosomal anomalies, with the exception 
of one study (Utens et al, 1994). However, the proportion of these patients was too small (N=3) 
to draw any conclusions, and as a result their inclusion did not seem to impact the results of the 
study. Down’s syndrome is one of the most common genetic causes of impaired intellectual and 
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cognitive functioning commonly found in CHD patients (Lott and Dierssen, 2010). Therefore, 
inclusion of these patients may bring down the average intelligence quotient and cognitive test 
performance in a study. Furthermore, the inclusion of these patients may obscure the impact of 
CHD and its related treatments on cognitive function, making it difficult to identify the exact 
cause of impairment. Alternatively, not including these patients may restrict understanding of 
those CHD patients that have these additional anomalies. Furthermore, it could be argued that 
the exclusion of these specific patients may result in the findings being more positively skewed 
with most patients performing in the normal range.  
 
The overall conclusions of the review conducted in 2016 did not differ from the review 
conducted in 2011 (See Appendix-B for published literature review). While collectively the 
available literature allows some insight into the cognitive functioning of ACHD patients, the 
methodological limitations of these studies should ideally be addressed in future research. First, 
larger sample sizes would provide more statistical power, which would in turn enable 
assessment of different surgical, and intervention related factors with a lot more precision. It 
would allow controlling for type-II error rate, which implies the identification of false-negative 
findings, which may result in the missed identification of impaired patients. Second, studies 
may benefit from assessing patients with different levels of structural complexity and 
comparing cognitive outcomes within different complexity groups, to get a better understanding 
of the impact of the different forms of ACHD on cognitive outcomes.  
 
Third, future studies may benefit from a more comprehensive assessment of cognitive 
functioning including both tests of IQ and independent cognitive domains, in order to identify 
impairments in cognitive functioning with more specificity. Lastly, adopting a longitudinal 
design would enable assessment of the stability of these functions and identify any intervening 
factors. For example, medical and/or psychosocial factors that may influence change in 
cognitive functioning over time. In addition, while there was some indication of the impact of 
reduced cognitive functioning on QoL, further research is needed to be able to evaluate the 
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influence of cognitive impairment on QoL outcomes in this patient group. The current study 
aimed to address some of these limitations. The specific aims and objectives of this study are 
presented in Chapter 6.  
 
4.7 Limitations of the systematic review  
In addition to the limitations of the reviewed studies, discussed in the previous section, the 
limitations of the systematic review need to be acknowledged. This systematic review was 
limited to studies written in English language, and published in peer-reviewed journals. It is 
acknowledged that the use of translational services may have expanded the scope of the review 
with the inclusion of articles published in other languages; however the lack of funding and 
access to translational services made this unavoidable. Furthermore while the literature searches 
aimed to be comprehensive up to August 2016; research papers may have been published since 
the searches were undertaken.  Examining the evidence on the impact of impaired cognitive 
functioning on other patient related long-term outcomes was outside the scope of this review, 
but remains an important area of research for future studies to investigate.  
 
4.8 Conclusions 
The published literature review and this updated systematic review were the first to synthesize 
the evidence on cognitive functioning in ACHD. The findings of the review showed the 
presence of cognitive impairment in ACHD patients, particularly in the areas of executive 
function, attention, cognitive speed and IQ. However the findings with regards to IQ were 
inconclusive. The review identified methodological limitations of the existing literature. These 
limitations have important implications for future research. Although the existing literature is 
characterized by mixed findings and methodological limitations, it does address an important 
area of research that has previously been neglected. It highlights the functional limitations of 
patients with ACHD, and presents an insight into the potential long-term implications of 
developmental impairment seen in children with CHD. Lastly it showed the potential impact of 
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cognitive functioning on long-term psychosocial outcomes such as QoL, however further 
research is warranted.   
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5 COGNTIVE FUNCTIONING AND QUALITY OF LIFE 
IN ACHD  
 
5.1  Prologue  
This chapter introduces the concept of Quality of Life (QoL), and discusses the evidence 
available on QoL in ACHD patients. It also discusses and presents the available evidence on the 
association between QoL outcomes and cognitive functioning in ACHD.  
 
5.2 Background 
As previously discussed in Chapter 4, the increasing survival rates of ACHD patients have lead 
to greater attention being focused on long-term outcomes other than morbidity and mortality; 
for instance, employment, emotional wellbeing, and cognitive functioning. One such outcome is 
QoL, which is emerging as an important patient reported psychosocial outcome in the ACHD 
literature (Uzark, 2016). Quality of life is a multidimensional construct that is conceptualized 
into broad domains, namely, physical, psychosocial, occupational and environmental (Ware et 
al, 2000). 
 
The congenital and chronic nature of CHD implies that some patients may have to undergo a 
lifetime of on-going medical care and treatment, particularly for those with more structurally 
complex forms of CHD that require constant monitoring. Furthermore the chronic nature of 
CHD not only poses physical challenges such as morbidity and mortality but may also present 
psychosocial challenges resulting from the illness such as poor emotional health and wellbeing 
including depression, anxiety and reduced QoL (Webb, 2005; Eslami et al, 2012). The British 
Cardiac Society Working Party and American College of Cardiology have recognized these 
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psychosocial challenges, and provide guidelines and recommendations for the management of 
ACHD patients (Webb & Williams, 2001; Report of the British Cardiac Society, 2002). These 
guidelines emphasize the importance of emotional and psychosocial health and recommend that 
emotional wellbeing should be a priority in the overall care provided to these patients.  
 
Impaired cognitive functioning has been associated with poorer physical and mental QoL in 
ACHD patients; suggesting the potential impact impaired cognitive functioning may have on 
different areas of the patient’s life (Idorn et al, 2013). This association between cognitive 
functioning and QoL has been reported both in the paediatric and adult CHD population (See 
Section 5.4 for details).   
 
The following section discusses QoL outcomes in ACHD. Given that QoL in ACHD is not the 
primary focus of the present study only a brief summary of the literature is presented below.  
 
5.3 Quality of Life in ACHD  
Some studies have indicated that quality of life in ACHD patients is lower in all domains except 
social functioning, when compared to the general population (Rose et al, 2005). Significantly 
worse physical QoL has been reported in ACHD patients when compared to the normal 
population across several studies (Lane, Lip and Millane, 2002; Kamphuis et al, 2002). These 
findings are understandable given that some forms of ACHD may include on-going morbidity 
and symptoms such as cyanosis, palpitations and arrhythmias, which may impact the patients’ 
general physical health and well-being, in turn affecting their physical QoL. Furthermore, some 
of these patients may also experience physical limitations due to their condition and/or are 
advised to follow certain restrictions in the intensity and type of physical activity they undertake 
on a day-to-day basis, leading to reduced physical QoL in comparison to the normal population.  
 
However, other studies have reported QoL in ACHD as being comparable to or better than the 
general population (Moons et al, 2006; Silva et al, 2011; Daliento et al, 2005). Fekkes et al, 
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(2001) assessed QoL in a group of ACHD patients with and without social impediments (i.e. 
social life limitations in relation to CHD as measured by a disease specific QoL measure, QoL-
CHD) and reported that patients experiencing social impediments have overall QoL comparable 
to that of the general population. Moreover, patients not experiencing any social impediments 
reported better QoL in comparison to general population in areas including daily activities, 
vitality and social functioning (Fekkes et al, 2001). Several studies have reported better QoL in 
ACHD patients in comparison to a healthy normal population in the areas of psychosocial, 
physical and environment QoL (Silva et al, 2011; Chen et al, 2011).  
 
Overall the findings with regards to the QoL in ACHD appear inconclusive with conflicting 
evidence which could be attributed to a number of factors, such as the different complexity 
groups assessed across studies and the variability in measures used to assess QoL (see 
Fteropoulli et al, 2013, and Kahr et al, 2014). 
 
5.3.1 QoL and the structural complexity of CHD 
Recently conducted systematic reviews of the QoL literature in ACHD reported that patients 
with more structurally complex forms of CHD such as TGA and SV generally report poorer 
QoL in comparison to less structurally complex forms such as ASD and VSD, mainly in the 
areas of physical, environmental and occupational QoL (Fteropoulli et al, 2013; Kahr et al, 
2014). Furthermore, patients with cyanotic forms of CHD have been reported as having poorer 
QoL in comparison to those with acyanotic forms (Lane, Lip and Millane, 2002).   
 
However, this association between the increased complexity of the heart conditions and reduced 
QoL outcomes is not always evident in the ACHD literature. The literature review by 
Fteropoulli and colleagues also found some studies that showed more structurally complex 
forms of CHD (such as ToF and SV patients) reporting better QoL in comparison to those with 
a less complex forms (ASD). This is especially notable, as the more complex forms will have 
had multiple surgical interventions, hospital admissions and everyday health related 
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complications (Saliba et al 2001; Ternestedt et al, 2001). A plausible explanation for these 
findings could be that patients with complex forms of CHD who perceive themselves as doing 
relatively well with regards to their QoL may score themselves higher, as their expectation of 
having a good QoL may have been lower than that of the general population, given the chronic 
nature of their condition and its associated limitations and complications.  
 
In order to improve QoL it is fundamental to identify and understand the factors that may have 
the potential to influence QoL outcomes. Quality of life may be influenced by a number of 
factors, both internal (e.g. physical health, emotional and cognitive functioning) and external 
(e.g. education, employment, social support) (Rose et al, 2005). As discussed above, one such 
factor that has the potential to influence QoL outcomes is cognitive functioning (Idorn et al, 
2013). The next section aims to present the literature examining the relationship between 
cognitive functioning and QoL outcomes in CHD patients.  
 
5.4 Relationship between cognitive functioning and QoL in CHD patients  
The majority of the available evidence on the association between cognitive functioning and 
QoL in CHD has focused on the child and adolescent population (DeMaso et al, 1990). The 
paediatric literature reported some association between cognition and QoL, with impaired 
cognitive functioning being associated with reduced QoL outcomes (DeMaso et al, 1990). For 
instance a study assessing children and adolescent patients with ToF, TGA and SV conditions 
reported mood and cognitive domains of executive functioning and gross motor ability as being 
key drivers of poorer QoL. The results showed demographic factors explaining 8-14% of the 
variance in QoL and executive function, gross motor skills, and mood predicting an additional 
11-37% of the variance (Marino et al, 2011). Similarly, with regards to IQ, a positive 
association between lower levels of verbal, performance and full scale IQ and the psychosocial 
domain of QoL in children with TGA has been reported, with lower levels of IQ being 
associated with poorer psychosocial QoL (Dunbar-Masterson, 2001).  
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With regards to ACHD literature, a recent study reported a significant correlation between 
cognitive functioning and psychosocial outcomes including QoL. A medium but significant 
negative correlation between cognitive speed and physical and psychosocial QoL was reported 
in adult SV patients. These results suggested that impaired cognitive speed was associated with 
poorer QoL outcomes in patients with different forms of SV conditions (Idorn et al, 2013).  
 
A systematic review assessing QoL in those born at high risk (including pre-term and CHD 
patients) reported that young adults living with childhood onset of developmental impairment 
including cognitive impairment are restricted in life roles, such as employment and 
interpersonal relationships, social adaptation, which may have a negative impact on their QoL 
(Dahan-Oliel, Majnemer and Mazer, 2011). These findings appear understandable if one 
assumes that those with CHD may, during their early years of education, be restricted by 
neurodevelopmental and cognitive impairments, as well as school absences due to recurring 
hospital appointments and admissions. These difficulties during their formative years may lead 
to challenges in social adaptation, education and employment in the adult years of these 
patients’ lives, which may in turn affect their QoL and well-being. Some support for this view is 
apparent in a study which reported that as ToF and ASD patients grow older they report a 
greater negative impact of their condition on their general well-being and QoL (Ternestedt et al, 
2001).  
 
The available evidence indicates an association between cognitive functioning and QoL in CHD 
patients, but warrants further investigation in the ACHD population that has not been 
adequately investigated. Assessing QoL in the adult population may provide more specific 
insight into the QoL issues pertinent to this patient group in adulthood, for instance employment 
and socio economic status etc. Furthermore, the lack of adult literature in this area restricts an 
understanding of whether the associations noted in childhood carry forward into adulthood and 
affect patient QoL, as they grow older.   
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5.5 Conclusions  
Overall there is lack of literature investigating the association between cognitive functioning 
and QoL in ACHD. There is evidence of an association between cognitive functioning and QoL 
in other chronic conditions. For instance patients undergoing coronary artery bypass grafting 
report a significant association between impaired cognitive outcomes and reduced QoL after 
cardiac surgery (Newman et al, 2001; Phillips-Bute et al, 2006). Evidence in other non-cardiac 
conditions such as multiple sclerosis (Benito-León, Morales and Rivera-Navarro, 2002; 
Samartzis et al, 2014), Huntington’s disease (Eddy and Rickards, 2013) and mild cognitive 
impairment (Teng, Tassniyom and Lu, 2012) also report an association between impaired 
cognitive functioning and reduced QoL. Given the evidence in other areas and that cognitive 
functioning is critical to an individual’s ability to function independently on a day-to-day basis 
(including abilities such as problem solving, decision making and reasoning) and may have the 
potential to affect different areas of a patient’s life for instance, educational attainment, 
employment, social adaptation, it could be considered critical in influencing QoL, warranting 
further research and investigation in the ACHD population. 
 
This study aimed to assess the relationship between cognition and QoL specifically in ACHD 
patients, and the related findings can be found in Chapters 8.   
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6 INTRODUCTION TO CROSS-SECTIONAL STUDY AND 
AIMS AND OBJECTIVES 
 
6.1 Summary of the background chapters and literature review 
ACHD is a heterogeneous group of conditions that vary in the level of structural complexity and 
severity. With improvements in treatments and surgical techniques the proportion of ACHD 
patients has escalated in recent times, with adults becoming the fastest growing segment of 
CHD population. Given the only recent increase in survival rates, research in CHD has largely 
focused on the paediatric population.  
 
As discussed in chapter 3 impairments in cognitive functioning have been reported in children 
with CHD, across a range of cognitive domains including attention, executive function and 
motor function when compared to normative data or a healthy control group. However, there is 
lack of clarity around the nature and longevity of these impairments noted in the paediatric 
population and how these could be extended to the adult population. In remains unclear from 
the available evidence if the impairments seen in children are deficits that last into adulthood or 
delays that will eventually develop to within the normal range.  
 
In order to address this gap in the literature cognitive functioning in the ACHD population 
needs to be investigated. A systematic review of the literature was conducted, and the results 
showed a limited number of studies assessing cognitive functioning in ACHD patients. The 
available evidence showed mixed findings with regards to the extent of cognitive impairment in 
ACHD patients. Inconclusive findings were reported with regards to IQ, and only two studies 
investigated and reported impairments in specific domains of cognitive functioning such 
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executive functioning, attention and cognitive speed. Furthermore, there was lack of research on 
the potential impact of cognitive impairment on long-term outcomes such as QoL. 
Overall a dearth of good quality evidence investigating cognitive impairment in ACHD patients 
was noted, and the need to comprehensively investigate the extent and impact of cognitive 
functioning in ACHD was highlighted.   
 
6.2  Limitations of the existing literature 
There were a number of methodological limitations in the studies reviewed. Some of the key 
issues that arose from the systematic review were; 
 
 Measurement of cognitive impairment  
The majority of the existing studies relied on a composite measure of cognitive functioning in 
the form of an IQ test. This method of assessment limited the information available on the 
specific impairment of cognitive functioning in different domains of cognition. More 
comprehensive evaluation of the specific domains of cognitive functioning is warranted.  
 
 Heterogeneous versus more homogeneous sampling  
Another limitation of the existing literature was the difference in sampling across the existing 
studies. While some studies utilized a heterogeneous sample and assessed cognition in a group 
of ACHD conditions with varying levels of complexity collectively, others only investigated a 
single condition. This discrepancy in the studies highlighted the lack of a gold standard for 
classifying the different forms of CHD, and also limited the generalizability of the findings to 
ACHD patients as a whole.  
 
 Factors influencing cognitive functioning  
There is a lack of research investigating the factors that may have the potential to impact 
cognitive functioning in ACHD. Very few studies have investigated this and those that have, 
include a limited number of factors (usually clinical factors) that do now allow a complete 
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understand of the range of variables that may have the potential to impact cognitive functioning. 
A more comprehensive investigation of the causality of these impairments in the adult 
population is warranted.  
 
6.3 Justification of the research  
This study addresses a novel area of research that has received little attention, but given the fast 
growing ACHD patient population, requires further research and investigation. The present 
study is designed to comprehensively investigate cognitive functioning in ACHD patients. At 
present there are no studies that investigate and compare cognitive impairment in different 
forms of ACHD with different levels of structural complexity, across different domains of 
cognitive functioning.  
 
In order to move away from the trend in the current literature to assess cognitive function using 
a composite measure such as IQ, this study included a wider range of measures assessing 
independent domains of cognition, with the aim of providing a more holistic overview of the 
extent of cognitive impairment in this patient group. Given that cognitive functioning is critical 
to an individual’s ability to be able to function independently, work, solve problems and 
maintain social relationships on a day-to-day basis, it is an important area to assess, as it may 
have the potential to impact the long-term outcomes such as the patient’s education, 
employment and QoL.  
 
Within this study a range of different ACHD conditions that vary in their levels of structural 
complexity were assessed. Each of these conditions is investigated independently, 
acknowledging the variability in each of their symptomologies, prognosis and treatments; and 
the differential impact these factors may have on the patient’s long-term outcomes such as 
cognitive functioning and QoL.  
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Furthermore, to enable a fuller examination of the potential factors that may have the ability to 
influence cognitive outcomes in this patient group, a wide range of clinical, psychosocial and 
demographic variables are included in the study when compared to existing literature.  
 
It is hoped that the findings of this study would help in the development of specific supportive 
and rehabilitative interventions to help patients that may be impacted.   
 
6.4 Research questions and objectives of the cross-sectional study  
Research question 1 
What is the extent of cognitive impairment in ACHD patients?  
Specific objectives related to the research question 1 included:  
 To investigate the extent of cognitive impairment in ACHD patients, in comparison to 
age matched normative data. 
 To investigate the most commonly affected domains of cognitive functioning in ACHD 
patients. 
 To investigate differences in cognitive functioning among different structural 
complexity groups. 
 
Research question 2 
What factors have the ability to influence and or impact cognitive functioning in ACHD 
patients? 
Specific objectives related to the research question 2 included:  
 To investigate the influence of demographic, clinical and psychosocial factors on 
cognitive functioning in ACHD patients as a group 
 To investigate the influence of demographic, clinical and psychosocial factors on 
cognitive functioning in different structural complexity groups 
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Research question 3 
Is cognitive functioning in ACHD patients associated with QoL? 
Specific objectives related to the research question 3 included:  
 To investigate if cognitive functioning is associated with physical and mental QoL in 
ACHD patients as group 
 To investigate if cognitive functioning is associated with physical and mental QoL in 
different structural complexity groups. 
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7 CROSS-SECTIONAL STUDY METHODOLOGY 
 
7.1 Prologue  
This chapter presents the methodology adopted for the cross-sectional study, including the study 
design, measures and the statistical strategy adopted for data analysis of each research objective.  
 
7.2 Design and setting of the cross sectional study 
A cross-sectional study was conducted at the Heart Hospital, London (University College 
London Hospitals (UCLH) NHS Foundation Trust). The NRES Committee London – Bentham 
and the University College Hospital Ethical Committee granted ethical approval for this study 
(Study Ref. No - 08/HO715/105). Relevant approvals were also gained from the Research & 
Development (R&D) department at UCLH. 
 
7.2.1 Participants and sampling procedures   
7.2.1.1 Inclusion and exclusion criteria 
Patients attending routine follow-up outpatient appointments (OPA) at the Grown-up 
Congenital Heart (GUCH) unit at the Heart Hospital, London were considered eligible for the 
present study. Specific inclusion/exclusion criteria were set for participation in the study.  
 
Inclusion criteria: 
 Aged 16 years and over 
 No major visual and hearing impairments or other sensory or motor impairments that 
could prohibit them for undertaking the neuropsychological assessments. 
 Fluent in spoken and written English language, sufficient to complete a self-report 
questionnaire and neuropsychological assessments 
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 Currently in a stable condition defined as not being critically ill, hospitalized or due to 
undergo any surgical procedures 
 Not pregnant at the time of the study 
 Diagnosed with one of the following conditions: ToF, TGA, SV, VSD, ASD, CoA, AS, 
PS (See Chapter 1 for details). 
 
Exclusion criteria: 
 Diagnosed with a Patent Foramen Ovale (PFO) in the absence of any other form of 
CHD; which is characterized by the presence of a hole between the left and right atria 
(upper chambers). PFO is known to be associated with cognitive dysfunction (Reisman 
& Fuller, 2009) and could potentially obscure other factors associated with cognitive 
functioning.    
 Patients with an arterial switch operation (as this procedure was adopted in late 1980’s, 
and majority of the study sample would not have had this procedure) 
 Immediately prior to or post (6-months) a surgical intervention 
 Diagnosed with chromosomal anomalies such as Trisomy21 (Downs syndrome) and 
22q11 deletion (DiGeorge syndrome), as chromosomal anomalies can cause cognitive 
impairment which could obscure the impairment caused due to the CHD 
 Diagnosed with learning difficulties  
 History of stroke  
 
7.2.1.2 Structural complexity groups  
As discussed in Chapter 1 Congenital Heart Disease (CHD) is a composite term for a group of 
conditions, which range from simple to very complex; and this study set out to examine the 
different forms of CHD. The sample was divided into four groups based on the level of the 
structural complexity of the condition determined by the anatomical complexity of the heart 
defect. The different structural complexity groups varied in their symptomology, prognosis and 
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treatment. This classification was established following deliberation, evaluation and agreement 
by two expert consultant cardiologists who treat and manage ACHD patients at the Heart 
Hospital, London. 
 
Participants were purposively sampled into the four groups (structural complexity groups):  
Tetralogy of Fallot (“TOF” group): patients in this group were diagnosed with ToF. Patients 
with pulmonary valve replacement, pulmonary atresia, and major aortopulmonary collateral 
arteries (MAPCAS) were also included in this group. ToF patients usually experience cyanosis 
(or blue baby syndrome), with ToF being one of the most common cyanotic conditions 
(Breitbart and Fyler, 2006).  
 
Transposition of the great arteries (“TGA” group): These patients are often born cyanotic. 
Patients in this group were diagnosed with TGA and had undergone a Mustard or Senning 
procedure (atrial switch) including those with implantable cardioverter defibrillators and 
pacemakers.  
 
Single ventricle physiology (“SV” group):  This group of patients were born cyanotic and 
included all patients with a single ventricle physiology and those with repairs including: Fontan 
operation and Total Cavopulmonary Connection (TCPC).  
 
 Simple lesions (“Simple” group): The “Simple” group comprises of patients in this group are 
acyanotic as they were born pink (without cyanosis). It included the following conditions- Atrial 
septal defect, Ventricular septal defect, Left Ventricular Outflow Track Obstruction-LVOTO 
(Valvular aortic stenosis and Coarctation of the aorta), and Right Ventricular Outflow Track 
Obstruction-RVOTO (Pulmonary valve stenosis). These conditions are collectively labelled as 
“Simple” to reflect their lower level of structural complexity in comparison to the other three 
groups (See Table 1.1 for details of the structural complexity group classification adopted in the 
present study).  
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7.2.1.3 Sample size calculation 
In order to estimate a statistically adequate sample size for the cross-sectional study, G-Power 
software was used to establish the number of participants needed in each group (Faul et al, 
2007). The sample size calculation was based on a four group cross sectional study to detect a 
significant group difference (using ANCOVA) in the level of cognitive functioning. A total of 
280 participants (70 in each group) were required in order to attain 80% power to detect a 
difference at 0.05 significance level, and a small to medium effect size of 0.25 (α =0.05, β 
=0.80, ES= 0.25). 
 
7.2.2 Participant recruitment procedures 
All participants were recruited from a single site (Grown-Up Congenital Heart disease (GUCH) 
unit) at the Heart Hospital, London. All patients who had routine follow-up appointments at the 
GUCH unit of The Heart Hospital between March 2009 and June 2011 were potentially eligible 
for the cross-sectional study. At the time of the present study a new electronic record system 
was being established at the Heart Hospital, however these electronic records were not complete 
and did not include all the patients seen at the hospital. As a result of this, two different methods 
of patient recruitment were adopted; these included i) the use of paper records and ii) the use of 
clinic lists. 
 
Paper records  
Hospital paper records were used to identify potential participants for the cross-sectional study. 
These paper records listed all patients actively being seen at the Heart Hospital, GUCH unit; all 
potential participants were identified in alphabetic order (Surname, name). Once identified a 
clinical GUCH nurse specialists reviewed the latest clinical notes for each potential participant 
to assess their eligibility using the study inclusion and exclusion criteria. Details of patients that 
met the inclusion criteria were entered into an electronic database and those that did not meet 
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the inclusion criteria were excluded at this stage and their details were recorded. Each 
participant was given a unique identification number in the database. 
 
All eligible participants were categorized into the four structural complexity groups (ToF, TGA, 
SV and Simple). In instances where the participants had two diagnoses, they were allocated into 
a group based on their more structurally complex diagnosis, so as to avoid including patients 
with complex conditions into the “simple” group. For instance, if a patient was diagnosed with 
both SV and VSD, they were allocated into the SV group. Clinical details of the four structural 
complexity groups are discussed in Chapter 1.  
 
Both randomized and purposive sampling were undertaken to recruit participants in the present 
study. Eligible participants meeting the criteria for the Simple and ToF groups, in the database 
prepared above, were selected randomly (using a random number generator) and invited to 
participate in the study. Random selection continued until a sufficient sample size was attained 
within these two groups. Purposive sampling was used to recruit patients for the TGA and SV 
groups as they had a limited number of patients meeting the eligibility criteria. To meet the 
sample size requirement all eligible participants in these two groups were purposively invited to 
participate in the study.  
 
Clinic lists  
Along with paper records, the outpatient clinic lists were reviewed monthly through the course 
of the study, in order to identify any more potential patients from the TGA and SV groups. 
These clinic lists were mainly reviewed to identify any potential participants that may not have 
been identified in the paper records. These participants were usually those that were only 
recently referred to the UCLH GUCH clinic from other clinics around the UK; hence, no paper 
records of them were available at the time. These identified patient were then added into the 
recruitment database and recruitment continued until the required sample size was obtained.  
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All potential participants were invited by post and were sent an invitation letter by their 
cardiologist along with an information sheet, and an interest form with a freepost return 
envelope, to indicate interest in participation (See Appendix-G for information sheet). The 
information sheet explained to the participant the purpose of the study and the procedures 
involved in it. It also informed the participant about data confidentiality and their right to 
participate and/or withdraw at any time. Patients were given two weeks to consider participation 
before a reminder letter was sent along with all the same documents. Lastly, a reminder 
telephone call was made to all participants a week before their prescheduled OPA as all 
assessments were conducted on the same day as the participants OPA in order to avoid 
additional travelling and expenses for the participants.  
 
The participation rates and study sample:  
Although the lack of comprehensive electronic patient record prevented an accurate estimation 
of the number of patients attending regular follow up appointments at the heart hospital, review 
by the clinic staff led to an estimation of approximately 5000 patients. Of these a total of 1199 
patients were identified for assessment of eligibility based on the inclusion and exclusion 
criteria discussed above. Seven hundred and eight patients meeting the study inclusion criteria 
were invited to take part in the study (See Figure 7.1 below for details). Two hundred and 
seventy three declined the invitation and 81 did not respond. Of the 354 consenting participants 
40 withdrew (without providing a reason) before their study appointment and 4 did not 
complete the neuropsychological assessment.  
 
In total, data from 310 participants were included in the analyses (Please see Figure 7.1 below 
for recruitment details). 
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Figure 7.1: Flow chart of the cross-sectional study recruitment procedure 
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7.3 Measures included in the cross-sectional study  
A wide range of measures were utilized in the cross-sectional study to assess cognitive and 
psychosocial outcomes. Detailed demographic and clinical information was also gathered for 
each participant. Details of the information collected and the measures utilized are presented in 
the following sections.  
 
Neuropsychological (NP) Measures   
All participants underwent a detailed NP assessment. A brief summary of each of the NP tests 
used is presented below (See Table 7.1 on page 131). The order in which the NP tests were 
conducted was; Trail Making Test (Part A and B), WAIS-III digit symbol coding, Controlled 
Oral Word Association Test, Stroop test, WAIS-III Arithmetic subtest, Grooved pegboard test, 
WAIS-III knowledge subtest, Wisconsin Card Sorting Test, Rey Auditory Verbal Learning Test 
and the Symbol Digit Modalities test (written and oral subtest) (See Appendix H for NP test 
battery). The order of the test was chosen such as to alternate and distribute the more difficult 
(cognitively challenging) tasks with the less difficult tasks across the test battery. This 
alternating order of the NP tests allowed switching between the different domains assessed to 
avoid any influence of practice on a particular cognitive function. Lastly, the ordering of the 
tests also helped prevent participants from being exposed to prolonged periods of complex 
demanding tasks, thus reducing patient burden. The psychometric properties of the measures 
will be stated where appropriate and reliable data is available; an omission indicates a lack of 
available data. Short forms of tests (WAIS-III- IQ, WCST-64- executive functioning) were used 
where available and appropriate for their brevity, with the aim of reducing participant burden. 
 
Given the large number of tests utilized and the overlap in the cognitive domains assessed (as 
discussed in Chapter two), tests were classified into overarching domains adapted from Strauss, 
Sherman and Spreen, (2006). These overarching domains included tests that largely assess some 
aspect of a similar cognitive function. For instance, executive functioning is a broad term 
encompassing a number of cognitive abilities, including problem solving and response 
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inhibition, therefore tests assessing these abilities were grouped under ‘measures of executive 
function’. The overarching domains (and tests) used in this study are described below.  
 
7.3.1 Measure of IQ  
7.3.1.1 Sub-scales from the Wechsler Adult Intelligence Scale-III (WAIS – III) 
Description 
The WAIS-III is a modified version of the Wechsler Adult Intelligence Scale-Revised (WAIS-
R) (Wechsler, 1981) and is used to measure general intellectual function in adolescents and 
adults (16-68 years). The WAIS is considered the ‘gold standard’ in the measurement of IQ 
(Ivnik et al, 1992).  The WAIS III comprises of 12 subtests and provides summary scores for 
full scale IQ, verbal IQ and performance IQ, along with four secondary indices including verbal 
comprehension, working memory, perceptual organization and processing speed. The 
completion of all 12 subtests requires approximately 50-60 minutes (Axelrod, 2001).  
 
To reduce patient burden, this study utilized a selected number of the subtests (N=3) of the 
WAIS-III to estimate the full scale IQ. Methods to calculate an estimated full-scale IQ from a 
limited number of sub-tests have been established in the literature (Jeyakumar et al, 2004, 
Schoenberg et al, 2003). The three subtests included in the present study were information, 
mental arithmetic and digit symbol.  This method of reducing the number of subscales rather 
than items per subscale was considered to be a more reliable technique to reduce test burden 
without compromising the overall assessment (Jeyakumar et al, 2004).  
 
The information subtest involves the examiner asking the participant questions to test their 
general knowledge (E.g. – Could you name all the continents for me please? Who was Mahatma 
Gandhi?). The arithmetic subtest assesses the participant’s ability to do mental arithmetic. 
Lastly the digit symbol subtest requires the participant to copy a number of symbols into blank 
squares with corresponding numbers on a sheet of paper, using a key provided with numbers 
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and matching symbols. The examiner records the responses and the time taken to complete the 
test on a response booklet. 
  
Scoring 
Estimated Full-scale IQ (estimated FSIQ) scores were derived from three subtests of the WAIS-
III using a specific formula and reference table provided by Jeyakumar and Colleagues, (2004). 
A score 1Standard Deviation (SD) below the mean (100) was considered a marker of 
impairment, as opposed to the 1.5 SD markers for all other NP tests (see Section 7.7.1 for 
details). This was done as the WAIS tests utilize “deviation IQ” as the standard scoring 
classification with the normative sample mean raw score defined as 100 and one standard 
deviation (defined as 15 points above or below the mean) used as a marker to indicate 
impairment. A marker of 1 SD below the mean also enables comparison to the published 
literature, which usually assesses IQ using 1SD below the mean to indicate impairment.  
 
Psychometric properties 
The median subtest reliability of the entire WAIS-III test has been established as (r=0.86). The 
composite reliabilities of the indexes have been reported as (0.94-0.95) and the verbal and 
performance IQ’s (0.94-0.97) thus demonstrating a good reliability of the measure (Ryan, 
Sattler and Lopez, 2000). 
 
The test-retest reliability (stability of the measure to assess the same concept upon re-
administration) of the subtests included in this study has been shown to be very high for the 
information subtest (>.90) and high for the arithmetic and digit symbol subtest (.80-.90) 
(Strauss, Sherman, and Spreen, 2006). The internal consistency is reported as being very high 
for the information subtest (>.90), and high for the arithmetic subtest (.80-.90). The authors do 
not provide the internal consistency measure of the digit symbol test as it is a timed test 
(Strauss, Sherman, and Spreen, 2006). 
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7.3.2 Measure of executive functioning  
7.3.2.1 Wisconsin Card Sorting Test- 64 (WCST-64) 
Description 
The WCST-64 (Kongs et al, 2000) is a short form of the original WCST test (128 cards) 
(Heaton et al, 1993). The WCST is designed to assess abstract reasoning ability and the ability 
to shift cognitive sets (the ability to switch between two distinct concepts, and to think and 
process different concepts simultaneously) (Luria, 1976). It requires concentration, attention, 
organization and cognitive flexibility (Welsh, Groisser and Pennington, 1988). The WCST is 
particularly sensitive to frontal lobe impairment (Demakis, 2003). 
 
The test involves four stimulus cards and a set of 64 response cards. Each of the cards depicts 
figures of varying shapes (triangles, stars, crosses, and circles), colours (red, green, yellow and 
blue) and numbers (one, two, three and four). The four stimulus cards are first placed in front of 
the participant (one red triangle, two green stars, three yellow crosses and four blue circles - See  
Figure 7.2 below).  
 
 
Figure 7.2: Wisconsin Card Sorting Test -64  
(Source: Jonides and Nee, 2005) 
 
 
The participant is then handed a deck of 64 cards, and instructed to match each consecutive card 
to one of the stimulus cards. The participant is not told how to match the cards but is told each 
time whether they were right or wrong. There are three sorting principles (by colour, shape and 
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number). After a set of 10 correct responses the examiner changes the sorting principle until all 
the cards are used.  The researcher does not inform the participant of the change in principles. 
This process is continued until all cards have been utilized. 
 
Scoring 
Multiple scores can be generated from the WCST including: the respondent’s ability/failure to 
maintain a set (the number of times one makes five or more correct responses in a row and then 
makes an error before successful completion of a category), number of trials required to 
complete the first category (i.e. total number of trials needed before attaining 10 consecutive 
correct responses), and total correct/error responses (total number of correct/incorrect responses 
made) (Kongs et al, 2000). A higher score on the failure to maintain score represents poorer 
performance, while on the categories completed and correct responses a higher score represents 
better performance.  
 
Five scores were calculated in the present study to reflect different aspects of executive 
function. 1) Total number of errors 2) conceptual level responses (consecutive correct responses 
occurring in runs of three), which reflects some insight into the correct sorting principle, 3) 
trials to complete first category, and 4) failure to maintain set which indicated the inability to 
continue using a successful strategy 5) total number of categories (total number of correctly 
completed categories upon completion of the test).  
 
Psychometric properties 
 The generalizability coefficients for the WCST-64 (single administration) have been reported 
as ranging from 0.60-0.85 averaging at 0.74, thus demonstrating good scale reliability (Kongs et 
al, 2000). 
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7.3.2.2 Stroop Neuropsychological Screening Test (SNST) 
Description 
The Stroop test has many versions; the one used in this study was the Stroop 
Neuropsychological Screening Testing (SNST) (Trenerry et al, 1989). The SNST is a two-part 
test, which assesses selective attention and executive functioning (cognitive flexibility and 
response inhibition) in 18-79 year olds. The test comprises a sheet of paper with a list of words 
(colour names) (N=112) randomly printed in 4 distinct colours; red, green, blue and tan 
(brown). At the beginning of the test a colour test is conducted to check for colour blindness, if 
a participant is found to be colour blind the test is discontinued. This is followed by the first half 
of the task; ‘Stroop colour’ which involves the participant reading aloud the list of words in a 
given time frame (2 minutes). The next half of the task ‘Stroop colour word’ involves the 
participant reading the colour of the ink in which the words are printed in the same time span (2 
minutes).  
 
Scoring 
Two scores are recorded for each task: the number of words/colour names correctly recited, and 
the time to complete the task. A higher score on the words correctly recited represents better 
performance but a higher score represents poorer performance on the time to completion. The 
score for the total number of colour names correctly recited was utilized in this study. 
 
Psychometric properties 
The test reportedly differentiates >79% of brain-damaged adults from normal adults (Trenerry 
et al, 1989). The measure has been shown to demonstrate good test-retest reliability i.e. 0.90 
(Trenerry et al, 1989)  
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7.3.2.3 Controlled Oral Word Association Test (COWA) 
Description 
The COWA is a test of executive functioning, verbal association and fluency (Benton et al, 
1994). It evaluates the spontaneous production of words under restricted conditions. The 
participant is asked to produce as many words as they can, beginning with each of the letters 
‘F’, ‘A’ and ‘S’ individually. They are instructed to exclude proper nouns, numbers and the 
same words ending with a different suffix (e.g. long, longer and longest). Participants are 
allocated one minute for each letter (F, A, S). The researcher records a list of all the words 
named by the participant. 
 
Scoring 
The total score is the sum of all admissible words for all three letters. A higher score indicates 
better performance.  
 
Psychometric properties 
The COWA-FAS has been shown to have moderate to high internal reliability (r=0.83) and high 
test-retest reliability(r=0.74) after 5 years (Tombaugh, Kozak and Rees, 1999).  
 
7.3.3 Measures of Attention  
7.3.3.1 Symbol Digit Modalities Test (SDMT)  
Description 
The SDMT (Smith, 2002) assesses divided attention, complex visual scanning, hand-eye 
coordination, and reading-writing ability. It is known to be sensitive for detecting acquired, 
acute or chronic cerebral dysfunction but is not specific for localization of the dysfunction 
(Smith, 2002).  
 
It is a paper and pencil test that comprises rows of 110 blank squares each with an assigned 
symbol. Above the rows there is a printed key with numbers from 1-9, each paired with a 
126 
 
randomly assigned abstract symbol. The task requires the respondent to match each symbol 
(110) with a corresponding number with the help of the key and write these down as rapidly as 
they can, consecutively in the order presented (it involves the opposite procedure to the WAIS-
III as discussed in Section 7.3.1.1 which requires copying symbols). Participants are asked to 
perform a practice trial on the first 10 symbols (See Figure 7.3 below). Following the practice 
session participants are given 90 seconds to complete the test. 
 
The SDMT test has two parts: written (SDMT-W) and oral (SDMT-O). This allows drawing 
comparisons between visual-motor and oral responses. The written assessment was presented 
first followed by the oral assessment in accordance with the test instructions (Lezak, 1995; 
Strauss, Sherman and Spreen, 2006).  
 
 
Figure 7.3 Symbol Digit Modalities Test 
(Source: Original scanned form) 
 
Scoring 
The score is the total number of correct responses within the specified time frame. A separate 
score is calculated for each part of the test (written and oral). A higher score on each part of the 
test is indicative of better performance. 
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Psychometric properties 
The test-retest reliability of the SDMT has been shown to be high (0.91) (Hinton-Bayre et al, 
1999).  
 
7.3.3.2 Trail Making Test: Forms A and B (TMT) 
Description 
The TMT (Reitan & Wolfson, 1995) is a two-part paper and pencil measure of divided 
attention, visual scanning, motor speed and mental flexibility. It is considered a good measure 
of generalized brain functioning (Reitan and Wolfson, 1995). Part A (TMT-A) requires 
participants to connect 25 randomly arranged numbers (in circles) in ascending order without 
lifting the pencil from the paper (no restrictions on lines crossing). Part B (TMT-B) requires the 
participant to connect randomly arranged letters and numbers in an alternate sequence (1-A, 2-
B, 3-C . . . 13) as quickly as possible (See Figure 7.4 below). Respondents are given a (short) 
practice trial prior to both parts to ensure familiarity with the test and comprehension of the test 
instructions. Both parts of the test are timed to completion. The TMT-B subtest is terminated if 
the respondent takes over 5 minutes to complete.  
 
Scoring 
The score is the total amount of time taken to complete the test, with lower scores indicating 
better cognitive functioning. Higher scores (time taken) on either part (A and B) have been used 
as an indicator of diffused brain damage. A high score on part A indicates difficulty in cognitive 
perceptual tracking and attention. Part B is more complex than Part A and may indicate 
difficulties in divided attention, executive functioning and cognitive flexibility along with 
conceptual motor tracking (Bremer et al, 1997). Both scores (TMT-A and TMT-B) are reported 
in this study. 
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Psychometric properties 
The test-retest reliability of the TMT varies with age-range and population, but is generally 
considered adequate, at least for the Part B (Strauss, Spreen and Sherman, 2006). The test-retest 
reliability coefficients over 11 months have been reported as 0.79 for Part ‘A’ and 0.89 for Part 
‘B’ (Dikmen et al, 1999). The inter-rater reliability has been reported as 0.94 for part A and 0.90 
for part B (Fals Stewart, 1992). 
 
Figure 7.4: Trail making (Part B) 
(Source: Original scanned form) 
 
7.3.4 Measures of motor functioning and dexterity 
7.3.4.1 Grooved Pegboard (GP)  
Description 
The Grooved Pegboard task (Matthews & Klove, 1964) measures motor function, dexterity and 
motor speed requiring manual precision and hand-eye coordination. It is known to be sensitive 
to both focal and diffused cerebral damage and can aid the detection of any lateralized disability 
or motor dysfunction even in the presence of a normal range of movement and motor 
functioning.  
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The test consists of a metal board with a grid matrix of 25 randomly positioned slots and 25 
metal pegs that are ridged to one side.  Participants are required to match the groove/ridge on 
the pegs with that of the slots and insert them as fast as possible consecutively across and down 
the grid (right to left for the left hand and vice versa) (See Figure 7.5 below). The participant 
continues until all pegs have been placed. The examiner records the time taken to correctly 
insert all the pegs and the number of pegs dropped in the process. A maximum of 5 minutes are 
allowed for test completion, after which the test is terminated. 
 
 
Figure 7.5: Grooved Pegboard and the pegs  
(Source: www.lafayetteeevaluation.com) 
 
Scoring 
The most commonly recorded score for the GP is the total time required to complete the task 
using either hand.  Two other scores can be calculated: number of pegs dropped and number of 
pegs inserted correctly. These two scores are considered critical for clinical use as these errors 
are rarely seen in neurologically intact individuals, but less useful for population research 
purposes (Heaton et al, 2004; Strauss, Sherman and Spreen, 2006). Time taken to completion 
was the only score utilized in the present study. A higher score on each hand indicates poorer 
performance.   
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Psychometric properties 
The test re-test reliability of the GP has been shown to be marginal/high (0.67 to 0.86) in normal 
populations aged 15 years and over (Strauss, Sherman, and Spreen, 2006). 
 
7.3.5 Measures of memory 
7.3.5.1 Rey Auditory Verbal Learning Test (RAVLT) 
Description 
The RAVLT is an auditory verbal memory and learning task that assesses immediate memory, 
working memory, and interference (Schmidt, 1996). It is a verbal test that consists of a list of 15 
words (nouns) (List- A), which are read aloud one second apart. Participants are asked to repeat 
as many words as they can remember in any order after each presentation. This is done a 
maximum of 5 consecutive times (fewer if participant recalls all 15 words). The instructions are 
repeated each time to ensure clarity. Following this, a new 15-word list (List –B) is presented 
and the participant is asked to recall as many words as possible from the new list. Finally, the 
participant is asked to again recall as many words as he/she can from List-A without being 
given any prompts.  
 
Scoring 
The score for each trial is the total number of words correctly recalled. Several different scores 
can be derived from the RAVLT including learning, forgetting, proactive and retroactive 
interference, and learning curve (Strauss, Sherman and Spreen, 2006). The total number of 
words recalled from trial 1 – trial 5 were summed to produce a total acquisition score which was 
the one score used in this study. This score was chosen as it represents the level of verbal 
learning and working memory. Furthermore, appropriate normative data applicable to this study 
sample was only available for this score.       
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Table 7.1 Details of the neuropsychological test battery used for assessment 
Tests 
utilized  
Cognitive 
function 
assessed 
Definition of 
cognitive function 
assessed 
Scoring Number of 
scores 
generated 
IQ 
Wechsler 
Adult 
Intelligence 
Scale – III 
Intelligence 
Quotient  
Measure of general 
intellectual function 
Estimated total 
intellectual quotient 
score 
1 
Executive functioning  
Controlled 
Oral Word 
Association 
test 
(COWAT-
FAS)
  
 
Verbal fluency Speed and ease of 
verbal production 
Total number of 
words produced per 
letter 
1 
Wisconsin 
Card Sorting 
Test -64 
(WCST-64)
  
 
 
 
 
Executive 
function: 
problem-
solving  
 
 
Ability to respond 
appropriately in 
novel situations; 
ability to plan and 
use initiative 
Number of errors 
made, conceptual 
level responses, 
failure to maintain 
set, and trials to 
complete first 
category, total 
number of 
categories 
completed 
5 
Stroop 
Neuropsych
ological 
Screening 
test (SNST)
 
 
Executive 
function: 
response 
inhibition  
Ability to respond 
appropriately in 
novel situations. To 
perform an action 
when faced with a 
competing and more 
familiar action 
Correct number of 
words recited in 2 
minutes 
2 
 
Attention 
Symbol 
Digit 
Modalities 
Test 
(SDMT) 
Complex 
visual 
scanning  
The ability to 
visually locate a 
target within a range 
of complex figures 
Total number of 
symbols & 
numbers correctly 
written and recited 
2 
Trail making 
test (TMT) 
A and B 
 
Divided 
attention  
The ability to 
respond to multiple 
tasks simultaneously 
and cognitive 
processing  
Speed 
 
Time taken to 
completion in 
seconds 
2 
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Tests 
utilized  
Cognitive 
function 
assessed 
Definition of 
cognitive function 
assessed 
Scoring Number of 
scores 
generated 
Motor functioning  
Grooved 
Pegboard 
(GP) 
Manual and 
motor 
dexterity and 
functioning 
Speed and accuracy 
of manipulation of 
fine objects with the 
hands 
Total time taken to 
complete task in 
seconds. 
2 
Memory 
Rey 
Auditory 
Verbal 
Learning 
Test 
(RAVLT) 
 
Verbal 
learning and 
memory, 
delayed and 
immediate 
recall 
Ability to learn new 
information and to 
store and retrieve 
information 
Total number of 
words correctly 
recalled.  
Total acquisition = 
Sum of Trial 1-
Trial 5 
1 
 
 
Psychometric properties 
The internal reliability of the total score for the RAVLT has been shown to be high (0.90) (Van 
Den Burg & Kingma, 1999). 
 
Table 7.1 (above) summarizes the NP tests used and the cognitive domains assessed by each. It 
also details the scoring procedures and the total number of scores generated by each of the tests 
utilized; for NP test battery see Appendix-H.  
 
Psychosocial Measures (mood and quality of life) 
Psychosocial self-report questionnaires assessing mood and quality of life were included in the 
present study. These measures were included to assess their relationship with cognitive 
functioning. Some of these measures, such as depression and anxiety are known to have the 
potential to influence cognitive functioning and hence were selected to assess their relationship 
to cognition and use as covariates (Lezak et al, 2012). See Appendix-I for psychosocial 
questionnaires used in the study.  
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7.3.6 Measures of Mood 
7.3.6.1 The Positive and Negative Affect Scale (PANAS) 
Description  
PANAS is a 20-item self-report measure of positive (PA) and negative affect (NA) (Watson, 
Clark and Tellegen, 1988). It includes 20 adjectives describing emotions of which 10 items 
describe negative affect (e.g. upset, guilty, scared) and 10 items describe positive affect (e.g. 
proud, alert, inspired). The respondent is asked to indicate the extent to which they have 
experienced these emotions on a 5-point scale, ranging from ‘very slightly or not at all’ to 
‘extremely’. The scale can be used to refer to 6 time-points from (‘right now’ to ‘the past year’) 
or generally depending on the aims of the study.  In the current study the time frame adopted 
was ‘generally’, as the objective of the study was to understand the general effect of the 
patient’s health on their mood as opposed to over a specific time frame. The scale takes 
approximately 5 minutes to complete.  
 
Scoring  
The scores are calculated by summing the item scores (1 to 5) for each scale (NA and PA) 
respectively to achieve an overall NA and PA score. The total score can range from 10-50. A 
higher score represents a higher level of positive / negative affect. 
 
Psychometric properties  
Both subscales of the PANAS have shown satisfactory internal consistency: PA (Cronbach’s 
alpha=0.89) and NA (Cronbach’s alpha=0.85). The test-retest reliability is reported as 0.68 (PA) 
and 0.71(NA) respectively (Watson, Clark and Tellegen, 1988). The correlation of the short 
form and the original version is reported as r=0.92 (p < .01) for PA and r=0.95 (p < .01) for NA 
(Thompson, 2007).  
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7.3.6.2 Spielberger State Anxiety Inventory-6 (STAI-6) 
Description 
The short version of the STAI (6 items) was used in the study to assess the level of state anxiety 
(Marteau and Bekker, 1992). The STAI was designed to measure anxiety as ‘state like’ referring 
to a situation related anxiety, and ‘trait like’ referring to the anxiety being more persistent and a 
personality trait. It is used in this study as a measure to assess state anxiety and the stress 
associated with a medical condition.  The STAI-6 involves 6 items: three items are Anxiety-
Present e.g. “I feel tense” and three Anxiety- absent e.g. “I feel calm”. The response scale is a 4-
point Likert scale range from “not at all” to “very much”.  
 
Scoring 
The three anxiety-absent items (positively framed) require reverse scoring. The summed score 
of the scale is obtained from the 6 items, which ranges from 6-24. A higher score on the 
measure represents greater state anxiety levels. 
 
Psychometric properties 
The short version of the scale demonstrates satisfactory levels of internal consistency and is 
highly correlated with the original measure with all internal consistency reliabilities reported to 
be greater than 0.90 (Tluczek, Henriques & Brown, 2009). The reliability coefficient of the 
measure has been reported as adequate at 0.82 (Marteau and Bekker, 1992).  
 
7.3.6.3 Centre for Epidemiological studies Short Depression Scale (CESD-10) 
Description 
The CESD-10 was used as a measure of depressive symptomology; it is a short version of the 
CESD-20 developed by Andresen et al, (1994). Respondents rate the level of depressive 
symptoms they experienced over the last week on a 4 point scale ranging from “0= rarely/none 
of the time” to “3= All of the time”. Some of the items are framed negatively and some 
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positively for instance “I felt that everything I did was an effort” (negative) and “I feel hopeful 
about the future” (positive).  
 
Scoring  
The two positively framed items (5&8) of the questionnaire are reversed scored (3-0). Items 1-4, 
6-7, 9, 10 are scored from 0-3. The summed scale score ranges from 0-30. A higher score 
represents higher depressive symptomology (<10=without depressive symptomology, 10-14 
=mild depression, and >14= severe depressive symptomology) (Swenson et al, 2008). The cut-
off score for clinical level of depression for the CESD-10 version has been established as ≥ 10 
(Andresen et al, 1994).  
 
Psychometric properties  
The test-retest correlations of the CESD-10 ranged from r=0.21 to 0.84, with an overall score 
correlation being r=0.71 (Andresen et al, 1994). The correlation between the original version 
and the short-form was reported to be high (r=0.97, p=0.001) (Zhang et al, 2012). 
 
7.3.7 Health Related Quality of Life measure (HRQoL):  
7.3.7.1 The Medical Outcome Survey 36-item Short-Form Health Survey Version 1®  (SF-
36 v1®) 
Description 
The SF-36v1® is an extensively used generic multidimensional measure of Health Related 
Quality of Life (HRQoL) (Ware et al, 2000). It comprises 36 items that measure health status 
with eight subscales that represent both physical and mental health status. The subscales 
include: physical functioning, social functioning, role-physical (role limitation due to physical 
health problems), role-emotional (role limitation due to emotional problems), mental health, 
vitality, bodily pain, and general health perceptions. Participants rate their health status in the 
last month using a Likert-scale.  
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Scoring 
The SF-36v1® and associated data scoring software is licensed by the Quality Metric Company. 
For the purpose of scoring the questionnaire, norm based scoring was undertaken using the 
official Quality Metric Health Outcomes™ Scoring software 4.0 in this study (Saris-Baglama et 
al, 2010). The software uses the 1998 general U.S. population norms. Norm based scoring was 
undertaken as it allows drawing comparisons with the general population norms and facilitates 
interpretability. Each scale is scored to have a standardized mean and standard deviation, 
relative to the general population scores/norms. The eight sub-scales are combined into two 
component scores: physical component and mental component summary score (PCS, MCS). 
Norm based scores are more advantageous as they simplify interpretation and allow direct 
comparison between the different scores including the two summary scores; PCS and MCS. The 
eight subscales were linearly transformed into T-scores with a mean of 50 and a standard 
deviation of 10. A score ranging from 0-100 was obtained for each subscale.  
 
Psychometric properties 
The reliability and validity of the SF-36v1® has been well established in the literature. A review 
of relevant literature reported the median reliability coefficient for each of the 8 subscales as 
0.80 and above (Ware et al, 2000). The SF-36 v1® questionnaire will be refered to as the SF-36 
from this point onwards.  
 
7.4 Clinical and demographic characteristics  
7.4.1 Medical history 
A consultant cardiologist and a clinical nurse specialist at the Heart Hospital collected clinical 
data from patient medical records (both paper and electronic records). A comprehensive and 
detailed account of the patient’s clinical information was collected using a standard medical 
form.  
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Cardiac treatments were recorded for each patient including details of previous medical 
interventions (number, time since last intervention, age at repair) and the types of interventions 
(palliative, repair, and catheter laboratory). Peri-operative details of surgical interventions were 
recorded (duration of Cardiopulmonary bypass-CPB, duration of Deep Hypothermic Circulatory 
Arrest-DHCA, number of days spent in the Intensive Care Unit (ICU) along with post-operative 
complications where relevant (central nervous system related complications, infections and 
ventricular dysfunction).
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Table 7.2: A summary of the clinical variables measured in the study 
Type of clinical 
variable 
Clinical factors measured Measurement details of the variables assessed 
 
 
Structural complexity 
group 
 
 
Native diagnosis Groups: 
1) Tetralogy of Fallot 
2) Transposition of the great arteries 
3) Single ventricle physiology 
4) Simple lesions 
Treatment 
(interventions 
history/profile) 
Interventions total (total number incl. repairs, palliations, cath labs) Count of the total number 
Reparative procedures Count of the total number 
Palliative procedures Count of the total number 
Catheterisation (cath) lab (non-invasive) procedures Count of the total number 
Palliation before repair  Yes/No 
Age at the time of repair (i.e. 1
st
 surgery of reparative nature) Age in months 
Years since last intervention (since the most recent) Count of years past since 
Operations (peri-
operative) 
Cardiopulmonary bypass (includes the use of extracorporeal 
circulation (ECC), which is used to take over the function of the 
heart and the lungs temporarily during surgery) 
Total count in minutes totalled for all 
interventions 
Hypothermic arrest (refers to cooling the body and stopping blood 
circulation for the purpose of surgery) 
Total count in minutes totalled for all 
interventions 
Intensive care unit (ICU) days (after operations) Count of days spent in ICU after surgical 
procedures 
Operations (post-
operative) 
Central nervous system complications Yes/No 
Infection Yes/No 
Ventricular dysfunction Yes/No 
Treatment 
(medication+) 
Medication total Total count of medications taken 
Pacemaker Yes/No 
ACE inhibitors Yes/No 
Diuretics Yes/No 
Beta blockers Yes/No 
Anti-arrhythmia Yes/No 
Anti-coagulant Yes/No 
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Table 7.2 – A summary of the clinical variables measured in the study (Continued.) 
Type of clinical 
variable 
Clinical factors measured Measurement details of the variables assessed 
 
 
Cyanosis 
 
Cyanosis days (up ‘till data collection date) 
Total number of days cyanosed up until the day of 
study data collection  
Current saturation  Percentage (%) 
Hospitalization 
history 
Hospitalization days  Total count of days spent in hospital  
Co-morbidities 
Co-morbidities total  Count of the total number 
Heart failure Yes/No 
Arrhythmias Yes/No 
Hypertension Yes/No 
Functional status New York Health Assessment (NYHA) Groups Class I, II, III, IV 
 Left Ventricular Ejection Fraction (LVEF) 
Right  Ventricular Ejection Fraction (RVEF) 
 
Percentage % 
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Details of the patient’s current medications (Beta-blockers, ACE medication, Diuretic, anti-
arrhythmia medications) and co-morbidities (arrhythmias, heart failure, and hypertension) were 
also recorded. Information regarding cyanosis was gathered including number of days (across 
life span) patients were cyanosed, and their latest blood oxygen saturation levels. Functional 
status was measured using the New York Health Assessment (NYHA) classification as part of 
the patient’s routine examination (New York Heart Association, 1964). Further details of 
clinical variables (e.g. unit of measurement) collected as part of this study can be found in Table 
7.2 (above).  
 
7.4.2 Demographic details 
Demographic information was collected from each participant using a standard self-report form. 
Information gathered included: age, gender, marital status, living status, education, ethnicity and 
employment status. Study procedures  
 
7.5 Study procedures 
7.5.1 Data Collection 
Patients were seen on the day of their regular outpatient appointment (OPA). Written consent 
was obtained from all participants prior to assessments. Each participant was explained the 
purpose of the study and taken through the information sheet prior to signing an informed 
consent form. The informed consent form stated that the participant had enough time to consider 
participation in the study and was willing to participate. A copy of the consent form was given 
to each participant for his or her records (see Appendix-J). Each participant was given a £5 
voucher to use for meals and refreshments.   
 
Following consent the assessments were conducted prior to the participants OPA where possible 
in order to avoid fatigue having an impact on the participant’s performance. Demographic 
information was collected at the start of the session followed by administration of the NP test 
battery. Finally, participants completed the self-report psychosocial questionnaires (mood and 
quality of life). This sequence of assessment was standard across all participants, and was 
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chosen in order to minimize any impact of fatigue on cognitive performance. Participants were 
given an optional break of 5 minutes between the NP assessment and completion of the 
psychosocial questionnaires. They were also advised to inform the examiner if they felt fatigued 
and needed a break between any of the assessments. 
 
All NP assessments were conducted in a standardized manner keeping the testing conditions 
similar for all participants. The assessments were conducted in a quiet and private room at the 
Heart Hospital London. Prior to commencing the assessment the examiner spent time talking to 
each participant asking them questions about themselves and their day, letting them know how 
long the study may take and what it would involve, with the aim of building a rapport with each 
participant and to put them at ease. Each participant was offered water, reminded to wear their 
glasses (if any) and made to feel comfortable before the assessment commenced. The NP 
assessment was discontinued temporarily (5-10 minutes) if the participant felt fatigued and 
required a break; the aim was to elicit optimum performance from participants. The NP 
assessment took approximately 45-60 minutes and administering the psychosocial 
questionnaires took approximately 60 minutes depending on the participant’s speed.  
 
7.6 Preliminary Analysis  
All the data collected was entered into SPSS and all analysis within this study was conducted 
using IBM SPSS (Statistical Package for the Social Sciences) version 21.  
 
7.6.1 Missing Values Analysis  
After checking the data for inconsistencies such as manual errors in data entry, incorrect 
missing values and scores outside of the normal range on any measure, a missing values 
analysis was conducted; both at item and scale level (Field, 2009). The types of missing data 
that emerged included: 
 NP raw scores missing  
 Individual items missing within sub-scales of questionnaires (psychosocial measures) 
 Entire sub-scales missing within a single administration of the questionnaires   
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 No questionnaires completed  
The overall amount of missing data was under 5% in the cross-sectional study (See Appendix-K 
for proportion of missing data on each variable). Although the level of missing data was not 
large a decision was made to carry out an imputation to obtain a complete data set, minimize 
loss of sample size and avoid different sample sizes across analyses.  
 
In the psychosocial measures where participants left blank items within a scale or an entire scale 
and reported the items as not applicable, these scores were labelled as 888 in the database. 
Similarly in the neuropsychological tests some scores were not applicable to all participants, 
one example of this is the WCST-64 - Failure to maintain set score, which can only be 
calculated if the participant has completed at least 2 categories and attempted a third. Therefore 
for those that did not complete adequate categories the score was considered not applicable and 
labelled as 888. These scores were considered not applicable as opposed to missing and were 
not subject to imputation.  
 
In the case of missing data at the item level, mean substitution (within a participant) was carried 
out in order to reduce the amount of missing data, followed by the calculation of scale level 
scores. Scale scores were calculated from the items within each case with the average score 
substituting the missing value. In cases with more than 50% of items missing the scale score 
was considered missing and treated at scale level. In the case of the SF-36 missing data was 
dealt with using the built-in algorithms provided (maximum data recovery) in the scoring 
software (QualityMetric health outcomes scoring software 4.0) (Saris-Baglama et al, 2010).     
 
Multiple imputation procedures were conducted for data missing at scale level. During the 
imputation process, one imputation was performed. Imputation models were conducted on the 
basis of predictive mean matching (PMM). PMM is a variant of linear regression that ensures 
that the imputed values are plausible and match an observed value (specifically, the observed 
value that is closest to the value drawn by the imputation model). The imputation process, for 
logistical reasons (i.e. processing power and time) was conducted in batches of 
143 
variables (clinical, demographic, psychosocial questionnaires, and NP assessment). However, 
the predictive model for all imputations had the same predictors i.e. all other variables within 
the dataset (clinical, demographic, psychosocial and NP assessment). The imputed values were 
then collated into a single dataset. Imputed values for items that were deemed non-applicable 
for particular cases (see above) were then replaced with an 888 code.  
 
7.6.2 Distribution of variables 
The assessment of the normality of data is a prerequisite for many statistical analyses, and is a 
key assumption in parametric tests. The distribution of all variables within this study was 
examined to assess normality. This was done visually using histograms, and statistically, by 
performing the Kolmogorov-Smirnov test for which a statistical significance level of p <0.001 
was used to detect non-normality (The Kolmogorov-Smirnov statistic for each variable is 
provided in Appendix-L).  
 
When conducting statistical analyses non-normally distributed or skewed data is often 
transformed using mathematic formulas to attain a more normal data distribution. However, the 
non-normally distributed data in this study was not transformed. There were two main reasons 
for this decision. First, when preliminary transformations (e.g. logarithmic base 10 and square 
root) were applied to non-normal variables it did not render the data correct (normally 
distributed). Second, transformations transform the nature of the variables (each data point) 
making the interpretation of data more complex (Osborne, 2005).  Based on the data distribution 
non-parametric tests were used where the data was non-normally distributed, unless stated 
otherwise.  
 
7.6.3 A note on the level of statistical significance 
A significance level of p<0.01 was used for all main effects in the study, unless otherwise 
stated. This more conservative significance level was used due to the large number of tests 
performed and the risk of obtaining a false-positive result i.e. rejecting the null hypothesis when 
it is in fact true (Type 1 error). While the main effects were only considered significant at 
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p<0.01, a less conservative significance level of p<0.05 was adopted for all preliminary 
analyses (identifying covariates for ANCOVA’s and identifying univariate predictor variables 
for regression analyses).  This approach was deemed appropriate for this exploratory study as it 
reduced the risk of removing any potential predictor variables based on stringent significance 
levels alone. Furthermore, it allowed for the observation of any critical interactions between the 
range of variables included within the present study. 
 
7.7 Statistical analysis strategy for each research question  
This section details the statistical analyses adopted for each of the research objectives of the 
study.  
 
7.7.1 Research question 1- What is the extent of cognitive impairment in ACHD patients? 
In order to examine the extent of cognitive impairment in ACHD, the participant data within 
this study was compared to age matched normative data from healthy individuals. In order to do 
so the study data was transformed into standardized scores to allow comparability to normative 
data. The procedures adopted to calculate these scores and the criteria established to indicate 
impairment in cognitive functioning is discussed below in the following sections.  
 
NP data scoring  
The NP data (raw scores) were transformed into standardized scores (z-scores). The reasons for 
this transformation were firstly that z-scores are standardized and enable comparison across 
different tests with different units of measurement (time taken, number of words etc.) and 
different distributions. Secondly, standardized scores enabled comparisons across studies. Z-
scores were calculated by subtracting the participant’s raw score from the mean value of the 
age-matched normative data, and dividing it by the Standard Deviation (SD) of the normative 
data (See formula below). This plots the participant’s performance in comparison to age 
matched normative samples, allowing the participant to be positioned relative to the normative 
data. Details of the normative data are presented in Appendix-M. The z-scores for all NP tests 
were used for all subsequent analyses. 
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X= Raw score 
M= Normative group mean score 
SD= Normative group Standard Deviation 
 
 
Establishing a criterion for cognitive impairment 
In order to compare the sample’s cognitive performance to normative data a criterion for 
cognitive impairment was established. Within the research literature, several cut-off criteria are 
used to define cognitive impairment including 1, 1.5 and 2 Standard Deviations (SD) below the 
normative group mean score on a neuropsychological assessment (Lezak et al, 2012). However, 
there is no established gold standard for defining cognitive impairment.  Assuming a normal 
distribution the likelihood of a healthy individual scoring greater than 1 SD below the mean on 
one neuropsychological test is approximately 15%. Using 1SD as the criterion for cognitive 
impairment may increase the number of false-positive results (more cognitively intact 
individuals will be classified as impaired) (Lezak et al, 2012). Conversely the use of a more 
stringent criterion of 2 or more SD below the normative data may increase the number of 
individuals with impairments that are ‘missed’ and judged as normal (False-negative) (Lezak et 
al, 2012).  
 
To try and balance the Type I and Type II errors while identifying individuals with impairment 
on a particular NP test a cut-off score of 1.5 or more SD below/above (depending on the 
direction of scoring) the respective age matched normative mean score on all NP tests was used 
to define impairment in this study. This criterion (1.5 SD) has also been used to diagnose Mild 
Cognitive Impairment (MCI) in different patient groups within the cognitive literature (Schinka 
et al, 2010, Petersen et al, 1999, Petersen, 2004).  Impairment on the IQ test was defined as a 
score 1SD below the normative mean score (See Section 7.3.1.1 for details). For ease of 
interpretation and consistency in this study, poor performance will be described as 1.5 SD below 
Z =   (X – M) ÷ SD 
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the mean irrespective of direction of scoring on all NP tests, and 1SD below the mean on the IQ 
test.  
 
As previously stated, within a normal distribution approximately 15% of individuals would be 
expected to fall below the 1 SD cut-off and 7% below the 1.5 SD cut-off point.  Therefore in the 
present study, if more than 7% of the sample scored 1.5 SD below the normative mean score on 
a NP test and more than 15% scored 1 SD below the normative mean score on the IQ test the 
sample were considered to show significant impairment (See Chapter 8, Section 8.3 further 
details).    
 
While these figures (15% and 7%) allow assessment of a participant on a single test in 
comparison to normative data, when using a large cognitive test battery additional factors need 
consideration. It has been reported that a normal healthy individual may score in the impaired 
range by chance on 1-2 tests in any given cognitive test battery (Taylor and Heaton, 2001, 
Lezak, et al, 2004).  Further given that 7% of the sample can be expected to score in the 
impaired range on one test, this proportion would be expected to inflate when a larger number 
of tests are included in the battery, as the same 7% of the participants are not likely to exhibit 
impairment across all tests included. For instance, if 5 tests are included the chances of scoring 
in the impaired range on one of those tests is inflated and 35% (i.e. 7x5) of the sample can be 
expected to score in the impaired range on one of those tests. In order to correct for this inflation 
Ingraham and Aieken, (1996) provide a mathematical formula based on binominal theory to 
calculate the probability of finding impairment in the normal population based on the number of 
tests utilized, and the established cut-off criteria for cognitive impairment employed (i.e. 1, 1.5 
and 2SD). This approach however assumes independence between the tests utilized and when 
the tests are not independent it is advised that the user exercise some caution, as the estimates of 
the percentage of the population exhibiting impairment may be reported as being higher than 
expected. 
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The technique provided by Ingraham and Aieken, (1996) was applied within this study, using 
cut-off criteria of 1.5 SD below the normative mean score on three or more tests, to establish 
what proportion of the ACHD patients exhibited impairment even after taking account of the 
number of tests. The present study included a total of 8 tests which produced 16 scores in total 
(See Chapter 8, Section 8.5 for details).  
 
Along with individual NP tests a mean z score was calculated to provide a mean total composite 
NP score. This score was computed in order to assess the overall level of cognitive functioning 
across the total sample and the different complexity groups, as assessed by the different 
measures used in this study. The total mean composite score was calculated by summing up the 
z-scores from all the tests, and dividing by the total number of scores included. All test scores 
were included with the exception of the WCST and WAIS-III. The WCST tests scores are not 
considered independent of each other and therefore including all the scores could cause 
imbalanced weighting amongst these variables. In order to deal with this problem, only one 
WCST score (total number of categories achieved) was included in the computation of the mean 
composite NP score. There were two main reasons for this decision; firstly the total number of 
categories completed scores is considered one of the most clinically useful WCST scores (Lezak 
et al, 2012). Secondly the association between the total number of categories completed score 
and the other WCST scores indicated a medium to strong association (p<0.001, range= -0.408 – 
0.869); thus suggesting that this score could be considered representative of the other scores. 
Further the measure of IQ was not included in this score as IQ in itself is considered a 
composite measure of cognitive functioning rather than an independent domain. When 
calculating the composite measure, scores on tests such as TMT A and B, and the GP where a 
higher score indicated poorer performance were reverse scored so a higher score in these tests, 
as well as in the cumulative score, indicated a better performance consistently.  
 
7.7.1.1 Testing structural complexity group differences in cognitive functioning 
The study aimed to assess the differences in the level of cognitive functioning across the 
different structural complexity groups. Group differences in demographic, cognitive and clinical 
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variables were tested using the Chi-square test (frequency / categorical data), the Kruskal-Wallis 
test (non-parametric continuously outcomes) and ANCOVA’s (parametric continuous 
outcomes) where appropriate. The values of the Fisher’s exact test are reported where the cell 
count is less than 5. The reported effect size for the continuous variables is ‘r’ and for the 
categorical variable is a Cramer’s V.  
 
ANCOVA’s were used to assess between-group differences on the NP test scores and the mean 
total composite score irrespective of the non-normal distribution, as the need to control for 
certain covariates was considered important and there are no non-parametric equivalents of an 
ANCOVA (Pallant, 2007). Potential covariates for these analyses were initially selected based 
on a theoretical rationale and their established association with the outcome variable in past 
empirical research (Lezak et al, 2012). Identified covariates were retained in the analyses if they 
were significantly (p<0.05) associated with the outcome variable. For post-hoc comparisons 
between the four groups, the Sidak test was used, as it is less conservative than its alternatives 
such as the Bonferonni correction and does not result in the loss of power (Field, 2009). The 
effect size of the ANCOVA analysis as determined based on Cohen’s guidelines (Cohen, 1988), 
whereby 0.01 is a small effect, 0.06 moderate and 0.14 large.   
 
7.7.2 Research question 2: Are demographic, clinical and mood factors associated with 
cognitive performance in ACHD patients?  
This study aimed to identify the demographic, clinical, and mood factors associated with 
cognitive functioning in ACHD patients. Hierarchical multiple regressions were conducted with 
IQ and each of the NP scores as dependent variables. Each NP score was used as a dependent 
variable, as opposed to a cumulative score for each domain, as domains of cognitive functioning 
are multidimensional and different tests assess different micro-skills within each of these 
domains, which may potentially be differentially affected by ACHD. Therefore, using a 
cumulative score may obscure or conceal these differences. Furthermore, assessing each 
independent score allowed more specificity with regards to identifying the factors that have the 
ability to influence and or impact different areas of cognitive function assessed.  
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Given the exploratory nature of this study, a more detailed approach to analysis was undertaken, 
including the assessment of the total group, and each sub-group independently. It was 
considered important to assess each group independently to be able to understand the impact of 
different structural complexity levels on different cognitive outcomes. These differences could 
have been obscured if the group was assessed as a whole. It is acknowledged that this may have 
led to a large number of analyses, and a loss of power given the smaller sample sizes in the sub-
groups. However, given the lack of evidence in this area of research, the benefits of this 
exploratory approach were considered to outweigh the risks associated with multiple analyses. 
To account for the large number of analyses conducted, a more stringent p-value (p<0.01) was 
chosen. However, some caution is warranted when interpreting the results of these analyses.  
 
Two sets of analyses were undertaken to identify factors significantly associated with cognitive 
functioning:  
(1) The entire cohort was analyzed to identify factors associated with cognitive functioning in 
ACHD patients in general 
(2) Subgroup analyses in which each structural complexity group was analyzed separately to 
identify any unique factors associated with a particular complexity group.  
The assumptions tested and the procedural aspects of the regression analysis are discussed 
below. 
 
7.7.2.1 Collinearity and Multi-collinearity  
Bivariate correlation analysis was used to identify significant correlations between the 
independent variables (IV’s) that would be indicative of collinearity, which may weaken the 
multivariate model by reducing the stability of parameter estimates and increasing standard 
error. In pairs of variables correlated at r=>.8, one was removed after careful consideration (e.g. 
the variable total number of days spent in hospital days was retained over number of hospital 
admissions, as the previous variable has been associated with cognitive functioning in the 
literature and provides more detailed information regarding the participants time spent in 
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hospital) (Tyagi et al, 2013). Multicollinearity was also assessed in the regression analysis by 
conducting tolerance tests and checking the Variance Inflation Factor values (ideally <4).  
 
7.7.2.2 Dummy coding of variables 
Categorical variables in the study were dummy coded, with all but one (to represent the 
reference category) of the dummy coded variables entered into the equation, following 
procedures recommended by Field, (2009). Further the distribution of some of the clinical 
variables (cyanosis, CPB minutes, HA minutes, age at repair) was such that the majority of the 
scores were concentrated on one end of the distribution given that the variable wasn’t applicable 
to all groups included in the study; for instance cyanosis, was only applicable to the cyanotic 
conditions and not the acyanotic. This caused the data to be severely skewed (See Figure 7.6a as 
example), and at risk of being unable to reliably explain variance in the regression analyses. 
Therefore, these variables were transformed into quartiles for two reasons i) to allow a more 
normal distribution (See Figure 7.6b below), and ii) to allow predictors to explain more 
variability in the outcome. Quartiles were computed separately for the total group as a whole 
and for each of the four complexity groups individually.  
 
 
 
 
Figure 7.6: Example of frequency distribution before (a) & after (b) transformation into 
quartiles 
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7.7.2.3 Screening for univariate predictors of cognitive functioning  
In order to identify factors potentially associated with cognitive function to enter into the 
multiple regression models, a univariate regression was run for each predictor and dependent 
variable. Only factors significantly associated with cognition at p<0.05, were entered into the 
multivariate regression models, this was done to reduce the number of redundant variables in 
the model. A significance level of p<0.05 was chosen for the univariate screen to allow the 
maximum number of variables to explain variance in the outcome. Univariate predictors were 
identified for the group as a whole and for each structural complexity groups separately (Please 
see Appendix-N for results of the univariate screening). Only results for the outcome variables 
with at least one significant predictor variable in the univariate screening will be presented.  
 
7.7.2.4 Order of the hierarchical regression blocks 
Significant variables were entered into a hierarchical multivariate regression model in 6 blocks. 
The first block included the participants’ demographic variables, which were followed by a 
block for the structural complexity groupings and functional health status variables. Once these 
variables were entered into the model the surgery related variables were added, to account for 
any procedural predictors of variance over and above the structural complexity groups. Oxygen 
saturation related variables (cyanosis and current saturation) were entered into the fourth block 
to assess its influence over and above surgery related variables, followed by the current health 
related variables in the fifth block. Lastly, Mood variables were entered to assess their impact 
on cognitive functioning having accounted for all clinical variables (See Figure 7.7). 
 
The rationale for the order of the regression blocks was to firstly take into account the 
demographic variables and the patient’s clinical history and structural complexity before 
assessing the impact of current health related variables for e.g. their current oxygen saturation 
levels and lastly mood variables. The objective was to identify unique predictors of cognitive 
functioning over and above the clinical history and diagnosis (Structural complexity groups) of 
the participants. It aimed to evaluate the association of both clinical and psychosocial factors 
with cognitive outcomes. 
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7.7.2.5 Dealing with outliers  
Outliers are defined as observations that deviate so much from other observations, that they 
arouse suspicion that they were generated by a different mechanism, implying that the deviated 
value is potentially an error of measurement or an invalid data point (Hawkins, 1980). Within 
this study it was ensured that all outliers were legitimate scores, and not mistakes in data entry.  
Multivariate outliers were identified using Cook’s distance. This index was chosen, as it 
accounts for the change in the predicted values when influential data cases with large residuals 
and/or a high leverage are excluded. Further it also takes into consideration the distance of the 
observed value from the others (Hair et al, 1998). A Cook’s distance >1 is considered large and 
a cause of concern (Stevens, 1984).  If a Cook’s distance of >1 was identified; analyses were re-
run with and without the outliers to see if their inclusion affected results. If differences are noted 
the results will be presented in Chapter 8.  
 
7.7.2.6 Examination of residuals 
While regression analysis does not make any assumptions about the data being normally 
distributed, it does expect a fairly normal distribution of the residuals after the analysis. For 
each of the regression analyses the distribution of the residuals was assessed visually using 
scatter plots. Scatter plots were assessed for a random distribution, the presence of any patterns 
e.g. funnelling and skewness at either end of the distribution was considered problematic and 
indicative of non-normally distributed residuals. While non-normally distributed residuals do 
not invalidate the analyses, it weakens it and thus caution is warranted when drawing 
conclusions (Tabachnick and Fidel, 2013). If non-normal residuals are noted the results will be 
presented in Chapter 8. 
 
7.7.3 Research question 3: Is cognitive functioning in ACHD patients associated with 
QoL? 
The association between QoL and the demographic, clinical factors and total mean composite 
NP score was assessed using hierarchical multiple regression. Again to explore the association 
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between cognitive functioning and QoL in ACHD patients as a group, but also to be able to 
investigate factors associated with QoL in specific structural complexity groups. A univariate 
screening using simple linear regressions was conducted for each outcome variable (PCS and 
MCS) and variables significant at <0.05 were entered into the multivariate regression models. 
Two sets of analyses were run for each outcome; one on the total sample, and another for each 
structural complexity group. Procedures and assumptions of the regression analysis were tested 
similar to the analysis discussed in the previous section (Section 7.7.2), and therefore have not 
been repeated here. 
 
The variables were entered into three regression blocks for the multivariate analyses. These 
consisted of the demographic variables, followed by the clinical and lastly cognition variable. 
The order of the regression blocks was chosen to be able to assess the unique variance in QoL 
explained by cognitive functioning after accounting for the patient related demographic and 
clinical characteristics.    
 
The next chapter, Chapter 8 discusses the results of the analysis discussed above.
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Note: NYHA= New York Health Assessment, CPB= Cardio Pulmonary Bypass, HA= Hypothermic Arrest, CNS= Central Nervous System, ACE= angiotensin-converting-enzyme , LV= Left 
Ventricle, RV= Right Ventricle  
Figure 7.7: The order of the hierarchical multiple regression blocks for Research question 2 
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8 CROSS -SECTIONAL STUDY RESULTS 
 
8.1 Prologue  
This chapter presents the findings of the cross-sectional study. Each section of the chapter aims 
to address the research questions detailed in Chapter 6. Firstly, the demographic and clinical 
characteristics of the sample are described, and assessed for group differences. Secondly, 
cognitive functioning in this sample is assessed in comparison to normative data. Thirdly, 
comparisons are made between the four structural complexity groups on cognitive outcomes. 
This is followed by an examination of possible factors (demographic, clinical and mood) 
associated with cognitive functioning. Finally, the relationship between cognitive functioning 
and QoL is examined.  
 
8.2 Demographic and clinical characteristics of the study sample 
The total study sample included 314 participants of whom 310 had complete 
neuropsychological assessment data and were included in the final analyses; the other 4 
participants were unable to complete NP tests due to time constraints. The final sample (N=310) 
consisted of 174 (56.13%) males and 136 (43.87%) females. The median age of the cohort was 
31 years ranging from 18-76 years. The demographic characteristics of the sample are presented 
in Table 8.1 (below). There were similar numbers of participants across three of the structural 
complexity groups (ToF= 81, TGA= 80, Simple=84), but fewer participants in the SV group 
(SV=65).   
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Table 8.1 Demographic characteristics of the sample by structural complexity groups 
Variable N (%) ToF TGA SV Simple Total 
sample 
χ2/H V/r 
(ES) 
p-
value 
df 
Gender 
Male  43  
(53.1) 
51  
(63.8) 
43 
 (66.2) 
37 
 (44) 
174 
 (56.1) 
9.82 
  
0.17 
  
0.020 
  
3 
Female  38 
 (46.9) 
29  
(36.3) 
22 
(33.8) 
47  
(56) 
136 
 (43.9) 
Ethnicity † 
White British  72 
(88.9) 
71 
(88.8) 
51 
(78.5) 
68 
(81) 
262 
(84.5) 
4.91 
  
0.12 
  
 
0.178 
  
3 
Others 9 
(11.1) 
9 
(11.3) 
14 
(21.5) 
16 
(19) 
48 
(15.5) 
Living status 
Cohabiting (with 
parent/spouse/frie
nd) 
72 
 (88.9) 
63  
(78.8) 
58  
(89.2) 
68  
(81) 
261 
 (84.2) 
5.02 
  
0.12 
  
0.170 
  
3 
Alone-on their 
own 
9 
(11.1) 
17 
 21.3) 
7 
 (10.8) 
16  
(19) 
49  
(15.8) 
Employment 
Employed/ 
student/in training 
63  
(77.8) 
66 
(82.5) 
51 
(78.5) 
64 
(76.2) 
244  
(78.7) 
2.18 
  
0.08 
  
0.530 
  
3 
Unemployed/ 
retired/ unable to 
work 
18 
 (22.2) 
14 
(17.5) 
14  
(21.5) 
20 
(23.8) 
66 
 (21.3) 
Occupation level ‡ 
Managerial/ 
Professional  
19  
(23.5) 
17 
(21.3) 
15  
(23.1) 
23  
(27.4) 
74  
(23.9) 
0.9 0.05 0.820 3 
Intermediate  14 
 (17.3) 
18 
(22.5) 
9  
(13.8) 
10  
(11.9) 
51 
 (16.5) 
Lower 26 
 (32.1) 
25 
(31.3) 
20  
(30.8) 
24  
(28.6) 
95 
 (30.6) 
Never 
worked/unemploy
ed 
22  
(27.2) 
20  
(25.0) 
21 
 (32.3) 
27 
 (32.1) 
90 
 (29.0) 
Marital Status 
Married 44 
(54.3) 
36 
(45) 
33 
(50.8) 
45 
(53.6) 
158 
(51) 
1.73 
  
0.07 
  
0.630 
  
3 
Unmarried/divorc
ed/single 
37 
(45.7) 
44 
(55) 
32 
(49.2) 
39 
(46.4) 
152 
(49) 
Age 
Age (Median, 
interquartile 
range) 
33.0 
(25-41) 
31.50 
(27-
36) 
28.60 
(23-
32) 
37.0 
(23-32) 
31.0 
(26-45)  
22.03 -.343 
– 
0.293 
<.001 3 
Education  
Yrs of education 
(Median, 
interquartile 
range) 
13.0 
(11-16) 
13.3 
(11-
16) 
13.7 
(11-
16) 
13.5 
(11-16) 
13.4 
(11-16)  
3.08 n/a 0.370 3 
V= Cramer's V, r= effect size for Kruskal Wallis, ES=Effect Size, † =the ethnicity variable was collapsed into a 
dichotomous variable due to low cell counts within categories (N=11). ‡= The National Statistics Socio-economic 
Classification (NS-SEC rebased on the SOC2010) (Rose and Pevalin, 2010) 
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 The ethnicity of the study sample was initially classified into 11 sub-groups but due to the 
small proportion in many categories (e.g. Asian, African American, White- British) groups were 
combined into a dichotomous variable (White British vs. Others), with most of the study sample 
being British. The majority of the study sample was employed and/or studying, and cohabiting 
with family and friends. A Kruskal-Wallis test revealed a significant difference between the 
groups in age. The SV group was significantly younger than the Simple (p <0.001, r=-.343) and 
ToF groups (p=.002 r=0.293). No other demographic variables differed significantly between 
the groups at p<0.01.  
 
The clinical characteristics of the study sample are presented in Figure 8.1– Figure 8.16 (box 
plots of the median values of each continuous variable) and Table 8.2 (for categorical variables). 
The reported effect size for the continuous variables is ‘r’ and for the categorical variable is a 
Cramer’s V. The pairwise comparisons conducted to identify significant group differences 
between the groups on the continuous variables (as seen in Figures 8.1-8.16) are presented in 
Appendix-P 
 
Figure 8.1 – 8.16 Boxplots with error bars for each continuous clinical variable by structural 
complexity group 
 
Figure 8.1: Data distribution for age at 
surgical repair by complexity group 
 
Figure 8.2: Data distribution for number 
of interventions by complexity group 
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Figure 8.3: Data distribution for number of 
repair surgeries by complexity group 
 
Figure 8.4: Data distribution for number 
of palliation procedures by complexity 
group 
 
 
 
 
Figure 8.5 Data distribution for number of 
catheter lab interventions by complexity 
group 
 
Figure 8.6 Data distribution for number of 
years since last surgery by complexity 
group 
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Figure 8.7 Data distribution for number of 
cyanotic days  by complexity group 
 
Figure 8.8 Data distribution for current 
oxygen saturation levels by complexity 
group 
 
 
 
 
Figure 8.9 Data distribution for days spent 
in ICU by complexity group 
 
Figure 8.10 Data distribution for minutes 
on CPB by complexity group 
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Figure 8.11 Data distribution for minutes 
under HA by complexity group 
Figure 8.12 Data distribution for number of 
days in hospital by complexity group 
 
 
 
 
Figure 8.13 Data distribution for number of 
co-morbidities by complexity group          
 
Figure 8.14 Data distribution for number 
of medications by complexity group 
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Figure 8.15 Data distribution for the level of 
RVEF by complexity group 
Figure 8.16 Data distribution for the level of 
LVEF by complexity group 
 
 
Figures 8.1 to 8.16, illustrate the differences between the groups on clinical variables (See 
Appendix-P for results). The four complexity groups differed significantly on symptomology 
related variables for example cyanosis, with the Simple group being significantly different from 
the ToF, TGA and SV group (Fig 8.7) and current saturation (Fig 8.8) with all groups being 
significantly different from each other. These differences could be expected given the cyanotic 
and acyanotic nature of the different structural complexity groups. Furthermore, the groups 
differed significantly on surgery related variables, including CPB minutes (Figure 8.10), and 
hypothermic arrest minutes (Figure 8.11) with the Simple group being significantly different to 
the ToF, TGA and SV groups on both these variables. The simple group consistently had a 
median score of zero on these surgery related variables, emphasizing the differences in the 
treatments undertaken for different forms of ACHD. The four groups did not differ significantly 
on the variable co-morbidities, thus suggesting that most differences were due to the differential 
diagnosis between groups (Figure 8.13). These figures illustrate the variability and spread of the 
different clinical characteristics across groups, making them clinically distinct.  
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Table 8.2 illustrates the significant differences in clinical characteristics across the four 
structural complexity groups on categorical clinical variables. The values of the Fisher’s exact 
test are reported where one or more cell counts were lower than 5. The four groups differed 
significantly on the majority of clinical variables with the exception of the New York Health 
Assessment classification (p=0.118), types of medication taken (beta-blockers (p=0.080) and 
diuretic (p=0.810) medication), post-operative CNS complications (p=0.011), ventricular 
dysfunction (p=0.015) and the presence of a pacemaker (p=0.056). Most of the differences 
found can be expected given the diverse nature of the forms of CHD, for example differences in 
procedures (number of palliation procedures before surgical repair) and complications (the need 
to attend heart failure clinics) can be expected given that the less complex forms of CHD 
generally do not undergo as many procedures nor experience as many complications. Post-
operative CNS complication was borderline significant with the Simple group not exhibiting 
any CNS complications (See Table 8.2). 
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Table 8.2: Clinical characteristics of the study sample by structural complexity groups (Categorical variables) 
Categorical clinical variables N (%) 
 Total sample ToF TGA SV Simple x
2
 Cramer's 
V (ES) 
df  p-value 
Palliation before repair 
No 153 
(49.4) 
47 
(15.4) 
12 
(3.9) 
10 
(3.20) 
84 
(27.1) 
156.41 
  
0.71 
  
3 
  
<0.001 
  
Yes 157 
(50.6) 
34 
(11.10) 
68 
(22.3) 
55 
(18) 
0 
(0) 
Post-operative CNS complications 
No 291 
(93.9) 
76 
(24.9) 
72 
(23.6) 
59 
(19.0) 
84 
(27.1) 
10.83
 a
 
  
 
0.16 
  
3 
  
0.011 
  
Yes 19 
(6.1) 
5 
(1.6) 
8 
(2.6) 
6 
(1.9) 
0 
(0) 
Post-operative infection  
No 233 
(75.2) 
54 
(17.7) 
56 
(18.4) 
44 
(14.2) 
79 
(25.5) 
22.264 
  
0.266 
  
3 
  
<0.001 
  
 Yes 77 
(24.8) 
27 
(8.9) 
24 
(7.9) 
21 
(6.8) 
5 
(1.6) 
Post-operative Ventricular dysfunction 
No 282 
(91.0) 
74 
(24.3) 
69 
(22.6) 
56 
(18.1) 
83 
(26.8) 
10.302 
  
0.182 
  
3 
  
0.015 
  
Yes 28 
(9.0) 
7 
(2.3) 
11 
(3.6) 
9 
(2.9) 
1 
(0.3) 
Heart failure clinic 
No 255 
(82.3) 
76 
(24.5) 
53 
(17.1) 
43 
(13.9) 
83 
(26.8) 
48.794 
  
0.397 
  
3 
  
<0.001 
  
Yes 55 
(17.7) 
5 
(1.6) 
27 
(8.7) 
22 
(7.1) 
1 
(0.3) 
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Categorical clinical variables N (%) 
 Total sample ToF TGA SV Simple x
2
 Cramer's 
V (ES) 
df  p-value 
Arrhythmias  
No 228 
(73.5) 
66 
(21.3) 
46 
(14.8) 
39 
(12.6) 
77 
(24.8) 
33.518 
  
0.329 
  
3 
  
<0.001 
  
Yes 82c 
(26.5) 
15 
(4.8) 
34 
(11) 
26 
(8.4) 
7 
(2.3) 
Hypertension 
No 278 
(89.7) 
80 
(25.8) 
74 
(23.9) 
63 
(20.3) 
61 
(19.7) 
38.007 
  
0.35 
  
3 
  
<0.001 
  
Yes 32 
(10.3) 
1 
(0.3) 
6 
(1.9) 
2 
(0.6) 
23 
(7.4) 
NYHA category 
Class 1 272 
(87.7) 
70 
(22.6) 
70 
(22.6) 
53 
(17.1) 
79 
(25.5) 
5.840
 a
 
  
  
  
0.122 
  
  
  
3 
  
  
  
0.118 
  
  
  
Class 2 28 
(9) 
10( 
3.2) 
5 
(1.6) 
8 
(2.6) 
5 
(1.6) 
Class 3 7 
(2.3) 
1 
(0.3) 
4 
(1.3) 
2 
(0.6) 
0 
(0) 
Class 4 3 
(1) 
0 
(0) 
1 
(0.3) 
2 
(0.6) 
0 
(0) 
Pacemaker 
No 293 
(94.5) 
81 
(26.1) 
70 
(22.6) 
60 
(19.4) 
82 
(26.5) 
14.434 
  
0.216 
  
3 
  
0.056 
  
Yes 17 
(5.5) 
0 
(0) 
10 
(3.2) 
5 
(1.6) 
2 
(0.6) 
ACE inhibitors medication 
No 244 
(78.7) 
74 
(23.9) 
56 
(18.1) 
49 
(15.8) 
65 
(21) 
11.872 
  
0.196 
  
3 
  
0.008** 
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Categorical clinical variables N (%) 
 Total sample ToF TGA SV Simple x
2
 Cramer's 
V (ES) 
df  p-value 
Yes 66 
(21.3) 
7 
(2.3) 
24 
(7.7) 
16 
(5.2) 
19 
(6.10) 
Diuretic medication 
No 275 
(88.7) 
73 
(23.5) 
70 
(22.6) 
56 
(18.1) 
76 
(24.5) 
0.964 
  
0.056 
  
3 
  
0.810 
  
Yes 35 
(11.30) 
8 
(2.6) 
10 
(3.2) 
9 
2.9) 
8 
(2.6) 
Beta-blocker medication 
No 258 
(83.2) 
74 
(23.9) 
61 
(19.7) 
53 
(17.1) 
70 
(22.6) 
6.759 
  
0.148 
  
3 
  
0.080 
  
Yes 52 
(16.8) 
7 
(2.3) 
19 
(6.1) 
12 
(3.9) 
14 
(4.5) 
Anti-arrhythmic medication 
No 274 
(88.4) 
75 
(24.2) 
69 
(22.3) 
48 
(15.5) 
82 
(26.5) 
22.116 
  
0.267 
  
3 
  
<0.001 
  
Yes 36 
(11.6) 
6 
(1.9) 
11 
(3.5) 
17 
(5.5) 
2 
(0.6) 
Anti-coagulant medication 
No 233 
(75.2) 
71 
(22.9) 
64 
(20.6) 
21 
(6.8) 
77 
(24.8) 
83.971 
  
0.52 
  
3 
  
<0.001 
  
Yes 77 
(24.8) 
10 
(3.2) 
16 
(5.2) 
44 
(14.2) 
7 
(2.3) 
Note- x2-chi square statistics calculated based on the 4 groups,  a Fisher’s exact chi square value and significance reported, **p<0.01, ES= Effect Size 
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8.3 Cognitive functioning in ACHD patients compared to normative data and different 
structural complexity groups  
 
In order to address these research objective two sets of analyses were undertaken. First, the 
performance of the ACHD patients on each neuropsychological test was compared to normative 
values both for the total sample (all groups combined) and for each structural complexity group 
independently. Finally, differences in cognitive functioning between the four structural 
complexity groups were assessed and presented in Section 8.6. 
 
As discussed in Chapter 7 (section 7.7.1) participants’ raw scores (See Table 8.3 below) on the 
neuropsychological (NP) assessments were converted into standardized z-scores. All the NP 
scores were calculated using normative data matched by the participant’s age, and, where 
available, educational level (See Appendix-M for further details and sources of the normative 
data).  
 
Cognitive impairment was defined as a score less than or equal to 1.5 SD below the normative 
mean score for all the tests; except IQ, for which the criteria for impairment was 1SD below the 
normative mean score. As discussed in Chapter 7 (section 7.7.1) the nature of a normal data 
distribution suggests approximately 15% of the sample can be expected to fall 1 SD below the 
mean and 7% can be expected to fall 1.5 SD below the mean on any test (See Lezak et al, 2012 
for a visual representation of the normal distribution). 
  
      
167 
 
Table 8.3: Mean (SD) NP raw scores for the sample by structural complexity group 
NP test raw score  ToF 
Mean  
(SD) 
TGA 
Mean  
(SD) 
SV 
Mean  
(SD) 
Simple 
Mean  
(SD) 
Total Sample  
Mean 
(SD) 
IQ 
WAIS III-Mental Arithmetic 12.20 
(4.34) 
11.81 
(3.97) 
12.32 
(4.00) 
13.34 
(4.06) 
12.46 
(4.13) 
WAIS III- Information 15.74 
(5.10) 
16.50 
(5.44) 
16.97 
(5.96) 
17.17 
(5.36) 
16.58 
(5.45) 
WAIS III- Digit Symbol 71.84 
(15.58) 
73.19 
(16.17) 
71.65 
(17.39) 
75.65 
(15.62) 
73.18 
(16.14) 
WAIS- Estimated Full scale 
IQ (FSIQ) 
95.04 
(15.40) 
95.26 
(15.78) 
96.63 
(15.67) 
100.44 
(14.64) 
96.89 
(15.45) 
Executive functioning 
COWA- F 11.86 
(3.69) 
11.20 
(4.4) 
12.82 
(4.44) 
12.17 
(4.11) 
11.97 
(4.19) 
COWA –A 9.63 
(4.01) 
9.91 
(4.74) 
11.72 
(4.23) 
10.83 
(4.40) 
10.47 
(4.41) 
COWA - S  13.99 
(4.58) 
14.19 
(4.69) 
14.83 
(5.03) 
14.75 
(4.47) 
14.42 
(4.67) 
Stroop Colour-Word 111.86 
(0.49) 
111.70 
(1.32) 
111.83 
(0.52) 
111.80 
(0.74) 
111.8 
(0.84) 
WCST- Errors 18.54 
(8.97) 
17.74 
(8.31) 
17.18 
(8.18) 
16.32 
(8.52) 
17.45 
(8.52) 
WCST-CLR  40.69 
(12.45) 
41.50 
(11.50) 
4 2.45 
(11.71) 
43.76 
(11.63) 
42.10 
(11.83) 
WCST- No. Cat 3.06 
(1.43) 
3.20 
(1.45) 
3.29 
(1.31) 
3.65 
(1.31) 
3.31 
(1.39) 
WCST-TTC 13.27 
(7.59) 
13.00 
(8.68) 
13.63 
(8.37) 
12.63 
(7.83) 
13.10 
(8.08) 
WCST- FTM 0.46 
(0.72) 
0.39 
(0.62) 
0.43 
(0.81) 
0.27 
(0.62) 
0.38 
(0.69) 
Attention 
TMT A 32.04 
(11.47) 
32.54 
(11.99) 
31.62 
(13.26) 
31.06 
(9.39) 
31.81 
(11.46) 
TMT B 67.15 
(25.75) 
62.60 
(18.92) 
65.17 
(19.08) 
60.74 
(25.03) 
63.82 
(22.65) 
SDMT- W 51.37 
(10.17) 
53.15 
(12.02) 
53.65 
(12.51) 
54.11 
(10.79) 
53.05 
(11.34) 
SDMT- O  61.90 
(12.70) 
63.58 
(13.93) 
65.06 
(13.54) 
63.57 
(14.37) 
63.45 
(13.64) 
Motor function 
GP-D time 72.99 
(11.58) 
72.44 
(13.92) 
73.69 
(17.86) 
69.61 
(13.31) 
72.08 
(14.16) 
GP-ND time 79.14 
(14.13) 
80.71 
(21.30) 
81.62 
(22.46) 
78.26 
(18.69) 
79.83 
(19.17) 
Memory 
RAVLT trial 1 8.62 
(2.06) 
8.50 
(2.60) 
8.97 
(2.43) 
8.39 
(2.29) 
8.60 
(2.35) 
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NP test raw score  ToF 
Mean  
(SD) 
TGA 
Mean  
(SD) 
SV 
Mean  
(SD) 
Simple 
Mean  
(SD) 
Total Sample  
Mean 
(SD) 
RAVLT trial 2 11.28 
(2.48) 
10.85 
(2.94) 
11.88 
(2.34) 
11.10 
(2.80) 
11.25 
(2.68) 
RAVLT trial 3 12.54 
(2.37) 
12.21 
(2.53) 
12.09 
(2.43) 
12.04 
(2.26) 
12.23 
(2.39) 
RAVLT trial 4 12.95 
(1.69) 
12.94 
(1.84) 
13.03 
(1.70) 
12.83 
(2.29) 
12.93 
(1.90) 
RAVLT trial 5 12.73 
(1.73) 
12.81 
(1.66) 
13.11 
(1.63) 
12.60 
(2.00) 
12.79 
(1.77) 
RAVLT list B 7.51 
(2.16) 
7.26 
(2.12) 
7.63 
(2.31) 
7.17 
(2.35) 
7.38 
(2.23) 
RAVLT trial 7 11.54 
(2.52) 
11.88 
(2.41) 
12.12 
(2.39) 
11.63 
(2.76) 
11.77 
(2.53) 
RAVLT total acquisition 58.12 
(6.79) 
57.31 
(8.48) 
59.07 
(6.78) 
56.95 
(8.96) 
57.79 
(7.87) 
Total composite score  -6.63 
(10.93) 
-7.61 
(15.07) 
-6.72 
(13.55) 
-1.75 
(10.40) 
-5.58 
(12.72) 
Note-SD- Standard Deviation, TMT= Trail Making Test, COWA= Controlled Oral Word Association test, 
WAIS= Wechsler Adult intelligence Scale, GP=Grooved Pegboard, WCST-CLR= Wisconsin Card Sorting Test – 
Conceptual Level Responses, WCST-TTC= Wisconsin Card Sorting Test – Trials to Complete first category, 
WCST-FTM= WCST- Wisconsin Card Sorting Test -Failure to Maintain Set, WCST-No.Cat =  Wisconsin Card 
Sorting Test – Total number of categories, SDMT-W= Symbol Digit Modalities Test-Written score, SDMT-O= 
Symbol Digit Modalities Test-Oral score.  
 
 
For the purposes of this thesis the magnitude of the cognitive impairment was only considered 
important if over 15% of the sample showed impairment on the IQ test and over 7% on the NP 
tests. The relative performance of the ACHD group as compared to an age matched normative 
sample was evaluated on each test, and is presented below, for IQ and the four overarching 
cognitive domains (executive functioning, attention, memory and motor function). Results for 
each test are discussed for the total sample followed by the structural complexity groups.  
 
8.3.1 IQ in ACHD patients compared to normative data 
8.3.1.1 Total sample 
The normative data for comparison of IQ scores was derived from the test manual consisting of 
scores from healthy participants, aged 16-89 years (Wechsler, 1997). The mean score of the 
total sample within this study was 96.89 (Figure 8.17), ranging from 53.80 – 137.80. IQ scores 
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in the total study sample showed that 24% of the sample had an IQ score at least 1 SD below the 
normative mean of 100, greater than the expected 15% for a normal distribution.  
 
8.3.1.2 Structural complexity groups 
The mean score of all four groups were within the ‘average’ IQ category as classified by 
Wechsler (IQ= 90-109). Within the different structural complexity groups 22.2% of the ToF 
group, 23.8% of the TGA group, 20% of the SV group and a 16.7% of the Simple group scored 
1 SD below (i.e. IQ <85) the normative mean score (i.e. IQ=100) (See Figure 8.17). In all 
groups more than 15% of the sample exhibited impairment in IQ. 
 
 
Figure 8.17 Mean full scale IQ scores, with 1SD error bars  
 
8.3.2 Executive functioning in ACHD patients compared to normative data  
The overarching domain of executive functioning was assessed using three NP tests WCST, 
COWA and Stroop. The normative data for comparison in the WCST test was acquired from the 
test manual consisting of scores from 445 healthy participants, aged 18-89 years (Kongs et al, 
2000). Normative data for the COWA and the Stroop tests were taken from a study including 
1,300 and 156 healthy participants aged 16-95 years and 18-75 years respectively (Tombaugh, 
Kozak and Rees, 1999; Trenerry et al, 1989).  
85 
90 
95 
100 
105 
110 
115 
ToF TGA SV Simple total  
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8.3.2.1 Total sample  
The data presented in Figure 8.18 illustrates the total proportion (%) of the sample exhibiting 
impaired performance (1.5 SD below norms) on tests of executive functioning. The sample 
exhibited impairments on most of the tests used.  More than 7% of the total sample exhibited 
impairment in executive functions as assessed by the WCST (No. of categories =25%, 
conceptual level responses= 23% and Errors= 22%). Almost one quarter of the sample exhibited 
impairment on the number of categories achieved score, which is indicative of frontal lobe 
dysfunction (Barcelo and Knight, 2002) and is also considered one of the most diagnostically 
useful scores to detect impairment in executive function (Lezak et al, 2012; Strauss, Sherman, 
and Spreen, 2006). The only exception was the trials to complete first category score (6%) and 
the failure to maintain set score (7%), on which participant’s demonstrated performance 
comparable to that expected in a normal distribution. A greater proportion of participants 
showed impairment on the Stroop test (18%) and the COWA test (22%) than would be expected 
in a normal distribution (7%). 
 
8.3.2.2 Structural complexity groups 
Figure 8.18 showed a large proportion of participants within each group were impaired on the 
Stroop, COWA and WCST (WCST- No. of categories, errors and conceptual level responses) 
which assess the ability to formulate concepts and solve problems respectively. It is of note that 
fewer participants in the SV and Simple groups displayed impairments on the ‘failure to 
maintain set’ score, and the ToF, TGA and Simple groups on the ‘trials to complete 1st category 
scores’ of the WCST (i.e. < 7% exhibiting impairments) demonstrating performance 
comparable to that expected in a normal distribution. 
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Note – COWA= Controlled Oral Word Association test, Stroop-CW= Stroop Colour Word score, WCST = 
Wisconsin Card Sorting Test, TTC= Trials to complete 1st category, WCST-conceptual= conceptual level 
responses, WCST No Cat= Number of categories, WCST-FTM= Failure to Maintain Set  
Figure 8.18 Proportion (%) of the sample with impairment on tests of executive 
functioning  
 
8.3.3 Attention in ACHD patients compared to normative data  
8.3.3.1 Total sample  
Attention was assessed using three tests, the TMT-A and TMT-B and the SDMT. The 
normative data for the TMT was derived from a study including a healthy sample (N=911) 
ranging from 18-89 years of age (Tombaugh, 2004). The SDMT normative data was taken from 
the test manual, based on 420 healthy individuals ranging from 18-75 years of age (Smith, 
1978).  
 
Figure 8.19 illustrates the proportion (%) of the total sample exhibiting impairment on the TMT 
and SDMT tests.  A greater proportion of participants showed impairment on the TMT (part A 
=20% and B= 24%) than would be expected in a normal distribution (7%). In the SDMT test 
participants showed an impairment on both the written (10%) and oral (12%) subtest in >7% of 
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the total sample. SDMT scores falling 1 to 1.5 SD below the norms are considered indicative of 
a cerebral dysfunction (Smith, 1982). 
8.3.3.2 Structural complexity groups  
Figure 8.19 illustrates the proportion (%) of each structural complexity group exhibiting 
impairment on the TMT and SDMT tests; all four groups exhibited an impairment on both part 
A and B of the test. More than 7% of the sample in each group exhibited impairment, which is 
greater than can be expected in a normal distribution. Similarly, a considerable proportion in 
each group exhibited impairment on both parts of the SDMT test. The only exception was the 
Simple group that showed performance similar to that expected in a normal distribution, with 
less than 7% of the sample showing impairments on the SDMT scores.  
 
 
Note – TMT= Trail Making Test  
Figure 8.19 Proportion (%) of the sample with impairment on tests of attention 
 
8.3.4 Memory in ACHD patients compared to normative data  
8.3.4.1 Total sample  
Memory and verbal learning in this study sample was assessed using RAVLT. The normative 
data for the RAVLT was taken from the test manual including healthy individuals (Schmidt, 
1996). A single score was computed from this test; total acquisition. Figure 8.19 illustrates the 
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proportion of the total sample exhibiting impairment in memory. Within the total sample only a 
small proportion of participants exhibited impairment in memory and verbal learning (8.7%), 
only marginally exceeding the 7%, which could be expected in a normal distribution.   
 
8.3.4.2 Structural complexity groups 
Although more than 7% of the sample in most complexity group exhibited impairments in 
memory, the SV group only marginally exceeded (8%) the 7%, which could be expected in a 
normal distribution. The only exception was the Simple group, which exhibited the smallest 
proportion of participants with impairments (6%), which is similar to that expected in a normal 
distribution. 
 
 
Figure 8.20 Proportion (%) of the sample with impairment on the  memory test (RAVLT) 
 
 
8.3.5 Motor function in ACHD patients compared to normative data  
8.3.5.1 Total sample 
Motor function and dexterity in this study was assessed using the Grooved Pegboard test. The 
normative data was taken from the test manual including scores of healthy individuals ranging 
from 15 to over 60 years of age (Grooved Pegboard user’s manual, 2003). Data presented in 
Figure 8.21 illustrates the proportion (%) of the total sample exhibiting impairment in motor 
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function (dominant and non- dominant hand time scores). Interestingly the total study sample 
exhibited more impairment in motor functioning when using their dominant hand (27%) as 
compared to the non-dominant (21%). More than 7% of the sample, higher than would be 
expected in the normal population showed impairment on both scores.  
 
 
Note – GP= Grooved Pegboard  
Figure 8.21 Proportion (%) of the sample with impairment on tests of motor functioning 
 
 
8.3.5.2 Structural complexity groups 
A similar pattern was noted across all the four groups, with a higher number of participants 
exhibiting impairments on the dominant hand in comparison to the non-dominant hand. The 
TGA group had the highest proportion of participants with impairments on both dominant and 
non-dominant hands (36% and 25% respectively). The simple group had the lowest proportion 
of participants with impairments on both the dominant and non-dominant (15% and 13% 
respectively) scores. All groups showed more than 7% of the sample exhibiting impairment on 
both tests scores.   
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8.4 Total mean composite NP score (all NP scores combined) in the total ACHD sample  
Along with identifying specific impairments in different cognitive domains a cumulative mean 
NP score was also computed by summing the z-scores of all the NP indices to obtain a total 
mean composite score for the NP tests. A total composite score enabled comparison of overall 
cognitive functioning to be made between the four structural complexity groups (See Figure 
8.22). Tests where a higher score demonstrated poorer performance were reverse scored such 
that in all tests a higher score represented a better performance. As stated in Chapter 7, Section 
7.7.1 with regards to the WCST test only a single score (Total number of categories completed) 
was incorporated in the computation of the composite score given that the test scores were not 
independent of each other, and could therefore inflate the score. 
 
 
Note: A lower score is indicative of a poorer overall performance on tests of cognitive functioning  
Figure 8.22 Mean composite NP z-scores with 1SD error bars 
 
 
The total sample had a mean composite cognitive score of -0.37. The error bars in Figure 8.22 
illustrate the range and spread of scores across the different structural complexity groups, 
demonstrating the varied levels of cognitive functioning.  
 
Section 8.6 details the analyses assessing statistically significant group differences on the 
different cognitive domains and the total composite score. 
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8.5 Corrective measures for multiple cognitive assessments 
The previous section (Section 8.3) discussed the proportion of the normal population that can be 
expected to exhibit impairment on each individual test. However, when using multiple test 
batteries for assessment additional factors need to be taken into account such as the risk of 
overestimating the extent of cognitive impairment. As discussed in Chapter 7, there is a widely 
used approach provided by Ingraham and Aieken, (1996), to account for the use of multiple 
tests in a cognitive test battery. The authors argue that an inter-correlation among the scores 
may result in the estimates of the percentage of the population exhibiting impairment being 
higher than expected, due to the additional variance correlated scores may add. To account for 
this assumption the correlation among the test scores was examined. Within this study the 
correlation between tests was not very large (i.e. r=>0.80) and ranged between 0.01- 0.70. One 
exception was that of the WCST-64 test where the scores were highly correlated (>.8) amongst 
themselves (See Appendix-Q); therefore only one WCST score was chosen in order to calculate 
the estimated proportion of the sample that would be likely to show impairment. Nonetheless 
the results must be interpreted with some caution, as this only provides an estimation of the 
extent of NP impairments (accounting for number of tests).  
 
Based on the number of test scores and the impairment criteria used in the present study, the 
estimation provided by Ingraham and Aiken suggests that ~4% of the sample can be expected to 
exhibit impairment on at least three tests using an impairment criterion of 1.5SD. Therefore, 
identification of >4% of cases with impairment (>1.5SD) on 3 or more tests could be indicative 
of the presence of overall cognitive impairment, even after accounting for multiple tests and 
chance findings.  
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Table 8.4 (below) shows the proportion of participants scoring 1.5 SD below the norms on at 
least one and three tests respectively in this study. As is evident, a considerable proportion of 
participants in each group had scores within the impaired range on at least three tests with the 
Simple group showing the lowest proportion of participants with impairments. Even after 
accounting for the 4% of cases that may be attributable to chance, a considerable proportion of 
participants (ToF= 24.4%, TGA=29.7%, SV=25.2% Simple=7.9%) exhibited impairments on 
three or more tests.  
 
Table 8.4: Percentage of patients scoring 1.5 SD below the normative mean on at least one and 
three tests 
Structural complexity  
Groups 
Percentage  >1.5 SD below 
the normative mean on at 
least 1 test score 
Percentage  >1.5 SD 
below the normative 
mean on at least 3 test 
scores 
TOF 64.2 28.4 
TGA 75.0 33.7 
SV 69.2 29.2 
Simple 59.5 11.9 
Note: SD=Standard Deviation 
 
8.6 Are there significant differences in cognitive functioning across different structural 
complexity groups? 
Statistically significant differences in cognitive functioning among the four structural 
complexity groups were investigated using Analysis of Covariance (ANCOVA).  It is 
acknowledged that the majority of the NP test data was non-normally distributed (See 
Appendix-L), however an ANCOVA (a parametric test) was chosen as it enables controlling for 
covariates. This was considered important as the covariates may have the potential to influence 
the outcome/dependent variable (NP test scores). Furthermore there is no non-parametric 
alternative to the ANCOVA (Pallant, 2007).   
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8.6.1 Rationale for covariate selection 
The potential covariates in the ANCOVAs were years of education and mood (depression and 
anxiety). These were selected based on previous research suggesting their potential influence on 
cognitive performance (Lezak et al, 2012). Age was not included as a covariate because 
participant scores (i.e. the NP test scores used as dependent variables (DV) in this analysis) 
were already corrected for age when transformed into standardized z-scores, using normative 
data. The internal consistency reliability estimates (Cronbach α) for each of the mood and 
psychosocial scales were calculated. The results are presented in Table 8.5 (below). All scales 
met the criterion for internal reliability satisfactorily whereby, a Cronbach‘s α of 0.7 and above 
is generally suggested to be an adequate measure of reliability (Field, 2013).  
 
Table 8.5: Internal reliability of the psychosocial scales and subscales 
Measures including sub-scales Total no. of items Cronbach α 
 
PANAS  
Positive Affect (PA) 
Negative Affect (NA) 
20 
10 
10 
- 
0.905 
0.861 
STAI 6 0.809 
CESD-10 10 0.851 
SF-36 
Physical Component Summary(PCS) 
Mental Component Summary (MCS) 
36 
18 
18 
- 
0.927 
0.911 
Note: PANAS= Positive And Negative Affect Scale, STAI=State and Trait Anxiety Inventory, CESD= 
Center for epidemiology Depression Scale, SF-36, Short form 36 
 
 
Prior to entry into the model the association of all potential covariates with each cognitive 
outcome was assessed using simple (univariate) linear regressions. The significance level 
applied was p<0.05 to avoid exclusion of any potential covariate, which may influence results. 
Only significant variables (p<0.05) were included as covariates in the main analyses (See Table 
8.6 below for correlation between covariates and outcome variables). The data presented in 
Table 8.6 shows a consistent association of education and positive affect with most of the test 
scores (13/15 and 10/15 respectively).  
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Further, the correlation between covariates was also assessed for collinearity (correlation 
between variables) as a significant correlation between two covariates makes one of them 
statistically redundant, as it would not affect the DV over and above the other covariate. Each 
ANCOVA was also tested for the assumption of homogeneity of regression slopes, and all 
analyses met the assumption satisfactorily (suggesting the relationship between the outcome 
variable and its covariates was similar across all groups). The results of the analyses are 
presented in Table 8.7 (page no. 181).  
 
Two scores including the TMT-B (attention) and the mean total composite score showed a 
significant difference between the structural complexity groups. ANCOVA revealed a 
significant (p<0.01) group difference in divided attention as measured by the Trail Making Test 
(TMT-B), after controlling for years of education (F (1,303)=5.54 p=.019, Partial ŋp
2
=.018) and 
positive affect (F(1,303)=9.97, p=.002, Partial ŋ2p=.032) (See table 8.7). The measure of state 
anxiety (STAI) had no significant association with the outcome (p= .891). The adjusted means 
of the TMT-B score are presented in Figure 8.23. 
. 
 
Note: A higher score (i.e. more time taken) is indicative of a poorer performance on the TMT test 
of divided attention  
Figure 8.23 Adjusted mean standardized scores on the TMT-B test with 99% 
error bars 
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Table 8.6: Correlation matrix of NP scores and potential covariates (mood and education) 
  
 
TMT 
- A 
TMT -
B COWA 
Stroop 
CW WAIS GP-D GP-ND 
WCST - 
Error 
WCST - 
CLR 
WCST-
No.Cat 
WCST
-TTC 
WCST-
FTM RAVLT  
SDMT
W 
SDMT
-O 
 
Edu  
-.065 -.175
**
 .286
**
 .238
**
 .326
**
 -.181
**
 -.155
**
 -.311
**
 .294
**
 .288
**
 -.126
*
 -.071 .299
**
 .303
**
 .257
**
 
 
PANAS
-PA 
-.058 -.217
**
 .163
**
 .165
**
 .168
**
 -.158
**
 -.141
*
 -.113
*
 .109 .076 -.075 .063 .172
**
 .249
**
 .266
**
 
 
PANAS
-NA 
-.023 .089 .025 -.216
**
 -.099 -.053 -.081 .078 -.074 -.081 .126
*
 -.033 -.038 -.086 -.086 
 
STAI 
 .044 .124
*
 -.071 -.266
**
 -.091 .055 .059 .108 -.092 -.014 .057 -.104 -.058 -.088 -.118
*
 
 
CESD 
 .011 .073 -.059 -.183
**
 -.116
*
 .022 -.022 .111 -.103 -.086 .152
**
 -.062 -.083 -.120
*
 -.135
*
 
Note: *p<0.05, ** p<0.01 Edu-Education, TMT= Trail Making Test, GP=Grooved Pegboard, WCST-CLR= Wisconsin Card Sorting Test – Conceptual Level Responses, WCST-TTC= Wisconsin 
Card Sorting Test – Trials to Complete first category, WCST-FTM= WCST- Wisconsin Card Sorting Test -Failure to Maintain Set, SDMT-W= Symbol Digit Modalities Test-Written score, SDMT-
O= Symbol Digit Modalities Test-Oral score
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Table 8.7 Analysis of covariance for NP test scores 
NP variable Adjusted means for groups  Test statistic for group 
variable 
p- value Partial 
ŋ2p ToF TGA SV Simple  
Domain – Attention 
TMT-A 0.634 0.839 0.824 0.42 F(3,306)=1.74 0.157 0.017 
TMT B 0.958
a
 0.838
a,b
 1.029
a
 0.147
b
 F(3,303)=5.01 0.002** 0.047 
SDMT-O 0.3 0.279 0.463 0.623 F(3,302)=.954 0.415 0.009 
SDMT-W -0.024 -0.03 0.026 0.462 F(3,303)=2.17 0.091 0.021 
Domain - Motor function and dexterity 
GP-D  1.103 1.134 1.242 0.503 F(3,304)=3.30 0.021 0.032 
GP-ND 0.741 0.929 0.869 0.465 F(3,304)=1.94 0.122 0.019 
Domain - Executive functioning 
Stroop-Word -0.265 -0.499 -0.579 0.085 F(3,301)=3.56 0.015 0.034 
COWA -0.768 -0.855 -0.502 -0.547 F(3,304)=2.19 0.089 0.021 
WCST-Error 0.708 0.692 0.621 0.38 F(3,304)=1.56 0.197 0.015 
WCST-CLR -0.666 -0.67 -0.609 -0.349 F(3,305)=1.57 0.195 0.015 
WCST-No.Cat -0.699 -0.668 -0.575 -0.212 F(3,305)=3.49 0.016 0.033 
WCST-FTM -0.765 -1.286 -0.839 -0.758 F(3,247)=1.09 0.354 0.013 
WCST-TTC 0.113 0.293 0.51 -0.051 F(3,303)=.945 0.419 0.009 
Domain – IQ 
WAIS-III -0.082 -0.102 0.091 0.114 F(3,299)=1.04 0.375 0.01 
Domain – Memory 
RAVLT 0.631 0.38 0.532 0.573 F(3,304)=1.03 0.377 0.01 
Total composite NP score  
Total NP score -4.542
a,b
 -6.18
a
 -5.219
a,b
 -1.044
b
 F(1,303)= 3.99 .002** .047 
Note: significant results (group differences) are reported using superscripts- with same superscripts (letter) indicating lack of a significant group difference);  ** p<0.01 TMT= Trail Making Test, GP=Grooved Pegboard, 
WCST-CLR= Wisconsin Card Sorting Test – Conceptual Level Responses, WCST-TTC= Wisconsin Card Sorting Test – Trials to Complete first category, WCST-No.Cat= Wisconsin Card Sorting Test – Total Number of 
Categories, WCST-FTM=  Wisconsin Card Sorting Test -Failure to Maintain Set, SDMT-W= Symbol Digit Modalities Test-Written score, SDMT-O= Symbol Digit Modalities Test-Oral score, RAVLT= Rey Auditory 
Verbal Learning Test.  
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Post-hoc tests (Sidak correction) revealed that the Simple group performed significantly better 
than the ToF (p= .009) and SV groups (p=. 007) on the TMT-B, however comparison to the 
TGA group did not reach significance (p= .040). A significant group difference in the mean 
composite neuropsychological test scores was found after controlling for covariates including 
education, and affect. The covariates Education: F= (1,303)= 33.29, p=.000, partial ŋ2p =.099, 
and positive affect: F (1,303)= 8.68, p=.003, partial ŋ2p =.028 were also significantly associated 
with the outcome between the groups. 
 
 
Post hoc tests (Sidak correction) revealed a significant difference between the TGA and Simple 
group only (p=. 008) on the mean NP composite score. The adjusted mean scores of the groups 
are presented in Figure 8.24 below. Post-hoc tests (Sidak correction) revealed that the Simple 
group performed significantly better than the ToF (p= .009) and SV groups (p=. 007) on the 
TMT-B, however comparison to the TGA group did not reach significance (p= .040).  
 
A significant group difference in the mean composite neuropsychological test scores was found 
after controlling for covariates including education, and affect. The covariates Education: F= 
(1,303)= 33.29, p=.000, partial ŋ2p =.099, and positive affect: F (1,303)= 8.68, p=.003, partial 
ŋ2p =.028 were also significantly associated with the outcome between the groups. Post hoc 
tests (Sidak correction) revealed a significant difference between the TGA and Simple group 
only (p=. 008) on the mean NP composite score. The adjusted mean scores of the groups are 
presented in Figure 8.24. 
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Note: A lower score  is indicative of a poorer performance on the TMT test of divided attention  
Figure 8.24 Adjusted mean standardized scores for NP composite score with 99% error bars 
 
 
Overall the results showed that the prevalence of cognitive impairments in ACHD patients was 
greater in comparison to that expected in a healthy normal population. Impairments were 
identified in a range of cognitive domains including attention, executive function and motor 
function. The domain of memory was the only one that showed performance comparable to a 
normal healthy population. There were two significant differences in cognitive functioning 
between the four complexity groups, the TMT-B test of attention and the total composite score.     
 
8.7 Are demographic, clinical and mood factors associated with cognitive performance in 
ACHD patients? 
The associations between demographic, clinical, and mood factors and cognitive functioning in 
ACHD patients were examined using hierarchical multiple regressions. Two approaches were 
taken; first the entire cohort was assessed to identify factors associated with cognitive 
functioning in ACHD irrespective of the specific structural complexity group. Second, each 
structural complexity group was assessed independently. This was done because the clinically 
diverse nature of ACHD conditions could lead to different factors being associated with 
cognitive outcomes across the complexity groups.  In addition, certain variables are only 
applicable to certain groups; for example, cyanosis (i.e. inadequate oxygenation in the blood) is 
-10.00 
-8.00 
-6.00 
-4.00 
-2.00 
0.00 
2.00 
4.00 
Total Composite Adjusted Mean Score  ToF TGA SV Simple 
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not relevant in the Simple group as this group includes only acyanotic conditions, which by 
nature do not involve lack of oxygenation in the blood.  
 
When assessing each structural complexity group independently the sample size for the sub-
groups was less than required according to convention for a regression analysis (Rule of thumb 
is usually ≥100) (Field, 2013). However more recent evidence from Austin and Steyerberg, 
(2015) states that two subjects per variable in a liner regression is sufficient to provide adequate 
estimation of regression coefficients, standard errors, and confidence intervals.  
 
Full details of the methodology adopted for this analysis are presented in Chapter 7, Section 
7.7.2. The full tables of the regression models and change statistics for the sub-group analyses 
can be found in Appendix-R. Given the large number of results from the sub-group analyses, a 
summary of the key factors consistently associated with specific cognitive domains in different 
structural complexity groups are presented in Tables 8.16-8.19 (page 199). Results presented in 
these tables are based on the final regression models only.  
 
A univariate screening was conducted using linear regression for each cognitive test (DV) using 
the demographic, clinical and mood variables (IV) to assess significance before entering into the 
multivariate analysis. This analysis was conducted for the total sample and repeated for each 
sub-group individually. Only those variables significant at a p<0.05 in the univariate screening 
were included in the multivariate model (See Appendix-N). The results of this analysis are 
presented in the following sections.  
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8.7.1 Demographic, clinical and mood factors associated with IQ 
Total sample  
Table 8.8 (below) illustrates the regression model for the demographic, clinical and mood 
factors associated with estimated Full Scale IQ (FSIQ) in the total study sample. The final 
regression model (F=11.834(15,294), p=<0.001) explained 36% of the total variance in the 
sample’s IQ scores. Years of education achieved and CNS complications after surgery 
explained unique variance in IQ scores over and above the other clinical and mood factors in the 
equation. The results showed that lower years of education achieved and the presence of a CNS 
complication were associated with lower IQ. The addition of mood to the model did not explain 
any significant additional variance in IQ scores.  
 
Table 8.8: Demographic, clinical and mood factors associated with WAIS-III  in the total study 
sample 
Block Predictor Variables R
2
 Adjusted R
2
 ΔR2 ΔF β Sig. 
1  .289 .285 .289 62.440  .000** 
 Education (Yrs.)     .521 .000** 
 Employment     .088 .071 
2  .299 .290 .010 2.136  .120 
 Education (Yrs.)     .511 .000** 
 Employment     .077 .121 
 NYHA     -.029 .579 
 HF clinic     -.089 .077 
3  .370 .344 .071 4.166  .000** 
 Education (Yrs.)     .488 .000** 
 Employment     .072 .139 
 NYHA     -.055 .299 
 HF clinic     -.063 .223 
 Interventions total      -.016 .815 
 Palliation Before 
Repair 
    -.047 .428 
 Post-Op CNS 
Complications 
    -.204 .000** 
 Post-Op Infection      -.073 .154 
 Cath lab total      -.007 .895 
 Hospital days Q2     -.097 .102 
 Hospital days Q3     -.057 .406 
 Hospital days Q4     .044 .559 
4  .376 .345 .007 1.065  .364 
 Education (Yrs.)     .487 .000** 
 Employment     .081 .100 
 NYHA     -.054 .361 
 HF clinic     -.040 .450 
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Block Predictor Variables R
2
 Adjusted R
2
 ΔR2 ΔF β Sig. 
 Interventions total      -.008 .907 
 Palliation Before 
Repair 
    -.048 .422 
 Post-Op CNS 
Complications 
    -.210 .000** 
 Post-Op Infection      -.072 .157 
 Cath lab total      -.007 .898 
 Hospital days Q2     -.088 .144 
 Hospital days Q3     -.049 .474 
 Hospital days Q4     .059 .440 
 ACE medication     -.077 .147 
 Diuretic medication     .041 .499 
 RVEF     .055 .296 
5  .400 .360 .023 2.811  .026 
 Education (Yrs.)     .464 .000** 
 Employment     .038 .451 
 NYHA     -.024 .682 
 HF clinic     -.051 .334 
 Interventions total      -.022 .747 
 Palliation Before 
Repair 
    -.050 .395 
 Post-Op CNS 
Complications 
    -.193 .000** 
 Post-Op Infection      -.091 .077 
 Cath lab total      .002 .973 
 Hospital days Q2     -.103 .088 
 Hospital days Q3     -.045 .507 
 Hospital days Q4     .066 .385 
 ACE medication     -.056 .285 
 Diuretic medication     .033 .585 
 RVEF     .050 .337 
 Positive affect (PA)     .140 .019 
 Negative affect (NA)     -.015 .823 
 Anxiety (STAI)     -.046 .469 
 Depression (CESD)     .008 .910 
Note: Q= Quartile HF= Heart Failure, ACE= angiotensin-converting-enzyme inhibitors, NYHA=New York 
Health Association classification, RVEF= Right Ventricular Ejection **p=<0.01 
 
Structural complexity groups 
The demographic, clinical and mood factors associated with IQ for each of the individual 
complexity groups are presented in Tables 8.16-8.19. In the ToF group the simple linear 
regression showed no significant association between clinical and mood variables with IQ, 
hence these are not presented in the Table 8.16 (page 199). In the TGA group the final model 
showed that CPB minutes and years of education significantly explained unique variance in IQ 
scores; with a positive association between the two variables, suggesting an increased duration 
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of CPB and higher years of education were associated with higher IQ scores (See Table 8.17). 
The final model in the regression analysis for the SV group revealed a significant negative 
association with post-operative CNS complication; suggesting CNS complications after surgery 
were associated with lower IQ scores (See Table 8.18 on page 203). Furthermore, a positive 
association between positive affect and years of education with IQ was also noted in the SV 
group. Lastly, in the simple group none of the variables explained significant unique variance in 
the IQ (See Table 8.19).  
 
8.7.2 Demographic, clinical and mood factors associated with executive functioning  
Executive functioning in this study was measured using the WCST, Stroop (response inhibition) 
and COWA (verbal fluency) tests. These tests include multiple scores, each of which assesses 
some aspect of executive functioning. A total of 5 WCST scores were used in this study, these 
included the WCST- conceptual level responses, total number of errors, total number of 
categories completed, failure to maintain set and trials to complete first set. The factors 
associated with each of these test scores will be discussed below; firstly for the total sample and 
then for each structural complexity group. 
 
8.7.2.1 Wisconsin Card Sorting Test (WCST) 
Total sample 
Table 8.9 illustrates the regression model for the WCST- Conceptual level responses score. The 
final model significantly (F= 6.605(10,299), p=<0.001) explained 15.4% of the variance in 
conceptual level responses. In the final step, education and CNS complications continued to 
explain unique variance in executive functioning over and above the other variables in the 
equation. Fewer years of education and post-operative CNS complications were associated with 
impaired conceptual level responses. The mood variables did not explain unique variance in the 
outcome. 
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Table 8.9 Demographic, clinical and mood factors associated with WCST Conceptual level 
responses in the total study sample 
Block Predictor Variables R
2 
 Adjusted R
2
 ΔR2  ΔF Β Sig. 
1  .086 .083 .086 29.139  .000** 
 Education (Yrs.)     .294 .000** 
2  .162 .146 .076 5.478  .000** 
 Education (Yrs.)     .252 .000** 
 Palliation before repair     -.049 .426 
 Post-op CNS 
complication 
    -.222 .000** 
 Hospital days Q2     -.055 .410 
 Hospital days Q3     -.088 .232 
 Hospital days Q4     -.121 .093 
3  .181 .154 .019 1.712  .147 
 Education (Yrs.)     .244 .000** 
 Palliation before repair     -.042 .495 
 Post-op CNS 
complication 
    -.215 .000** 
 Hospital days Q2     -.043 .520 
 Hospital days Q3     -.067 .364 
 Hospital days Q4     -.057 .459 
 Medication total     -.013 .830 
 Anti-arrhythmia 
medication 
    -.043 .477 
 LVEF     .096 .092 
 Diuretic medication     -.064 .278 
Note: Q= Quartile, LVEF= Left Ventricular Ejection Fraction 
 
The demographic, clinical and mood factors associated with the WCST-error score are 
presented in Table 8.10 (below). The final model was significant (F=6.467(10,299), p=<0001), 
and explained 14.9% of the total variance in the number of errors made on the WCST test. The 
variables education and CNS complications continued to explain significant unique variance in 
the final model even after the addition of the mood variable (positive affect) thus suggesting that 
education and post-operative CNS complication explained unique variance in the errors made. 
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Table 8.10 Demographic clinical and mood factors associated with WCST Error score in the 
total study sample 
Block Predictor Variables R
2 
 Adjusted R
2
 ΔR2  ΔF Β Sig. 
1   .097 .094  .097 32.981  .000** 
 Education (Yrs.)     -.311 .000** 
2  .161 .142 .064 3.863  .001** 
 Education (Yrs.)     -.270 .000** 
 Hospital days Q2     .041 .543 
 Hospital days Q3     .102 .172 
 Hospital days Q4     .099 .187
  
 Post-op CNS 
complication 
    .187 .001** 
 Post-op infection     .041 .481 
 Palliation before repair     .040 .516 
3   .178 .150 .017 2.026  .110 
 Education (Yrs.)     -.258 .000** 
 Hospital days Q2     .031 .645 
 Hospital days Q3     .081 .280 
 Hospital days Q4     .040 .615 
 Post-op CNS 
complication 
    .184 .001** 
 Post-op infection     .039 .499 
 Palliation before repair     .034  .581 
 Medication total     .027 .645 
 LVEF     -.100 .076 
 Diuretic medication     .068 .249 
4  .179 .149 .001 .439  .508 
 Education (Yrs.)     -.252 .000** 
 Hospital days Q2     .034 .616 
 Hospital days Q3     .082 .276 
 Hospital days Q4     .037 .637 
 Post-op CNS 
complication 
    .182 .001** 
 Post-op infection     .044 .457 
 Palliation before repair     .037 .520 
 Medication total     .022 .708 
 LVEF     -.098 .081 
 Diuretic medication     .067 .255 
 Positive affect (PA)     -.036 .508 
Note: Q= Quartile, LVEF= Left Ventricular Ejection Fraction, **p=<0.01 
 
The demographic, clinical and mood factors associated with the WCST number of categories 
score are presented in Table 8.11 (below). The final model (F=3.261(25,284), p=<0.001) 
explained 15.5% of the total variance in the number of categories achieved. Two variables 
education and CNS complications continued to explaining unique variance in the score over and 
above all the other variables in the equation demonstrating that greater years of education was 
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associated with greater number of categories completed. CNS complications after surgery were 
associated with fewer categories completed. None of the mood variables explained unique 
variance in the outcome. 
 
Table 8.11 Demographic clinical and mood factors associated with WCST No. of categories 
score in the total study sample 
Block Predictor Variables R
2
  Adjusted R
2
 ΔR2  ΔF β Sig. 
1  .086 .080 .086 14.514  .000** 
 Age     -.058 .298 
 Education (Yrs.)     .277 .000** 
2  .129 .106 .043 2.472  .024 
 Age     -.074 .219 
 Education (Yrs.)     .258 .000** 
 TOF     -.185 .005** 
 TGA     -.156 .032 
 SV     -.118 .103 
 NYHA     -.034 .556 
 HF clinic     -.033 .615 
 Arrhythmias     -.056 .392 
3  .184 .143 .055 2.828  .007 
 Age     -.067 .365 
 Education (Yrs.)     .217 .000** 
 TOF     -.081 .303 
 TGA     -.045 .585 
 SV     .028 .766 
 NYHA     -.034 .567 
 HF clinic     -.024 .710 
 Arrhythmias     -.058 .388 
 Palliation total      -.079 .279 
 Post-op CNS 
complication 
    -.188 .000** 
 Post-op infection     -.068 .249 
 Cath lab total      -.041 .523 
 Hospital days Q2     -.038 .604 
 Hospital days Q3     -.094 .252 
 Hospital days Q4     -.046 .615 
4  .192 .142  .008 .948  .418 
 Age     -.075 .216 
 Education (Yrs.)     .214 .000** 
 TOF     .032 .899 
 TGA     .090 .725 
 SV     .110 .642 
 NYHA     -.047 .439 
 HF clinic     -.024 .707 
 Arrhythmias     -.055 .411 
 Palliation total      -.085 .250 
 Post-op CNS 
complication 
    -.196 .001** 
 Post-op infection     -.072 .225 
 Cath lab total     -.048 .460 
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Block Predictor Variables R
2
  Adjusted R
2
 ΔR2  ΔF β Sig. 
 Hospital days Q2     -.041 .576 
 Hospital days Q3     -.091 .269 
 Hospital days Q4     -.039 .665 
 Cyanosis days Q2     -.130 .587 
 Cyanosis days Q3     -.157 .520 
 Cyanosis days Q4     -.047 .848 
5  .223 .155 .031 1.614  .131 
 Age     -.042 .507 
 Education (Yrs.)     .213 .000** 
 TOF     .064 .799 
 TGA     .105 .681 
 SV     .198 .407 
 NYHA     -.020 .772 
 HF clinic     .011 .873 
 Arrhythmias     .003 .971 
 Palliation total      -.083 .267 
 Post-op CNS 
complication 
    -.182 .002** 
 Post-op infection     -.070 .239 
 Cath lab total     -.035 .593 
 Hospital days Q2     -.040 .592 
 Hospital days Q3     -.083 .320 
 Hospital days Q4     -.011 .907 
 Cyanosis days Q2     -.159 .506 
 Cyanosis days Q3     -.198 .420 
 Cyanosis days Q4     -.077 .754 
 Medication total     -.056 .496 
 ACE medication      -.038 .590 
 Diuretic medication     -.003 .967 
 B-Blocker medication     -.061 .355 
 Anti-arrhythmia 
medication 
    -.050 .445 
 RVEF     -.028 .705 
 LVEF     .165 .021 
Note: Q= Quartile HF= Heart Failure, ACE= angiotensin-converting-enzyme inhibitors, NYHA=New York 
Health Association classification, RVEF= Right Ventricular Ejection Fraction LVEF= Left Ventricular Ejection 
Fraction, **p<0.01 
 
 
Table 8.12 illustrates the regression model for the demographic, clinical and mood factors 
associated with WCST failure to maintain set scores. The final model was significant; however 
no individual predictors were significant. The addition of the variables RVEF and LVEF in the 
final step rendered the total number of repair surgeries non-significant from the previous model. 
The final model showed no significant unique factors associated with the ability to maintain set. 
None of the mood variables explained any unique variance in the outcome.  
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Table 8.12 Demographic clinical and mood factors associated with WCST Failure to maintain 
set score in the total study sample 
Block Predictor Variables R
2
  Adjusted R
2
 ΔR2  ΔF β Sig. 
1  .017 .014 .017 5.478  .020 
 NYHA     .132 .020 
2  .038 .032 .021 6.563  .001** 
 NYHA     .119 .034 
 Repair surgery total     .144 .001** 
3  .047 .034 .009 1.383
  
 .252 
 NYHA     .097 .096 
 Repair surgery total     .136 .020 
 RVEF     -.038 .590 
 LVEF     -.070
  
.298 
Note: NYHA=New York Health Association classification, RVEF= Right Ventricular Ejection Fraction LVEF= 
Left Ventricular Ejection Fraction, **p=<0.01 
 
The regression model for the WCST trials to complete the first category score is presented in 
Table 8.13. The final model was significant and explained 12.3% of the total variance in the 
scores (F=6.758(8,301), p=<0.001). Post-operative CNS complications continued to explain 
unique variance in the scores over and above all other variables in the equation, demonstrating 
that a post-operative CNS complication was associated with an increased number of trials taken 
to complete the first category of the test. None of the other clinical or mood variables explained 
any unique variance in the outcome. The addition of the mood variables did not explain 
significant additional unique variance in the model. 
 
Table 8.13 Demographic clinical and mood factors associated with WCST (Trials to complete 
1st category) score in the total study sample 
Block Predictor Variables R
2
  Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
1  .016 .013 .016 4.955  .027 
 Education (Yrs.)     -.126 .027 
2  .095 .089 .079 26.877  .000** 
 Education (Yrs.)     -.096 .081 
 Post-Op CNS 
complications 
    .283 .000** 
3  .139 .119 .044 3.050  .011 
 Education (Yrs.)     -.064 .247 
 Post-Op CNS 
complications 
    .262 .000** 
 Medication total      -.010 .885 
 Diuretic medication     .132 .028 
  
      
193 
 
 Anti-arrhythmic 
medication 
    .042 .487 
 Anti-coagulant 
medication 
    .066 .348 
 LVEF     -.077 .177 
4  .148 .123 .010 1.712  0.181 
 Education (Yrs.)     -.058 .294 
 Post-Op CNS 
complications 
    .252 .000** 
 Medication total      -.024 .748 
 Diuretic medication     .125 .038 
 Anti-arrhythmic 
medication 
    .056 .364 
 Anti-coagulant 
medication 
    .064 .358 
 LVEF     .072 .208 
 Negative affect (NA)     .036 .620 
 Depression (CESD)     .073 .321 
Note: LVEF= Left Ventricular Ejection Fraction, **p=<0.01 
 
8.7.2.2 Controlled Oral Word Association test (COWA) 
The factors associated with executive functioning and verbal fluency as measured by the 
COWA is presented in Table 8.14. 
 
The final model in the regression analysis for the COWA test was significant, explaining almost 
15% of the variance in verbal fluency and executive functioning. The addition of the mood 
variables (Positive Affect) in the final model did not explain any significant additional unique 
variance in the outcome. Education and age consistently continued to explain unique variance 
over the other variables in the equation, with higher years of education and an older age 
associated with higher scores and better performance. Results demonstrated that no significant 
unique variance in COWA scores was explained by clinical or mood factors. 
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Table 8.14 Demographic, clinical and mood factors associated with COWA test in the total 
study sample 
Block Predictor Variables R
2 
 Adjusted R
2
 ΔR2  ΔF β Sig. 
1  .135 .130 .135 24.021  .000** 
 Age      .236 .000** 
 Education (Yrs.)     .333 .000** 
2  .151 .134 .016 1.405  .232 
 Age      .195 .001** 
 Education (Yrs.)     .320 .000** 
 Post-op CNS 
complication 
    -.083 .125 
 Age at repair Q2     .035 .589 
 Age at repair Q3     .003 .961 
 Age at repair Q4     .108 .123 
3  .165 .140 .014 1.700  .167 
 Age      .190 .002 
 Education (Yrs.)     .323 .000** 
 Post-op CNS 
complication 
    -.085 .118 
 Age at repair Q2     -.080 .333 
 Age at repair Q3     -.112 .198 
 Age at repair Q4     .009 .916 
 Cyanosis days Q2     -.120 .121 
 Cyanosis days Q3     .067 .333 
 Cyanosis days Q4     .040 .551 
4  .176 .149 .011 4.003  .046 
 Age      .171 .005** 
 Education (Yrs.)     .300 .000** 
 Post-op CNS 
complication 
    .081 .137 
 Age at repair Q2     .092 .267 
 Age at repair Q3     .122 .159 
 Age at repair Q4     .013 .882 
 Cyanosis days Q2     .137 .075 
 Cyanosis days Q3     .063 .360 
 Cyanosis days Q4     .038 .568 
 Positive affect (PA)     .110 .046 
Note: Q= Quartile, **p=<0.01 
 
 
8.7.2.3 Stroop test 
The last test of executive function was the Stroop test. The factors associated with executive 
functioning as measured by the Stroop test (colour-word score) are presented in Table 8.15. The 
final model was significant and included the addition of the mood variables (F=3.678(19,290), 
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p=<0.001). The final model collectively explained 17.2% of the variance explained in executive 
functioning.  
 
The variables education and post-operative CNS complications continued to explain unique 
variance in the outcome over and above the other variables in the equation, in the final step. The 
results showed that higher years of education were associated with a higher score demonstrating 
better performance; while the presence of post-operative CNS complications was associated 
with lower scores demonstrating poorer performance. 
 
Table 8.15 Demographic, clinical and mood factors associated with Stroop test (Color-Word) in 
the total study sample 
Block Predictor Variables R
2
  
Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
1  .075 .069 .075 12.427  .000** 
 Education (Yrs.)     .224 .000**
<0.001 
 Employment     .136 .014 
2  .111 .096 .036 4.119  .007** 
 Education (Yrs.)     .226 .044 
 Employment     .147 .007** 
 TOF     -.104 .112 
 TGA     -.171 .009** 
 SV     -.209 .001** 
3  .117 .093 .006 .668  .572 
 Education (Yrs.)     .220 <0.001 
 Employment      .139 .015 
 TOF     -.097 .143 
 TGA     -.134 .057 
 SV     -.176 .010 
 Arrhythmias      -.038 .553 
 NYHA     -.005 .934 
 HF Clinic     -.059 .367 
4  .184 .142 .067 3.443  .001** 
 Education (Yrs.)     .201 .000** 
 Employment     .145 .010 
 TOF     -.054 .497 
 TGA     -.080 .391 
 SV     -.146 .116 
 Arrhythmias      -.064 .311 
 NYHA     -.038 .534 
 HF Clinic     -.054 .404 
 Palliation Before 
Repair 
    .039 .623 
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Block Predictor Variables R
2
  
Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
 Post-Op CNS 
Complications 
    -.182 .002** 
 Post-Op Infection      -.080 .179 
 Post-Op Ventricular 
dysfunction 
    -.047 .422 
 Hospital days Q2     .020 .792 
 Hospital days Q3     -.112 .175 
 Hospital days Q4     .096 .291 
5  .198 .149 .014 1.754  .156 
 Education (Yrs.)     .199 .000** 
 Employment     .143 .012 
 TOF     -.054 .502 
 TGA     -.065 .502 
 SV     -.084 .404 
 Arrhythmias      -.059 .357 
 NYHA     -.027 .664 
 HF Clinic     -.053 .415 
 Palliation Before 
Repair 
    .044 .576 
 Post-Op CNS 
Complications 
    -.197 .001** 
 Post-Op Infection      -.072 .225 
 Post-Op Ventricular 
dysfunction 
    -.062 .292 
 Hospital days Q2     .022 .765 
 Hospital days Q3     -.105 .202 
 Hospital days Q4     .114 .212 
 Current saturation Q2     .019 .754 
 Current saturation Q3     -.076 .225 
 Current saturation Q4     -.139 .065 
6  .198 .146 .000 .000  .990 
 Education (Yrs.)     .199 .000** 
 Employment      .143 .012 
 TOF     -.054 .510 
 TGA     -.065 .503 
 SV     -.084 .407 
 Arrhythmias      -.059 .377 
 NYHA     -.027 .665 
 HF Clinic     -.053 .418 
 Palliation Before 
Repair 
    .044 .580 
 Post-Op CNS 
Complications 
    -.197 .001** 
 Post-Op Infection      -.072 .228 
 Post-Op Ventricular 
dysfunction 
    -.062 .293 
 Hospital days Q2     .022 .765 
 Hospital days Q3     -.105 .209 
 Hospital days Q4     .114 .219 
 Current saturation Q2     .019 .755 
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Block Predictor Variables R
2
  
Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
 Current saturation Q3     -.076 .226 
 Current saturation Q4     -.139 .066 
 Medication total      -.001 .990 
7  .233 .172 .035 3.273  .012 
 Education (Yrs.)     .181 .001** 
 Employment      .112 .053 
 TOF     -.048 .551 
 TGA     -.076 .432 
 SV     -.075 .452 
 Arrhythmias      -.058 .375 
 NYHA     .013 .833  
 HF Clinic     -.062 .339  
 Palliation Before 
Repair 
    .040 .611 
 Post-Op CNS 
Complications 
    -.168 .004** 
 Post-Op Infection      -.084 .157 
 Post-Op Ventricular 
dysfunction 
    -.065 .267 
 Hospital days Q2     .013 .860 
 Hospital days Q3     -.108 .190 
 Hospital days Q4     .094 .306 
 Current saturation Q2     .025 .681 
 Current saturation Q3     -.059 .336 
 Current saturation Q1     -.119 .111 
 Medication total      .021 .742 
 Positive affect (PA)     .024 .723 
 Negative affect (NA)     -.085 .273 
 Anxiety (STAI)     -.159 .026 
 Depression (CESD)     .047 .589 
Note: Q= Quartile HF= Heart Failure, NYHA=New York Health Association classification, **p=<0.01 
 
Executive functioning  
Structural complexity groups 
The results of the sub-group regression analyses on measures of executive functioning are 
presented in Tables 8.16-8.19.  Results for the ToF group showed no significant association of 
clinical or mood factors with measures of executive functioning. Only education was 
significantly associated with the WCST-error and conceptual level response score (See Table 
8.16 on page 201). The TGA group showed a significant negative association of post-operative 
CNS complications with the WCST-number of categories completed score and the conceptual 
level responses score. In contrast a significant positive association was noted between post-
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operative CNS complications and the WCST- errors and trials to complete 1
st
 category score. 
Thus suggesting that the presence of CNS complications after a surgical procedure was 
associated consistently with impaired executive functioning (4/5 scores) (See Table 8.17). 
None of the demographic, clinical or mood variables were significantly associated with the 
Stroop test. A significant positive association was noted between negative affect, education and 
the COWA scores.  
 
A similar pattern was noted on the WCST scores in the SV group, with 3/5 scores showing a 
significant association of CNS complications post-surgery with reduced executive functioning 
(See Table 8.18). Additionally, current saturation showed a significant negative association with 
conceptual level responses; again suggesting its association with reduced executive functioning. 
None of the other two tests (Stroop & COWA) were associated with any demographic, clinical 
or mood variables.  
 
Lastly, the Simple group showed a significant positive association between age at repair, and 
WCST-Conceptual level responses, Number of categories completed, and a negative association 
with WCST-errors. These results demonstrate that a younger age at repair was associated with 
reduced executive functioning (WCST scores) (See Table 8.19). The Simple group also 
exhibited a positive association of anti-coagulant medication and score for trials required to 
complete the first category suggestive of reduced executive function being associated with 
taking anti-coagulant medication.  
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Table 8.16 Demographic, clinical & mood factors associated with cognitive functioning in multiple hierarchical regression analysis for ToF group by cognitive 
domain (N=81) 
Factors associated with cognitive 
functioning 
Attention Executive functioning Motor Function Memory 
TMT-B SDMT-
Written 
STROOP WCST 
ERROR 
WCST 
CLR 
WCST 
FTM 
WCST No 
Cat 
WCST 
TTC 
GP-ND RAVLT 
Model Significance (p-value) .108 <0.01 <0.001 .003 .060 .018 .140 .105 .027 <0.01 
Adjusted R2 .216 .178 .256 .117 .084 .133 .025 .064 .087 .192 
Age           
Gender           
Education   ▲  ▲ ▲     ▲ 
Employment           
Arrhythmias           
NYHA           
HF Clinic           
Age at repair Q2 
Age at repair Q3 
Age at repair Q4 
          
          
         ▲ 
Palliation total           
Palliation before repair           
Post-op CNS complications            
Post-op Ventricular dysfunction           
Cyanotic days Q2 
Cyanotic days Q3 
Cyanotic days Q4 
          
          
          
Medication total            
ACE medication           
B-blocker medication           
Anti coagulant medication           
LVEF           
Positive affect (PA)    `        
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Factors associated with cognitive 
functioning 
Attention Executive functioning Motor Function Memory 
TMT-B SDMT-
Written 
STROOP WCST 
ERROR 
WCST 
CLR 
WCST 
FTM 
WCST No 
Cat 
WCST 
TTC 
GP-ND RAVLT 
Negative affect (NA)           
Anxiety (STAI)           
Depression (CESD)           
Note: All results are based on the final model of the hierarchical regression analysis Interpretation Key: ▲Increase in value of IV = significant improvement in cognitive test performance 
(p<0.01), ▼Increase in value of IV = significant decline in cognitive test performance (p<0.01) Increase in value of IV = non-significant improvement in cognitive test performance 
(p<0.01) = Increase in value of IV = non-significant decline in cognitive test performance (p<0.01), blank cells= not included in the model, NYHA= New York Health Assessment, CNS= 
Central Nervous System, Q=Quartile, CPB= Cardio Pulmonary Bypass, ACE= Angiotensin-Converting-Enzyme Inhibitor, RVEF= Right Ventricular Ejection Fraction LVEF= Left Ventricular 
Ejection Fraction. 
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Table 8.17 Demographic, clinical and mood factors associated with cognitive tests in the multiple hierarchical regression analysis for the TGA group (N=80) 
Factors associated with 
cognitive functioning 
Attention Executive functioning Motor IQ Memory 
TMT- 
A 
TMT- 
B 
SDM
T- W 
SDMT -  
O 
STROOP WCST  
Error 
WCST 
CLR 
WCST 
FTM 
WCST 
No Cat 
WCST 
TTC 
COWA GP-D GP-
ND 
WAIS RAVLT 
Model Significance (p value) .010 <0.001 <0.01 <0.001 <0.01 <0.01 <0.001 .004 <0.001 <0.001 <0.001 <0.01 .005 <0.001 <0.001 
Adjusted R
2
 .116 .279 .286 .276 .207 .204 .205 .109 .257 .200 .263 .175 .174 .510 .273 
Employment   ▲              
Education            ▲   ▲  
Gender                
HF Clinic                
Age at repair Q2 
Age at repair Q3 
Age at repair Q4 
               
               
               
Repairs total                
Palliation before repair                
CPB minutes Q2 
CPB minutes Q3 
CPB minutes Q4 
               
             ▲  
             ▲  
Post-op CNS complications   ▼    ▼ ▼  ▼ ▼      
Post-op Infections                 
Hospital days Q2 
Hospital days Q3 
Hospital days Q4 
               
               
               
Cyanotic days Q2 
Cyanotic days Q3 
Cyanotic days Q4 
               
               
               
Pacemakers                
ACE medication                
Diuretic medication                
Anti coagulant medication                
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Factors associated with 
cognitive functioning 
Attention Executive functioning Motor IQ Memory 
TMT- 
A 
TMT- 
B 
SDM
T- W 
SDMT -  
O 
STROOP WCST  
Error 
WCST 
CLR 
WCST 
FTM 
WCST 
No Cat 
WCST 
TTC 
COWA GP-D GP-
ND 
WAIS RAVLT 
RVEF                
LVEF    ▲            
Positive affect (PA)                  
Negative affect (NA)   ▲        ▲     
Anxiety (STAI)                
Depression (CESD)                
Note: All results are based on the final model of the hierarchical regression analysis Interpretation Key: ▲Increase in value of IV = significant improvement in cognitive test performance (p<0.01), 
▼Increase in value of IV = significant decline in cognitive test performance (p<0.01) Increase in value of IV = non-significant improvement in cognitive test performance (p<0.01) = Increase 
in value of IV = non-significant decline in cognitive test performance (p<0.01), blank cells= not included in the model, NYHA= New York Health Assessment, CNS= Central Nervous System, 
Q=Quartile, CPB= Cardio Pulmonary Bypass, ACE= Angiotensin-Converting-Enzyme Inhibitor, RVEF= Right Ventricular Ejection Fraction LVEF= Left Ventricular Ejection Fraction. 
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Table 8.18: Demographic, clinical and mood factors associated with cognitive tests in the multiple hierarchical regression analysis for the SV group (N=65) 
Factors associated with 
cognitive functioning 
Attention Executive functioning Motor IQ Memory 
TMT 
A 
TMT 
B 
SDMT
W 
SDMT 
O 
COWA WCST 
Error 
WCST 
CLR 
WCST 
FTM 
WCST 
No Cat 
WCST 
TTC 
STROOP GP-ND WAIS RAVLT 
Model significance (p value) <0.01 .008 <0.01 <0.01 <0.01 <0.001 <0.001 .005 <0.001 <0.001 .121 .036 <0.001 .004 
Adjusted R
2
 .203 .091 .279 .115 .218 .369 .434 .132 .347 .287 .090 .053 .530 .281 
Age               
Education              ▲  
Employment               
Hypertension                
Palliation before repair               
CPB minutes Q2 
CPB minutes Q3 
CPB minutes Q4 
              
              
              
HA minutes Q2 
HA minutes Q3 
HA minutes Q4 
             ▲ 
              
              
Post-op CNS complications        ▼  ▼ ▼   ▼  
Post-op Infections   ▼ ▼            
Years since last operation               
Current saturation Q1 
Current saturation Q2 
Current saturation Q3 
              
      ▼        
              
Pacemakers               
Diuretic medication               
B-blocker medication               
Anti arrhythmia medication               
Anti coagulant medication               
Positive affect (PA)               ▲  
Negative affect (NA)               
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Factors associated with 
cognitive functioning 
Attention Executive functioning Motor IQ Memory 
TMT 
A 
TMT 
B 
SDMT
W 
SDMT 
O 
COWA WCST 
Error 
WCST 
CLR 
WCST 
FTM 
WCST 
No Cat 
WCST 
TTC 
STROOP GP-ND WAIS RAVLT 
Anxiety (STAI)               
Depression (CESD)               
Note: All results are based on the final model of the hierarchical regression analysis. Interpretation Key: ▲Increase in value of IV = significant improvement in cognitive test performance 
(p<0.01), ▼Increase in value of IV = significant decline in cognitive test performance (p<0.01) Increase in value of IV = non-significant improvement in cognitive test performance (p<0.01) 
= Increase in value of IV = non-significant decline in cognitive test performance (p<0.01), blank cells= not included in model, HA= Hypothermic Arrest, Central Nervous System, Q=Quartile 
. 
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Table 8.19 Demographic, clinical and mood factors associated with cognitive tests in the multiple hierarchical regression analysis for the Simple group (N=84) 
Factors associated with 
cognitive functioning 
Attention Executive functioning Motor IQ Memory 
 TMT 
A 
SDMT
W 
SDMT 
O 
COWA STROOP WCST 
Error 
WCST 
CLR 
WCST 
No Cat 
WCST 
TTC 
GP-D GP-ND WAIS RAVLT 
Model significance (p-value) <0.01 <0.01 .027 <0.001 <0.01 <0.001 <0.001 <0.001 <0.001 <0.01 <0.001 <0.001 <0.01 
Adjusted R
2
 .173 .220 .124 .307 .237 .261 .240 .277 .314 .193 .176 .378 .186 
Age              
Education    ▲        ▲  
Employment              
Gender              
Hypertension               
HF Clinic              
NYHA              
Palliation total               
Repairs total               
Catheter lab total               
Years since last operation            ▼   
Age at repair Q2 
Age at repair Q3 
Age at repair Q4 
             
     ▲ ▲ ▲      
             
CPB minutes Q2 
CPB minutes Q3 
CPB minutes Q4 
             
             
             
HA minutes Q2 
HA minutes Q3 
HA minutes Q4 
             
             
             
Current saturation Q1 
Current saturation Q2 
Current saturation Q3 
             
             
             
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Factors associated with 
cognitive functioning 
Attention Executive functioning Motor IQ Memory 
 TMT 
A 
SDMT
W 
SDMT 
O 
COWA STROOP WCST 
Error 
WCST 
CLR 
WCST 
No Cat 
WCST 
TTC 
GP-D GP-ND WAIS RAVLT 
Post-op Ventricular dysfunction              
ACE medication              
Anti arrhythmia medication           ▼   
Diuretic medication              
Anti coagulant medication         ▼     
LVEF              
Positive affect (PA)            ▲    
Negative affect (NA)              
Anxiety (STAI)              
Depression (CESD)             
Note: All results are based on the final model of the hierarchical regression analysis. Interpretation Key: ▲Increase in value of IV = significant improvement in cognitive test performance 
(p<0.01), ▼Increase in value of IV = significant decline in cognitive test performance (p<0.01), Increase in value of IV = non-significant improvement in cognitive test performance , = 
Increase in value of IV = non-significant decline in cognitive test performance (p<0.01), blank cells= not included in the model, NYHA= New York Health Assesment, CNS= Central Nervous 
System, Q=Quartile, CPB= Cardio Pulmonary Bypass, HA= Hypothermic Arrest, ACE= Angiotensin-Converting-Enzyme Inhibitor, LVEF= Left Ventricular Ejection Fraction
  
      
207 
 
8.7.3 Demographic, clinical and mood factors associated with attention  
Attention was examined in this study using three measures; the TMT (Part A and B) and the 
SDMT (written and oral subtest). Both these tests generate two scores each. Factors associated 
with each score are discussed below both by total sample followed by the different structural 
complexity groups.  
 
8.7.3.1 Trail Making Test (TMT) 
Total sample 
The factors associated with the TMT A and B scores are presented in Table 8.20 and Table 8.21 
respectively.  
Table 8.20 Demographic and Clinical factors associated with TMT-A scores (Divided attention) 
Block Predictor Variables R
2
 Adjusted 
R
2
 
ΔR2  ΔF Β Sig. 
 
1  .025 .021 .025 7.753  .000** 
 Age      -.157 .006** 
2  .056 .044 .031 3.378  .019 
 Age      -.152 .007** 
 Current saturation Q1      .146 .020 
 Current saturation Q2      .007 .911 
 Current saturation Q3     -.064 .310 
3  .071 .056 .015 5.073  .025* 
 Age      -.154 .006** 
 Current saturation Q1     .127 .043 
 Current saturation Q2     .008 .896 
 Current saturation Q3     -.073 .246 
 Pacemaker     . 126 .025 
Note: Q= Quartile, **p=<0.01,  
 
The final model for the TMT-A was significant (F= 4.676(5,304), p=<0.001), explaining 5.6% 
of the variance in attention. Age consistently continued to explain unique variance over the 
other variables in the equation showing a negative association, suggesting that the older 
participants performed better than younger participants. No clinical or mood variables explained 
unique variance in attention (on the TMT-A) (See Table 8.20). 
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Table 8.21 Demographic, clinical and mood factors associated with TMT-B scores 
Block Predictor Variables R
2
 
 
Adjusted R
2
 ΔR2  ΔF β Sig. 
1  .116 .108 .116 13.422  .000** 
 Age     -.233 .000** 
 Education (Yrs.)     -.203 .000** 
 Employment     -.176 .001** 
2  .146 .126 .029 2.602  .036 
 Age     -.207 .000** 
 Education (Yrs.)     -.185 .001** 
 Employment     -.174 .002** 
 NYHA     .054 .347 
 TOF     .177 .007** 
 TGA     .121 .071 
 SV     .142 .035 
3  .195 .145 .049 1.607  .096 
 Age     -.199 .001** 
 Education (Yrs.)     -.162 .004** 
 Employment     -.159 .005** 
 NYHA     .075 .220 
 TOF     .120 .165 
 TGA     .083 .398 
 SV     .128 .179 
 Interventions     .018 .821 
 Palliation Before 
Repair 
    -.030 .738 
 Years Since Last Op     -.073 .267 
 Post Op CNS 
Complications 
    .127 .024 
 Post-Op Infection     .099 .094 
 HA arrest Q2     .158 .026 
 HA arrest Q3     .064 .402 
 HA arrest Q4     .029 .702 
 Hospital days Q2     .022 .762 
 Hospital days Q3     .019 .829 
 Hospital days Q4     -.090 .345 
4  .234 .169 .039 2.432  .026 
 Age     -.159 .008** 
 Education (Yrs.)     .115 .011 
 Employment     .107 .011 
 NYHA     -.014 .197 
 TOF     .095 .417 
 TGA     .054 .754 
 SV     .057 .432 
 Interventions     -.054 .714 
 Palliation Before 
Repair 
    -.062 .810 
 Years Since Last Op     -.078 .276 
 Post Op CNS 
Complications  
    .122 .023 
 Post-Op Infection     .110 .060 
 HA arrest Q2     .149 .034 
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Block Predictor Variables R
2
 
 
Adjusted R
2
 ΔR2  ΔF β Sig. 
 HA arrest Q3     .049 .526 
 HA arrest Q4     .036 .636 
 Hospital days Q2     .013 .860 
 Hospital days Q3     .020 .818 
 Hospital days Q4     -.098 .304 
 Cyanosis days Q2     .074 .756 
 Cyanosis days Q3     -.061 .804 
 Cyanosis days Q4     -.169 .489 
 Current-saturation 
Q1 
    -.078 .205 
 Current-saturation 
Q2 
    -.098 .115 
 Current-saturation 
Q3 
    .064 .397 
5  .252 .184 .019 3.522  .031 
 Age     -.132 .029 
 Education (Yrs.)     -.116 .041 
 Employment     -.112 .054 
 NYHA     .058 .345 
 TOF     .268 .293 
 TGA     .146 .577 
 SV     .255 .292 
 Interventions     .037 .642 
 Palliation Before 
Repair 
    -.017 .844 
 Years Since Last Op     -.064 .319 
 Post-Op CNS 
Complications  
    .118 .038 
 Post-Op Infection     .124 .034 
 HA arrest Q2     .155 .028 
 HA arrest Q3     .053 .485 
 HA arrest Q4     .041 .585 
 Hospital days Q2     .024 .744 
 Hospital days Q3     .018 .828 
 Hospital days Q4     -.100 .290 
 Cyanosis days Q2     .029 .904 
 Cyanosis days Q3     -.120 .629 
 Cyanosis days Q4     -.225 .359 
 Current-saturation 
Q1 
    -.079 .199 
 Current-saturation 
Q2 
    -.110 .076 
 Current-saturation 
Q3 
    .047 .527 
 Positive affect (PA)     -.159 .013 
 Anxiety (STAI)     -.020 .755 
Note: Q= Quartile, **p=<0.01 
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The final model for the TMT-B, which included the addition of the mood variables, explained a 
total of 18.4% of the variance in divided attention (F= 3.625(24,285), p=<0.001). The addition 
of mood variables rendered the demographic variables (education, age) non-significant. None of 
the clinical or the mood variables explained any unique variance in the TMT-B scores (See 
Table 821). In summary no clinical or mood factors explained any unique variance in divided 
attention and executive functioning as measured by the TMT.  
 
8.7.3.2 Symbol Digit Modalities Test (SDMT) 
The demographic, clinical and mood factors associated with attention and complex visual 
scanning as measured by the oral subtest of the SDMT are presented in Table 8.22 (below). The 
final model was significant (F= 10.09(3,306), p<0.001) explaining a total of 12.2% of the total 
variance in attention and complex visual scanning. Education and positive affect explained 
unique variance in attention over and above the other variables in the equation. None of the 
clinical variables significantly explained any unique variance in this score.  
 
Table 8.22 Demographic, clinical and mood factors associated with SDMT-O 
Block Predictor Variables R
2
  
Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
1   .066 .063 .066 21.823  .000** 
 Education (Yrs.)     .257 .000** 
2  .090 .081 .024 4.023  .019 
 Education (Yrs.)     .238 .000** 
 Post-op CNS 
complication 
    -.130 .022 
 Post-op infection     -.058 .303 
3  .140 .122 .049 5.800  .001** 
 Education (Yrs.)     .195 .000** 
 Post-op CNS 
complication 
    -.120 .033 
 Post-op infection     -.075 .180 
 Positive affect (PA)     .248 .000** 
 Anxiety (STAI)     .035 .612 
 Depression (CESD)     .013 .858 
 
Note -**p=<0.01 
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Table 8.23 Demographic, clinical and mood factors associated with SDMT –W score  
Block Predictor Variables R
2
  
Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
1  .126 .120 .126 22.116  .000** 
 Education (Yrs.)     .284 .000** 
 Employement     .185 .001** 
2  .191 .167 .065 3.459  .001** 
 Education (Yrs.)     .261 .000** 
 Employment      .186 .001** 
 Interventions total      .008 .908 
 Palliation before repair      -.087 .186 
 Post-op CNS 
complication 
    -.146 .008** 
 Post-op CNS infection     -.127 .027 
 Hospital days Q2     -.080 .231 
 Hospital days Q3     -.042 .577 
 Hospital days Q4     .029 .720 
3  .204 .172 .013 1.586  .193 
 Education (Yrs.)     .261 .000** 
 Employment      .177 .001*** 
 Interventions total      .014 .845 
 Palliation before repair      -.061 .372 
 Post-op CNS 
complication 
    -.156 .005** 
 Post-op CNS infection     -.129 .025 
 Hospital days Q2     -.072 .280 
 Hospital days Q3     -.030 .689 
 Hospital days Q4     .055 .507 
 Current saturation Q2     .012 .832 
 Current saturation Q3     .006 .923 
 Current saturation Q1     -.116 .075 
4  .234 .197 .030 5.727  .004** 
 Education (Yrs.)     .233 .000** 
 Employment     .143 .011 
 Interventions total      .017 .806 
 Palliation before repair      -.072 .285 
 Post-op CNS 
complication 
    -.151 .006** 
 Post-op CNS infection     -.140 .014 
 Hospital days Q2     -.809 .180 
 Hospital days Q3     -.030 .686 
 Hospital days Q4     .065 .432 
 Current saturation Q2     .010 .866 
 Current saturation Q3     .013 .822 
 Current saturation Q1     -.107 .099 
 Positive affect (PA)     .215 .001** 
 Depression (CESD)     .079 .227 
Note: Q= Quartile, **p=<0.01 
 
 
  
      
212 
 
Table 8.23 illustrates the factors associated with the written sub-test of the SDMT measuring 
attention and complex visual scanning. The final model was significant (F(12,297), = 
6.342p<0.001) and explained 19.7% of the variance in SDMT written scores. The final model 
revealed that education, post-operative CNS complication and positive affect explained unique 
variance in attention. Higher years of education achieved and positive affect was associated 
with better performance; while the experience of a post-operative CNS complication was 
associated with impaired performance.    
 
Structural complexity groups 
The summary results of the final models for the sub-group analyses related to the domain of 
attention are presented in Tables 8.16-8.19. Results for the ToF group showed no significant 
unique association between the demographic, clinical and mood factors with attention as 
measured by both the TMT. A significant positive association was found between education and 
SDMT-W score (See Table 8.16). The TGA group showed a significant negative association 
between employment status and impaired divided attention, with those currently employed 
performing better on the test. A significant positive association between CNS complications 
after surgery and impaired divided attention (TMT-B) was also noted. Further, a significant 
positive association was also noted between the SDMT-O scores and LVEF, suggesting a low 
ejection fraction was associated with lower scores and impaired attention. In the written subtest 
the TGA group showed a significant positive association between attention and negative affect 
suggesting that higher level of negative affect was associated with better performance on the 
written subtest (See Table 8.17). 
 
The SV group exhibited a significant positive association between post-operative infections 
with TMT-B scores and a negative association with the SDMT-W scores, suggesting the 
occurrence of an infection after surgery is associated with impaired attention and complex 
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visual scanning (See Table 8.18). Lastly, in the Simple group no demographic, clinical and 
mood variables explained any unique variance in the outcomes (See Table 8.19). 
 
8.7.4 Demographic clinical and mood factors associated with memory performance 
Rey Auditory Verbal Learning Test (RAVLT) 
Total sample  
Demographic, clinical and mood factors associated with memory are presented in Table 8.24. 
The final regression block was significant (F=14.319(4,305), p=<0.001) explaining 15.9% of 
the overall variance in memory and verbal learning. The results showed that education and 
female gender consistently continued to explain unique variance in memory over the other 
variables in the equation. 
 
Table 8.24 Demographic, clinical and mood factors associated RAVLT (total acquisition) score  
Block Predictor Variables R
2
  
Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
1  .126 .120 .126 22.166  .000** 
 Education (Yrs.)     .269 .000** 
 Gender (Males)     -.244 .000** 
2  .151 .142 .025 8.828  .003** 
 Education (Yrs.)     .273 .000** 
 Gender (Males)     -.241 .000** 
 Hypertension      -.157 .003** 
3  .158 .147 .007 2.686  .102 
 Education (Yrs.)     .261 .000** 
 Gender (Males)     -.233 .000** 
 Hypertension      -.122 .032 
 ACE medication     -.094 .102 
4  .173 .159 .015 5.333  .022 
 Education (Yrs.)     .240 .000** 
 Gender (Males)     -.239 .000** 
 Hypertension      -.128 .023 
 ACE medication     -.078 .175 
 Positive affect (PA)     .124 .022 
Note: ACE= angiotensin-converting-enzyme inhibitors, **p=<0.01 
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Structural complexity groups  
The final model for the sub-group analysis conducted to identify factors associated with 
memory across the different groups is presented in Table 8.16-8.19. The ToF group 
demonstrated a significant positive association between years of education and age at repair 
with memory, suggesting that fewer years of education and younger age at repair were 
associated with poorer memory (See Table 8.16). The SV group showed a significant positive 
association of memory and the minutes the patient spent under hypothermic arrest suggesting 
that a longer duration of HA was associated with better performance on the memory test (See 
Table 8.18). None of the variables explained unique variance in memory for the TGA and 
Simple groups.  
 
8.7.5 Demographic clinical and mood factors associated with motor functioning and 
dexterity 
Grooved Pegboard (GP) 
Motor functioning and dexterity in the study sample was measured using the Grooved Pegboard 
test. The test included two parts: one completed by the participant using their dominant hand 
and one using the non-dominant hand in that order. The demographic, clinical and mood 
variables associated with motor function (dominant hand scores) are presented in Table 8.25. 
 
Table 8.25 Demographic, clinical and mood factors associated with GP-D score  
Block Predictor Variables R
2
  Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
1  .065 .059 .065 10.724  .000** 
 Education (Yrs.)     -.189 .001** 
 Gender (Males)     .181 .000** 
2  .084 .069 .019 2.110  .099 
 Education (Yrs.)     -.186 .001** 
 Gender (Males)     .158 .005** 
 TOF     .121 .070 
 TGA     .126 .061 
 SV     .149 .024* 
3  .104 .080  .020 2.227  .085 
 Education (Yrs.)     -.185 .001** 
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Block Predictor Variables R
2
  Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
 Gender (Males)     .149 .008** 
 TOF     .118 .155 
 TGA     .126 .123 
 SV     .159 .038 
 CPB minutes Q2     .126 .115 
 CPB minutes Q3     -.026 .752 
 CPB minutes Q4     -.015 .864 
4  .116 .083  .012 1.329  .265 
 Education (Yrs.)     -.195 .001** 
 Gender (Males)     .141 .013 
 TOF     -.164 .516 
 TGA     -.170 .506 
 SV     -.116 .618 
 CPB minutes Q2     .119 .142 
 CPB minutes Q3     -.034 .683 
 CPB minutes Q4     -.024 .780 
 Cyanosis days Q2     .314 .206 
 Cyanosis days Q3     .239 .342 
 Cyanosis days Q4     .336 .176 
5  .125 .089  .009 2.946  .087 
 Education (Yrs.)     -.183 .001** 
 Gender (Males)     .133 .018 
 TOF     -.142 .572 
 TGA     -.178 .486 
 SV     -.108 .640 
 CPB minutes Q2     .120 .137 
 CPB minutes Q3     -.034 .687 
 CPB minutes Q4     -.027 .755 
 Cyanosis days Q2     .321 .195 
 Cyanosis days Q3     .237 .344 
 Cyanosis days Q4     .323 .193 
 ACE medication     .097 .087 
6  .141 .104 .017 5.734  .017 
 Education (Yrs.)     -.158 .005** 
 Gender (Males)     .138 .014 
 TOF     -.115 .646 
 TGA     -.143 .571 
 SV     -.089 .699 
 CPB minutes Q2     .127 .113 
 CPB minutes Q3     -.026 .749 
 CPB minutes Q4     -.017 .845 
 Cyanosis days Q2     .297 .227 
 Cyanosis days Q3     .212 .395 
 Cyanosis days Q4     .297 .227 
 ACE medication     .083 .145 
 Positive affect (PA)     -.133 .017 
Note: Q= Quartile, CPB=Cardio Pulmonary Bypass, ACE= angiotensin-converting-enzyme inhibitors,  **p=<0.01 
 
 
  
      
216 
 
Table 8.26 Demographic, clinical and mood factors associated with GP-ND score  
Block Predictor Variables R
2
  
Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
1  .039 .032 .039 6.171  .002** 
 Education (Yrs.)     -.161 .004** 
 Gender (Males)     .121 .032 
2  .048 .039 .009 2.957  .087 
 Education (Yrs.)     -.151 .007** 
 Gender (Males)     .113 .044 
 HF clinic     .097 .087 
3  .069 .054 .021 3.436  .033 
 Education (Yrs.)     -.134 .017 
 Gender (Males)     .111 .046 
 HF clinic     .077 .173 
 Post-op CNS 
complication 
    .085 .142 
 Post-op CNS infection     .101 .083 
4  .087 .066 .018 2.966  .053 
 Education (Yrs.)     -.121 .033 
 Gender (Males)     .103 .064 
 HF clinic     .041 .487 
 Post-op CNS 
complication 
    .085 .140 
 Post-op CNS infection     .093 .110 
 ACE medication     .137 .030 
 Diuretic medication     .008 .896 
5  .098 .074 .011 3.728  .054 
 Education (Yrs.)     -.103 .073 
 Gender (Males)     .107 .054 
 HF clinic     .043 .460 
 Post-op CNS 
complication 
    .077 .176 
 Post-op CNS infection     .104 .076 
 ACE medication     .126 .045 
 Diuretic medication     .002 .975 
 Positive affect (PA)     -.109 .054 
Note: HF= Heart Failure, ACE= angiotensin-converting-enzyme inhibitors, **p=<0.01 
 
The final model was significant and explained 10.4% of the total variance in motor functioning. 
The results revealed years of education achieved had a significant negative association with 
motor functioning, suggesting more years of education was associated with less time taken to 
complete the task demonstrating better motor functioning. The model for the non-dominant 
hand is presented in Table 8.26. The final model revealed no significant factors explaining 
unique variance in motor functioning as assessed by the non-dominant hand (F=4.103(7,302), 
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P<0.001). In summary, the results of the grooved pegboard test suggest the absence of any 
clinical or mood factors explaining unique variance in motor function.  
 
Structural complexity groups 
The sub-group analyses conducted to identify factors associated with motor functioning and 
dexterity across the different structural complexity groups are presented in Tables 8.16-8.19. 
The results showed no significant factors associated with motor functioning in three groups; 
ToF, TGA and SV. The simple group showed a significant positive association between motor 
functioning (non-dominant hand) and years since last intervention and anti-arrhythmia 
medication. These results suggest poorer motor functioning was associated with more years 
since the last intervention and taking anti-arrhythmia medication. Analyses for the dominant 
hand showed a negative association of positive affect suggesting that lower positive affect was 
associated with poorer motor functioning (See Table 8.19).  
 
Distribution of residuals  
The distribution of residuals (assumption of homoscedasticity) was checked for each regression 
analysis. The results showed a slight pattern (funnelling) in the residuals for some variables 
including the RAVLT and COWA. A plausible explanation for this is the presence of 
categorical predictor variables that by their nature do not allow the data to be randomly 
distributed leading to a pattern. Therefore, caution is advised when interpreting findings related 
to these analyses, as the assumption of homoscedasticity may be violated (See Appendix-S for a 
graphical representation of this data). 
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Summary  
Overall the results showed a number demographic, clinical and mood factors explaining unique 
variance in cognitive outcomes of ACHD patients. Education and CNS complications were 
most consistently associated with the different domains assessed, when the total sample was 
assessed together. The sub-group analyses showed a considerable amount of variability in the 
factors associated with cognitive outcomes in each group. The Simple group was the only one 
showing a significant association between medication taken (anti-arrhythmia and anti-
coagulants) and cognitive outcomes. Within the mood variables only positive and negative 
affect explained unique variance in cognition across all groups, with depression and anxiety not 
explain any significant variance. Clinical variables largely explained the majority of the 
variance in cognitive outcomes as compared to demographic and mood variables.  
 
8.8 Cognitive functioning and Quality of Life (QoL) 
This section investigates the association between QoL and the composite NP score to assess the 
impact the overall extent of cognitive functioning has on QoL outcomes for ACHD patients. A 
univariate analysis was conducted using simple linear regression for each QoL outcome (DV) 
and the demographic, clinical, mood and composite cognitive functioning measures (IV) to 
assess significance before entering into the multivariate analysis. Simple linear regressions were 
chosen over the use of correlation analysis as regression analysis allows the selection of the 
directionality of the analysis by determining the dependent and independent variables. This 
analysis was conducted for the total sample and repeated for each sub-group individually. Only 
those variables significant at a p<0.05 in the univariate screening were included in the 
multivariate model. Similar to the previous set of regression analyses this was done to reduce 
any redundant predictor variables.  
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8.8.1 Univariate screening results to identify factors associated with QOL 
8.8.1.1 Univariate screening of Mental QoL (MCS) 
Total sample 
The univariate screening for the total sample showed no significant association of cognitive 
functioning and MCS. Only demographic (employment status), clinical (total and ACE 
medication, post-op infection, CPB and HA minutes, cyanosis) and mood (positive and negative 
affect, anxiety and depression) variables demonstrated a significant association with MCS 
(p<0.05) (See Appendix-O for the full analysis results).  
 
Structural complexity groups 
Within the subgroup analyses, factors significantly associated with MCS in the ToF group 
included demographic (age, employment), clinical (HA minutes, days spent in hospital and in 
ICU, current saturation, RVEF) and mood (positive and negative affect, anxiety and depression) 
factors.  
 
The TGA group demonstrated a significant association between mental QoL and gender, total 
number of medications taken and mood (positive and negative affect, anxiety and depression). 
No significant association was noted with cognitive functioning.  
 
The SV group showed a significant association between mental QoL and the demographic (age, 
employment status), clinical (ACE medication and current saturation), and mood (positive and 
negative affect, anxiety and depression) factors. The ToF, TGA and SV groups showed no 
significant association between QoL (MCS) and cognitive functioning.  
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Lastly, the Simple group showed a significant positive univariate association of mental QoL 
with cognitive functioning and mood (positive and negative affect, anxiety and depression). 
(See Appendix-O for details on univariate screening).    
 
8.8.1.2 Univariate screening of Physical QoL (PCS) 
Total sample 
The univariate screening for factors associated with PCS in the total sample showed a 
significant association with demographic (age, education, employment), clinical (e.g. 
arrhythmias, age at repair, total interventions, years since last intervention, medication, LVEF, 
and cyanosis) and mood (positive and negative affect, anxiety, depression) variables. No 
significant association was noted between PCS and cognitive functioning for the cohort as a 
whole (See Appendix-O for details).   
 
Structural complexity groups  
Within the sub-group analysis, the ToF group demonstrated no significant association between 
cognitive functioning and physical QoL. A significant association was noted with demographic 
(employment status) and clinical (e.g. arrhythmias, NYHA, interventions total, current 
saturation, post-operative infection and days spent in the hospital) variables in the ToF group.   
The TGA group showed no significant association of physical QoL with cognitive functioning 
and demographic factors. Only one clinical variable was significant (NYHA) along with mood 
(positive affect and depression).   
 
In the SV group demographic (gender), clinical (NYHA, days spent in hospital, cyanosis, 
current saturation) and mood (positive and negative affect and depression) variables were 
significantly associated with physical QoL. The SV group did not show a significant association 
between physical QoL with cognitive functioning.  
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Lastly, the Simple group demonstrated a significant association between physical QoL and 
demographic (age and education), clinical (e.g. NYHA, age at repair, medications total, days 
spent in hospital) and mood (positive and negative affect, anxiety, depression) factors. No 
significant association was noted with cognitive functioning across all complexity sub-groups 
(Please see Appendix-O for details). 
 
8.8.2 Multivariate regression analysis to identify factors associated with QoL (PCS, MCS) 
in ACHD patients 
The primary aim of this research question was to investigate the association between cognitive 
functioning and QoL after taking account of the clinical and mood factors. However, given that 
cognitive functioning was consistently not associated with PCS or MCS in the groups and the 
total sample, little merit was considered in running multivariate regression models without the 
key variable of interest i.e. cognition. The only exception was the Simple group on the MCS 
sub-scale. Therefore, a multivariate regression analysis was only conducted for the Simple 
group on the MCS sub-scale.  
 
The analysis was conducted using hierarchical multiple regressions (See Figure 7.7 for the order 
of regression blocks). The results of the analysis for the MCS scale are presented in Table 8.27. 
The final model was significant (F=26.162(19,290), p<0.001) and revealed negative affect and 
depression explained unique variance in mental QoL. The addition of the cognition variable in 
the final block did not explain any additional variance in the model.  
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Table 8.27 Demographic, clinical, mood and cognitive factors associated with mental QoL in 
the Simple group 
Block Predictor Variables R
2
  
Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
1  .631 .612 .631 33.712  .000** 
 Positive affect (PA)     .043 .671 
 Negative affect (NA)     -.311 .006** 
 Anxiety (STAI)     -.005 .964 
 Depression (CESD)     -.494 .000** 
2  .631 .607 .000 .015  .904 
 Positive affect (PA)     .045 .661 
 Negative affect (NA)     -.310 .006** 
 Anxiety (STAI)     -.007 .950 
 Depression (CESD)     -.496 .000** 
 Cognitive functioning     -.010 .904 
**p<0.01 
 
Overall the results of the multivariate analysis showed no significant association between 
cognitive functioning and physical or mental quality of life in any of the complexity groups.   
 
8.9 Summary  
The results of the cross-sectional analyses showed the presence of cognitive impairment in the 
ACHD sample and within structural complexity groups, in comparison to normative data. All 
domains of cognitive functioning assessed showed some impairment, with the exception of 
memory, where the performance of the ACHD sample was comparable to normative data. The 
four groups showed significant differences on divided attention and mean composite cognitive 
functioning. Several factors (demographic, clinical and mood) explained unique variance in the 
cognitive domains assessed. The results showed considerable variability in the factors 
explaining unique variance in cognition across the different groups.  No relationship was found 
between cognitive functioning and QoL. Chapter 9 will discuss the findings in more detail and 
in the context of the wider literature.   
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9 CROSS-SECTIONAL STUDY DISCUSSION  
 
9.1 Prologue 
This chapter discusses the findings of the cross-sectional study detailed in Chapter 8. The 
primary aim of this chapter is to understand, interpret and discuss the findings of this study in 
the context of the existent literature.  
 
9.2  Extent of cognitive impairment in ACHD patients in comparison to normative data 
and other structural complexity groups 
A comprehensive range of cognitive domains were assessed in a group of common ACHD 
conditions. An impairment criterion (score< 1.5SD below norms) was established to evaluate 
the relative performance of ACHD patients to that of the normal healthy population. It is 
considered important to emphasize prior to interpreting results that this study was exploratory in 
nature and these criteria were not used to diagnose a clinically significant impairment.  
 
9.2.1 The extent of cognitive impairment in the total ACHD sample when compared to 
normative data  
Cognitive functioning in this study was assessed using both a measure of IQ and tests of 
independent cognitive domains. With regards to the IQ a quarter of the present study sample 
showed impairment when compared to the normative data. This proportion was larger than the 
15% that can be expected to show impairment in the general population. Despite this, the mean 
performance of the study sample was within the ‘average’ IQ category as classified by Wechsler 
(Wechsler et al, 1997).  
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These results support some other studies, which reported IQ in ACHD to be lower in 
comparison to normative data (Wernovsky et al, 2000; and Eide et al, 2006). Similar to the 
present study, while the mean IQ scores of the study sample in these studies were lower in 
comparison to the normative data mean score, they were still within the normal range as 
specified by the respective tests. It is of note however that one of these studies included both 
children and adults (Wernovsky et al, 2000), while the other study included only male 
participants (Eide et al, 2006). The present study is larger in comparison to the study conducted 
by Wernovsky and colleagues by over three quarters (86%), and more than double in size of the 
study conducted by Eide and colleagues (133%), and includes a mixed gender sample that 
comprises of all adult CHD patients, thus providing more substantial support for the finding that 
IQ in ACHD patients is impaired in comparison to the normal population. The findings of the 
present study were contrary to those of other studies which reported IQ in ACHD patients as 
being comparable to that of the normal population (Utens et al, 1994 and Utens et al, 1998), 
however as discussed previously the methodological quality of these studies was considerably 
low in comparison to the present study, thus providing little confidence in these contrary 
finding.  
 
With regards to specific domains of cognitive functioning, the results of the present study 
showed that a considerable proportion of the study sample exhibited impairments on a number 
of cognitive domains, above that which could be expected to fall below the 1.5SD by chance. 
Impairments were noted in the domains of executive functioning, attention, and motor 
functioning. The domain of memory was not impaired in this study, with majority of the sample 
demonstrating memory and verbal learning comparable to that of the normal population. These 
findings are similar to those reported in the ACHD literature, with studies reporting the 
presence of impaired executive function and divided attention in ACHD patients (Idorn et al, 
2013; Daliento et al, 2005; Franklin et al, 2014). Similar to the present study Daliento and 
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colleagues also reported only a small proportion of their study sample exhibiting impairment in 
memory function (<10%) (Daliento et al, 2005). Motor function was not assessed in any of the 
existing studies within the adult literature. 
 
The largest proportion of participants with impairments was noted on tests that assessed 
attention (TMT) and executive functioning (WCST, COWA and Stroop) in some capacity. For 
instance, the TMT while being a test of divided attention, is also known to assess executive 
functioning given the cognitive flexibility, and ability to shift sets that the nature of the test 
demands (Arbuthnott and Frank, 2000). Similarly, the WCST being a cognitively complex task 
also requires the test taker to exercise attention and cognitive flexibility along with the ability to 
shift sets, and develop and maintain a problem solving strategy. Therefore, overall these 
findings suggest that patients with ACHD may particularly struggle with problem solving, 
dealing with novel situations, multitasking and decision making skills.   
 
A significant association has previously been reported between the WCST and TMT-B test in 
the cognitive literature (Kortte, Horner and Windham, 2002). Within the present study a weak 
but significant association was noted between TMT-B and 3/5 WCST scores (error, conceptual 
level response and trials to complete 1
st
 category); thus reinforcing the patterns noted above.  
 
The lack of impairments noted on the memory test is further strengthened by the lack of 
impairments noted on the WCST failure to maintain set score which only marginally exceeded 
the >7% criteria. The ability to maintain a set in the WCST largely depends on the working 
memory of the tests taker; as it requires the participant to remember and retain the strategy 
applied to complete the sets, while being presented with interference in the form of changing 
categories (i.e. colour, shape, number). Therefore, these results collectively provide findings to 
support the view that memory in ACHD patients is not impaired.  
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9.2.2 Cognitive impairment across structural complexity groups  
The following sections discuss the extent of cognitive impairments in the different forms of 
ACHD, and the differences in cognitive functioning between the four structural complexity 
groups. However, it must be noted that the paucity of literature (N= 2 studies) assessing 
independent cognitive domains in different forms of ACHD limits the comparison that can be 
drawn with the existing evidence.  
 
Intelligence Quotient (IQ) 
The mean IQ scores of the different structural complexity groups were lower than the age 
matched normative mean, with the exception of the Simple group which demonstrated IQ scores 
comparable to norms.  Although some proportion of each structural complexity groups (16%-
24%) scored 1 SD below the normative data, overall the results showed that each of the 
structural complexity groups had a mean IQ score within the ‘average’ IQ category (IQ= 90-
109).  
 
No statistically significant differences between the structural complexity groups were noted on 
IQ. These results are largely indicative of a good overall cognitive functional status in the 
ACHD sample when compared to a healthy normal population. Furthermore, the lack of 
statistically significant differences between groups demonstrates that the IQ between the 
different levels of structural complexity was comparable, with those with structurally complex 
conditions performing similar to those with a simpler form of ACHD. These results also suggest 
that the complexity of the ACHD condition does not play a role in determining the IQ in this 
study sample. However, the findings of this study are contrary to those of Utens et al, (1998), 
who reported lower IQ in patients with structurally complex forms of CHD (TGA), when 
compared to those with less structurally complex forms (ASD, VSD).  
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Executive functioning  
Each of the structural complexity groups (ToF, TGA SV and Simple) exhibited some level of 
impairment in executive functioning, across the different tests used to assess this domain. The 
different complexity groups had impairments in different areas of executive functioning 
including problem solving (ToF exhibited highest proportion of participants with deficits), 
verbal fluency (TGA exhibited highest proportion of participants with deficits), response 
inhibition and cognitive flexibility (SV exhibited highest proportion of participants with 
deficits). The simple group consistently had the lowest proportion of participants with 
impairments across the different tests of executive functioning. These results demonstrated the 
variability in impairment within the same domain, highlighting the importance of assessing the 
different areas of this broad domain, among patients with different levels of structural 
complexity. 
  
The finding of the large proportion of ToF patients with impairments in problem solving 
(executive function) noted in this study can be compared to the study of ToF patients reported 
by Daliento et al, (2005). These authors also reported that a large proportion of their ToF 
sample exhibited impairment in executive function, problem solving, and planning strategies (as 
measured by the Verbal fluency test, Ravens test, Tower of London test) (Daliento et al, 
2005).Within the present study however the ToF groups did not report the largest proportion of 
patients with impairments on the measure of verbal fluency (COWA) suggesting that the 
similarities across the studies were mainly limited to the problem solving aspect of this broad 
domain. These results show that ToF patients struggle with problem solving, planning and 
processing information. Executive functioning is one of the key domains of cognitive 
functioning, which is essential for an individual to be able to function independently, work, and 
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be able to think and solve problems. The high proportion of impairments noted in this domain 
highlights the challenges faced by ToF patients in these areas.  
 
No statistically significant differences in executive functioning were identified between the 
structural complexity groups in the present study. This finding could be explained by the fact 
that all the structural complexity groups exhibited impairment in some aspect of executive 
functioning as measured across different tests. Consequently, despite the more structurally 
complex conditions (e.g. TGA and SV) showing a greater proportion of participants with 
impairments when compared to the ‘Simple’ group, these differences were however not 
statistically significant. These findings suggest that the structural complexity of the condition 
does not seem to play a significant role in determining the level of executive function 
impairment. 
 
Attention  
With regards to the domain of attention more structurally complex forms of CHD such as ToF, 
TGA and SV had a higher proportion of participants with impairments, across the different 
measures used, in comparison to the Simple group. The SV group consistently showed the 
highest proportion of participants with impairments in attention.  
 
Interestingly more participants in the TGA group had impairment on the TMT-A subtest than 
the TMT-B in comparison to the other groups. This is at odds with what one might expect, 
given that the TMT-B is a more cognitively challenging task which requires the test taker to 
exercise multiple skills simultaneously including, divided attention, cognitive flexibility, and 
executive control, and therefore more likely to identify impairments in attention. A potential 
explanation for this finding may be the order of the assessment. Given that the TMT-A is 
presented before TMT-B, there may be some practice effect due to familiarization to the test 
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format; however, this pattern of findings was not noted across the different structural 
complexity groups. 
 
An alternative interpretation could be that the TGA group experienced more difficulty in 
cognitive processing speed and visual numerical scanning as measured by TMT-A in 
comparison to divided attention, cognitive flexibility and executive control as measured by Part 
B, when compared to the other groups. This notion is further supported by their performance on 
the WCST test of executive functioning, which showed that the TGA group almost consistently 
(4/5 subscales) had a smaller proportion of participants with executive function impairments 
compared to the ToF group.   
 
With regards to the comparison between structural complexity groups on the measures of 
attention, TMT-B scores significantly differed between the four groups, with a small to medium 
effect size. The post-hoc analyses did not show any significant differences between the TGA 
and Simple groups, but the Simple group did perform significantly better than the ToF and SV 
groups. These findings suggest that ToF and SV patients experience more impairment in 
attention when compared to the TGA and the Simple group. The findings of this study 
corroborated those of Franklin et al, (2014) who reported significantly more impairments in 
attention in patients with structurally complex forms of CHD (ToF, SV) as compared to the 
Simple forms (ASD, VSD) using a computerized battery of NP tests- the CNS Vital Signs 
(CNS-VS) and the Bethesda Conference guidelines to define structural complexity groups 
(Gualtieri and Johnson, 2006). While these results provide some indication of the differences in 
cognitive functioning among the different levels of structural complexity; the use of a wider 
range of measures to assess attention would allow drawing fuller conclusions, as drawing 
conclusions based on a single test is difficult. 
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Memory 
With regards to the domain of memory the ACHD sample in this study did not show 
impairments. The performance of the sample was similar to that expected in the normal 
population. These results are again similar to those of Daliento et al, (2005) who also reported 
only a small proportion of ToF patients exhibiting impairment in memory (<10%). No 
statistically significant differences in memory were identified between the structural complexity 
groups in the present study, showing comparable memory function across different levels of 
structural complexity.  
 
Motor functioning 
Impairments in motor function were observed within the present study, particularly in the more 
structurally complex forms of CHD. The TGA group in particular had the highest proportion of 
participants with impairments on both hands while the Simple group had the lowest proportion. 
A consistent pattern was noted across the four groups, with a greater proportion of participants 
in each group exhibiting impairments on the task involving the dominant hand in comparison to 
the non-dominant hand. This finding could be considered contrary to expectation, as one might 
expect participants to do better when using their dominant hand; however, it is also not entirely 
unusual for an individual to score lower when using the dominant hand (Lezak et al, 2012).  
 
Some authors have suggested the role of ‘transfer of training’ that may occur between the 
hands; whereby the first hand used (usually the dominant hand is assessed first) would improve 
the performance on the other hand. This transfer of training or familiarization with the test 
format may explain the better performance noted on the non-dominant hand across the study 
sample. Therefore, this finding may not necessarily be associated with CHD or be indicative of 
a cognitive impairment, although understanding the underlying mechanisms of handedness is 
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outside the scope of this study. Similar to the domains of executive functioning, and memory 
the structural complexity groups showed no significant differences in motor functioning.  
 
Mean total composite cognitive functioning score  
The overall cognitive functioning for the total sample indicated poorer overall cognitive 
performance for the ACHD group as a whole. The TGA group demonstrated the poorest overall 
cognitive performance, while the Simple group had the highest mean composite score. These 
findings indicate, to some extent, that the more structurally complex forms of CHD overall 
experienced more cognitive impairments in comparison to the less complex forms, potentially 
suggesting some association between structural complexity and cognitive outcomes. Post hoc 
tests showed a significant difference between the TGA and the Simple groups. 
 
 Individual Cognitive tests and Structural Group Differences 
When the total percentage of individuals who were performing 1.5 SD below the mean was 
calculated the ACHD sample in the present study exhibited impairments across a wide range of 
cognitive tests compared to age matched normative data. The proportion of participants 
performing 1.5 SD below the mean by structural complexity groups showed that the more 
structurally complex forms such as ToF, TGA and SV consistently had a greater proportion of 
participants with impairments when compared to the less complex forms of ACHD such as 
ASD and VSD.  
   
However, when inspecting these differences statistically, only the domain of attention (1 test) 
showed significant differences between the SV, ToF and the Simple group. Furthermore, 
significant group differences were noted between the TGA and Simple groups on the total 
composite cognitive score. As discussed earlier findings of the present study are similar to 
Franklin et al, (2014) who assessed motor function, attention, memory and executive function in 
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ACHD patients (Gualtieri and Johnson, 2006) and reported that the more structurally complex 
groups performed worse on all measures of the CNSVS when compared to the simple groups. 
Further significant differences in complex attention, cognitive flexibility and overall executive 
functioning between the groups were reported. The authors concluded that the more complex 
conditions (e.g. TGA, SV, and other cyanotic conditions) performed significantly poorer on 
measures of attention and executive functioning, as is also the case within the present study. 
Similarly, Utens et al, (1998) also reported impaired cognitive functioning (impaired IQ) in 
patients with more complex forms of CHD such as TGA when compared to those with simpler 
forms such as VSD and ASD.   
 
Overall the existing literature on cognitive functioning in ACHD and the results of the present 
study indicate an association between more structurally complex conditions and impaired 
cognitive functioning across domains. One explanation for this could be that the more 
structurally complex conditions are characterized by cyanosis; given that cyanosis can lead to 
the lack of oxygen supply to the body including the brain it can have detrimental effects such as 
cognitive impairment. Within the present study the more structurally complex conditions like 
SV and TGA which showed the highest proportion of participants with impairments were 
cyanotic and had the longest duration of cyanosis and the lowest levels of blood oxygen 
saturation levels in comparison to the other structural complexity groups, thus suggesting the 
potential role of cyanosis in causing cognitive impairment.  
 
Furthermore, patients with more structurally complex conditions (TGA, SV, ToF) are generally 
more likely to undergo multiple procedures and interventions, when compared to the less 
complex counterparts (ASD, VSD) as was the case in this study. As discussed earlier these 
multiple procedures may increase their risk of surgery related brain injury and neurological 
complications. 
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This raises the question of whether it is the symptoms and complexity of the condition, the 
sequale of the treatments, or a combination of the two, that explain variance in these domains of 
cognitive functioning. 
 
9.3 Demographic, clinical and mood factors associated with cognitive functioning in 
ACHD  
Another objective of the cross-sectional study was to identify factors that may potentially have 
the ability to influence and/or impact cognitive functioning in ACHD. The data in the present 
study was subjected to a twofold investigation with the aim of identifying unique factors 
(clinical, demographic and psychosocial) associated with cognitive functioning both for the total 
study sample (all complexity groups combined) and the independent structural complexity 
groups.  
 
9.3.1 Demographic, clinical and mood factors associated with cognitive functioning in the 
total ACHD sample (all groups combined)  
The results of the present study showed that post-operative CNS complications and fewer years 
of education were consistently associated with poorer cognitive functioning across the domains 
of attention, executive functioning and IQ in patients with ACHD.   
 
Although cardiac surgery and treatments for CHD have advanced and led to an increase in 
survival rates, these techniques often lead to other additional complications. The deleterious 
effect of surgery is well reported in the cardiac literature; with studies reporting central nervous 
system complications post surgery (Newman et al, 2006). These complications can result in 
damage to the brain, and may manifest in a number of ways including cognitive impairment 
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(Arrowsmith et al, 2000). Within the present study, postoperative CNS complications were 
associated with lower IQ and impairment attention and executive functioning.  
 
Given that the assessment of CNS complications was dichotomous (i.e. yes / no) the 
information about the exact nature or kind of the CNS complications was unavailable within 
this study, making it difficult to draw conclusions about the particular type of complications, 
only that CNS complications post surgery does appear to influence overall cognitive functioning 
in ACHD. In some ways this could be expected as the most common CNS postoperative 
complication post cardiac surgery appears to be impairment in cognitive functioning and what 
this study demonstrates is that these impairments appear to persist into adulthood.  Future 
studies may benefit from assessing these different kinds of CNS complications post surgery 
separately, to identify their independent influence on cognitive function.  
 
The association between fewer years of education and lower levels of cognitive functioning 
found in this study is consonant with this general literature, (Lezak et al, 2012). This gives 
support to the validity of the results of the study. The on-going need for treatment, surgical 
procedures and repeated hospitalization in CHD has an impact on education through a reduced 
attendance at school (Wray and Sensky, 2001). It does however remains unclear on the data 
presented here whether poor cognitive functioning impacts educational attainment and/or 
whether poor academic performance is due missing school as a result of the heart condition. 
These interruptions in the formative years cumulatively may affect the academic performance in 
this patient group (Razzaghi, Oster and Reefhuis, 2015). Further research is warranted in order 
to examine this relationship.  
 
Higher levels of positive affect were associated with better performance on the test of attention 
(SDMT) reflecting findings elsewhere in the literature, which report improved cognitive 
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functioning with increased positive affect (Dreisbach and Goschke, 2004; Dhinakaran et al, 
2013). Within the cognitive literature the role of increased dopamine levels in the brain as a 
result of positive affect has been used to explain better performance in cognitive outcomes such 
as working memory and executive attention (Ashby and Isen, 1999).  
 
In line with the general literature on gender, male ACHD patients exhibited poorer working 
memory in comparison to female patients (Knox et al, 2007). The differences in memory 
function have been attributed to men and women using different neural networks when 
exercising working memory (Hill, Laird and Robinson, 2014). Greater cerebral blood flow in 
the left temporal pole has been associated with better immediate and delayed recall in a verbal 
memory task among women but not men (Ragland et al, 2000). While the findings of the 
present study reflect those in the literature, understanding these underlying mechanism in 
ACHD remain outside the scope of this study. 
 
Overall the findings in the total study sample emphasize the deleterious impact of post-
operative CNS complications on long-term cognitive outcomes in ACHD. The results also 
demonstrated in line with the existing literature the role of demographic factors such as 
education and gender in influencing cognitive functioning in ACHD.  
 
9.3.2 Demographic, clinical and mood factors associated with cognitive functioning in 
different structural complexity groups 
Given the wide range of sub-group analyses conducted within this study, only the most common 
and consistent factors associated with cognitive functioning across all of the cognitive domains, 
are discussed for each structural complexity group independently- ToF, TGA, SV and Simple.  
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In the case of the ToF group only younger age at the time of surgical repair was associated with 
poorer memory. Performing surgery at a very young age may make the patient more vulnerable 
to embolization, hypoxia and brain damage due to the immature and frail development of the 
brain at that early stage, leading to long-term complications such as cognitive impairment 
(Newburger and Bellinger, 2006). Surgical treatment (complete repair or palliation) for children 
with ToF in the first year of their lives is the basis of therapy in this patient group (Monaco and 
Williams, 2012; Lee, Kwak and Lee, 2014). Age at repair for CHD has also been found to be 
associated with increased cerebral and neurological damage (Trittenwein et al, 2003), along 
with impairments in cognitive domains and lower IQ (DeMaso et al, 2010; Chira and Ciotlaus, 
2013). The results of this study demonstrate that these associations appear to persist into 
adulthood, thus highlighting the implications that clinical decisions made early in the patient’s 
life can have in the long-term.    
 
In the TGA group clinical factors including the duration of CPB, post-operative CNS 
complications, LVEF were associated with cognitive functioning. Interestingly, a longer 
duration of CPB was associated with higher IQ in this group. This is at odds with some of the 
existing literature that reports an increased duration of CPB being associated with deleterious 
effects on cognitive functioning in adults (Newman et al, 2001). However other studies report 
no association between CPB and cognitive functioning (Tan and Amoako, 2013). One could 
hypothesize that the longer duration of CPB (total minutes across lifespan) may have led to an 
improvement in symptoms such as cyanosis, low oxygen saturation levels as a result of the 
surgical treatment, in turn leading to improved cognitive function. These findings suggest that 
the increased interventions may have resulted in improvements in functioning and reduced the 
impact of the heart condition on cognition. 
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Post-operative CNS complications and lower levels of LVEF in TGA were associated with 
impaired executive function and attention, respectively. Both the association of CNS 
complications after a surgical procedure (Arrowsmith et al, 2000) and the association of ejection 
fraction (EF) with reduced cognitive functioning in coronary artery disease have been reported 
in the cardiac literature (Gottesman et al, 2009). LVEF has also been associated with brain 
injury and found to be a significant predictor of worse scores on neuropsychological tests in 
heart failure patients (Jefferson et al, 2011; Vogels et al, 2007; Nussbaum, Allender and 
Copeland, 1995; Almeida and Tamai, 2001). One suggested mechanism of this association is 
cerebral perfusion homeostasis (the stability, or the lack of, in cerebral blood flow) caused by 
lower levels of LVEF (Jefferson et al, 2011). Further research is needed to understand these 
relationships specifically in this group of patients.  
  
Lastly, mood was associated with cognitive functioning in the TGA group. Higher levels of 
negative affect were associated with better performance on tests of executive functioning and 
attention in the TGA group. This association between increased negative affect and better 
executive functioning has previously been reported in the cognitive literature (Mitchell and 
Phillips, 2007).  Mitchell and Phillips explain the association between mood and executive 
functioning using the mood-as-information theory, which proposes that a positive mood is 
likely to result in heuristic processing, and negative mood in analytic processing (Mitchell and 
Phillips, 2007). One possible explanation for improved executive functioning when 
experiencing negative affect may be that, when an individual experiences negative mood it may 
potentially signal a problem or challenge in the environment which may motivate the individual 
to carry out information processing and problem solving and in turn improving the underlying 
executive function (Mitchell and Phillips, 2007; Park and Banaji, 2000). 
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The positive association between improved attention and negative affect in the TGA group is 
contrary to the findings of the total study sample, which showed a positive association between 
positive affect and attention (on both SDMT written and oral) as discussed above in Section 
9.3.1. Furthermore, this finding is also contrary to existing literature, which shows poorer 
cognitive function in those with higher negative affect (Payne and Schnapp, 2014). Given the 
complex relationship between mood and cognition much more work is needed to establish and 
understand the mechanisms underlying these relationships in patients with ACHD.  
 
In the case of the SV group, clinical factors were associated with impaired IQ, and executive 
functioning. These included the presence of post-operative CNS complications and infections, 
current blood oxygen saturation level and the time spent under Hypothermic Arrest (HA 
minutes). As mentioned above CNS complications due to surgical procedures can have long-
term neurological and cognitive implications (Arrowsmith et al, 2000).  
 
Several of the findings within the SV group were contrary to expectation. Firstly, lower current 
levels of blood oxygen saturation (i.e. the most recent blood oxygen saturation level at time of 
assessment) were associated with more conceptual level responses on the WCST, showing 
better performance on the test of executive functioning. This finding appears unusual given that 
lower blood oxygen saturation levels (chronic hypoxia and hypoxic spells) are characteristic of 
cyanotic CHD and are often known to cause cognitive impairment and brain damage (Bass et al, 
2004). Within the present study the SV group had the lowest mean oxygen saturation levels 
compared to the other complexity groups. However, the mean oxygen saturation levels of the 
SV group were 93% (range 60-100%), which is not below the normal threshold and is a 
relatively acceptable oxygen saturation level, which may not lead to detrimental effects. This 
may help explain the lack of a negative association between the two variables, however the 
positive association noted within this study remains elusive and warrants further investigation. 
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Furthermore, a number of measures were used to assess executive function, however no patterns 
in the findings were observed to support this association. Alternatively, these findings could 
suggest the role of additional unaccounted for confounding variables that were either not 
included or identified in this analysis.  
 
Secondly, longer duration of HA was associated with better performance on the memory and 
learning test in SV patients. This finding is contrary to existing evidence, which reports a 
negative association between increased duration of HA, and cognitive functioning (Ziganshin 
and Elefteriades, 2013; Wypij et al, 2003). However other studies have reported that HA 
duration ranging from 14-40 minutes might not adversely affect cognitive function post-cardiac 
surgery in adults (Uysal et al, 2012). It has been reported that patients can usually tolerate 30 
minutes of HA without significant neurological impairment (Conolly, Arrowsmith and Klein, 
2010). The HA duration in the present study ranged from 28-34.5 minutes with the median 
duration of the SV group being 30 minutes. Hence it could be speculated, that the mean duration 
of the HA in this study may not have been long enough to result in a deleterious effect on 
cognitive function. While these studies explain the lack of a negative association between the 
variables, the positive association noted in this study remains unexplained and warrants further 
investigation.   
 
With regards to the Simple group factors associated with cognitive functioning included current 
medication (anti-coagulant/anti-arrhythmia), age at repair and years since the last operation. The 
simple group was the only group in which the use of medication was associated with impaired 
cognitive functioning. Anti-coagulant medication is often used in some forms of ACHD and 
other heart conditions, to control symptoms of Atrial Fibrillation (AF) (Walsh and Cecchin, 
2007). Poor anticoagulation control in patients with AF has been associated with impaired 
cognitive functioning and a faster rate of cognitive decline (Van Deelen et al, 2005; Flaker et al, 
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2010; Wozakowska-Kapton et al, 2009 Thacker et al, 2013). The association between anti-
coagulation medication and impaired cognitive functioning in the present study could reflect the 
association between AF and impaired cognition. However, given that AF was not assessed as 
part of the present study this relationship cannot be directly assessed and further research is 
warranted specifically within the ACHD population.  
 
Similar to the ToF group, the Simple group also showed a significant association between 
younger age at repair and impaired cognitive functioning (executive control). As discussed 
above, the vulnerability of younger patients due to the immature development of their brain may 
put them at an increased risk of embolization, hypoxia and brain damage when undergoing 
cardiac surgery, causing long-term complications such as cognitive impairment (Newburger and 
Bellinger, 2006).  
 
Longer time (years) since the last surgery was associated with poorer motor function in the 
Simple group. Although these findings appear contrary to expectation given that one would 
expect to see more cognitive impairment immediately after surgery. However, given that these 
groups of patients are generally operated very early on in life when their brains are weaker and 
fragile, these procedures may cause permanent damage in the form of cognitive impairments, 
which may then persist or remain stable over a period of time, potentially resulting in the 
observed relationship.  
 
Similar findings have been reported in patients undergoing coronary artery bypass surgery, with 
cognitive impairment persisting up to 5 years after cardiac surgery (Stygall et al, 2003). 
Alternatively, it could be speculated that longer duration since surgery is indicative of a younger 
age at the time of repair, which as discussed above can impact cognitive outcomes (Newburger 
and Bellinger, 2006). However, more work and longitudinal examination is required to make 
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conclusive judgments, as the cross-sectional nature of this data does not allow the determination 
of causality. 
 
Summary  
Overall the results of these analyses demonstrate that a wide range of clinical, demographic and 
mood related factors have the potential to influence cognitive functioning. Amongst all the 
variables, clinical factors were more frequently associated with cognitive outcomes than 
demographic or mood factors. Within the clinical variables post-operative CNS complications 
was a key explanatory variable across the different domains assessed, both by total sample and 
in independent groups. Given that CNS complications may reflect cognitive problems; it is not 
surprising to see that these are predictive in this study. However, it does suggest that at least 
some of the cognitive difficulties in this patient group do persist into adulthood.  
 
The two-fold analyses demonstrated considerable variability in factors associated with cognitive 
functions across the different structural complexity groups. This confirms the diverse nature of 
CHD and the role that different structural complexities and their associated treatments may play 
in the evolution of cognitive impairments in adulthood.  
 
9.4 Cognitive functioning and QoL in ACHD patients 
The results of the univariate screening conducted to identify the association between cognitive 
functioning and QoL showed no significant association between cognitive functioning and 
physical QoL in either the total sample, or the four structural complexity groups. Similarly, the 
total study sample showed no significant association between cognitive functioning and mental 
QoL. When the structural complexity groups were assessed individually a significant univariate 
linear association was noted with cognitive functioning showing a positive association with 
mental QoL in the Simple group alone.  
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Within the multivariate analysis, reduced mental QoL in the Simple group was associated with 
higher levels of depression and negative affect, but no unique variance in the outcome was 
explained by cognitive functioning. These results demonstrate that the effect of cognitive 
functioning on mental QoL might have been obscured with the addition of other variables such 
as mood, which explained more unique variance in mental QoL.  
 
It is possible that the QoL measure (SF-36) used in the present study was not sufficiently 
sensitive to detect any relationship with cognition. Alternatively, it is possible that this group of 
patients do not present with extremes of cognitive impairment which may be sufficient to find a 
relationship to QoL. However, contrary to the findings of the present study Idorn et al, (2013) 
reported a significant negative association between cognitive speed and poorer physical and 
mental QoL as measured by the SF-36. However, this study only included patients diagnosed 
with SV, thus limiting the generalizability of the findings. 
 
Future studies may benefit from conducting a more in-depth exploration of the association 
between QoL and cognitive functioning, perhaps using a wider range of both generic and 
disease specific measures of QoL, to be able to evaluate the aspects of QoL important to this 
patient group (See chapter 15 for a more detailed discussion on the subject).  
 
The strengths, limitations and implications of this study are discussed in detail in Chapter 15 
(Final overall discussion) and the following chapters present the background, methodology and 
results of the follow-up study conducted.  
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10 STABILITY AND LONGITUDINAL ASSESMENT OF 
COGNITIVE FUNCTIONING IN ACHD 
 
10.1 Prologue  
Following a discussion of the concept of longitudinal cognitive research this chapter examines 
the stability of cognitive functioning in ACHD. Finally, it presents the methodological 
challenges associated with the longitudinal assessment of cognitive functioning; the different 
technique commonly used to assess change in cognitive functioning; and discusses how these 
informed the techniques applied within this study. 
 
10.2 Stability of cognitive functioning in the normal adult population 
Cognition is dynamic and may be subject to change, even in the absence of any 
pathophysiology. Age is one of the dominant factors driving change in cognition. Studies have 
reported that different domains of cognitive functioning have a differential pattern of change 
over time. While domains such as verbal and numerical ability are associated with little age-
associated decline, other domains of cognitive functioning such as memory, processing speed 
and executive function tend to show more age related decline (Deary et al, 2009). It has been 
reported that these declines in cognitive functioning can begin as early as the middle age (i.e. 
thirties) or sometimes even sooner (Park and Reuter-Lorenz, 2009).  
 
Considerable individual variability has been reported in the degree to which declines are noted 
across individuals that are within “normal cognitive ageing”. Assessing the stability of cognitive 
function can be done to investigate age related changes in cognitive functioning i.e. ‘cognitive 
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ageing’. Alternatively changes in cognitive functioning can also be assessed over shorter 
periods of time, to investigate the level of within individual variability in cognitive functioning, 
which may be driven by factors other than ageing. The objective of the present study was to 
investigate the short-term stability of cognitive function as opposed to cognitive ageing.    
 
Cognitive functioning has the ability to influence different areas of an individual’s life for 
instance their ability to work, earn a living, maintain meaningful relationships, self-care and 
overall wellbeing. Assessing the stability (or lack of) of cognitive functioning is critical given 
that these mental abilities and functions are essential to an individual’s ability to live, sustain 
independently and lead fulfilling lives, and decline in these functions can have wide spread 
implications.   
 
10.3 Longitudinal assessment of cognitive functioning in adult congenital heart disease  
The existing literature showed a lack of longitudinal studies assessing the stability of cognitive 
functioning in ACHD patients; the available longitudinal evidence only focused on the 
paediatric population (Snookes et al, 2010; Griffin, Elkin and Smith, 2003). A systematic 
review of studies assessing cognitive and motor outcomes in children with CHD, reported 
limited number of longitudinal studies assessing cognitive functioning (N=8).  Furthermore, the 
authors emphasized the importance of a well-designed longitudinal study as a potentially 
valuable basis for research aimed at identifying techniques to decrease the incidence of brain 
injury and its long-term impact such as cognitive impairments (Snookes et al, 2010).  
 
Bellinger and Newburger, (2016), assessed a group of TGA patients longitudinally and 
conducted neurodevelopmental and cognitive assessments between the ages of one and sixteen. 
The authors reported that this group of patients consistently demonstrated neurodevelopmental 
and cognitive impairment over the years. Furthermore, the patients experienced increasing 
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cognitive impairment with age, perhaps due to the growing cognitive demands placed on them 
with advanced education and more complex situations (Bellinger and Newburger, 2016). These 
results showed the presence of persistent cognitive impairment in children with CHD over time 
and demonstrated the importance of continually assessing cognitive functioning in TGA 
patients and CHD patients in general. Although these longitudinal studies showed the 
persistence and development of cognitive impairment as these groups of patient’s grow older, 
given that cognitive functioning is still in its developmental stages in childhood the stability of 
cognition cannot be assessed.  
 
There is a lack of studies assessing stability of cognitive functioning in adult CHD patients. This 
lack of longitudinal evidence limits the understanding of the long-term trajectory i.e. stability 
and/or decline of cognitive functioning in patients with ACHD. Furthermore, it also limits the 
understanding of whether cognitive stability in the different structural complexity groups varies 
over time.  
 
More longitudinal research assessing cognitive changes in ACHD will enable a better 
understanding of the stability of cognitive functioning in the ACHD population along with 
identifying predictors of any change in these functions. Information about the modifiable factors 
(if any) impacting the long term cognitive outcomes in these group of patients will not only 
enable the development of protective strategies but also help provide age appropriate support 
and interventions where necessary in the adult population. Given the rise in the number of 
ACHD patients due to increased survival rates, understanding the long-term trajectory of 
cognitive outcomes is important, as evidence from longitudinal studies could have implications 
for clinical management of this patient group.  
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10.4 The concept and rationale for longitudinal assessment of cognitive functioning 
Longitudinal cognitive assessments involve examining the same set of individuals on more than 
one occasion, using the same or similar measures. The length of time between these consecutive 
assessments varies greatly in studies and relates both to pragmatics (e.g. funding) and to the 
question being asked (i.e. whether there is an expected rapid disease progression e.g. dementia). 
Longitudinal assessments can be done for a number of different reasons including i) assessing 
individual performance on different cognitive domains over time in order to identify any 
changes, positive and/or negative, associated with age, e.g. early detection of mild cognitive 
impairment (MCI) and dementia; ii) to investigate the impact of different treatments and 
therapeutic techniques on cognitive outcomes, thus enabling the  assessment of long-term 
treatment related benefits and/or complications (Griva et al, 2006; Newman et al, 2001); iii) to 
assess the cognitive stability or decline over time in long term neurological disorders such as 
aphasia and Parkinson’s disease (Starkstein et al, 1992); iv) to assess the stability of cognitive 
functioning in long-term chronic conditions that are known to have an impact on the patients 
cognitive outcomes for instance CHD.  In relation to the last category, individuals with ACHD 
may show greater variability in their cognitive performance when assessed at different time 
points in comparison to the normal population. This is the question that is addressed in this 
follow-up study.  
 
10.5 Methodological considerations of conducting longitudinal cognitive testing 
With longitudinal cognitive testing the phenomenon of ‘practice effect’ may occur, which is 
described as an improvement in a test takers score from one assessment to the other and is 
characteristic of nearly all longitudinal cognitive assessments (Bartels et al, 2010; Goldberg et 
al, 2015). Several factors could be considered important in explaining the practice induced 
effects of repeated testing, for instance increased familiarity with the test and what the testing 
procedure involves, test sophistication, which is the test takers improved knowledge of how to 
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respond advantageously to a test given their prior experience of solving the problem/task and 
improvement of an underlying function as a result of practice, may all contribute to the practice 
induced effects (Erickson, 1972; Bartels et al, 2010). The time frame between the two 
assessments can also be a contributing factor to the extent of practice effects. A shorter duration 
is more likely to facilitate practice effects, as the test taker is more likely to remember the test 
and the strategy applied upon reassessment. Evidence shows that practice effects may persist for 
as long as two years after the initial assessment (Lezak et al, 2012). The presence of practice 
effects makes it difficult to establish a distinction between a ‘real change’ and change due to 
prior exposure to the test being administered.  
 
Within the cognitive literature the use of an alternate form of a test is recommended when 
conducting longitudinal cognitive assessments to address the issue of practice effects. The 
rationale behind the use of alternate forms is to measure the underlying cognitive function in 
question, using a different measure with subtle changes, which assesses the same function to 
provide comparable results to those of the original measures. The alternate form is believed to 
help reduce the presence of any practice effects that may be present due to familiarity with the 
original test utilized. However alternate forms are not available for all tests of cognitive 
functioning and in the absence of one, examiners generally repeat the same measure on different 
time points. When using an alternate form, it is essential to check if the reliability and validity 
of the measure has been assessed in comparison to the original form, in order to ensure that it 
assesses the same function. Therefore, alternate forms must match the original measures in 
terms of style, number of items, type of content and the method of administration (Groth-
Marnat, 2009).  
 
However, the use of alternate test versions may not eradicate the problems of repeated testing 
entirely (Lezak et al, 2012). While the use of alternate forms enable changing the content of the 
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test, the examinee may have adapted or learned the overall style and format of the test 
administered, making it easier to complete upon reassessment. A good example of this would be 
the WCST test of executive functioning, which requires the test taker to identify a pattern and 
strategy in order to be able to solve the task by matching a set of cards to 4 key cards using 
three principles i.e. by colour, form and number (See Chapter 7 for details). While one may 
attempt to change the colour or the shape of the test symbols, the fundamental concept of 
matching them to the key cards using the three principles needs to remain the same, in order for 
the two test forms to be comparable. Thus making it relatively easy for the test taker to replicate 
the strategy previously applied, given that the ‘novelty’ of the test may be lost upon 
reassessment, due to familiarization with the test and its execution (Groth-Marnat, 2009). 
 
Lastly, it is important to note that while practice effects can be considered an interference when 
interpreting test results, they could also reflect some level of cognitive ability. For example, the 
ability of an individual to learn and remember a strategy previously applied, and to re-apply it 
upon re-assessment in itself indicates some cognitive skills.  
 
Another common challenge associated with repeated testing is that of ‘regression to the mean’. 
This statistical phenomenon implies that extreme scores (i.e. towards the upper or lower end of 
the range of scores) at first assessment are statistically more likely to show a significant change 
upon reassessment, and appear closer to the mean/norm in a repeated measures design when 
compared to those with a moderate score at the first assessment (Barnett, Van Der Pols and 
Dobson, 2005). The presence of regression to the mean complicates the measurement of change 
over time as it can make a natural variation in repeated data look like a real change, and can 
therefore affect the true magnitude of change observed (Barnett, Van Der Pols and Dobson, 
2005). For instance, if the regression to the mean is not taken into account an improvement in a 
test score over time may be interpreted as an improvement in the underlying cognitive domain, 
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while in fact it may simply be a result of regression to the mean. One way of dealing with this 
issue is the use of residualized change scores, as these scores control for baseline variance (See 
Section 10.6 for description of change scores) (Levine et al, 2007).  
 
10.6 Measurement of change in cognitive functioning over time 
In order to assess change in performance (i.e. improvement or decline in cognitive functioning) 
it is important to be able to reliably quantify the difference between the first (Time 1) and 
second (Time 2) assessment scores, while controlling for the influence of confounding factors 
that may be responsible for the change observed. There are several ways to detect a statistically 
significant change in cognitive functioning over time but each technique has its own advantages 
and disadvantages. Some of the common methods used to assess change in cognitive 
functioning are discussed below.  
 
One technique is the use of simple change (delta) scores, which assess change in cognitive 
functioning simply by calculating the difference between the scores on the first and second 
assessment. Another technique is the use of Reliable Change Index (RCI) scores, which are 
derived by calculating the difference between the T1 and T2 scores, and dividing this value by 
the standard error of the difference of the test scores, to obtain a standardized score (See Figure 
10.1). A modified version of the RCI, RCIPE has been developed in order to control for practice-
induced effects (Chelune et al, 1993). Calculating the RCIPE involves calculating the difference 
between the discrepancy of test scores (T1 and T2) and the discrepancy of the mean from the 
control group (M1 and M2), divided by the standard error of the difference (See formula 
below). 
 
An alternative method commonly adopted is the use of residualized change scores. This 
approach utilizes a regression equation by regressing T1 scores onto T2 scores resulting in a 
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standardized change score (derived from the two scores of each participant). These residualized 
change scores are adjusted for baseline variance, by removing the correlation between the two 
scores (Prochaska et al, 2008). 
 
 
Formula used to calculate the Reliable Change Index (RCI) and RCIPE 
  
 
 
 
 
 
T2= time two scores 
T1= time one scores 
M1= control group mean at time one 
M2= control group mean at time two 
Sdiff= Standard Error of difference between two test scores 
SED= Standard Error of the Difference 
 
* Formula adopted from Jacobson and Truax, (1991) and Duff, (2012) 
 
 
There are advantages and disadvantages to each of the methods discussed above. Although 
mathematically straightforward and easy to execute, the simple (delta) change score has been 
criticized for its over simplicity and measurement error (difference in actual value versus value 
obtained by the measure/technique used) in comparison to other techniques. As all 
measurements contain some degree of error (i.e. not perfect reliability), any change score 
calculated by subtracting T1 scores from T2 scores would contain error from both time points 
(Llabre et al, 1991). Further the use of unstandardized scores such as simple change scores may 
restrict comparison across different measures, if they use a different unit of measurement, for 
instance timed tests versus vocabulary tests (Russell, 2000). Lastly the simple scores do not take 
into account other statistical challenges such as regression to the mean, which may affect the 
true magnitude of change observed.  
 
RCI =   (T2 – T1) ÷ Sdiff 
RCIPE= (T2 – T1) - (M2 – M1) ÷ SED 
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While the RCIPE method is often used to assess significant change in cognitive functioning 
while controlling for practice effects, it is limited by certain methodological challenges. The 
RCIPE method assumes that the change in an individual test score equals the mean score of the 
normative group, which makes the presumption that the degree of change in the measure over 
time is equal across different groups (i.e. subjects and control group), therefore not allowing for 
differential practice effects across individuals. Given that the level of cognitive functioning in 
certain patient groups such as ACHD may not be the same as the normative group, assuming 
that the degree of change due to practice effects over time will be the same, may lead to an 
incorrect estimation of change.  
 
Calculating residualized change scores is a regression based technique, which takes into account 
the association between the two scores (T1 and T2) and removes any correlation between them, 
thereby controlling for the problem of regression to the mean (Van Der Elst et al, 2008). 
Additionally, the resultant score is standardized in nature, which allows different measures to be 
compared directly irrespective of the original test score metrics (Strauss, Sherman and Spreen, 
2006).   
 
Given the nature of the data in this study and the non-normally distributed nature of some of the 
NP test scores, the use of the regression approach (residualized change score) was considered 
the most appropriate (See Chapter 12 for details of the methodology). 
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11 INTRODUCTION TO THE FOLLOW-UP STUDY AND 
AIMS AND OBJECTIVES  
 
11.1 Summary of the background chapter and rationale for research   
The objective of this section of the thesis was to assess the stability of cognitive functions in 
ACHD patients, and to establish if the impairments noted in the cross-sectional study remained 
stable, improved, or declined over time.  
 
It also aimed to assess if the stability of cognitive functioning varied across different structural 
complexity groups over time. Furthermore, predictors of the observed change in cognitive 
functioning were also identified in order to better understand the factors that may have the 
ability to influence changes in cognitive functioning. 
 
Lastly, this study also aimed to compare the stability and/or change in cognitive functioning in 
the ACHD sample to that of the normal healthy population in order to establish if the stability of 
cognitive functioning was different within this patient population.  
 
11.2 Research questions and objectives of the follow-up study  
Research question 1: Does cognitive functioning in ACHD patients change over time?  
Specific objectives related to the research question 1 included:  
 To assess the stability of cognitive functioning in ACHD patients  
 To investigate differences in cognitive functioning between the complexity groups   
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 To investigate if the level of cognitive functioning changed differentially in the 
different structural complexity groups over time 
 To compare the stability of cognitive functioning in ACHD patients to that of a 
normal healthy population. 
 
Research question 2: What factors predict change in cognitive functioning in patients with 
ACHD?  
Specific objectives related to the research question 2 included:  
 To identify clinical, mood, and demographic predictors of change in cognitive 
functioning in ACHD patients.  
 
11.3 Hypotheses  
No specific hypotheses were formulated for the purpose of this study, as these investigations 
were exploratory in nature.  
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12 FOLLOW-UP STUDY METHODOLOGY  
 
12.1 Prologue  
This chapter presents the methodology adopted for the follow-up study. It is divided into the 
following sections; first, the study design and procedures are detailed; followed by a description 
of the measures utilized; and lastly the statistical strategy adopted for data analysis is explained 
for each research objective. 
 
12.2 Study design and setting 
This study adopted a within-subject repeated measures design, and followed-up a subset of the 
sample from the cross-sectional study. Participants with complete NP data in the cross-sectional 
study were invited to participate in the follow-up study, in order to investigate the stability of 
their cognitive functioning over time. It was conducted at the Heart Hospital, London 
(University College London Hospitals NHS Foundation Trust). The NRES Committee London 
– Bentham and the University College Hospital Ethical Committee granted an extension on the 
ethical approval obtained for the cross-sectional study (Study Ref. No- 08/HO715/105).  
 
12.3 Participants and Sampling procedures  
12.3.1 Sample size calculation 
A sample size calculation was conducted using G-Power software (Faul et al, 2007), for a study 
including four groups, to detect a significant change in cognitive functioning over time (using 
repeated measures ANOVA and/or Multilevel Modelling). Based on repeated measures sample 
size calculations, 55 participants in each group were needed (α=0.05, β=0.80, r= 0.90) to be able 
to detect a significant change in cognitive functioning. 
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12.3.2 Inclusion and exclusion criteria 
In addition to the inclusion and exclusion criteria established for the cross-sectional study, 
additional criteria were used for the follow-up study. Participants were eligible if i) they had 
complete cross-sectional NP data, and ii) their cross-sectional assessment must have been 
completed at least a year and a half prior to the follow-up assessment. This was done to try and 
minimize the influence of practice effects and to try and recruit as many potential participants as 
possible within the study time-frame. In addition, participants were excluded if they had 
recently (within last 6 months) undergone a surgical procedure; this was done, as the use of 
anesthetics during the surgical procedure could have resulted in cognitive changes which may 
have obscured the impact of ACHD on cognitive outcomes.   
 
12.3.3 Study sample and recruitment procedure 
All eligible participants included in the cross-sectional study (N=310) were sent a letter inviting 
them to take part in the follow-up study, along with an information sheet detailing the study 
procedures and an interest form to indicate his or her willingness to participate in the study (see 
Appendix-T for information sheet). Two weeks were allowed for patients to consider 
participation before a reminder letter was sent. For patients who agreed to participate, a week 
before their prescheduled hospital outpatient appointment (OPA) a reminder telephone call was 
made, to confirm the study appointment. Following the assessment all participants were sent a 
letter thanking them for taking part. 
 
A total of 210 (68% of total cross-sectional study sample) patients indicated an interest in 
participating in the follow-up study. Of these, 153 (73%) consenting participants completed the 
follow-up assessment, resulting in 49% of the cross-sectional study sample being followed-up 
(See Figure 12.1 below for recruitment details). There were an equal number of participants in 
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the TGA and SV group and a similar proportion of participants in the ToF and Simple group 
(TGA= 35 (22.88%), SV=35 (22.88%), ToF= 42 (27.45%), Simple=41 (26.79%). The 
remaining participants could not be recruited due to time constraints of the research project.  
 
12.3.4 Data collection 
Patients who indicated an interest in participation were assessed on the day of their regular 
OPA. The purpose of the study was explained to each participant using the information sheet 
prior to signing an informed consent form; data was gathered only after written consent was 
obtained. Participants were given a signed copy of the consent form for their records (See 
Appendix-U).  
 
All the assessments were conducted at the Heart Hospital London and prior to the participants’ 
OPA, where possible, in order to avoid fatigue having an impact on the participants’ 
performance. Demographic information was collected at the start of the session followed by 
administration of the NP test battery and the self-report questionnaires assessing mood. This 
sequence of assessment was consistent across all study participants; and each participant was 
given an optional break of 5 minutes between the NP assessment and completion of the 
questionnaires.  
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Figure 12.1: Flow chart of the follow-up study recruitment procedure 
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12.4 Measures utilized in the follow-up study 
12.4.1 Neuropsychological (NP) measures  
The NP test battery used in the cross-sectional study was re-administered to each participant at 
follow-up. To control for practice effects, alternate versions of the NP tests were used where 
available (TMT, SDMT, COWA, and RAVLT) (See Table 12.1 for details). Tests with no 
appropriate alternate versions were re-administered using the original test utilized in the cross-
sectional study (WCST-64, Stroop test and Grooved pegboard). Details of all the tests, 
including the alternate versions of the NP tests where used, are presented in Table 12.1 below.  
 
The IQ test (WAIS-III) was the only test that was not re-administered at follow-up. Intelligence 
as a construct has been reported as being stable over time, with tests producing similar scores 
upon reassessment (Moffitt et al, 1993; Canivez and Watkins, 2001). The NP test administration 
procedures including the order of assessment, consenting procedures and the test-taking 
environment were consistent with those in the cross-sectional study (See Chapter 7, Section 
7.5.1 for details).  
 
12.4.1.1 Scoring procedures used for NP tests  
All NP tests were scored using the same scoring procedures utilized in the cross-sectional study 
(i.e. z-scores). Normative data used in the cross sectional study was utilized again for the 
purpose of comparison to the normal population, in the follow-up study. This was done as 
normative data for the alternate test versions were not available. Furthermore, this allowed 
consistency of the normative data used for the purposes of comparing the performance over 
time.  
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Table 12.1Description of the NP test battery and alternate NP tests used at follow-up 
Tests utilized* 
 
Domain 
assessed 
Alternate 
form  
Alternate form/ test-
retest reliability 
Description of the alternate form, in comparison to the 
original measures 
Alternate version of Trail Making Test 
(TMT) (Franzen, Paul and Iverson, 1996) 
Divided 
attention 
 
 
Part C, r= 0.70 
Part D, r= 0.78  
Two alternate versions are used, one for each part of the test. 
TMT-C is used to replace TMT-A and TMT-D to replace TMT-
B. Both the alternate forms have the same relative positions of 
the circles with inverted label sequences compared to the 
original. The test administration and scoring procedure remain 
the same as the cross-sectional study. 
Alternate version of Controlled Oral Word 
Association Test (COWA) (Dikmen et al, 
1999) 
Executive 
function 
 
 
r= 0.72 
 
The alternate version includes three new letters B, D and T, 
which replace the original letters, F, A and S. The test 
administration and scoring procedure remain the same as the 
cross-sectional study. 
Stroop neuropsychological screening test 
(Trenerry et al, 1989) 
Executive 
function 
X r=0.90 N/A 
Grooved Pegboard (GP) (Matthews & 
Klove, 1964; Wang et al, 2011)  
Motor 
function 
X Dominant-r=0.91 
Non-dominant-r=0.85 
N/A  
Wisconsin Card Sorting Test -64  (WCST-
64) (Kongs et al, 2000) 
Executive 
function 
X N/A N/A 
Alternate version of Symbol Digit 
Modalities Test (SDMT) (Hinton-Bayre 
and Geffen, 2005) 
Attention   
 
r= 0.74  The symbols in the alternate version are different to the original 
form; but the mirrored symbol pairings are maintained to ensure 
comparability. The response array is matched to the original 
form to ensure the same level of visual scanning is required. The 
test administration and scoring procedure remain the same as the 
cross-sectional study. 
Alternate version of Rey Auditory Verbal 
Learning Test (RAVLT) (Lezak, 1983) 
Memory 
and 
learning 
 
 
RAVLT total 
acquisition, r= 0.60-
0.77 (across trials) 
In the alternate version the original list of words is replaced by a 
new list and a new distracter list. The test administration and 
scoring procedure remain the same as the cross-sectional study. 
*Please see Appendix-V for the complete NP test battery (follow-up study),  N/A- Not Applicable 
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12.4.2 Measures of mood 
Along with the NP tests, measures of mood were also re-administered at follow-up. This 
decision was made for two reasons: i) to be able to control for mood as a covariate in 
subsequent analyses, and ii) to be able to investigate if a change in mood state was a predictor of 
change in cognitive functioning.  
 
A total of three self-report questionnaires were re-administered at follow-up, i) The Positive and 
Negative Affect Scale (PANAS) (Watson, Clark and Tellegen, 1988), ii) Spielberger State 
Anxiety Inventory-6 (STAI-6) (Marteau and Bekker, 1992) and iii) Centre for Epidemiological 
studies Short Depression Scale (CESD-10) (Andresen et al, 1994). Standard scoring procedures 
were used to score all the questionnaires (See Section 7.3.6 for details and Appendix-I for copy 
of questionnaires).  
 
12.4.3 Demographic details 
Demographic information was collected from each participant using a standard self-report form. 
Information gathered included: age, marital status, living status, total years of education and 
employment status. Demographic variables such as ethnicity and gender were considered 
constant and not recorded again; information regarding these variables was obtained from the 
cross-sectional study database. 
 
12.4.4 Clinical measures 
The clinical history of the participants was not recorded again at follow-up; the data gathered in 
the cross-sectional study was utilized for the purpose of analyses. Only information regarding 
any additional interventions, surgical procedures and/or changes in medication that patients may 
have undergone in the time between the two assessments was recorded. This was done to enable 
the assessment of any influence these factors may have had on cognition.  
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12.5 Statistical Analysis 
This section details the statistical strategy applied to assess the aims and objectives of the 
follow-up study. Details of the preliminary analyses (missing data, data distribution) and the 
main analysis (Multilevel Modelling - MLM) are presented below. All analyses were conducted 
using IBM SPSS (Version 21).  
 
12.5.1 Missing data analysis  
After checking the data entered into SPSS for any inconsistencies, such as manual data entry 
errors (and correcting where necessary through checking of the paper data collection forms), a 
missing values analysis was conducted; both at item level and scale level (Field, 2009). The 
patterns of missing data that emerged included: 
 Individual items missing within sub-scales of self-report psychosocial 
questionnaires  
 Entire sub-scales missing within a single administration of a questionnaire  
 
No NP data was found to be missing in the follow-up study, and the overall proportion of 
missing data was under 5%. The exact proportion of missing data on each variable is presented 
in Appendix-W. A decision to carry out an imputation was made for three reasons: i) in order to 
be able to obtain a complete data set, ii) to minimize the loss of sample size, and iii) to avoid 
different sample sizes across analyses. Imputation procedures were conducted for data missing 
at scale level, and one imputation was performed using SPSS 21.0. Multiple Imputation 
procedures were conducted on the basis of the predictive mean matching (PMM) (Please see 
Chapter 7 for details). As discussed in Chapter 7, some neuropsychological tests scores were not 
applicable to all participants, for example the WCST-64 - failure to maintain set score, which 
can only be calculated if the participant has completed at least 2 categories and attempted a 
third. Therefore for those that did not complete adequate categories the score was considered 
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not applicable and labelled as 888. As these scores were not applicable as opposed to missing 
they were not subject to imputation. The imputed dataset was used for all further analyses.  
 
12.5.2 Differences between responders and non-responders  
A sensitivity analysis was conducted to assess whether there were any differences between 
patients that participated in the follow-up study and those that did not. T-tests and Pearson’s chi 
square tests were performed to compare characteristics of patients who had only completed the 
cross-sectional assessment and those that completed both the cross-sectional and follow-up 
assessment, on all variables including clinical, mood, demographic and NP scores. Furthermore, 
an analysis of variance (ANOVA) was conducted to investigate if the test-retest interval differed 
significantly between the structural complexity groups in the follow-up study. 
 
12.5.3 Distribution of variables 
The data distribution of each variable was examined to assess the normality of the data points. 
This was done visually using histograms, and statistically, by performing the Kolmogorov-
Smirnov test, for which a statistical significance level of p <0.001 was used to detect non-
normality (See Appendix-X). When conducting statistical analysis non-normally distributed 
data is generally transformed using mathematical formulas to obtain a normal distribution. The 
data in the follow-up study was not transformed for two reasons: i) to maintain comparability 
with the cross-sectional data, which was not transformed and ii), because data transformations 
can hinder the interpretation of the results, by changing the nature of the data (Osborne, 2005).  
 
12.5.4 A note on the level of statistical significance 
A significance level of p<0.01 was used, unless stated otherwise. This was done to avoid the 
risk of obtaining a false-positive result i.e. rejecting the null hypothesis when it is in fact true 
(Type 1 error), due to the large number of tests performed. Furthermore, post hoc tests were 
employed to adjust for multiple testing where necessary. The main effects in the study were 
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only considered significant at p<0.01. A less conservative significance level of p<0.05 was 
adopted when identifying potential covariates and conducting univariate screening to identify 
predictor variables for a hierarchical regression analyses. This was done in order to reduce the 
risk of removing any potential predictor variables based on stringent significance levels.  
 
12.6 Statistical analyses adopted for each research objective  
This section details the statistical analyses adopted in order to address each of the research 
objectives in the follow-up study.  
 
12.6.1 Stability of cognitive functioning in ACHD patients  
To assess change in cognitive functioning over time, Multilevel Modelling (MLM) was utilized 
for each NP outcome variable (Marques and Hamilton, 2014). MLM was the preferred method 
as, in comparison to more traditional methods such as repeated measures ANOVA:  i) it allows 
the hierarchical structure of the data to be considered, by accounting for the non- independence 
of scores given on the same test/questionnaire by the same participant at multiple time points, 
i.e. data points are more similar within individuals over time than they are between individuals 
(Cartwright, Traviss and Blance, 2012); and  ii) it has the ability to include all collected data 
points despite missing data. The application of MLM approaches are increasingly being 
recommended in designs where the data has been collected from individuals on more than one 
occasion, as multilevel models imply that scores are clustered within each individual (Queńe 
and Van den Bergh, 2004).    
 
Recommendations for dealing with repeated measures data using SPSS software have been 
provided by Heck and colleagues (2014). These recommendations were used to guide the 
analysis within this study. In preliminary steps to prepare the data for analysis, the data was 
restructured (into a 2- level dataset) to recognize its hierarchical nature. This resulted in a 
vertical arrangement of the data points, with each participant having two rows of observed 
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scores, with each row representing one time point (See Figure 12.2 for a conceptual visual 
representation of the data structure) (Heck, Thomas and Tabata, 2014). The specifics of the 
MLM analysis are presented in the following sections - Section 12.6.1.1 discusses the 
preliminary MLM analysis (assumption testing) and Section 12.6.1.2 details the main MLM 
analysis (assessing the main effect of time, group and ‘time x group’ interaction on each NP 
score).  
 
 
Figure 12.2: A conceptual visual representation of the MLM hierarchical data structure 
 
 
12.6.1.1 Preliminary MLM analysis 
Prior to running the MLM analysis, in order to check the assumption that scores within each 
participant were highly correlated an initial MLM analysis was run for each NP outcome, which 
included no predictors and a scaled identity covariance type for both levels one and two in order 
to calculate the Interclass Correlation (ICC). ICC estimates the amount of variance in the 
outcome that can be explained by the between-subject variance. A higher ICC suggests that 
scores within a participant are more similar than between participants, therefore violating the 
assumption of independence (Heck, Thomas and Tabata, 2014). This statistic indicates whether 
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the higher-level grouping has an impact on the estimates in a way that makes MLM suitable for 
the data analysis. A cut-off score of 0.05 was used as a criterion with an ICC smaller than this 
suggesting little advantage in conducting MLM (Heck, Thomas and Tabata, 2014). If an 
outcome variable in this test achieved ICC>0.05, MLM was performed in its main analyses. 
Alternatively, if this ICC>0.05 was not achieved more traditional methods such as repeated 
measures ANOVA would be implemented.  
 
12.6.1.2 Main MLM analysis  
Each NP score was used as the dependent variable (DV) in the main MLM analysis, with the 
participants’ years of education, and mood used as covariates. No new potential covariates were 
identified in the follow-up analyses; this maintained consistency and comparability between the 
cross-sectional and follow-up analyses. Covariates were selected based on a significant 
association with the DV (p<0.05).  
 
A covariance structure representing the relationship between repeated measures needs to be 
specified for the data in the MLM analysis. SPSS provides a range of covariance structures 
suitable for repeated measures data including, i) unstructured, ii) diagonal variance, and iii) 
first-order autoregressive structure (AR1). An AR1 structure was chosen theoretically to model 
the correlation structure of within participant effects for these analyses, as scores at adjacent 
time points of each DV were likely to be correlated and are not assumed to be heterogeneous or 
unpredictable within each participant. The AR1 parameter takes into account the correlation 
between repeated measures (Field, 2009). A Restricted Estimate Maximum Likelihood (REML) 
method was used as a parameter for estimating a model, as opposed to the Maximum likelihood 
method, as REML is recommended for smaller sample sizes (Bryk and Raudenbush, 1992). 
 
The main effect of time (a difference in scores between the two assessments), group (a 
difference between the groups irrespective of time-points) and time x group interaction 
  
      
 
266 
(difference in the pattern of means between the 4 groups across time points or change in the 
means of the groups across time) was assessed using adjusted mean scores. If the main effect for 
the group or the time x group interaction was found to be significant, pairwise comparisons 
were performed on the adjusted mean scores. The pairwise comparison allows comparing all 
possible time point combinations whilst controlling for family wise error rates (i.e. the inflated 
error from conducting several statistical tests on the same data), by correcting the level of 
significance for each test so that the overall Type 1 error rate across comparisons remains at 
0.05 (Field, 2009). To measure the standardized effect size of the fixed effect of time, partial eta 
squared (ŋp
2) was calculated (Lakens, 2013), and were interpreted using Cohen’s criteria 
whereby 0.01 is a small effect, 0.06 is a moderate effect and 0.14 is a large effect (Cohen, 
1988). 
 
12.6.1.3 Graphical representation of the data 
In addition to the MLM analysis, three additional graphs of the repeated measures were plotted 
to enable a visual representation of the data. This was done i) to enable assessing the stability of 
NP scores over time across the different complexity groups, and ii) to enable determining if the 
observed change was of a clinically significant magnitude (i.e. did the sample change from 
being impaired to non-impaired and vice versa over time), and iii) how stability in the study 
sample compared to the normal population. While MLM analyses utilized the entire study 
sample (i.e. those with and without data at both time-points) as MLM accounts for missing data, 
the graphs only represent the participants that have data for both time points. The three graphs 
and their interpretations are detailed below: 
 
 Error bar plots (of means and their 95% Confidence Intervals - CI) were plotted for 
each structural complexity group and the total sample for both time-points. These were 
utilised to evaluate the relative mean performance of each group and the total sample in 
comparison to the normative mean score – which was set at the 0 i.e. representing no 
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standard deviation difference from the norms (indicated by a blue line in the figures). 
This helped evaluate if the groups declined/improved over time and if the group mean 
was different to the normative mean (i.e. the 95% CI do not cross the normative mean).  
 Box-plots to evaluate the spread and variability of the data across the two time-points 
for each group were plotted. This helped identify differential variability of the data 
across time one and time two, within and between the groups. The whiskers in the 
graphs help see the shift in scores over time across the different groups, and indicate 
where the largest and smallest non-outlier scores are.  
 Scatter plots to evaluate the correlations between time one and time two scores (i.e. test-
retest correlation) for each group were plotted to assess stability of scores over time. 
They showed the best line of fit and the regression slopes for each group, which 
indicate the magnitude of the correlation between scores across time points. A higher 
correlation shows that scores at both time points were related and moved in a similar 
direction.  
 
Test-retest reliability  
The test-retest reliability of scores within this study sample was also compared to existing 
literature, on test-retest correlation from normal healthy adults, to compare the stability of 
cognitive functioning in the ACHD sample relative to that of a normal healthy population. Test 
re-test reliability refers to the temporal stability of a test from one assessment to the other when 
giving the same test to the same individual after a period of time; and the correlation between 
these two scores on the same test is in effect the test-retest reliability of the measure (Drost, 
2011).  
 
When considering the test-retest reliability across measures some limitations must be 
considered. One such limitation is the time interval between the first and second assessment. It 
has been reported that a very short duration may affect the retest results as participants may 
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remember their responses, causing memory to influence the results. On the contrary when the 
time frame between assessments is too long ‘maturation’ may occur (Drost, 2011). Drost, 
(2011) defines ‘maturation’ as the changes in the respondents or the subject factors that occur 
over time and cause a change in the measurement across time. The premise of the argument is 
that respondents could be exposed to things and confounders, which may affect or change their 
perception or underlying function in turn affecting the test-retest reliabilities. Therefore, when 
drawing comparisons across different samples, the time interval between assessments must be 
carefully considered.  
 
Generally, a test-retest correlation of ≥ 0.7 is considered good (Field, 2009), however within the 
present study a slightly less stringent test-retest reliability coefficient of ≥0.6 was considered 
acceptable, given that the mean time between assessments was relatively large at 3.3 years, 
compared to the 1 month/1 year intervals commonly used by authors (of the measures used) for 
assessing test-retest reliability in the literature. 
    
12.6.2 Identifying predictors of change in cognitive functioning  
Another objective of the follow-up study was to assess if changes in cognitive functioning could 
be predicted by clinical and demographic factors and/or changes in mood state over time. 
Residualized change scores were calculated for each of the NP scores and the mood variables. 
There are several methods that can be utilized to calculate change scores, as discussed in 
Chapter 10 (See Section 10.6 for details). Residualized change scores were utilized for the 
purpose of this study; these change scores were then used for all further analyses.  
 
In order to identify the demographic, clinical and mood related variables that predict change in 
cognitive functioning, hierarchical multiple regressions were performed. First, a univariate 
screening of all predictor variables was performed, by conducting a simple linear regression 
between each IV (cross-sectional demographic and clinical variables and mood change scores) 
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and DV (NP change scores). Only significant variables (p<0.05) in the univariate screening 
were included in the multivariate analysis, in order to reduce the number of redundant predictors 
from the model. 
 
 The order of the regression blocks and testing of all the related parametric assumptions (e.g. 
collinearity and multi collinearity) were kept consistent to those in the cross-sectional study 
analysis. The order of the regression blocks included i) demographics, ii) structural complexity, 
iii) procedural and surgical variables, iv) cyanosis/current saturation, v) current 
health/medication and vi) mood (See Chapter 7 -Section 7.7.2 for details and rationale of 
analysis). Lastly the regression analyses to identify predictors of change were only conducted 
for test scores that demonstrated a significant difference over time within the MLM analysis, as 
the other scores showed no significant difference over time. 
 
The results of the follow-up study are presented in the next chapter – Chapter 13.  
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13 FOLLOW-UP STUDY RESULTS  
 
13.1 Prologue  
The primary aim of this chapter is to present the results of the follow-up study with each section 
of the chapter addressing the research questions presented in Chapter 11.  It presents a 
description of the demographic and clinical characteristics of the study sample, followed by the 
results of the preliminary analyses conducted. Then the results of the multilevel modelling 
(MLM) analyses assessing change in cognitive functioning over time are discussed. Lastly the 
demographic, clinical and psychosocial predictors of cognitive change are presented.   
 
13.2 Sample description (demographic and clinical characteristics) at follow-up 
The follow-up study sample included 153 participants (49% of the cross-sectional study 
sample), with a median age of 35 years. The demographic characteristics of the sample are 
presented in Table 13.1 below. A very small proportion of participants had an additional 
surgical intervention between the two assessments (N=4; 2 participants from the SV group and 
2 from the TGA group). Given the small proportion of participants with additional 
interventions, these variables were not included in any further analyses. Clinical history 
recorded in the cross-sectional study was utilized for all analyses pertaining to clinical variables. 
 
13.3 Differences between responders and non-responders 
There were no statistically significant differences noted between the responders and non-
responders on any of the clinical, demographic or NP variables (See Appendix-Y).  
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13.4 Distribution of variables 
The frequency distribution for each of the variables assessed was examined to evaluate 
normality. This was done visually by using histograms, and statistically, by performing the 
Kolmogorov-Smirnov test to detect non-normality (significance level of p <0.001; See 
Appendix-X). The majority of the variables were non-normally distributed (i.e. Kolmogorov 
Smirnov statistic p<0.001), with the exception of positive affect, both the SDMT written and 
oral subtest scores, and the COWA test scores, which were normally distributed. 
 
Table 13.1 Demographic characteristics of the follow-up study sample 
Demographic variables N (%) or Median & 
interquartile range 
Gender Males 84 (54.9%) 
Females 69 (45.1%) 
Living status 
 
Cohabiting (living with parent, spouse or friend) 130 (86.7%) 
Living alone (living independently on their own) 20 (13.3%) 
Employment 
status 
Employed/ Student/in training 125 (83.33%) 
Unemployed/ retired/ unable to work 25 (16.66%) 
Occupational 
level*
a
 
Managerial/ Professional 38 (25.3%) 
Intermediate 25 (23.3%) 
Lower 47 (31.3%) 
Never worked/unemployed 30 (20.0%) 
Marital status Married 105 (70.0%) 
Unmarried / Divorced/ Single 45 (30.0%) 
Ethnicity British (white) 134 (87.59%) 
Others 19 (12.41%) 
Age Age (Median, interquartile range) 35.00 (29.5 – 42.5) 
Education Years of education (Median, interquartile range) 13.00 (11-16) 
*a = The National Statistics Socio-economic Classification (NS-SEC rebased on the SOC2010)  (Rose and 
Pevalin, 2010) 
 
 
13.5 Are there changes in cognitive functioning over time in ACHD patients?  
The following sections detail the results of the MLM analysis conducted to investigate changes 
in cognitive functioning in ACHD patients over time [range of time since the cross-sectional 
assessment= 1.7 – 4.6 years, Mean (SD)= 3.36(0.67)]. ANCOVA analysis indicated that the 
time-interval between the cross-sectional and follow-up assessments was not significantly 
different between diagnostic groups [f (3,149)= 1.21, p= .307]. The MLM results are presented 
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separately for each cognitive domain: executive functioning, attention, motor function and 
memory.  
 
13.5.1 Changes in executive function over time   
The results of the MLM analysis pertaining to the domain of executive functioning are 
presented in Table 13.2. The only test of executive functioning that showed a significant 
difference between time-points was the COWA, with a significant main effect for time (F 
(1,165.74)=14.04, p<0.001). The mean difference across the two time points showed a gain in the 
scores (i.e. more words correctly recited) from time one (mean= -0.663; SE= .054) to time two 
(mean= -0.459; SE= .054), demonstrating an improvement in the scores upon re-assessment, 
with a medium effect size (ŋp
2
=0.07). 
 
The main effect of group was not significant, demonstrating no differences in the test 
performance of the structural complexity groups, irrespective of time. Furthermore, the time x 
group interaction did not reach significance, thus demonstrating i) no difference in the pattern of 
means between the four groups at each time-point and ii) no differential change in the means of 
the groups across time. The adjusted means of the four groups on the COWA test at the two 
time-points are presented below in Figure 13.1.  
 
The main effect of time on the Stroop test (p=0.799) and the WCST test scores; error (p=0.131), 
conceptual level (p=0.751), number of categories (p=0.400), trials to complete first category (p= 
0.828), and failure to maintain set (p=0.189) were non-significant showing no difference in 
performance over time on these tests of executive functioning. Similarly, the main effect of 
groups was non-significant (all p>0.01) showing no differences in the test performance of the 
four structural complexity groups (irrespective of time). The time x group interaction term did 
not show any significant effects across all tests of executive function.  
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Table 13.2 MLM results (main and interaction effects) across groups on the measures of executive functioning  
Measure Effect of time Effect size  ŋp
2
 Effect of groups Effect size  ŋp
2
 Time X group interaction Effect size  ŋp
2
 
COWA F1,165.74=14.04,p=<0.001** 0.078 F3,327.61= 2.41,p=. 066 0.021 F3,166.72= 0.307, p=. 820 
 
0.005 
STROOP W F1,158.24= .065,p=. 799 0.001 F3,318.60= 3.34,p=. 019 0.030 F3,155.13= 0.60, p=. 615 
 
0.011 
WCST- Error F1,193.69=2.30,p=. 131 0.011 F3,317.59= 1.41,p=. 237 0.011 F3,194.11= 1.36, p=. 256 0.020 
WCST- Conceptual 
level response  
F1,188.54=0.10,p=. 751 0.001 F3,317.72= 1.58,p=. 193 0.014 F3,188.24= 1.24, p=. 297 0.019 
WCST- No of 
categories 
F1,190.13= .711,p=. 400 0.003 F3,325.32= 2.22,p=. 086 0.020 F3,190.11= 1.49, p=. 217 0.022 
WCST- Trials to 
complete 1
st
 
category 
F1,287.13= .047,p=. 828 0.000 F3,324.05= .875,p=. 454 0.008 F3,287.15= 0.185, p=. 907 0.001 
WCST- Failure to 
maintain set 
F1,250.86= 1.73,p=. 189 0.006 F3,270.83= 1.12,p=. 338 0.012 F3,250.45= 1.38, p=. 249 0.016 
Note- WCST= Wisconsin Card Sorting Test, COWA= Controlled Oral Word Association test, **=p<0.01, ŋ2p- eta squared (0.01=small, 0.06=medium, 0.14=large) 
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Figure 13.1 Graphical representation of change in COWA scores 
 
As discussed in Chapter 12, in order to visually explore the results of the MLM analysis, and 
assess the stability of scores over time, where a significant main effect of time was observed, 
additional graphs of the data were plotted. The graphs associated with the COWA scores are 
presented below (figures 13.2 to 13.4).  
 
Figure 13.2 shows the mean score of the total sample below the normative mean (set at zero) on 
both time 1 and time 2, with the 95% CI not crossing the normative mean. Within the different 
groups, all complexity groups showed mean scores below the normative mean score, with the 
95% CI not crossing the normative mean at time 1. At time 2, the ToF, TGA and Simple group 
did not cross the normative mean suggesting that the mean score of these groups was below the 
norms at both time points; the SV group showed mean scores closest to the normative mean, 
with the 95% CI crossing the normative mean at time 2, indicating that this group may not be 
significantly different to the normal population. In all groups time 2 means were greater than 
time 1 means, reflecting the main effect of time in the MLM analysis, suggesting an 
improvement in scores over time 
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Figure 13.2 Error bar plot (Means and 95% CI) for COWA Time 1 and Time 2 scores 
 
 
 
Figure 13.3: Variability of the COWA 
scores at both time points (Box plot) 
 
Figure 13.4 Correlation between T1 and T2 
COWA (Scatter plot) 
 
  
Figure 13.3 shows the median scores for the groups are relatively similar across time 1 and time 
2; with the IQR also relatively similar and overlapping between time points per group. The 
TGA group showed similar spread, but a shift to higher scores at time 2 with a higher median; 
the SV and Simple groups showed slightly less spread at time 2 than time 1, but their scores 
were in similar ranges; in comparison the TOF group showed a greater spread of scores at time 
two, and a slight shift to higher scores.  
 
Total Sample 
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The scatter plot in Figure 13.4 shows the lines of best fit for each group, demonstrating the 
correlations between the time one and time two scores (i.e. the regression slopes for each 
group). The time 1-time 2 correlations for each group are similar in direction (ToF r=0.76, TGA 
r=0.84, SV r=0.90 and Simple r=0.63), with the test –retest correlation in the Simple group 
being the smallest in comparison to the other groups, which suggests lower stability of scores 
over time in this group. All four groups performed in a similar manner over time, with those 
scoring low at time one scoring low at time two and vice versa.  
 
When compared to published test-retest reliability data in healthy adults (r=0.72, 12 month 
interval), all complexity groups showed comparable or higher test-retest correlation indicating 
similar stability of scores over time in comparison to the normal population (Dikmen et al, 
1999). (See Table 13.3 for test-retest correlation comparisons on all tests across the complexity 
groups, total sample and normal population data).  
 
13.5.2  Changes in attention over time 
Table 13.4 (below) presents the MLM results for the tests of attention (TMT and SDMT). With 
regards to the TMT the main effect of time was significant with a large effect size (ŋp
2
 =0.15) 
for the TMT-A score (F1, 206.2=38.05, p=<0.001), with time two scores (mean=0.103, SE=0.073) 
being lower than time one (mean=0.676, SE=0.096) scores (i.e. less time taken for completion) 
demonstrating an improvement in performance over time. The main effect of the structural 
complexity groups (p=0.017), and the time x group interaction (p=0.027) did not show an 
overall significant effect; thus demonstrating i) no difference in the pattern of means between 
the four groups at each time-point and ii) no differential change in the means of the groups 
across time. The adjusted means of the four structural complexity groups on TMT-A are 
presented in Figure 13.5.  
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Table 13.3 Test retest correlation (reliability) on tests that showed a significant change over time across different structural complexity groups and the total sample in 
comparison to the normal population data 
 
 
 
 
 
Table 13.4 Results of the MLM analysis (main and interaction effects) across groups on measures of attention 
 
NP Tests 
TRT 
ToF group 
TRT  
TGA group 
TRT 
SV group 
TRT 
SIMPLE group 
TRT 
Total sample 
TRT normal  
population
b
 
T1 T2 interval for 
normal population 
COWA .76 .84 .90 .63 .78 .72 12 months 
TMT-A .39
a
 .27
 a
  .84 .61 .60 .79 12 months 
SDMT-O .83 .80 .89 .37
 a
  .73 .76 1 month 
GP-D .60 .82 .77 .29
 a
  .65 .86 12 months 
GP-ND .57
 a
  .19
 a
  .60 .76 .47
 a
  .86 12 months 
RAVLT .38
 a
  .48
 a
  .67 .47
 a
  .48
 a
  .60 12 months 
Note: TRT- Test Re-test; a test-retest correlation below the ≥0.6 criteria applied within this study; b the mean test-retest interval for the total sample was 3.3 years  
Measure Effect of time Effect size ŋp
2
 Effect of groups Effect size ŋp
2
 Time X group interaction Effect size ŋp
2
 
TMT-A F1,206.2=38.05,p=<0.001** 0.155 F3,338.16=3.45, p=. 017 0.033 F3,201.86=3.13, p=. 027 0.044 
TMT-B F1,208.1= .826,p=. 365 0.003 F3,296.11= 4.46,p=.004** 0.043 F3,208.44=1.16, p=. 323 0.016 
SDMT-Written  F1,173.08=6.77,p= 0.01 0.037 F3,327.35= 2.98,p=. 032 0.026 F3,170.74=2.01, p=. 114 0.034 
SDMT- Oral F1,170.05=12.88,p= <0.001**  0.070 F3,329.45= 1.18,p=. 342 0.011 F3,167.69=0.19, p=. 903 0.003 
Note - TMT= Trail Making Test, SDMT= Symbol Digit Modalities Test, **=p<0.01, ŋ2p- eta squared (0.01=small, 0.06=medium, 0.14=large) 
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TMT-B scores did not significantly differ between the two assessments, with the main effect of 
time being non-significant (p=.365). The main effect of the structural complexity groups 
(irrespective of time-points) was significant (F3,296.11= 4.46,p=.004), demonstrating a difference 
between groups on the TMT-B score. Pairwise comparison indicated a significant difference 
(p=0.003) between the SV group (mean=1.229, SE=.200) and the Simple group (mean=0.272, 
SE=.180); but no other significant group differences were identified with the ToF (mean=.814, 
SE=.181) and TGA (mean=.898, SE=.191) groups. Furthermore the time x group interaction 
was not significant (p=0.323); thus demonstrating i) no difference in the pattern of means 
between the four groups at each time-point and ii) no differential change in the means of the 
groups across time.  
 
 
Figure 13.5 Graphical representation of change in TMT-A scores  
 
The additional graphs plotted to visually explore the results of the MLM analysis and assess the 
stability of TMT-A scores are presented below (figures 13.6 to 13.8). 
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Figure 13.6 Error bar plot (Means and 95% CI) for TMT-A T1 and T2 scores 
 
In Figure 13.6 the total sample showed TMT-A scores above the normative mean score (i.e. it 
did not cross the normative mean, with 95%CI), thus suggesting poorer performance with 
longer time taken to complete task, in comparison to normative data at time 1. However, at time 
2 the scores of the total sample decreased and the 95% CI crossed the normative mean score, 
suggesting that scores at time 2 could be similar to the normative data.  
 
With regards to the different complexity groups the ToF, TGA, SV and Simple groups scored 
above the normative mean at time one on the TMT-A score, with 95% CI (i.e. poorer 
performance with more time taken to complete task). While all the groups showed a decline in 
mean scores at T2, only the 95% CI of the TOF, TGA and Simple groups crossed the mean of 
the normative group, suggesting that their performance was similar to that of the normative 
mean at time 2, demonstrating an improvement in scores. The SV group continued to perform 
below the normative group at both time points.  
Total 
Sample 
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Figure 13.7: Variability of the TMT-A 
scores at both time points (Box plot) 
 
Figure 13.8 Correlation between T1 and T2 
TMT-A scores (Scatter plot) 
 
In Figure 13.7 the median scores are lower at time 2 for all the groups; with the IQR’s 
overlapping between time points per group, but with a relative shift to lower scores at time 2. 
All the groups showed a slightly smaller spread, a shift to lower scores and a lower median at 
time 2. 
 
Figure 13.8 shows the lines of best fit for each group and demonstrates that correlations 
between the time 1 and time 2 scores (i.e. the regression slopes for each group) are in a similar 
direction for the ToF, TGA and simple group, but the regression slope for the SV group shows a 
larger correlation between time 1 and time 2 scores (r=0.84) in comparison to the other groups 
(ToF r=0.39, TGA r=0.27, Simple r=0.61). These indicate that the scores for this group are 
highly correlated between time-points, than those for the other groups. The ToF and TGA group 
showed low test-retest correlations suggesting poor stability of scores over time, with scores at 
both time-points being considerably different.  
  
When compared to published test-retest reliability data in healthy adults (r=0.79, 12 month 
interval), the Simple and SV group’s test-retest correlations indicated similar stability of scores 
over time (See Table 13.3 on page 277). On the contrary the ToF and TGA groups showed a 
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considerably lower test re-test correlation demonstrating less stability of scores in comparison to 
the normal population (Dikmen et al, 1999). 
 
The results of the MLM analysis for the SDMT test of attention and complex visual scanning is 
also presented in Table 13.4. The results showed that the main effect of time was not significant 
for the written subtest of the SDMT demonstrating no significant difference between scores 
over time (F1,173.08=6.77, p= 0.01). The main effect for the structural complexity groups was also 
non-significant demonstrating no differences in the test performance of the groups (p= 0.032) 
(irrespective of time-points). Lastly, the time x group interaction term (p=0.114) was also not 
significant, demonstrating i) no difference in the pattern of means between the four groups at 
each time-point and ii) no differential change in the means of the groups across time.  
 
 
Figure 13.9: Graphical representation of change in SDMT-O scores 
 
The oral subtest of the SDMT showed a significant main effect of time (F1, 170.05=12.88, 
p<0.001) with a significant decrease in the scores (fewer numbers correctly recited) from time 
one (mean= 0.417; SE= 0.084) to time two (mean= 0.106; SE= 0.103) demonstrating a decline 
in performance over time. Similar to the written subtest, the main effect of groups (p=0.342) 
and the time x group interaction (p=0.903) was not significant. The adjusted means of the four 
structural complexity groups on SDMT-O are presented in Figure 13.9. 
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The additional graphs plotted to visually explore the results of the MLM analysis and assess the 
stability of scores, for the SDMT-O score are presented below (Figures 13.10 to 13.12). 
 
 
Figure 13.10 Error bar plot (Means and 95% CI) for SDMT-O T1 and T2 scores 
  
 
In Figure 13.10 the total sample showed SDMT-O scores above the normative mean score at 
time 1, but the 95% CI crossed the normative mean at time 2, showing a decline in scores over 
time, indicating poorer performance at time 2. With regard to the different complexity groups 
all but the Simple group scored similar to the normative mean at both time points, (95% CI 
crossing normative mean). However, all three groups demonstrated a decline in scores at time 2, 
with all 4 groups moving closer to the normative mean.  
 
Figure 13.11 shows the median scores for all groups are lower at time 2; with the IQR’s 
showing a relative shift to lower scores. The ToF group showed a larger spread of scores, at 
Total 
Sample 
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time 2 than time 1; the TGA, SV and simple groups showed smaller spread at time 2 than time 
1, showing less variability than the ToF group.  
 
In Figure 13.12 the lines of best fit for each group showed the test-retest correlations between 
the time 1 and time 2 scores (i.e. the regression slopes for each group). The time 1- time 2 
correlations for the ToF (r=0.83), TGA (r=0.80) and SV (r=0.89) groups were similar, but the 
Simple group showed a much smaller correlation between time 1 and time 2 scores in 
comparison (r=0.37), thus showing poorer stability of scores, with the scores for this group not 
being similar over time, in comparison to the other groups. 
 
 
Figure 13.11: Variability of the SDMT-O 
scores at both time points (Box plot) 
 
Figure 13.12 Correlation between T1 and 
T2 SDMT-O scores (Scatter plot) 
 
When compared to published test-retest reliability data in healthy adults (r=0.76, 1-month 
interval), the ToF, TGA and SV group showed good SDMT-O test-retest correlations indicating 
better or similar stability of scores over time in comparison to the healthy population (Smith, 
1982). The Simple group, however, showed a considerably lower test-retest correlation 
indicating less stability of scores in comparison to the normal population (See Table 13.3).  
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13.5.3 Changes in motor functioning and dexterity over time    
The MLM analysis for the Grooved Pegboard test of motor function and dexterity are presented 
in Table 13.5. With regards to the performance on the dominant hand score, the main effect of 
time was significant with a significant difference in the GP-Dominant hand score between the 
two time-points (F1,187.84=22.23, p=<0.001). The mean difference indicated an improvement in 
performance with less time taken to complete the task from time one (mean= 0.996; SE=0.098) 
to time two (mean= 0.456; SE=0.125) with a medium effect size (ŋ p
2
=0.10).  
 
Table 13.5 Results of the MLM analysis (main and interaction effects) across groups on the 
measures of motor functioning over time 
Measure Effect of time Effect 
size  ŋp
2
 
Effect of 
groups 
Effect 
size  ŋp
2
 
Time X group 
interaction 
 
Effect 
size  ŋp
2
 
GP-D F1,187.84=22.23, 
p=<0.001** 
0.105 F3,335.81= 2.28, 
p=. 078 
0.006 F3,187.82= 0.52, 
p=. 667 
0.008 
GP-ND F1,234.61=7.44, 
p=.007** 
0.031  F3,331.11=1.97, 
p=.118 
0.017 F3,234.87= 0.259, 
p=. 855 
 
0.003 
Note - GP= Grooved Pegboard, *=<0.05, **=p<0.01 ŋ2p- eta squared (0.01=small, 0.06=medium, 0.14=large) 
 
 
The main effect for the structural complexity groups was non-significant (p= 0.078) with no 
differences between the groups (irrespective of time point). The interaction term between the 
time and structural complexity group was also non-significant (p=0.667); thus demonstrating i) 
no difference in the pattern of means between the four groups and ii) no differential change in 
the means of the groups across time. The adjusted means of the four structural complexity 
groups on GP-Dominant hand scores are presented in Figure 13.13. 
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Figure 13.13 Graphical representation of change in GP-D scores 
 
 
The additional graphs plotted to visually explore the results of the MLM analysis and assess the 
stability of scores, for the GP-Dominant hand are presented below in Figures 13.14 to 13.16.  
 
 
 
Figure 13.14 Error bar plot (Means and 95% CI) for GP-D T1 and T2 scores 
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In Figure 13.14 the total sample showed GP-Dominant hand scores above the normative mean 
score at time 1 (i.e. it did not cross the normative mean, with 95%CI), thus suggesting poorer 
performance, longer time taken to complete task, in comparison to normative data. At time 2 the 
scores of the total sample decreased but still remained above the normative data.  
 
With regards to the different complexity groups the ToF and SV groups scored above the 
normative mean at both time points on the GP-Dominant hand score. The Simple and TGA 
groups showed the 95% CI of their means crossed the normative mean score at time 2; thus 
suggesting that their performance was similar to that of the norms. All groups showed a 
decrease in scores over time, with scores moving closer to the normative mean score suggesting 
improvement over time in all groups. These results are consistent with the results of the MLM 
analysis, which showed an improvement in scores over time, consistent in all groups.   
 
 
Figure 13.15: Variability of GP-D scores at 
both time points (Box plot)                       
 
Figure 13.16 Correlation between T1 and 
T2 GP-D scores (Scatter plot)                                     
 
 
In Figure 13.15 the median scores are lower at time 2 for all the groups; with the IQR’s 
overlapping between time points per group, but with a relative shift to lower scores at time 2. 
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The TGA group showed similar spread, but a shift to lower scores and a lower median in time 
2; the SV and simple groups showed slightly less spread at time 2 than time 1, and a shift to 
lower scores; in comparison the TOF group showed a greater spread of scores at time 2, but still 
a shift to lower scores. 
 
In Figure 13.16 shows lines of best fit for each group, demonstrating correlations between time 
1 and time 2 scores (i.e. the regression slopes for each group) which are in a similar direction 
for the ToF, TGA and SV group (ToF r= 0.60, TGA r=0.82, SV r=0.77), in comparison the 
regression slope for the Simple group shows a smaller correlation (r=0.29) indicating that the 
scores for this group are less similar between time 1 and time 2, than those for the other groups, 
indicating poorer stability of scores over time.  
 
When compared to published test-retest reliability data in healthy adults (r=0.86, 12-month 
interval), the ToF, TGA and SV group showed comparable test-retest correlations indicating 
similar stability of scores over time when compared to a healthy normal population. On the 
contrary the Simple group showed a much lower correlation demonstrating less stability of 
scores in comparison to the normal population (Dikmen et al, 1999) (See Table 13.3).  
 
Similar to the dominant hand score the GP-Non-Dominant hand scores showed a significant 
main effect of time, demonstrating a difference in scores between the two assessments (F1, 
234.61=7.44, p= 0.007). The mean comparison showed a decrease in the time taken to complete 
the task from time one (mean= 0.749; SE=0.089) to time two (mean= 0.399, SE=0.122), again 
demonstrating an improvement in performance over time. The main effect of the structural 
complexity groups (irrespective of time points) was not significant (p= 0.118), showing no 
differences in the performance of the groups (irrespective of time point). 
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Furthermore, the time x group interaction term was also non-significant (p=0.855); thus 
demonstrating i) no difference in the pattern of means between the four groups and ii) no 
differential change in the means of the groups across time. The adjusted means for the GP-Non-
Dominant hand score is presented in Figure 13.17, showing the change in the scores from 
assessment one to assessment two in the four structural complexity groups.  
 
 
Figure 13.17: Graphical representation of change in GP-ND scores  
 
 
The additional graphs plotted to visually explore the results of the MLM analysis and assess the 
stability of scores, for the GP-Non-Dominant hand are presented below (figures 13.18 to 13.20).  
In Figure 13.18 the total sample showed GP-Non-Dominant hand scores above the normative 
mean score, i.e. it did not cross the normative mean on time 1 and time 2, with 95% CI, thus 
suggesting poorer performance (i.e. longer time taken to complete task) in comparison to norms. 
However at time 2 the scores of the total sample decreased and were much closer to the 
normative mean (but still the 95% CI did not cross the normative mean).  
 
With regards to the different complexity groups the ToF group scored above the normative 
mean at both time points, (95% CI not cross 0). The TGA, SV and Simple groups crossed the 
normative mean at time 2, suggesting that their performance at time 2 may not be significantly 
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different to the normative data. Overall the mean scores of all four groups reduced over time, 
moving closer to the normative mean suggesting improvement over time in all groups. These 
results are consistent with the results of the MLM analysis, which showed an improvement in 
scores over time in the total sample.  
 
 
Figure 13.18 Error bar plot (Means and 95% CI) for GP-ND T1 and T2 scores 
 
 
Figure 13.19: Variability of the GP-ND 
scores at both time points (Box plot) 
 
Figure 13.20 Correlation between T1 and 
T2 GP-ND scores (Scatter plot) 
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In Figure 13.19 all groups showed lower median scores at time 2; with the IQR’s overlapping 
between time points per group, and with a relative shift to lower scores at time 2. The ToF and 
TGA groups showed a greater spread, but a shift to lower scores and a lower median at time 2; 
the SV and simple groups showed less spread at time 2 than time 1, and a shift to lower scores 
and a lower median. 
 
In Figure 13.14 shows lines of best fit for each group, which demonstrate that correlations 
between the time 1 and time 2 scores (i.e. the regression slopes for each group) are in a similar 
direction for the ToF, SV and Simple group (ToF r=0.57, SV r= 0.60, Simple r=0.76); while the 
TGA group shows a much smaller correlation (r=0.19), indicating that the scores for this group 
are less similar between time 1 and time 2, thus indicating poorer stability of scores over time in 
comparison to the other structural complexity groups. 
 
When compared to published GP-Non-Dominant hand test-retest reliability data in healthy 
adults (r=0.86, 12-month interval) the total sample showed a slightly lower test-retest 
correlation in comparison. With regards to the different complexity group the ToF, SV and 
Simple groups showed a comparable test-retest correlation; demonstrating similar stability of 
scores in comparison to the normal population (Dikmen et al, 1999). The TGA group showed a 
considerably lower test-retest correlation with scores showing very little stability over time, 
which may explain why the test-retest reliability of the total sample may have been pulled down 
(See Table 13.3). 
 
13.5.4  Changes in memory function over time  
Table 13.6 presents the results of the MLM analysis for the RAVLT test of memory function. 
There was a significant difference in the scores on the RAVLT test over time with the main 
effect of time being significant (F1, 210.26=63.42, p= 0.001), with a large effect size (ŋp
2
= 0.23). 
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The mean difference showed a decline in performance over time, with fewer words correctly 
recalled from time one (mean=0.530; SE= 0.061) to time two (mean= -0.136; SE= 0.082). The 
main effect of the groups was not significant (p= .907), showing the absence of differences 
between the groups on memory (irrespective of time-points).  
 
 
 
 
Table 13.6  Results of the MLM analysis (main and interaction effects) across groups on the 
measures of memory  
Measure Effect of time Effect 
size ŋp
2
 
Effect of 
groups 
Effect 
size  ŋp
2
 
Time X group 
interaction 
 
Effect 
size  ŋp
2
 
RAVLT F1,210.26=63.42, 
p=<0.001**  
0.23 F3,330.88= .184, 
p=. 907 
0.001 F3,214.24= 1.33, 
p=. 263 
 
0.016 
Note – RAVLT= Rey Auditory Verbal Learning Test, *p<0.05 **p<0.01 ŋ2p- eta squared (0.01=small, 
0.06=medium, 0.14=large) 
 
Figure 13.21 illustrates the adjusted means for the four structural complexity groups on the 
RAVLT over the two time points. Although the figure shows crossing lines, indicating some 
interaction between the groups, the interaction term for time x category was non-significant (p= 
0.263); thus demonstrating i) no difference in the pattern of means between the four groups and 
ii) no differential change in the means of the groups across time. 
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Figure 13.21 Graphical representation of change in RAVLT scores 
 
The additional graphs plotted to visually explore the results of the MLM analysis and assess the 
stability of RAVLT scores is presented below (figures 13.22 to 13.24).  
 
 
Figure 13.22 Error bar plot (Means and 95% CI) for RAVLT T1 and T2 scores 
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In Figure 13.22 the total sample showed RAVLT scores above the normative mean score at 
time1 but moved towards the normative mean at time 2, with 95% CI crossing the mean of the 
normative group. These results indicate that the sample performed better than the normative 
data at time 1 (more words correctly recited); however at time 2 the scores moved down and 
crossed the normative mean suggesting that the mean score of the sample was similar to the 
normative data at time 2.  
 
With regards to the different complexity groups all groups followed a similar pattern to the 
overall sample i.e. time 1 mean scores were above the normative mean, and the 95% CI did not 
cross the normative mean. By time 2 the mean scores of all the groups shifted down showing a 
decline in scores over time, and crossed the normative mean. This pattern reflects the results of 
the MLM analysis (main effect of time), which reported a significant decrease in scores over 
time. 
 
 
Figure 13.23: Variability of the RAVLT 
scores at both time points (Box plot) 
 
Figure 13.24 Correlation between T1 and 
T2 RAVLT scores (Scatter plot) 
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As seen in Figure 13.23 the median scores were lower at time 2 for all groups; with the IQR’s 
overlapping between time points per group. A relative shift to lower scores and an overall 
higher spread in scores across all groups at time 2 was noted. The ToF, TGA and SV groups 
showed relatively greater spreads at time 2 in comparison to the Simple group, which showed a 
similar spread at time 2. 
 
Figure 13.24 showed the lines of best fit for each group, which demonstrates that correlations 
between the time 1 and time 2 scores (i.e. the regression slopes for each group), which are in a 
similar direction for the ToF, TGA and simple group (ToF r=0.38, TGA r=0.48, Simple r=0.47). 
The SV group showed a larger correlation between time 1 and time 2 scores in comparison to 
the other groups (r=0.67) indicating that the scores for this group are more similar between 
time-points, thus indicating greater stability of scores over time.  
 
When compared published test-retest reliability data in healthy adults (r=0.60, 12-month 
interval), the total sample showed a slightly smaller test re-test correlation in comparison to the 
normal population. With regards to the structural complexity groups the SV group showed 
comparable test-retest correlations indicating similar stability of scores over time when 
compared to a healthy normal population. On the contrary the ToF, TGA and Simple groups all 
showed a lower correlation demonstrating less stability of scores in comparison to the normal 
population (Carstairs, Shores and Myors, 2012) (See Table 13.3).  
 
Summary of MLM and test retest analysis  
Overall majority of test scores, across all assessed domains showed a significant difference in 
scores over time. It is of note that two tests RAVLT and SDMT-Oral subtest showed a 
statistically significant (p<0.01) decline in performance over time, with the change in memory 
showing a large effect size (ŋp
2
= 0.23). On the contrary, other tests (TMT-A, COWA) showed 
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an improvement in scores over time (with a large effect size -ŋp
2
 =0.15) thus demonstrating 
variability in the pattern of change across the different tests. The MLM results showed that the 
time x group interaction term consistently remained non-significant across all the domains 
assessed. These results suggest that there were no differences in the pattern of means between 
the four groups at each time-point and no differential change in the means of the groups was 
noted across the two time-points. A significant between group differences was only noted on the 
TMT-B test score (irrespective of time point). 
 
With regards to the test-retest reliability the total sample showed some similarity in the test-
retest correlations when compared to the normal data, with the exception of two scores (GP-ND 
and RAVLT) which showed smaller correlations. With regards to the different structural 
complexity groups; ToF, TGA and the Simple group showed lower test-retest reliabilities on 
tests of motor function, attention and memory, while the SV group had good test-retest 
reliability on all tests when compared to the normal population.  
 
13.6 Which factors predict change in cognitive functioning over time in ACHD patients?  
Multivariate hierarchical regression analysis was conducted to identify predictors of change in 
cognitive functioning. Residualised change scores were calculated for each variable that showed 
a significant difference in scores over time in the MLM analysis (e.g. COWA, RAVLT, TMT-
A).  
 
13.6.1 Univariate screening for potential predictors of change in cognitive functioning 
Prior to conducting the multiple hierarchical regressions, a univariate screening of the potential 
predictor variables was undertaken, using simple linear regressions. Patients’ demographic, 
clinical and mood residualized change scores were used as independent variables and each of 
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the NP residualized change scores were used as dependent variables in the simple linear 
regression analysis.  
 
The data distribution of the NP change scores was assessed for normality using the 
Kolmogorov-Smirnov test, for which a statistical significance level of p <0.001 was used to 
detect non-normality (The Kolmogorov-Smirnov statistic for each variable is provided in 
Appendix-X). Furthermore, a visual inspection of the distribution of the data points was also 
conducted using histograms. Regression analysis on the change scores was conducted despite 
any variables being non-normally distributed, as regression analysis does not assume a normal 
data distribution (Field, 2009).  
 
Variables significant at p<0.05 in the univariate linear regressions were used in the hierarchical 
multiple regression models for the respective NP change scores. The order of the regression 
blocks was consistent with that utilized in the cross-section study analysis (See Figure 8.8). This 
decision was made for two reasons, firstly to maintain consistency in the approach taken to 
analyse the data, and secondly to enable drawing comparisons between the cross-sectional and 
follow-up study results.  
 
Univariate predictors of change in cognitive functioning  
Only demographic and clinical factors were significant univariate predictors of the NP Change 
scores (DV). None of the mood change scores were significant predictors of change in cognitive 
functioning over time, within this sample, thus demonstrating that a change in mood did not 
predict a change in cognitive functioning over time. The results of the univariate screening for 
each NP change score are presented in Appendix-Z.  
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13.6.2 Predictors of change in executive functioning over time in ACHD patients   
With regards to the domain of executive functioning, only one test showed a significant 
difference in performance over time (COWA). The univariate predictors of the COWA change 
score were education and diuretic medication. Table 13.7 (below) presents the results of the 
hierarchical multiple regression analysis conducted to identify significant unique predictors of 
COWA change scores. The final model was not significant (F=5.609, p=0.019) and only 
explained a total of 4.1% variance in COWA change scores. None of the variables significantly 
explained any unique variance in change in executive functioning and verbal fluency as 
assessed by the COWA. 
 
 
Table 13.7 Demographic and clinical predictors of change in executive functioning (COWA) 
Block Predictor Variables R
2
 
 
Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
1  0.036 0.029 0.036 5.609  0.019 
 Education      0.189 0.019 
2  0.054 0.041 0.018 2.892  0.091 
 Education      0.160 0.05 
 Diuretic medication     -0.138 0.091 
 
13.6.3 Predictors of change in attention over time in ACHD patients 
With regards to the domain of attention, two tests showed a significant difference in scores over 
time in the MLM analysis; the oral subtest of the SDMT test (SDMT-O), and the TMT test of 
divided attention (TMT-A).  
 
13.6.3.1 Symbol digit modalities test (SDMT-O) 
The univariate predictors of the SDMT-O change score included demographic (employment 
status) and clinical (total number of palliations, and anti-coagulant medication) variables.  The 
results of the regression analysis identifying predictors of change in the SDMT-O scores are 
presented in Table 13.8. The results showed that neither the individual steps nor the final 
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regression model reached statistical significance (p<0.01). None of the demographic or clinical 
variables explained any significant unique variance in the change scores, at any step.   
 
Table 13.8  Demographic and clinical predictors of change in attention (SDMT-Oral) 
Block Predictor Variables R
2
 
 
Adjusted 
R
2
 
ΔR2  ΔF Β Sig. 
1  0.03 0.024 0.03 4.657  0.033 
 Employment      0.174 0.033 
2  0.053 0.04 0.023 3.565  0.061 
 Employment     0.177 0.028 
 Palliations total     -0.151 0.061 
3  0.062 0.043 0.009 1.477  0.226 
 Employment     0.162 0.046 
 Palliations total     -0.113 0.189 
 Anti-coagulant 
medication 
    -0.105 0.226 
  
 
13.6.3.2 Trail Making Test - Part A (TMT-A) 
The univariate predictors of change in TMT-A scores included education and a range of clinical 
variables including: NYHA classification, total numbers of intervention, years since the last 
intervention, number of days spent in hospital, age at repair, oxygen saturation levels, LVEF 
and the medication taken (beta-blocker medication, anti-arrhythmia medication and anti-
coagulant medication).  
 
The results of the multivariate regression model for the TMT-A change score are presented in 
Table 13.9. The first block showed education as a significant predictor of change in TMT-A. 
However, upon entering the complexity variables none of the variables remained significant. In 
the third block the age at repair variable emerged as a significant predictor (p=0.009) of TMT-A 
change scores. The following blocks (four - current saturation and, five- current health and 
medications) and the final model were not significant and none of the variables explained any 
significant unique variance in the outcome in the final model.  
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Table 13.9 Demographic and clinical predictors of change in attention (TMT-A) 
Block Predictor Variables R
2
 Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
1  0.05 0.043 0.05 7.885  0.006** 
 Education      -0.223 0.006** 
2  0.094 0.076 0.044 3.632  0.029 
 Education     -0.193 0.016 
 NYHA     0.124 0.121 
 HF clinic     0.152 0.057 
3  0.215 0.153 0.121 2.711  0.008** 
 Education     -0.19 0.017 
 NYHA     0.062 0.442 
 HF clinic     0.092 0.261 
 Interventions total     0.174 0.073 
 Yrs. Since last operation     -0.032 0.723 
 Age at repair Q2     0.23 0.014 
 Age at repair Q3     0.262 0.009** 
 Age at repair Q4     0.136 0.186 
 Hospital days Q2     0.045 0.631 
 Hospital days Q3     -0.188 0.069 
 Hospital days Q4     0.061 0.579 
4  0.234 0.156 0.02 1.174  0.322 
 Education     -0.205 0.010 
 NYHA     0.042 0.601 
 HF clinic     0.071 0.391 
 Interventions total     0.15 0.129 
 Yrs. Since last operation     -0.043 0.636 
 Age at repair Q2     0.212 0.027 
 Age at repair Q3     0.249 0.014 
 Age at repair Q4     0.076 0.486 
 Hospital days Q2     0.011 0.91 
 Hospital days Q3     -0.216 0.042 
 Hospital days Q4     0.024 0.832 
 Current saturation Q1     0.156 0.113 
 Current saturation Q1     -0.025 0.771 
 Current saturation Q1     0.02 0.831 
5  0.271 0.16 0.036 1.098  0.367 
 Education     -0.209 0.011 
 NYHA     0.004 0.961 
 HF clinic     -0.029 0.761 
 Interventions total     0.119 0.269 
 Yrs. Since last operation     -0.034 0.718 
 Age at repair Q2     0.208 0.031 
 Age at repair Q3     0.221 0.031 
 Age at repair Q4     0.04 0.725 
 Hospital days Q2     -0.022 0.825 
 Hospital days Q3     -0.225 0.037 
 Hospital days Q4     -0.006 0.962 
 Current saturation Q1     0.089 0.380 
 Current saturation Q1     -0.046 0.602 
 Current saturation Q1     0.015 0.874 
 Pacemaker      0.042 0.663 
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Block Predictor Variables R
2
 Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
 Beta-blocker medication      0.07 0.471 
 Anti-arrhythmia 
medication 
    0.069 0.463 
 Anti-coagulant 
medication  
    0.058 0.585 
 LVEF     -0.156 0.073 
 Medication total     0.038 0.723 
**p<0.01, Q=Quartile, LVEF- Left Ventricular Ejection Fraction, HF-Heart Failure, NYHA= New York Health 
Assessment  
 
 
 
13.6.4 Predictors of change in motor functioning over time in ACHD patients   
The MLM analysis showed a significant change in motor functioning over time (on both the 
dominant & non-dominant hand scores). Results of the regression analysis to identify 
significant predictors of change in motor functioning are presented below in Table 13.10 
(Dominant hand) and Table 13.11 (Non-dominant hand).  
 
 The univariate predictors of change in motor function as measured by the dominant hand 
included: NYHA classification, total number of interventions, ACE medication and the left and 
right ejection fraction. The first (p=.003) and second (p=.006) regression steps for the predictors 
of GP-Dominant hand score showed NYHA classification as a significant predictor of change in 
motor functioning over time. The final model explained 9.5% of the variance in the outcome; 
however, upon the addition of the current health status variables, the NYHA class was rendered 
non-significant. Thus no statistically significant predictors of change in motor functioning (GP-
Dominant hand change scores) were identified. 
 
The univariate regression analysis for the non-dominant hand score showed heart failure clinic 
attendance and years since last intervention as significant predictors. However, the final 
multivariate regression model for the non-dominant hand score did not show any significant 
unique predictors of change in motor functioning. 
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Table 13.10 Demographic and clinical predictors of change in motor functioning (GP-D) 
Block Predictor Variables R
2
 Adjusted R
2
 ΔR2  ΔF β Sig. 
1  0.058 0.052 0.058 9.299  0.003** 
 NYHA     0.241 0.003** 
2  0.082 0.07 0.024 3.968  0.048 
 NYHA     0.22 0.006** 
 Interventions total      0.157 0.048 
3  0.125 0.095 0.043 2.395  0.071 
 NYHA     0.17 0.036 
 Interventions total      0.118 0.146 
 ACE medication      0.147 0.069 
 RVEF     -0.097 0.297 
 LVEF     -0.071 0.434 
**p<0.01, NYHA= New York Health Assessment, LVEF- Left Ventricular Ejection Fraction, RVEF- Right 
Ventricular Ejection Fraction, ACE- Angiotensin-Converting-Enzyme  
 
 
Table 13.11 Demographic and clinical predictors of change in motor functioning (GP-ND) 
Block Predictor Variables R
2
 Adjusted R
2
 ΔR2  ΔF β Sig. 
1  0.038 0.032 0.038 6.025  0.015 
 HF clinic      -0.196 0.015 
2  0.07 0.058 0.032 5.138  0.025 
 HF clinic     -2.337 0.021 
 Yrs since last operation     2.267 0.025 
HF clinic- Heart Failure clinic 
 
13.6.5 Predictors of change in memory over time in ACHD patients   
The results of the MLM analysis showed a significant change in memory over time (RAVLT 
score). The univariate predictors of change in memory included years of education achieved and 
the blood oxygen saturation levels. The results of the multivariate regression analysis to identify 
predictors of change in memory function are presented in Table 13.12. The first block was 
significant (p= 0.005), with education significantly predicting change in memory function over 
time, explaining 4.5% of the unique variance on the RAVLT change scores. The final block 
included current oxygen saturation variables, which explained additional unique variance.  A 
total of 8% of the variance in memory change scores was explained by education and oxygen 
saturation. Both variables education and oxygen saturation were significant predictors of change 
in memory over time. The positive association of education (β = 0.227) and current saturation (β 
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= 0.249) with change in memory demonstrates that higher years of education and saturation 
levels were associated with higher scores suggesting improvement over time and vice versa, 
however the total variance explained by these variables was considerably small (8%), with the 
overall model not being significant.   
 
Table 13.12 Demographic and clinical predictors of change in memory (RAVLT) 
Block Predictor Variables R
2
 Adjusted R
2
 ΔR2  ΔF β Sig. 
1  0.052 0.045 0.052 8.229  0.005** 
 Total years of education      0.227 0.005** 
2  0.104 0.08 0.052 2.874  0.038 
 Total years of education      0.224 0.005** 
 Current saturation Q1     0.089 0.318 
 Current saturation Q2     0.249 0.004** 
 Current saturation Q3     0.056 0.531 
**p<0.01, Q= Quartile 
  
13.7 Conclusions 
The results of the MLM analysis conducted to identify changes in cognitive performance over 
time showed a significant difference in scores across all the domains assessed, but not across all 
test scores. There was variability in the directionality of change observed with some domains 
demonstrating an improvement over time while others a decline. However visual inspection of 
the data suggested that while there were changes across scores, they were not large enough to be 
of a clinically significant magnitude (i.e. the sample/group did not go from being impaired to 
non-impaired and vice versa). Hierarchical regression analysis conducted to identify predictors 
of change showed more years of education and higher oxygen saturation levels as significant 
predictors of change in memory function; however, the total proportion of the variance 
explained by these variables was small. No demographic, clinical or mood predictors were 
identified for the other domains of cognitive functioning that changed over time. The next 
chapter presents a discussion of the finding of the follow-up study in the context of the existing 
literature.    
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14 FOLLOW-UP STUDY DISCUSSION  
 
14.1 Prologue  
This chapter discusses the findings of the follow-up study in the context of the existing 
literature. The main findings from the follow up study are discussed under key themes, 
including i) stability of cognitive functioning in ACHD, and how this compares to the stability 
of cognitive functioning in the normal population; ii) differences in cognitive functioning across 
structural complexity groups; and iii) predictors of change in cognitive functioning. The 
limitations of the follow-up study and its implications will be discussed in the final discussion 
in Chapter 15.  
 
14.2 Stability of cognitive functioning in ACHD 
In order to investigate change and/or stability of cognitive functioning over time within and 
across the different structural complexity groups, MLM analyses were conducted. The results 
showed that the time x group interaction in each analysis was consistently non-significant 
indicating that the structural complexity groups did not change differentially over time across 
the domains assessed. The main effect of time was significant in some measures within the 
domains of attention, executive function and memory; indicating statistically significant 
changes over time within this ACHD sample. Further, the main effect of group on one test, 
(TMT-B) was significant, suggesting a difference in cognitive functioning between structural 
complexity groups.  
 
The findings of the MLM analyses are discussed in depth below both for the main effect of 
time, followed by the main effect of group. First the stability and/or change of scores over time 
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is discussed (i.e. main effect of time). These results are discussed in conjunction with each 
measure’s test-retest results and comparing the performance of the ACHD sample to that of the 
normal population (using visual representations) in order to evaluate if the mean performance of 
the group(s) differed over time relative to the normal population. It is of note that the test-rest 
comparisons were only done for those participants that had both time one and time two scores 
(due to the nature of the index calculation). However, given that no statistically significant 
differences were noted between the responders and non-responders at time two on any of the 
variables assessed, the performance of these could be considered comparable.  
 
14.2.1 Changes in cognitive functioning over time 
 A considerable amount of variability was noted in changes across the different domains (tests); 
with five out of nine scores showing an improvement in performance over time while two 
scores showed a decline; and some showed no significant changes. However, no observable 
patterns were noted across the specific cognitive domains to indicate a significant, consistent 
trend in changes over time; these are explored in more detail below. 
 
Measures within the domains of attention (TMT-A), executive functioning (COWA) and motor 
function (Grooved Pegboard) showed statistically significant improvement in scores over time, 
with the study sample showing better performance upon reassessment with medium to large 
effect sizes. In contrast, a statistically significant decline in performance over time was observed 
in measures within the domains of memory (RAVLT) and attention (SDMT-Oral subtest) with 
medium to large effect sizes. No other tests showed a statistically significant difference in 
scores over time. Each structural complexity group showed a consistent, similar pattern of 
change (improvement or decline); with no individual group changing in a different direction 
from the others (as evident from the regression slopes in scatterplots and mean scores).       
 
  
      
305 
 
14.2.1.1 Clinical significance of the observed change and stability of cognitive functioning 
when compared to the normal population  
Having identified some statistically significant changes in cognitive functioning over time, it 
was important to ascertain whether the level of observed changes were also of clinically 
significant magnitudes, i.e. meaningful in practice. In order to do so a combination of factors 
was assessed.  
 
First, the test-retest correlations of the study sample (total sample and each structural 
complexity groups) were compared to those of the normal healthy population to establish if the 
stability of cognitive functioning in ACHD was similar in comparison. Second, the 
change/stability of scores was assessed using visual representations of the data to evaluate how 
much the sample changed relative to the normative mean over the two time points; and to see if 
the magnitude of change was large enough for the sample (and each structural complexity 
group) mean scores to move from the impaired to non-impaired range over time or vice versa. 
The results for each of these evaluations are discussed below before providing potential 
explanations for the observed changes.  
 
When assessing the test-retest reliability of scores, the determination of what constitutes good 
test–retest reliability largely depends on the time frame between two assessments, as with an 
increase in time between assessments the likelihood of the reliability coefficient being lower 
increases (Calamia, Markon and Tranel, 2012). These lower test-retest correlations are generally 
attributed to, i) the increased chances of change in the underlying function, ii) potential 
confounding factors that may emerge over a longer period of time (such as years) and iii) less 
influence of practice effects, as with a longer time between assessments individuals are more 
likely to have forgotten the way the test is performed. Conversely, when assessing test-retest 
reliabilities over a shorter period of time factors such as memory may facilitate performance, as 
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one is more likely to remember tests and its characteristics over a short period of time (such as a 
few weeks/months). Considering that the majority of the published test-retest data for the 
measures used, was based on a testing interval that ranged from a few months to a year; a less 
stringent reliability estimate (≥0.6) was considered acceptable within the present study to 
account for the time-frame between assessments, which was three times longer than the 
published data.  
 
Nevertheless, within this study the total sample showed overall similar test-retest correlations 
when compared to the normative data (‘healthy’ reference groups) across most tests. 
Comparatively smaller test-retest correlations were only noted on two scores (GP-ND and 
RAVLT); however, these test-retest correlations were not very small (0.48 and 0.49) and could 
potentially be attributed to the differences in the test-retest interval of the present study and 
published data (i.e. 3.3 years vs. 1 year).  
 
With regards to test-retest of the different structural complexity groups; i) the SV group had 
good test-retest correlations on all tests when compared to the normal population, this finding 
could be considered contrary to expectation given that the SV group had a considerable 
proportion of participants with cognitive impairment when compared to others groups such as 
the ‘Simple group’; and ii) the ToF, TGA and the Simple group showed lower test-retest 
correlations on tests of motor function, attention and memory, suggesting poorer stability of 
scores on these domains of cognitive functioning within these structural complexity groups.  
 
However, more than half of the test-retest values below the ≥0.6 cut off within these groups 
were nearing 0.5, thus not suggesting a very large drop in the reliability coefficients in 
comparison to the normal population. Therefore, it could be speculated that most of these 
differences may be indicative of a normal variation in scores (in either direction) that could also 
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be observed in a normal population if tested over such a long time interval. Also some level of 
changes or fluctuations in scores can be expected when using a repeated measures design in a 
healthy population (Calamia, Markol and Tranel, 2012; Drost, 2011).  
 
With regards to the comparison of mean scores relative to the normative data, the visual 
representation of the results (e.g. box plots and error bar plots) indicated that despite the 
statistically significant changes observed within the MLM analyses, the level of change across 
the different domains was not large enough in the total study sample or within the different 
structural complexity groups to move the group mean from being impaired at time one to non-
impaired at time two or vice versa. For instance, although some tests in the domains of memory 
and attention showed a decline in performance over time, the performances of the groups were 
still similar to that of the normative data; thus not suggesting a decline that may be of a 
clinically significant magnitude, or indicative of cognitive deterioration. Similarly, tests that 
showed an improvement in scores over time such as the COWA, were still performing below 
the mean of the normative data, not indicating improvement of a clinically significant 
magnitude. Therefore, the observed changes could be considered normal variations in scores 
that can be expected in repeated measures designs, when using the same or equivalent test on 
different occasions. 
 
Collectively the findings showed relative stability of scores as the sample did not change level 
of impairment across the time points and overall had test retest correlations relatively 
comparable to those of the normal population on most tests of cognitive functioning.  However, 
when drawing these conclusions, it must be considered that these are only speculative in nature, 
given the differences in the time frame between the assessments for the normal sample and the 
present study sample.  
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Future studies will benefit from including a comparator/control group which is followed up over 
the same time frame as the study sample, to be able to get more reliable and robust comparisons 
of the stability (and variability) of cognition in ACHD when compared to the normal 
population. Furthermore, such an analysis would also allow examining any differences in 
cognitive ageing i.e. age related changes in cognitive function in ACHD patients when 
compared to the normal healthy population. Assessing these changes could be considered 
important for the ACHD sample as patients with ACHD are cognitively impaired from 
childhood and continue to exhibit impairment into adulthood. Given that one would not expect 
any more developmental changes, any differences in scores could be indicative of a cognitive 
decline.  
 
14.2.1.2 Potential explanations for the differential patterns of change in cognitive 
functioning  
A wide range of NP tests were used to assess different aspects of the domains of cognitive 
functioning examined in this study. Interestingly despite the wide range of NP tests used to 
assess each domain, a significant improvement and/or decline in performance over time was 
only noted on one test in each of these domains. There could be a number of potential 
explanations for these differential changes observed across tests. These could include test 
related factors such as the nature of the test (i.e. testing modality), practice effects, the level of 
difficulty etc. Furthermore, these could also include other non-test related factors such as the 
testing environment and mood. Some of the potential factors that may explain the observed 
changes within this study are discussed below.  
 
The results of this study showed a differential pattern of change both across and within the 
different domains assessed with some scores showing an improvement/decline while others 
remained unchanged. One potential explanation for only some tests demonstrating a significant 
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difference in scores over time within the different domains may be that the different tests assess 
different aspects of the cognitive domain being evaluated. For instance, the TMT-A test (which 
showed an improvement) assesses cognitive processing speed and visual numerical scanning, 
while the TMT-B test (showed no change) assesses divided attention, executive control and 
cognitive flexibility. Similarly, this explanation could also be applied to the SDMT test, 
whereby the oral subtest (which showed a decline) assesses verbal responses and complex 
visual scanning, while the written subtest (showed no change) assesses visuomotor responses 
and writing ability. Therefore, decline in performance on a specific subtest could be as a result 
of decline in that specific function or response modality (i.e. written versus verbal) within a 
domain.  These results emphasize the importance of specificity when assessing change in 
cognitive function and suggest that different aspects of each domain need to be assessed 
independently as the change within domains can be variable, and using one test as a 
representative of a cognitive domain may not allow enough specificity to assess and detect 
subtle changes in cognitive domains. 
 
Another potential explanation for some of the observed changes could be practice effects, which 
refers to an improvement in a subject’s test scores as a result of prior exposure to the test. 
Studies have reported practice effects persisting for up to 3-5 years after initial assessment (Van 
Der Elst et al, 2008; Ronnlund et al, 2005).  For instance, the Grooved Pegboard test of motor 
function used in this study, showed improvement on both components of the test (Grooved 
pegboard dominant and non-dominant hand score) with participants being faster and more 
efficient at completing the task at follow-up. However, there was no appropriate alternate form 
for the grooved pegboard test, therefore the improvement in motor function could be indicative 
of and interpreted as practice effects, as prior exposure to the test can enable participants to gain 
knowledge of the test structure and technique; thereby removing the element of novelty from 
the task and facilitating better performance.  
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Previous studies have reported that motor function tests which have a large speed component 
and/or an unfamiliar response such as inserting mental pegs into the pegboard in motor function 
tasks (e.g. grooved pegboard test), can easily be conceptualized once the correct response is 
attained, and therefore can be more susceptible to practice effects, which could also be 
interpreted as the ability of patients with ACHD to learn a strategy, suggestive of intellectual 
and cognitive abilities (Lezak et al, 2012; McCaffrey et al, 1992). Studies have reported practice 
effects on the Grooved Pegboard test over a period of 4-24 months (Dikmen et al, 1999; Strauss, 
Sherman and Spreen, 2006). A steady improvement in scores is reported when conducting 
repeated assessments using the Grooved Pegboard test to assess motor function (Strauss, 
Sherman and Spreen, 2006). The unusual nature of the task perhaps increases the likelihood of 
participants remembering the experience. This familiarity with the task could help explain the 
results of the present study, especially over the lengthened period between time points.  
 
Along with practice effects some authors have also suggested the role of mood in the 
improvement of cognitive test performance over time, as test takers are likely to be less anxious 
during the second or third assessment given the familiarity with both the examiner and the test 
itself, potentially allowing them to perform better (Lezak et al, 2012). The potential association 
between change in mood state and change in cognition over time was examined in the present 
study. No significant association between a change in mood state and change in cognition were 
noted, within this sample (See Section 14.3 for predictors of change). 
 
No particular patterns across test features were noted within these results for instance both tests 
with and without alternate forms showed improvement (e.g. TMT and GP), the type/difficulty 
of test i.e. more complex domains such as executive function and comparatively less complex 
domains such as motor function did not demonstrate a differential pattern of change 
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(interaction). Furthermore, both test with and without a speed component showed decline in 
performance (RAVLT and SDMT-O), and lastly tests with difference response modalities 
(tactile, verbal, and written) all showed improvement over time (GP, COWA). Lastly, mood did 
not seem to play a significant role in change in cognitive function over time within this study. 
 
Overall the pattern of change in cognitive functioning over time was variable. This variability 
was noted within the same domains, across the different tests. Furthermore, it is of note that the 
variability in performance over time was not only observed between different domains and tests 
but also within tests. As discussed above one explanation for this could be that the different 
parts of the test assess different abilities, thereby leading to differential patterns of change over 
time (improvement and/or decline). These finding are not entirely unusual, as previous studies 
have established that the level of change in cognitive functioning is not uniform and can be 
variable across different domains of cognitive functioning (Glisky, 2007). These results 
emphasize the need to assess different domains of cognitive functioning independently, using a 
wide range of tests to be able to capture the variations in change across domains. 
 
14.3 Differences between the structural complexity groups in cognitive function over time 
The MLM analysis also assessed the overall difference in cognitive functioning between the 
four structural complexity groups (irrespective of time point). Across the battery of tests, only 
the TMT-B test of attention significantly differed between the four structural complexity groups 
(main effect of group – i.e. across the time-points as a whole). Pairwise comparisons showed 
that the Simple group performed significantly better than the SV group, suggesting that less 
structurally complex conditions (ASD, VSD) performed better than the more structurally 
complex conditions i.e. SV.  
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It is of note however that only the TMT-B test of attention demonstrated a significant difference 
between the different structural complexity groups both cross-sectionally and longitudinally, 
thus suggesting that divided attention was significantly different across different structural 
complexities. These findings are similar to those reported in the ACHD literature, which reports 
more structurally complex conditions performing worse on test of attention and executive 
function when compared to less structurally complex conditions (Franklin et al, 2014), a more 
detailed discussion on the subject is presented in Chapter 15. 
 
As discussed in Chapter 9, a potential explanation for these differences between the groups on 
TMT-B could be the fact that the TMT-B is a cognitively challenging task, which assesses 
several domains including divided attention, executive functioning, and visual scanning, 
requiring the test taker to exercise multiple cognitive skills simultaneously. The complex nature 
of this task may increase the likelihood of identification of participants with subtle or specific 
cognitive impairments. Moreover, no differences between the groups were observed on Part A 
of the test, which is considered less complex and less cognitively demanding than part B.  
 
14.4 Predictors of change in cognitive functioning over time in ACHD patients  
A further objective of this study was to identify statistically significant predictors of change in 
cognitive functioning. Predictors were only identified for test scores that demonstrated a 
statistically significant change in scores over time in the MLM analysis (i.e. TMT-A, COWA, 
GP- dominant and non-dominant, RAVLT and SDMT-O). Furthermore, predictors of change 
were only identified for the total follow-up study sample, as sample size of the follow-up study 
did not allow sufficient statistical power to run sub-group analyses (i.e. assess each structural 
complexity group independently).  
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The results showed that overall while significant univariate associations of demographic, 
clinical and mood variables with cognitive functioning were noted, none of these factors 
explained any significant unique variance in changes in cognitive functioning over time within 
the multivariate analyses. The only exception to this was the domain of memory (RAVLT); 
where results demonstrated that a lower level of current oxygen saturation (at the time of first 
assessment) and fewer years of education were associated with a decline in memory function. 
Interestingly, the lower levels of oxygen saturation was not associated with memory scores in 
the cross-sectional study but was apparent when assessing predictors of change; perhaps 
suggesting the role that the level of oxygen saturation can play in predicting changes in 
cognitive performance (memory) over time.  
 
A positive association between oxygen saturation levels and memory function in healthy adults 
has been reported. A statistically significant improvement in word recall rates with a 30% 
increase in oxygen saturation levels; suggestive of better memory function being associated 
with higher oxygen saturation levels was reported by Chung and Lim, (2008). Scholey and 
colleagues also reported that oxygen administration coinciding with word presentation resulted 
in enhanced word recall rates; thus suggesting that blood oxygen levels may be available to 
neural memory consolidation processes (Scholey, Moss and Wesnes, 1998). Although when 
drawing comparisons between the above mentioned studies and the present study it must be 
noted that the level of oxygen saturation within the present study sample was recorded at Time 
1 (cross-sectional), whereas the studies discussed had a contemporaneous measure of oxygen 
saturation recorded at the time of assessment. Furthermore, these studies assessed the 
relationship between oxygen saturation levels and absolute NP scores, whereas the present 
study assessed NP change scores. Therefore, the association of oxygen saturation noted within 
the present study is specific to change in cognitive functioning (memory) over time and not 
performance on a memory test (at one time-point). One potential explanation for these findings 
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could be the role of other intervening or mediating factors that may not have been recorded or 
identified within the present study. Further work assessing the longitudinal relationship between 
these variables specifically in the ACHD patient population is warranted, to be able to draw 
more robust conclusions. 
  
With regards to the association between years of education and memory, studies have reported 
that higher education is associated with less age related decline in memory function. An 
association between more years of education and a statistically significant improvement in 
memory performance in adulthood has been reported (Glymour et al, 2008). Furthermore, fewer 
years of education has been found to play a role in accelerating cognitive decline in memory 
and the onset of dementia (Schmand et al, 1997). A meta-analysis of the literature reported that 
fewer years of education might in fact be a risk factor for the onset of dementia (Caamaño-
Isorna et al, 2006). One potential explanation for the findings of this study and the existing 
literature could be that more years or higher level of education could mean that the brain is more 
functionally active over the years, and the mental stimulation provided by educational process 
may play a potential role in maintaining cognitive functioning and preventing a decline in 
cognitive functioning (Bosma et al, 2003). Within the present study, years of education was 
associated with memory both cross-sectionally and longitudinally, demonstrating the stability of 
this association over time, and the potential role education may play in long-term memory 
function. However, this relationship was not noted within any other domains within the present 
study. 
 
Furthermore, when interpreting the results of the regression analysis to identify predictors of 
change in memory function in the present study, it must be noted that the total amount of 
variance in memory explained by these variables (oxygen saturation and education) was 
considerably small (8%). These results showed that a large proportion of the variance in 
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changed memory scores was unaccounted for, and perhaps variables explaining this change 
were not measured or recorded within the present study. These could include a range of 
variables such as clinical factors including co-morbidities or other non-cardiac coexisting 
conditions, psychosocial factors such as social support and self-esteem (Daliento et al, 2005), 
and socio demographic factors such as socio-economic status (Wernovsky et al, 2000).  
 
Another potential explanation for the lack of significant predictors of change identified in the 
present study could also be due to the approach undertaken to analyze the data, i.e. combining 
all complexity groups together. As seen in the results of the cross-sectional study (Chapter 8), 
doing so can lead to the dilution of specific effects which may explain significant variance in 
the outcomes for specific groups if assessed independently. However as discussed above the 
small sample size of the subgroups in the follow-up study did not allow enough statistical power 
to run sub-group analysis. Future studies may benefit from including a larger sample size and a 
longer follow up period to examine changes in cognition over time in this group. Furthermore, 
inclusion of a comparator group matched closely to the characteristics of the study sample will 
provide more robust and reliable comparisons to the normal population. 
 
14.5 Summary 
Overall the results of this study demonstrated considerable variability in the pattern of change 
across different domains of cognitive functioning. However, none of the changes observed were 
indicative of a clinically significant magnitude (over the given time period), and were mostly 
comparable to those of the normal population. But, given that some observable decline in 
cognitive function was noted over a period of three years, ongoing assessment of these domains 
is warranted. This ongoing assessment and more longitudinal research would help monitor the 
rate of decline within this patient group i.e. it would help assess if the impairment remained 
stable and/or increased with longer periods of time (relative to the normal population) and the 
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protective effects (in halting or reducing rates of decline) of clinical, demographic and 
psychological variables. Similar studies would help validate the results of the present study, and 
enable a better understanding of the stability of cognitive functioning in this patient population.  
 
The current findings should be considered hypothesis generating, requiring future work to 
explore a wider range of variables (psychosocial, clinical, socio-demographic, and 
environmental) that may explain variation in cognitive outcomes over time. Furthermore, future 
studies may benefit from a larger sample size per condition that would allow investigating 
change in cognitive functioning independently in different structural complexity groups, to 
allow more specificity on the analysis, and a better understanding of the potentially different 
trajectories of change in cognition across different conditions.  A fuller discussion on the 
strengths and limitations of this study and its implications will be addressed in more detail 
within the next chapter (Chapter 15). 
 
 
  
      
317 
 
 
15 OVERALL DISCUSSION 
 
15.1  Prologue  
This chapter presents the overall aims and objectives of this thesis, the findings and 
contributions of both the studies to the literature. It then discusses the overall strengths and 
limitations of this thesis, followed by the implications of the findings for clinical practice and 
future research.  
 
15.2 Thesis aims and objectives  
The overall aim of this thesis was to investigate the extent, impact and stability of cognitive 
functioning in ACHD patients with different levels of structural complexity. The cross-sectional 
study aimed to investigate the extent of cognitive impairment in ACHD patients with different 
levels of structural complexity. It also aimed to identify the different factors that may influence 
and or impact on cognitive functioning. It investigated the impact of impaired cognitive 
functioning on patient related outcomes including quality of life. The longitudinal study aimed 
to investigate the stability of cognitive functioning in ACHD patients, along with identifying 
predictors of change in cognitive functioning.   
  
15.3 Novel contributions to the literature  
This study addressed an area of research that has previously received little attention.  It is one of 
the first and largest studies to assess and compare different structural complexity groups of 
ACHD on a comprehensive range of cognitive domains and investigate the stability of cognitive 
functioning over time. The contributions of this thesis to the literature are discussed below. 
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15.3.1 The extent and stability of cognitive functioning in the ACHD patient 
An overview of the literature on cognitive functioning in CHD patients showed that the majority 
of the evidence in this area of research focused on children with CHD. However, given the fact 
that these studies did not follow up into adulthood no conclusions could be drawn about 
whether the findings in childhood persisted into adulthood. Investigation of cognitive function 
in adulthood enables an examination to be made, as to whether the same pattern of cognitive 
problems observed in childhood persists into adulthood.  
 
 A systematic review of the literature on cognitive functioning in ACHD was conducted. The 
results showed limited research conducted to investigate cognitive functioning in adult 
survivors of CHD.  This paucity of evidence in ACHD is understandable given only the 
relatively recent increase in the survival rates of the CHD patient, due to improvements in 
treatment techniques and medical advances. Overall the presence of cognitive impairment in 
ACHD patients when compared to the normal healthy population was noted in the existing 
literature. With regards to the extent of cognitive impairment mixed findings in relation to IQ 
were observed (Wernovsky et al, 2000; Utens et al, 1998). Only two studies examined specific 
domains of cognitive functioning in ACHD, and reported impairments in the domains of 
executive functioning, attention and cognitive speed (Daliento et al, 2005; Idorn et al, 2013).  
 
Along with the small number of studies, the existing literature on cognitive functioning in 
ACHD was marked by many methodological limitations including the small sample sizes, the 
overreliance on IQ as a composite measure of cognitive functioning, and the variability in the 
sampling procedures used across studies (i.e. heterogeneous versus homogeneous sampling of 
different structural complexities). These limitations made drawing generalizations across the 
studies difficult.  
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Extent of cognitive impairment in ACHD  
In order to address these methodological limitations identified in the review and to bridge the 
gap in the literature with regards to the extent of cognitive impairment in ACHD, a cross-
sectional study was undertaken to investigate a wide range of cognitive domains including 
attention executive function, memory and motor function in a large group of ACHD patients. 
Participants were recruited from across a range of common ACHD conditions in order to enable 
greater generalizability of the findings and also assess any differences in cognitive functioning 
across structural complexity groups. 
 
The results of the cross-sectional study showed that a considerable proportion of patients with 
different forms of ACHD, higher than would be expected in the general population, exhibited 
impairment in a number of cognitive domains including executive functioning, attention and 
motor functioning and IQ. These results supported other studies that reported impairments in 
executive functioning and attention in ACHD patients (Daliento et al, 2005; Franklin et al, 
2014).  
 
The evidence with regards to IQ in the existing literature is inconclusive. Importantly the 
methodological limitations of the existing literature including large amounts of missing data, 
not using reliable normative data for the purposes of comparison, and variability in measures all 
make drawing conclusions challenging. In comparison the present study was the largest study 
conducted to date, that investigated the extent of cognitive impairment in a wide range of 
ACHD conditions by using reliable cognitive measures and a robust methodology, providing 
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more confidence in the finding that ACHD patients have impaired IQ when compared to the 
normal population. 
 
The present study employed a four-group classification based on the level of structural 
complexity of ACHD to examine whether there were differences in cognitive performance 
between these groups. This is important as some of the previous literature used mixed groups 
and failed to examine for differences (Heinrichs et al, 2014) whilst others studied only one 
structural complexity group (Daliento et al, 2005). Between group test performance was 
compared to identify differences in cognitive functioning across different ACHD structural 
complexity levels. A significant group difference was noted in attention and the total mean 
composite NP score in the present study. In both instances the Simple group performed 
significantly better than the SV and TGA groups. These results are similar to those of Franklin 
et al, (2014) and Utens et al, (1998) who reported significant differences in complex attention, 
cognitive flexibility and overall executive functioning and IQ in ACHD patients; with patients 
with structurally complex conditions (SV, TGA) performing significantly worse when 
compared to less structurally complex conditions  (ASD, VSD). The results of the present study 
added to this growing body of literature which suggests that more structurally complex 
conditions exhibit more cognitive impairment in comparison to less structurally complex 
conditions. 
 
There are several factors that can contribute to these differences between complexity groups, for 
example patients with structurally complex forms of CHD are more likely to undergo surgical 
repairs and interventions, thus making them more vulnerable to brain injury and insults 
associated with cardiac surgery. Within the present study the more structurally complex 
condition underwent significantly more number of surgical procedures which may have made 
them more vulnerable to these impairments. Furthermore, more complex conditions such as SV 
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and TGA are cyanotic in nature, leading to a lack of blood oxygen supply to the body, including 
the brain. These differences were evident in the present study sample with more structurally 
complex conditions having a much longer duration of cyanosis and a lower level of blood 
oxygen saturation in comparison to the Simple group. Oxygen deprivation makes cyanotic 
patients more prone to cognitive impairment and brain injury, as the lack of oxygen supply to 
the brain can lead to death of brain tissue causing long term implications (Licht et al, 2004). 
 
 
Factors associated with cognitive functioning in ACHD   
Having established the extent of cognitive impairment in ACHD patients, it was considered 
important to understand the factors that have the potential to influence cognitive performance. 
The results of the systematic review discussed in Chapter 4 demonstrated some variables 
associated with cognitive functioning, including demographic (education and socio-economic 
status) (Eide et al 2006; Daliento et al, 2005), clinical (cyanosis, cardiac surgery) (Wernovsky et 
al, 2000) and psychosocial (self-esteem) factors (Daliento et al, 2005). The present study builds 
on these findings in the existing literature, with an extensive range of variables included to 
examine factors associated with cognitive functioning both in the total study sample and each of 
the structural complexity groups.  
 
When considering the ACHD sample both as a whole and each of the structural complexity 
groups the factors most consistently associated with domains of cognitive functioning 
(attention, executive functioning and IQ) were post-operative CNS complications and years of 
education. Interestingly when the different structural complexity groups were assessed 
independently, greater variability was noted with a range of other variables found to be 
significantly associated with cognitive functioning within the specific structural complexity 
groups. For instance, factors such as age at surgical repair and oxygen saturation levels only 
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emerged significant when groups were assessed independently. Overall clinical factors (surgery 
related variables, medication) explained more unique variance in cognitive outcomes, when 
compared to demographic (employment, gender) or psychosocial (anxiety, depression) factors. 
These findings could be expected given the diverse nature of different forms of ACHD and their 
associated symptoms, treatments and prognosis, which vary greatly across conditions. 
 
The findings with regards to the CNS complications could be considered particularly relevant to 
the current set of ACHD patients as this group of patients were born and treated approximately 
30-40 years ago when the use of neuro-protective strategies to safeguard the CNS during a 
surgery were not well established and the primary focus of clinicians was to reduce mortality 
rates. With the advances in neuro-protective strategies it is hoped that the patients undergoing 
surgical correction in infancy in the current era will experience fewer of these long-term 
problems due to cardiac surgery and its associated post-surgical CNS complications (See 
Albers, Bichell and McLaughlin, (2010) for a review on the subject). The findings of the present 
study indicate the potential long-term role that surgical treatment and its associated 
complications can play in determining the level of cognitive functioning in ACHD.   
 
Similarly, a better understanding of the association between CHD, education and cognition 
would be informative in enabling the provision of appropriate and timely support to these 
groups of patients earlier in life. This support could be offered to children in different forms 
targeting different areas of development. Firstly, support in the form of remedial or special 
education and additional one to one support may help children make up for lost time due to ill 
health and cope with any educational challenges that they may face in a supportive environment 
(Riehle-Colarusso et al, 2015). Secondly further support in the forms interventions or 
therapeutic techniques to improve cognitive functioning and strengthening cognitive skills could 
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help patients improve their levels of cognitive functioning, and perhaps reduce cognitive decline 
and the persistence of impairment in adulthood as noted within this study.  
 
These results reflect the fact that different forms of ACHD are not only varied with regards to 
their structural complexity, treatments, morbidity and long-term disease trajectory but also with 
regards to the level of cognitive functioning and the factors that influence cognition. The results 
of this study highlight the fact that like the nature of the different ACHD conditions the long-
term outcomes for each are also diverse, thus emphasizing the need to address the concerns of 
each condition independently. The clinical implications of these findings are discussed later in 
Section 15.5.  
 
Lastly, the association between cognitive functioning and QoL was also assessed within the 
present study to get a better understanding of the potential impact cognitive functioning may 
have on patient related long term outcomes. The results of the present study indicated no 
significant association between cognition and QoL, suggesting that cognitive functioning and 
QoL in this patient group were not related.  
 
Stability of cognitive functioning in ACHD 
In order to assess whether the stability of cognitive functioning in ACHD patients differs from 
that of the normal population a longitudinal assessment of cognitive functioning was 
undertaken. This area of research has largely been overlooked, with no evidence on the stability 
of cognitive functioning in adult CHD patients. The present study was the first to assess 
cognitive stability in ACHD patients, compared to the normal population.  
 
When the stability of the scores in this study sample was compared to the normal population 
data in the form of test retest correlations, the sample demonstrated relatively similar test-retest 
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correlations in comparison, particularly when taking into consideration the interval between the 
two assessments.  Results of this follow-up study showed some variability in change across 
different domains of cognitive functioning, with some demonstrating an improvement and 
others a decline. The pattern of changes across the different cognitive domains in the present 
study demonstrated a large amount of intra-individual variability in cognitive functioning. It 
also emphasized the fact that different domains of cognition are subject to different degrees of 
change (improvement and/or decline), which can be expected as the rate of change is not 
uniform and can be variable across different domains of cognition (Glisky, 2007).  
 
Overall however the observed changes within this study did not appear to be of a clinically 
significant magnitude, as the sample remained in the same relative category of impairment over 
time. No major shift in the pattern of cognitive impairment was noted across the total sample 
and the different complexity groups, suggesting that these may be normal variations in scores 
over time, associated with repeated measures designs.  
 
Future research may benefit from conducting a comparative study of cognitive ageing in ACHD 
patients and healthy adults. This form of research could help inform important questions with 
regards to the rate of cognitive decline in ACHD and their susceptibility to age related cognitive 
impairments such as dementia, mild cognitive impairment and Alzheimer’s disease in 
comparison to the normal population.  
 
Cognitive impairment in ACHD –delay or deficit? A synthesis of the thesis findings 
Overall the key findings of this thesis have implications for the delay versus deficit argument 
raised in Chapter three. The findings of the systematic review and the two present studies 
collectively showed the persistence of some cognitive impairments noted in childhood in the 
adult population. For instance, studies of ACHD patients continued to report the presence of 
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impairments in the domains of attention, executive function, and IQ (Daliento et al, 2005; 
Franklin et al, 2014). Similarly, both the child and the adult CHD literature report IQ as being 
lower in comparison to the normative data but within the ‘normal range’ as specified by the 
tests (Bellinger et al, 2003; Krueger et al, 2015; Wernovsky et al, 2000). These results offered 
some support to the deficit argument, suggesting that these impairments in childhood may 
actually be deficits in cognitive functioning as opposed to delays in development, which would 
have been resolved eventually and not still been evident in adulthood, as is the case in the 
present study.  
 
This pattern of similarity was also evident across the different structural complexity groups with 
both the child and adult literature showing more cognitive impairments in the structurally 
complex conditions. Patients with ToF and TGA showed more impairment in attention and 
executive function when compared to the normal population and less structurally complex 
conditions including VSD and ASD across the two literatures (Cassidy et al, 2015; Hovels-
Gurich et al, 2007).  
 
The results of the follow-up study further support this argument, with these cognitive deficits 
still being apparent over time, suggesting that the cognitive impairments in children with CHD 
may in fact be deficits that last well into adulthood and continue to remain impaired.  
 
The early onset and stability of these impairments in the ACHD population may also help 
explain the lack of association noted between cognition and QoL in the present study. Given 
that these patients have had impaired cognition since childhood, they are likely to have adjusted 
to this level of cognitive functioning and consider their level of cognitive ability as ‘normal’. 
Therefore, they may not recognize and/or perceive it as a limitation on their QoL. Other 
evidence suggests that often patients diagnosed with chronic conditions adjust their aspirations 
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in the long term and may not view a limitation as one given that they have adjusted to the 
situation over time (Turner and Kelly, 2000).  
 
A better understanding of the longevity of these impairments noted in children with CHD could 
have important implications for patient care, as this information could help inform future 
interventions designed to improve cognitive functioning and /or reduce the rate of cognitive 
impairment and potential decline at an early stage. This would not only help improve 
educational and academic achievement in these groups of patients when they are younger but 
also reduce the extent of cognitive impairment in adulthood, which could help patients lead 
more normal lives, and reduce the impact of impaired cognitive functioning on patient related 
long-term outcomes.  
 
However, given that the findings of the child literature and the present study are from different 
samples, a more robust assessment of this theory is warranted in the ACHD population in the 
form of longitudinal research that follows up a group of patients from childhood into adulthood. 
Such a study would enable a more robust evaluation of the stability of the noted impairments 
along with assessing different developmental milestones in this patient population over time.  
 
15.3.2 The use of structural complexity to categorize ACHD for the purpose of research 
ACHD is a diverse group of conditions consisting of various diagnoses and, different levels of 
structural complexity, severity, prognosis and treatment courses etc. The majority of the 
existing literature on cognitive functioning in ACHD patients has included this heterogeneous 
collection of ACHD conditions as a single group, whereby conditions with levels of structural 
complexity and severity are assessed collectively. It is evident from the existing literature that 
the lack of a gold standard in classifying these conditions has led to mixed findings that limit 
the ability to draw clear inferences about the impact of different conditions that fall under the 
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umbrella term of ACHD.  
 
Several governing bodies have attempted to impose a structure on the heterogeneous nature of 
CHD and ACHD. Guidelines from various organizations across the world have proposed 
various categorizations of ACHD, each suggesting that their categorization guide clinical 
practice and research within CHD.  
 
Some of the most widely recognized categorizations include the Task force 1 classification of 
the American Heart Association, which uses the patient’s diagnosis and the need for regular 
follow-up as a basis for their classification (Warnes et al, 2001). Another commonly used 
categorization is using functional status to classify patients by applying the New York Health 
Association (NYHA) classification. This is, however, not specific to ACHD.   
 
These forms of categorizations have received criticism for their lack of specificity and inability 
to capture the true diverse nature of the condition and their impact on patient related outcomes 
and experiences. For instance, the Task force 1 categorization, groups a number of conditions 
under the label ‘complex’ and as a result this categorization classifies SV and TGA as complex 
conditions that are grouped together. However, what such a classification fails to take into 
account is the higher levels of long-term complications, morbidity and mortality that are 
associated with SV conditions, but may not be characteristic to the TGA patient (Jackson et al, 
2015).  
 
Most of the existing categorizations in the literature are broad and differ in the way they classify 
different conditions. However, they all usually include a varied range of conditions under broad 
labels such as severe, moderate, and simple/mild which are essentially categories based on a 
measure of severity, and do not capture and/or allow the assessment of the specific impact of 
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each of the conditions that make up CHD on patient related outcomes (Jackson et al, 2015).  
Consequently, the majority of the existing literature on cognitive functioning in ACHD patients 
includes heterogeneous samples with a range of conditions investigated collectively. It has 
become clear that for both research and clinical reasons there is a need to find some form of 
grouping or classification of patients with CHD.  
 
Given the above-mentioned limitations of the existing classifications and the lack of specificity 
in the disease categorizations, these guidelines were not used to categorise CHD within this 
study. Instead a new classification was adopted based on the nature of the congenital heart 
problem and how it affected the anatomical structure of the heart.  
 
The present study included four groups and distinguished between the four groups based on 
their level of structural complexity. This categorization was based on the anatomical description 
and complexity of the different forms of ACHD, and was also a general marker for the 
treatments required and the presence of cyanosis within these groups (See Chapter 1 for details). 
Unlike the other classifications in the literature the four group categorization adopted in the 
present study allowed each of the anatomically different conditions that make up CHD to be 
assessed independently, which enabled more specificity and a better understanding of the 
different long-term outcomes in these groups and factors that have the ability to influence them. 
Furthermore, such a categorization also enabled drawing comparisons across the different 
conditions included.   
 
As discussed in Chapter 7, the classification adopted in this study was established using the 
clinical expertise of the consultant cardiologists at the Heart Hospital, London and follows the 
established subdivisions of CHD, as used widely in the literature, for instance by the American 
College of Cardiology and American Heart Association (Warnes et al, 2001; Warnes et al, 
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2008). The categorization was finalised after careful deliberation, evaluation and agreement of 
the cardiologists. The objective was to examine whether this categorization based on structural 
differences was useful both clinically and for research purposes. 
 
The results of this study highlighted the advantage of using such a categorization as the findings 
not only showed differences in cognitive functioning across the different structural complexity 
groups, but also in factors associated with cognitive functioning in these different conditions. It 
is evident from the results that merging together these groups does not allow for a consideration 
of the specific factors that explain variability in cognitive functioning; as some of the clinical 
variables may not be applicable to all structural complexity groups included in the study. A 
good example of this is the variable ‘cyanosis’, which could be considered inapplicable to the 
Simple group, given that these conditions are acyanotic in nature. These differences emphasized 
the importance of assessing different conditions independently as examining a heterogeneous 
sample could lead to dilution of specific effects, which may be pertinent to some conditions.  
 
Overall the use of structural complexity as a classification in the present study has provided 
some valuable insights and differentiation of the different forms of ACHD and cognitive 
outcomes. This form of categorization provides a working model for future studies to build 
upon. The merits of this form of categorization could be tested and used in future studies to 
evaluate other long-term outcomes specific to each complexity group.  
 
15.4 Overall limitations and strengths of the studies in the thesis  
15.4.1 Study limitations 
15.4.1.1 Representativeness of study sample 
With regards to the representativeness of the study sample, the exclusion criteria applied in this 
study may have limited the generalizability of the findings and potentially biased the results of 
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the study. For instance, this study excluded patients undergoing or about to undergo a surgical 
procedure, as with these cases it would be challenging to differentiate between the extent of 
cognitive impairment and change in cognitive functioning caused by CHD and that caused by 
the surgical procedures and anesthetics, as these factors are known to influence cognition 
functioning (Mason, Noel-Storr and Ritchie, 2011). The exclusion of these cases may have led 
to more seriously ill patients that require surgical treatment being excluded from the study, 
thereby resulting in the missed identification of the cognitive impairments and/or declines in the 
more seriously ill groups of patients in turn causing systematic bias. However the inclusion of 
these patients could have resulted in further challenges when assessing the stability of cognitive 
functioning over time, as any observed changes over time could have potentially been as a result 
of the recently conducted surgical procedures and/or anaesthetics. 
  
Within the present study patients with chromosomal anomalies such as Downs (Trisomy21) and 
Di George (22q11 deletion) syndrome were excluded, as these conditions are known to have an 
impact on cognitive functioning, and would therefore make it difficult to identify the specific 
impact of ACHD on cognitive functioning, over and above chromosomal anomalies. However 
the exclusion of these patients restricts the generalization of the findings of this study to the 
CHD population as a whole. Furthermore this exclusion may also have led to the 
underestimation of the extent of cognitive impairment in CHD patients as a group.  
 
Only patients fluent in English language were recruited in this study; this decision was made 
due to practical reasons, as there were limited resources to translate and interpret the cognitive 
tests and psychosocial questionnaires into different languages. Further changing the language of 
the NP tests could interfere with the psychometric properties of the instruments and also create 
additional challenges associated with identifying appropriate normative data for comparison in 
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different foreign languages. Therefore the findings of this study are limited to patients fluent in 
English language.  
 
With regards to the ethnic representativeness of the sample, there was an overrepresentation of 
the White British population in this study, with other ethnic groups not being adequately 
represented, thus limiting the generalizability of the findings to all ethnic groups. As discussed 
in Chapter one there is evidence of ethnic susceptibility to different forms of CHD, and a largely 
White British population as in this study may not be representative of this (Nembhard et al, 
2010). Lastly, the study eligibility criteria and the resulting sample limits the findings of this 
study to patients being treated within the UK. Furthermore, the data was gathered from a single 
specialist hospital site (although it has a wide catchment area), which may also reduce 
generalizability and variability in the data gathered. 
 
Lastly, this study included a large heterogeneous group of patients with varying levels of 
structural complexity providing good differentiation in complexity levels while also including 
the most common form of ACHD. However, it must be stated that not all conditions 
encompassed in ACHD were included (e.g. less common conditions like Truncus arteriosus) 
thus limiting the findings of this study to the conditions involved. In a related matter, another 
limitation of the study relates to the ‘Simple’ category, which included a mixed diagnosis (ASD, 
VSD, and CoA), due to the small number of participants available for this study. This did not 
allow for specific ‘Simple group’ conditions to be examined independently. Further research is 
needed to be able to identify if conditions with a similar level of structural complexity (e.g. 
ASD, VSD) differ with regards to their cognitive outcomes.  
 
15.4.1.2 Measures used for assessment and data collection  
NP test battery  
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While a number of cognitive tests were employed, not all domains and sub-domains of 
cognitive functioning could be covered for instance not all types of memory could be assessed 
(e.g. long-term and episodic). Conducting a comprehensive NP assessment, is difficult and not 
always feasible in a research and/or clinical setting, as assessing a range of domains including 
its different aspects can be lengthy and time consuming and not feasible, given the burden this 
may place on the participants. As discussed earlier in Chapter two, it is difficult to assess a 
domain of cognition using a single test, and future studies may benefit from examining aspects 
of cognitive functioning that have not been investigated within this study.    
 
It is also considered important to acknowledge that while the use of normative data to draw 
comparisons with the normal population is useful and informative, some caution must be 
exercised when using normative data particularly for tests of IQ.  As most studies reporting 
normative data were conducted several years earlier; it may subject the results to the well-
known “Flynn effect” (Flynn, 2007). The “Flynn effect” suggests a rise in the IQ curve i.e. an 
increase in the level of intelligence over generations. As a result using historically gathered 
normative data might not allow an accurate comparison, potentially leading to a false negative 
effect (Karsdorp et al, 2007). However, obtaining normative data that is a perfect match to a 
study sample may not always be possible or achievable. To limit potential biases of this type, 
existing normative datasets were evaluated and those that closely matched this study sample 
were chosen. All normative data was matched by age and method of test administration and the 
scoring procedures used within this study. Normative data was also matched by gender and 
education where available. Future studies may benefit from sampling a healthy 
comparator/control group matched on demographic factors such as age, gender and education, 
which may provide a better and more customized set of data, for the sample being assessed and 
allow for a more robust and reliable comparison. However, the sheer magnitude of the data 
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required could pose logistical challenges including the sample size required and the cost of 
running such a study, which would need to be considered. 
 
Lastly, the short versions of some NP tests were used where appropriate and available, in order 
to reduce patient burden. However, this resulted in the omission of certain scales from some 
measures, for instance the measure used to assess IQ (WAIS-III), which may not be as sensitive 
as the full length measure. However as discussed in Chapter two using a shorter version of IQ 
tests to calculate an estimated IQ is common practice in a research setting. 
 
Measures used to evaluate mood and QoL in ACHD  
Given the wide range of variables assessed in this study the short versions of psychosocial 
questionnaires were used where appropriate and available, in order to reduce patient burden. 
However, this may have resulted in the measures not being sensitive enough to detect an 
association within this patient group. Further, a lack of disease specific QoL measure within this 
study may have reduced the sensitivity of the measure to detect group differences within the 
different forms of ACHD, given the generic nature of the questionnaire utilized.  
 
Disease specific measures are often designed to measure aspects of ill health that are most 
salient to the condition in question, as opposed to the generic measures, making them a lot more 
sensitive. Furthermore with regards to the self-report measures used to assess QoL, depression 
and anxiety, the data was gathered in the presence of the researcher, which may have led to 
some bias as the responses could be subjected to experimental demand characteristics which 
refers to the artefact whereby participants subconsciously change their behaviour to fit their 
interpretation of the tasks purpose and/or social desirability bias; whereby the participant 
provides responses that they believe will be viewed favourably by the examiner (Stevenson et 
al, 2000).  
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Lastly, it is important to acknowledge that the CESD-10 questionnaire used to assess depressive 
symptomology in this study, includes somatic items that may inflate the rate of depression 
observed (e.g. my sleep was restless). However, given that mood was only included within the 
study as a control variable and not a key outcome variable, it allowed more stringent control of 
both depressive and physical symptomology that may impact cognitive functioning.  
 
Clinical history data  
A detailed clinical history was gathered for each participant, in order to be able to investigate 
the clinical factors that are most likely to affect cognitive functioning. However, it must be 
acknowledged that the presence of other co-morbidities or co-existing conditions may have 
obscured the effect of other variables on the outcomes being measured.   
 
Further, it is acknowledged that one of the drawbacks of this study is the lack of data regarding 
the specific nature of the CNS complications experienced by the patients. Therefore, while the 
results of this study can be used to draw conclusions about the association of post-operative 
CNS complications and cognitive functioning; it cannot be specific regarding the precise nature 
of the CNS complications. Further work is required to identify and understand the specific 
mechanism underlying this association, and identification of the specific form of CNS 
complication associated with cognitive impairment in ACHD patients. 
 
15.4.1.3 Follow-up data  
The time constraints of the follow-up study did not allow the assessment of all participants at 
the same time-point; however, no statistically significant differences between the groups were 
noted on the time frame. Furthermore, given the time constraints the required sample size for 
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the follow-up study could not be achieved, leading to a difference in sample sizes across groups 
and the lack of sufficient power when conducting sub-group analysis.  
 
Given that the test-retest data from a normal healthy control group was not available within the 
present study, the available published data was utilized to assess the stability of cognitive 
functioning over time. However, the considerable differences in the time interval between the 
assessments for the two groups posed some limitations and made drawing comparisons 
challenging.   
 
15.4.1.4 Data analysis  
Given that most studies conducted in the past utilised a heterogeneous sample with different 
forms of CHD assessed collectively, little was known about different conditions and what 
factors influenced cognitive functioning in these groups. The present study was exploratory in 
nature and aimed to assess each condition included independently, on each of the cognitive 
functions assessed. Consequently, this exploratory approach led to a large number of analyses 
being conducted. It is acknowledged that the large number of analysis as a result of conducting 
sub-group analysis and using each cognitive test score as a dependent variable could have 
resulted in some chance findings. However, where possible steps were undertaken to control for 
these limitations - for instance a more stringent p-value (p<0.01) was chosen. This method was 
preferred over the Bonferroni correction, which involves dividing the p-value by the number of 
tests used, as this approach was considered too conservative and may have obscured true effects 
that may exist.  
 
15.4.2 Strengths of the study 
This section addresses the strengths of the present study with regards to its design, measures 
utilized and sampling procedures.  
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15.4.2.1  Study design 
One of the main strengths of the present study is the novelty of its design and research 
objectives; this study is one of the largest and first to assess and compare cognitive functioning 
in patients with ACHD, with varying levels of structural complexity both cross-sectionally and 
longitudinally. Thus providing specific insights into the long-term outcomes of the different 
structural complexity groups. Furthermore, this study includes a relatively large sample size in 
comparison to the existing literature, which provides more statistical power to detect significant 
effects and provides more confidence in the findings of the present study. Although the sample 
size for the sub-group analysis i.e. when the groups were assessed independently was 
considered small, statistically significant trends in the data were still evident with a range of 
small to large effect sizes. Future studies with larger sample sizes for each structural complexity 
group would aid conformation of the findings of this study. 
 
 
15.4.2.2 Measurements of cognition 
With regards to the assessment of cognitive functioning this study moved away from the trend 
in the literature to use a single composite measure of cognition (i.e. IQ), and assessed a wide 
range of cognitive domains. A comprehensive neuropsychological test battery was employed to 
assess the key domains of cognition including attention, executive functioning, memory and 
motor functioning. These tests enabled identification of specific areas of cognitive impairment 
within the different structural complexity groups. This was done to allow more specificity in 
measurement, as it could be that only some domains of cognition were impacted, and this could 
have been obscured if only a composite measure such as IQ was used. Nevertheless an IQ 
measure was included within this study to enable comparison with the existing literature, which 
primarily uses IQ as the only measure of cognitive functioning.  
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The advantage of conducting a comprehensive assessment was evident from the results of this 
study. For instance, the IQ within this study sample was in the normal range as classified by 
Wechsler, however there was a considerable proportion of participants with impairments in 
specific domains of cognitive functioning including executive functioning and motor function 
when compared to age matched normative data. Therefore, had only the measure of IQ been 
used one could conclude that the level of cognitive functioning in ACHD is largely comparable 
to the general population, while in fact these groups of patients experienced cognitive 
impairments in specific domains, that could have been overlooked in the absence of a 
comprehensive assessment.  
 
Furthermore, when interpreting the magnitude of cognitive impairment, this study 
acknowledged the complexities associated with cognitive assessment and took into account the 
proportion of the normal healthy population that could be expected to exhibit the same level of 
impairment when drawing conclusions, to ensure that the estimated proportion of participants 
with impairments was not inflated (i.e. reduce false positives).  
 
It has been established that the likelihood of the normal population scoring 1.5 SD below the 
normative mean score is 7% on any given test assuming a normal distribution. However, when 
using multiple tests of cognitive functioning as is the case in this study, this proportion is 
inflated dependent on the number of tests utilized. When comparing the performance of the 
study sample to the normative data, it is essential to take into account the number of tests 
utilized, in order to draw a more informed conclusion. Therefore, the mathematical formula 
provided by Ingraham and Aiken, (1996) was used in this study to establish the extent of 
cognitive impairment in comparison to the normal population (See Chapter 7 for a more 
detailed description).   
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In summary, this study addresses an important area of research that has previously been 
neglected. As evidenced from the systematic review very few studies have assessed cognitive 
functioning in the ACHD population. With the increase in the number of adult survivors of 
CHD, and the rapidly growing adult patient population this study provides valuable information 
regarding the long-term outcomes of this patient group. The results of the cross-sectional and 
follow-up study provides an insight into the long-term outcomes and repercussions of the 
treatments and the nature of the condition; allowing the identification of vulnerable patient 
groups that are more likely to experience cognitive impairment as a result of their condition and 
its treatments. Some of the potential contributions of this study to the clinical practice and care 
of these patients are discussed below. 
 
15.5 Implications of the study findings   
The findings of the present study have a number of implications for clinical practice. The results 
of the cross-sectional study demonstrated the potential impact of ACHD and its associated 
treatments on a patient’s cognitive performance. A significant and consistent association 
between the treatment and surgery related factors (post-operative CNS complications, CPB and 
hypothermic arrest duration, age at repair etc.) and cognitive functioning was noted across 
different domains. Furthermore, the results of the follow-up study discussed in chapter 14 
demonstrated that clinical factors such as oxygen saturation levels may play a role in predicting 
cognitive decline over time in patients with ACHD, however the mechanisms underlying these 
associations remains elusive and warrants further research.  
 
These results could have implications for the surgeons and clinicians that are involved in the 
treatment and care of this patient population; as the results of this study highlight the factors that 
have the ability to cause impairment in cognitive functioning as this patient group ages into 
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adulthood. This information emphasises the importance of the treatments, in particular the 
surgical interventions on long term cognition.  Whilst most of these are currently being taken 
into account it is worthwhile emphasizing that they are potentially modifiable factors that can be 
managed so as to reduce or mitigate the risk of cognitive impairments in ACHD. Some such 
potential factors could include minimizing the length of the surgery and a smaller duration of 
the use of CPB or HA. Furthermore, to reduce potential CNS complications, CNS protective 
strategies could be incorporated when conducting a surgical procedure.  
 
The recognition of these cognitive impairments can have implications for patients and their 
families in the form of better management and increased support. The cognitive domains 
affected in ACHD appear important for an individual to function independently in day-to day 
activities such as self-care, adherence to medication and treatment, and social and work related 
demands. Identifying which ACHD patients have particular cognitive problems will help 
identify where health care resources should be directed. It is therefore useful to consider a 
routine screening cognitive assessment in ACHD clinics.  
 
It is acknowledged that cognitive testing can be an expensive and time consuming exercise 
requiring expert psychologists, thus posing challenges in making this a part of routine care. 
However more advanced forms of cognitive testing such as computerized tests are now 
increasingly being used. These tests may help reduce the manpower and the potential costs 
needed to conduct such an assessment, making it more economically feasible in health care 
settings. It is hoped that this study and similar research along with routine assessment of 
patients would allow clinicians and researchers to identify vulnerable individuals/ groups and 
provide appropriate support and rehabilitation where necessary.  
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The evidence on the use of cognitive rehabilitative and remedial interventions within the ACHD 
population is limited, and could benefit from the application of techniques proven to be useful 
within the paediatric CHD literature; for instance, intensive computerised training to improve 
domains such as working memory (Calderon and Bellinger, 2015). Furthermore, there is some 
evidence of cognitive interventions including activities such as problem-solving, guided 
imagery and mnemonic training that have proven useful in improving cognitive outcomes in 
adults with mild cognitive impairment (Martin et al, 2011). Studies have also reported the 
usefulness of meditation and mindfulness training in the improvement of working memory, 
executive functioning and visuo-spatial processing (Zeidan et al, 2010). However, much work is 
needed to be able to assess the effectiveness and usefulness of these techniques in ACHD 
patients. Potentially such techniques may be useful for ACHD patients that have impairment in 
specific domains of cognitive functioning, that limit their ability to function in an optimal 
manner or interferes with their ability to function independently.  
 
Lastly, the findings of this study could have implications for the education services that can be 
better informed and more mindful about the challenges faced by this group of patients. As seen 
from the results of the cross-sectional and longitudinal studies the impairments seen in 
childhood indicate the presence of cognitive deficits as opposed to delays, therefore suggesting 
the early onset of the impairments noted in the adult population. Acknowledging the problems 
faced by these groups of patients and providing the appropriate educational support in a timely 
manner could have long lasting implications for the patients, not just with regards to their 
academic performance but also their future employability and professional prospects.    
 
15.6 Directions for future research  
There are a number of avenues for research that have been generated from this study and the 
systematic review discussed in Chapter four. A general finding from the systematic review was 
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the overall lack of evidence on cognitive functioning in ACHD patients. More research is 
needed to strengthen and expand the findings of the present study, bearing in mind it’s 
limitations. For example, the limitations associated with the use of normative data suggest that 
future studies may benefit from using a control or comparator group which is matched to the 
sample demographic characteristics such as age, gender and education.  
 
The follow-up study conducted was one of the first to assess the stability of cognitive functions 
in ACHD patients along with identifying predictors of change in cognitive functioning. 
However, the results of this study could not identify significant predictors of change in 
cognition over time, with the exception of the domain of memory. Therefore, future research 
may benefit from looking at a longer time interval so as to examine the impact of ageing in the 
population.  
 
In addition, exploring alternative variables that may not have been included within the present 
study may also illustrate the interaction of psychosocial factors and cognition. For example, one 
area of research could consider the impact of psychosocial factors such as social support and 
self-esteem on cognitive functioning; as there is some evidence to suggest an association 
between psychosocial functioning and cognitive outcomes in ACHD (Daliento et al, 2005).   
 
Furthermore, the small sample size in this follow-up study did not allow enough statistical 
power to conduct a sub-group analysis, similar to that of the cross-sectional study. Future 
studies may benefit from a larger sample size that would enable examining change in 
independent complexity groups as this could allow more specificity in the identification of 
predictors of change pertinent to each complexity group.  
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Another area of research that has not received much attention is the patient’s subjective 
perspective of their cognitive functioning and an account of how this impacts them on a day-to-
day level. Qualitative investigation of the patient’s subjective perception of their level of 
cognitive functioning was outside the scope of this thesis, but may provide a valuable 
contribution to the literature. A qualitative insight would provide information based on patients’ 
first hand experiences, and would be useful for future research and practice to design 
interventions and support strategies specific to the patient group and their needs.  
 
15.7 Overall conclusions  
This study addressed a novel area of research and made several contributions to the existing 
literature. This thesis not only demonstrated the extent of cognitive impairments within domains 
such as executive functioning, attention and motor function in patients with ACHD, but also 
identified differences in cognitive outcomes among different levels of structural complexity. 
Furthermore, this study was the first to investigate the stability or change in cognitive 
functioning in ACHD patients, along with identifying factors associated with this change. The 
study addressed an important area of research with regards to the classification of ACHD, and 
demonstrated the benefits of using structural complexity as a way of grouping these 
heterogeneous conditions. Most importantly the findings of the present thesis highlight the 
potential early onset of cognitive impairment in ACHD patients, which could have major 
implications for this patient group if recognized and treated early. The findings from this thesis 
not only make contributions to the existing literature but can also be considered hypothesis 
generating offering several avenues for further research.   
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(e.g., publication bias, selective reporting within studies).  
No Study quality 
was assessed not 
risk of bias 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, 
meta-regression), if done, indicating which were pre-specified.  
No No additional 
analysis 
conducted 
RESULTS    
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the 
review, with reasons for exclusions at each stage, ideally with a flow diagram.  
81 - 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study 
size, PICOS, follow-up period) and provide the citations.  
81-86 - 
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Section/topic  # Checklist item  
Reported 
on page #   
Notes  
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any outcome level 
assessment (see item 12).  
No Study quality 
was assessed not 
risk of bias 
Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) 
simple summary data for each intervention group (b) effect estimates and 
confidence intervals, ideally with a forest plot.  
80-99 - 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and 
measures of consistency.  
No Data was not 
meta-analysed 
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  No Study quality 
was assessed not 
risk of bias 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, 
meta-regression [see Item 16]).  
n/a - 
DISCUSSION    
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main 
outcome; consider their relevance to key groups (e.g., healthcare providers, users, 
and policy makers).  
95-99 - 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-
level (e.g., incomplete retrieval of identified research, reporting bias).  
99-100 - 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and 
implications for future research.  
100 - 
FUNDING    
Funding  27 Describe sources of funding for the systematic review and other support (e.g., 
supply of data); role of funders for the systematic review.  
No Will be 
provided for 
publication 
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Appendix C: Systematic Review Literature Search Strataegy 
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Database  Key word search (same for all 
databases and consistent with 
paper) 
Subject heading search (selected 
from those provided by the 
database) 
Total 
hits  
Allied and 
complementary 
Medicine 
Database 
(AMED)  
i) cognition terms:  
cogniti* OR neuropsycholog* OR 
neurocogniti* OR intelligence OR IQ  
ii) adult terms: adult OR "grown up"  
iii) CHD terms: congenital heart 
disease OR congenital heart defect  
 
i) Cognition disorders/ or Cognition/ or 
cognitive functioning.mp 
ii) Adult/ or adult.mp. 
iii) Heart defects congenital/ 
 
 
0 
Excerpta 
Medica 
dataBASE 
(EMBASE)  
i) cognition terms:  
cogniti* OR neuropsycholog* OR 
neurocogniti* OR intelligence OR IQ  
ii) adult terms: adult OR "grown up"  
iii) CHD terms: congenital heart 
disease OR congenital heart defect 
i) neuropsychological test/ or cognitive 
defect/ or memory/ or cognition/ or 
cognitive functioning.mp. or executive 
function/ 
ii) adult 
iii) congenital heart malformation/ or 
congenital heart disease/ or congenital 
heart block/ or congenital heart.mp. or 
heart ventricle septum defect/ 
 
177 
CHOCORANE 
REVIEWS 
i) cognition terms:  
cogniti* OR neuropsycholog* OR 
neurocogniti* OR intelligence OR IQ  
ii) adult terms: adult OR "grown up"  
iii) CHD terms: congenital heart 
disease OR congenital heart defect 
i) cognitive functioning.mp 
ii) adult  
iii) congenital heart malformation/ or 
congenital heart disease/ or congenital 
heart block/ or congenital heart.mp. or 
heart ventricle septum defect/ 
 
2 
GOOGLE 
SCHOLAR  
(cognitive* and neurocognitive* or neuropsychology* or intelligence or IQ) and 
(adults or "grown up") and ("congenital heart") 
 
25 
MEDLINE  i) cognition terms:  
cogniti* OR neuropsycholog* OR 
neurocogniti* OR intelligence OR IQ  
ii) adult terms: adult OR "grown up"  
iii) CHD terms: congenital heart 
disease OR congenital heart defect 
i) (MH "Cognition") OR (MH 
"Executive Function") OR "cognitive 
functioning" OR (MH "Mild Cognitive 
Impairment") OR (MH "Intellectual 
Disability")  
ii) (MH "Adult") OR "adult" OR (MH 
"Young Adult") 
iii)(MH "Heart Defects, Congenital") 
OR (MH "Hypoplastic Left Heart 
Syndrome") OR "congenital heart"  
 
278 
Cumulative 
Index to 
Nursing and 
Allied Health 
Literature 
(CINHAL) 
i) cognition terms:  
cogniti* OR neuropsycholog* OR 
neurocogniti* OR intelligence OR IQ  
ii) adult terms: adult OR "grown up"  
iii) CHD terms: congenital heart 
disease OR congenital heart defect 
i) cognitive functioning  
ii) (MH "Adult") OR "adult" OR (MH 
"Young Adult") OR (MH "Wechsler 
Adult Intelligence Scale-Revised") 
iii) MH "Hypoplastic Left Heart 
Syndrome") OR (MH "Heart Septal 
Defects, Ventricular") OR (MH "Heart 
Septal Defects, Atrial") OR (MH 
"Tetralogy of Fallot") OR (MH 
"Transposition of Great Arteries") OR 
(MH "Tricuspid Atresia") OR (MH 
"Heart Defects, Congenital") OR (MH 
24 
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Database  Key word search (same for all 
databases and consistent with 
paper) 
Subject heading search (selected 
from those provided by the 
database) 
Total 
hits  
"Aortic Coarctation") OR (MH 
"Ventricular Outflow Obstruction")  
 
PSYCHINFO i) cognition terms:  
cogniti* OR neuropsycholog* OR 
neurocogniti* OR intelligence OR IQ  
ii) adult terms: adult OR "grown up"  
iii) CHD terms: congenital heart 
disease OR congenital heart defect 
i) "Executive Function" OR DE 
"Neuropsychology" OR DE "Problem 
Solving" OR DE "Memory" OR DE 
"Cognitive Impairment" OR DE 
"Cognitive Ability" OR DE "Cognitive 
Assessment"  
ii) (DE "Wechsler Adult Intelligence 
Scale") OR (DE "Adult") iii) 
congenital heart  
15 
WEB OF 
SCIENCE  
i) cognition terms:  
cogniti* OR neuropsycholog* OR 
neurocogniti* OR intelligence OR IQ  
ii) adult terms: adult OR "grown up"  
iii) CHD terms: congenital heart 
disease OR congenital heart defect 
i) (MH "Cognition") OR (MH 
"Executive Function") OR "cognitive 
functioning" OR (MH "Mild Cognitive 
Impairment") OR (MH "Intellectual 
Disability")  
ii) (MH "Adult") OR "adult" OR (MH 
"Young Adult")  
iii) (MH "Heart Defects, Congenital") 
OR (MH "Hypoplastic Left Heart 
Syndrome") OR "congenital heart" 
 
31 
TOTAL  552 
Note- all terms searched only in abstract and abstract and title where the option of only abstract was not available in the 
database  
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Appendix D: Example of One Electronic Database Search Strategy 
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Database searched = Psychinfo  
 
 
Interface used = Ebscohost  
 
 
Search string including key words and subject headings=  
 
 
“cogniti*” OR  “neuropsycholog*” OR  “neurocogniti*” OR  “intelligence” OR “IQ” AND 
"Executive Function" OR DE "Neuropsychology" OR DE "Problem Solving" OR DE "Memory" 
OR DE "Cognitive Impairment" OR DE "Cognitive Ability" OR DE "Cognitive Assessment"  
 
 
AND 
 
“adult” OR "grown up" AND (DE "Wechsler Adult Intelligence Scale") OR (DE "Adult") 
 
 
AND  
 
 
“congenital heart disease” OR “congenital heart defect” AND “congenital heart*” 
 
 
Limits instated= none  
 
Total hits= 15  
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Appendix E: Data Extraction Form used for the Systematic Review 
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General Information 
 
 
Article Title: 
 
Author(s):  
 
Source: 
 
Sample Characteristics 
 
Study sample size:  
 
Inclusion Criteria:  
 
Exclusion Criteria:  
 
Sample Characteristics/ structural complexity groups:  
 
Normative/Control group: 
 
Study Characteristics 
 
Aim(s):  
 
Design:  
 
Cognitive impairment criteria: 
 
Neuropsychological assessment measures:  
 
Other Measures:  
 
Statistical Analysis: 
 
Main Findings: 
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Appendix F: Quality Index used for Systematic Review  
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Quality index items Yes 
(Score=2) 
Partially 
(Score=1) 
No 
(Score=0) 
Unable to 
determine 
(Score=0) 
REPORTING  
The hypothesis/ aim/ objective(s) of the study 
were clearly described  
    
The main outcomes to be measured were 
clearly described in the Introduction or 
Methods section 
    
The characteristics of the patients included in 
the study were clearly described 
    
Is the definition of cognitive impairment clearly 
defined in the study 
    
The principal confounders in the sample were 
clearly described 
    
The main findings of the study were clearly 
described  
    
Does the study provide estimates of the random 
variability in the data for the main outcomes? 
    
Actual probability values have been reported 
(e.g. .035 rather than <.05) for the main 
outcomes except where the probability value 
was less than .001 
    
EXTERNAL VALIDITY 
The persons asked to participate in the study 
were representative of the entire population 
from which they were recruited  
    
The persons who were prepared to participate 
were representative of the entire population 
from which they recruited 
    
Is the context/ location of the study clearly 
described? 
    
INTERNAL VALIDITY (Bias) 
Were the statistical tests used to assess the main 
outcomes were appropriate 
    
Did the study include a normative/control group 
for comparison on the NP tests?  
    
Were the main outcome measures used 
accurate? (valid and reliable) 
    
INTERNAL VALIDITY (Selection bias) 
Where there any participants excluded from the 
study that may result in a bias? (for e.g 
syndrome patients)
a
 
    
Were all patients recruited over the same period 
of time?  
    
There were adequate adjustment for 
confounding in the analyses from which the 
main findings were drawn 
    
Was a power calculation reported?     
Did the study meet sample size requirement?      
Note: Maximum possible score = 38, with higher scores representing better study quality; 
a
Item reverse 
scored 
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Appendix G: Cross-Sectional Study Patient Information Sheet  
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Appendix H: NP Test Battery Cross-Sectional Study 
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Appendix I: Cross-Sectional Study Questionnaires  
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Questionnaire - SF-36 (v1) 
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Questionnaire - PANAS 
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Questionnaire – STAI-6 
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Questionnaire- CESD-10 
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Appendix J: Cross-Sectional Study Consent Form 
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Appendix K: Cross-Sectional Study Missing Data 
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Variable  Missing data (%) 
Clinical variables  
Age At Repair  11.8 
Interventions Total  1.0 
Repair total  1.6 
Palliation total  1.6 
Catheter lab total 1.6 
Palliation before repair 1.6 
RVEF .0 
LVEF .0 
Cyanosis Total  1.0 
Current Saturation  1.3 
ICU Total days  7.0 
CPB Total minutes  11.1 
HA Total minutes 13.4 
In Hospital Days  2.5 
Co-Morbidities Total  1.0 
Arrhythmias  1.0 
Hypertension  1.0 
Medication Total  1.0 
Yrs Since Last Intervention 2.9 
Post-op CNS Complications 12.4 
Post-op Infections 11.8 
HF Clinic 1.0 
NYHA classification 1.0 
Pacemaker 1.0 
ACE medication 1.0 
Diuretic medication  1.0 
BBlocker medication 1.0 
Anti Arrythmia medication 1.0 
Anticoagulant medication 1.0 
Category .0 
RepairsTotal  2.5 
PalliationsTotal 2.5 
Cath LabsTotal 2.5 
Palliation before repair 2.5 
NP measures 
PegDom Tim  1.3 
PegNonDoTime  2.5 
WCST Errors  2.5 
WCS Conceptual Level  2.5 
WCT No Categories  2.5 
WST Trials1stCategory  2.5 
CST Failure To Maintain Set  2.5 
RAVLT TRIAL 1  1.6 
RAVLT TRIAL 2  2.9 
RAVLT TRIAL 3  14.0 
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Variable  Missing data (%) 
RAVLT TRIAL 4  28.3 
RAVLT TRIAL 5  48.1 
RAVLT TRIAL 6  1.9 
RAVLT TRIAL 7  1.6 
Psychosocial measures  
SF36_PhysicalFunctioning_2 3.5 
SF36_PhysicalFunctioning_3 3.5 
SF36_PhysicalFunctioning_4 3.5 
SF36_PhysicalFunctioning_5 3.5 
SF36_PhysicalFunctioning_6 3.5 
SF36_PhysicalFunctioning_7 3.8 
SF36_PhysicalFunctioning_8 4.1 
SF36_PhysicalFunctioning_9 4.1 
SF36_PhysicalFunctioning_10 3.5 
SF36_RolePhysical_1 3.8 
SF36_RolePhysical_2 3.8 
SF36_RolePhysical_3 4.1 
SF36_RolePhysical_4 3.8 
SF36_RoleEmotional_1 4.1 
SF36_RoleEmotional_2 3.8 
SF36_RoleEmotional_3 3.8 
SF36_SocialFunctioning_1 3.8 
SF36_Pain_1 3.5 
SF36_Pain_2 3.5 
SF36_Vitality_1 3.8 
SF36_MentalHealth_1 3.8 
SF36_MentalHealth_2 3.5 
SF36_MentalHealth_3 3.8 
SF36_Vitality_2 3.5 
SF36_MentalHealth_4 3.8 
SF36_Vitality_3 3.5 
SF36_MentalHealth_5 3.8 
SF36_Vitality_4 3.5 
SF36_SocialFunctioning_2 3.5 
SF36_GeneralHealthPerception_2 3.8 
SF36_GeneralHealthPerception_3 4.1 
SF36_GeneralHealthPerception_4 3.8 
SF36_GeneralHealthPerception_5 3.8 
PANAS_PA_1 3.8 
PANAS_NA_1 4.1 
PANAS_NA_2 3.8 
PANAS_PA_3 4.5 
PANAS_NA_3 4.1 
PANAS_NA_4 3.8 
PANAS_NA_5 4.1 
PANAS_PA_4 3.8 
PANAS_PA_5 3.8 
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Variable  Missing data (%) 
PANAS_NA_6 4.5 
PANAS_PA_6 4.8 
PANAS_NA_7 4.1 
PANAS_PA_7 3.8 
PANAS_NA_8 3.8 
PANAS_PA_8 4.1 
PANAS_PA_9 4.1 
PANAS_NA_9 4.1 
PANAS_PA_10 3.8 
PANAS_NA_10 3.8 
STAI_1 3.5 
STAI_2 3.5 
STAI_3 3.5 
STAI_4 3.5 
STAI_5 3.5 
STAI_6 3.5 
CESD10_1 4.5 
CESD10_2 3.8 
CESD10_3 4.1 
CESD10_4 4.1 
CESD10_5 4.1 
CESD10_6 4.1 
CESD10_7 4.5 
CESD10_8 4.1 
CESD10_9 4.1 
CESD10_10 4.5 
Demographic variables 
Years of Education 3.5 
Gender .0 
Ethnicity .0 
Marital Status  .0 
Living Status  .0 
Employment Status  3.5 
Occupation Category  3.5 
NYHA= New York Health Assessment, CNS= Central Nervous System, Q=Quartile, CPB= Cardio 
Pulmonary Bypass, ACE= Angiotensin-Converting-Enzyme Inhibitor, RVEF= Right Ventricular Ejection 
Fraction LVEF= Left Ventricular Ejection Fraction. 
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Appendix L: Cross-Sectional Study Kolmogorov-Smirnov Test Results 
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Kolmogorov-Smirnov test results for the clinical variables 
Variables Kolmogorov-Smirnov 
Statistic  p value 
Age at repair 0.263 <0.001 
Interventions total 0.259 <0.001 
Repair Surgeries total 0.373 <0.001 
Palliation Interventions total 0.398 <0.001 
Catheter lab interventions total 0.309 <0.001 
Palliation Before Repair  0.344 <0.001 
Years Since Last Operation  0.135 <0.001 
Cyanotic Days Total  0.316 <0.001 
Current Saturation  0.266 <0.001 
Intensive Care Unit Days  0.188 <0.001 
Peri-Op Cardiopulmonary Bypass Minutes  0.102 <0.001 
Peri-Op Hypothermic Arrest Minutes  0.138 <0.001 
Post-Op CNS Complications  0.539 <0.001 
Post-Op Infection  0.469 <0.001 
Post-Op Ventricular Dysfunction  0.533 <0.001 
Hospitalisation Days  0.231 <0.001 
Heart Failure Clinic  0.501 <0.001 
Co-Morbidities Total  0.244 <0.001 
Arrhythmias  0.461 <0.001 
Hypertension  0.529 <0.001 
Medication Total  0.356 <0.001 
Pacemaker  0.548 <0.001 
ACE inhibitor Medication  0.485 <0.001 
Diuretic Medication  0.526 <0.001 
B-Blocker Medication  0.505 <0.001 
Anti-Arrhythmic Medication  0.525 <0.001 
Anti-Coagulant Medication  0.469 <0.001 
NYHA classification 0.509 <0.001 
LVEF 0.153 <0.001 
RVEF 0.132 <0.001 
Note- CNS- Central Nervous System, ACE-angiotensin converting enzyme, NYHA- New York Health 
Association, LVEF- Left Ventricular Ejection Fraction, RVEF- Right Ventricular Ejection Fraction 
Interpretation key- A significant (p<0.001) Kolmogorov-Smirnov statistic is indicative of a non-normal 
distribution.  
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Kolmogorov-Smirnov test results for the psychosocial variables (Scaled scores) 
 
Variables 
Kolmogorov-Smirnov 
Statistic  p value 
SF-36 Physical Functioning  0.219 <0.001 
SF-36 Role Physical  0.403 <0.001 
SF-36 Bodily Pain  0.279 <0.001 
SF-36 General Health  0.107 <0.001 
SF-36 Vitality 0.112 <0.001 
SF-36 Social Functioning  0.263 <0.001 
SF-36 Role Emotional  0.432 <0.001 
SF-36 Mental Health   0.126 <0.001 
Physical component summary 0.132 <0.001 
Mental component summary  0.151 <0.001 
PANAS- Positive affect 0.093 <0.001 
PANAS- Negative affect 0.143 <0.001 
Sum STAI 0.125 <0.001 
Sum CESD-10 0.156 <0.001 
Note- SF= Short Form, PANAS= Positive and Negative Scale, STAI= State and Trait Anxiety Inventory, CESD= 
Centre for Epidemiology Short Depression Scale,  
Interpretation key- A significant (p<0.001) Kolmogorov-Smirnov statistic is indicative of a non-normal 
distribution.  
 
 
Kolmogorov-Smirnov test results for the demographic variables 
 
Variables 
Kolmogorov-Smirnov 
Statistic  p value 
Employment status  0.435 <0.001 
Occupation Category  0.473 <0.001 
Gender 0.373 <0.001 
Ethnicity 0.511 <0.001 
Marital Status 0.346 <0.001 
Living Status 0.509 <0.001 
Total Years in Education  0.224 <0.001 
Age 0.122 <0.001 
Interpretation key- A significant (p<0.001) Kolmogorov-Smirnov statistic is indicative of a non-normal 
distribution.  
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Kolmogorov-Smirnov test results for the Neuropsychological test scores (raw scores) 
 
Variables 
Kolmogorov-Smirnov 
Statistic  p value 
Trail Making Test A 0.132 <0.001 
 Trail Making Test B 0.118 <0.001 
Controlled Oral Word Association Test - F 0.091 <0.001 
Controlled Oral Word Association Test – A 0.075 <0.001 
Controlled Oral Word Association Test – S 0.094 <0.001 
Stroop colour correct 0.489 <0.001 
Stroop word correct 0.233 <0.001 
WAIS-III – Arithmetic  0.086 <0.001 
WAIS-III – Information 0.088 <0.001 
WAIS-III – Digit symbol 0.052 0.039 
Grooved pegboard time – Dominant hand 0.118 <0.001 
Grooved pegboard time – Non-Dominant hand 0.143 <0.001 
WCST- Error 0.129 <0.001 
WCST-Conceptual level 0.134 <0.001 
WCST-No. categories 0.184 <0.001 
WCST-trials to complete first category 0.395 <0.001 
WCST-failure to maintain set 0.419 <0.001 
Rey Auditory Verbal Learning Test – Trial 1 0.133 <0.001 
Rey Auditory Verbal Learning Test – Trial 2 0.115 <0.001 
Rey Auditory Verbal Learning Test – Trial 3 0.156 <0.001 
Rey Auditory Verbal Learning Test – Trial 4 0.164 <0.001 
Rey Auditory Verbal Learning Test – Trial 5 0.152 <0.001 
Rey Auditory Verbal Learning Test – Trial 6 0.125 <0.001 
Rey Auditory Verbal Learning Test – Trial 7 0.141 <0.001 
Symbol Digit Modalities Test – written 0.048 0.076 
Symbol Digit Modalities Test – oral 0.038 0.200 
Note- WCST- Wisconsin Card Sorting Test, WAIS- Wechsler Adult Intelligence Scale   
Interpretation key- A significant (p<0.001) Kolmogorov-Smirnov statistic is indicative of a non-normal distribution 
 
 
  
      
438 
 
 
Appendix M: Normative Data Mean Scores for the Neuropsychological 
Test Battey used  
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Normative data scores for the Trail making test A and B 
TMT age groups Trail making A Trail making B 
Normative 
data  
Study sample 
score 
Normative 
data 
Study sample  
score 
18-24 
years  
Mean 22.93 29.46 48.97 64.51 
Std. Deviation 6.87 10.293 12.69 23.977 
N 
Education 
155 
12.92 (1.01) 
65 
14.28(2.72) 
155 
12.92 (1.01) 
65 
14.28(2.72) 
25-34 
years 
Mean 24.40 31.51 50.68 61.16 
Std. Deviation 8.71 11.891 12.36 19.370 
N 
Education 
33 
14.18 (1.61) 
135 
14.61(2.86) 
33 
14.18 (1.61) 
128 
14.61(2.86) 
35-44 
years 
Mean 28.54 31.97 58.46 63.83 
Std. Deviation 10.09 9.706 16.41 21.127 
N 
Education 
39 
13.59 (2.06) 
67 
13.23(3.11) 
39 
13.59 (2.06) 
65 
13.23(3.11) 
45-54 
years  
Mean 31.78 33.68 63.76 58.74 
Std. Deviation 9.93 15.283 14.42 16.802 
N 
Education 
41 
13.68 (2.80) 
25 
13.88(3.44) 
41 
13.68 (2.80) 
23 
13.88(3.44) 
55-59 
years  
Mean 31.72 38.29 68.74 72.14 
Std. Deviation 10.14 9.742 21.02 27.619 
N 
Education (12+ 
years) 
37 
15.32 (1.93) 
7 
12.43(1.81) 
37 
15.32 (1.93) 
7 
12.43(1.81) 
60-64 
years 
Mean 33.22 41.00 74.55 82.00 
Std. Deviation 9.10 9.648 19.55 36.241 
N 
Education (0-12 
years) 
86 
10.84 (1.27) 
11 
10.33(0.81) 
86 
10.84 (1.27) 
11 
10.33(0.81) 
65-69 
years 
Mean 39.14 42.6 91.32 118.67 
Std.Deviation 11.84 7.09 28.89 53.17 
N 
Education (0-12 
years) 
65 
10.87 (1.71) 
3 
6.50 
65 
10.87 (1.71) 
3 
6.50 
75-79 
years 
Mean 41.74 33.50 100.68 65.5 
Std.Deviation 15.32 23.33 44.16 44.54 
N 
Education (12+ 
years) 
34 
15.29 (1.80) 
2 
14.50 
34 
15.29 (1.80) 
2 
14.50 
*No participants in age group 70-74 in study sample therefore not included in table  
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Normative data for the Stroop Neuropsychological Screening Test 
Age groups Stroop colour 
no correct 
Stroop word 
no correct 
Normative 
data 
Study 
sample 
Normative 
data 
Study 
sample 
15-49 
years  
Mean  111.94 111.81 104.90 101.55 
Std. Deviation 0.23 .840 10.22 15.634 
N 106 278 106 275 
50+ 
years 
Mean  111.92 111.79 93.98 95.28 
Std. Deviation 0.27 .774 18.41 16.699 
N 50 29 50 29 
  
 
Normative data scores for the symbol digit modalities test 
 
Age groups Symbol digit copy Symbol digit Oral  
Normative 
data  Study sample  
Normative 
data  Study sample  
18-24 
years  
Mean 55.2 54.20 62.7 66.09 
Std. Deviation 7.5 10.393 9.1 14.675 
N 69 65 69 65 
25-34 
years 
Mean 53.6 54.10 61.2 64.90 
Std. Deviation 6.6 11.985 7.8 12.821 
N 72 135 72 135 
35-44 
years 
Mean 51.1 52.52 59.7 61.39 
Std. Deviation 8.1 9.963 9.7 10.982 
N 76 67 76 67 
45-54 
years  
Mean 46.8 50.68 54.5 60.36 
Std. Deviation 8.4 8.577 9.1 12.741 
N 75 25 75 25 
55-64 
years 
Mean 41.5 46.77 48.4 55.54 
Std. Deviation 8.6 12.995 9.1 16.384 
N 67 13 67 13 
65-75 
years 
Mean 37.4 44.80 46.2 53.60 
Std. Deviation 11.4 22.231 12.8 31.667 
N 61 5 61 5 
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Normative data scores for the grooved pegboard test  
Age Groups 
Peg dominant hand time 
Peg Non-dominant hand 
time 
Normative 
data  Study sample  
Normative 
data Study sample  
15-19 
years 
Mean 66.05 72.45 70.50 78.18 
Std. Deviation 10.40 16.597 11.10 18.600 
N 172 11 172 11 
20-29 
years 
Mean 63.40 71.11 69.10 79.36 
Std. Deviation 7.90  12.700 18.70 18.971 
N * 122 * 121 
30-39 
years 
Mean 62.95    71.38 67.15 76.96 
Std. Deviation 8.40 14.562 12.20 16.008 
N 319 109 319 106 
40-49 
years 
Mean 63.50 75.23 69.05 80.21 
Std. Deviation 7.20 17.600 9.80 15.215 
N 319 39 319 39 
50-59 
years 
Mean 68.10 70.33 74.70 77.44 
Std. Deviation 9.42 9.456 10.51 12.430 
N 134 18 134 18 
60+ 
years 
Mean 82.70 81.09 87.95 105.00 
Std. Deviation 18.70 14.003 26.20 27.796 
N 100 11 100 11 
*Data not available  
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Normative data scores for the WCST-64 test   
WCST age groups 
WCST Errors 
WCST Conceptual 
Level 
WCST No. 
Categories 
WCST Trials1st 
Category 
WCST Failure to 
Maintain set 
Norms  
Study 
sample  Norms  
Study 
sample  Norms  
Study 
sample  Norms  
Study 
sample  Norms  
Study 
sample  
18-19 
years 
 
Mean 16.24 14.82 42.94 45.09 3.39 3.82 14.53 11.18 0.42 0.18 
SD 8.78 5.896 13.75 7.930 1.38 .982 9.57 1.328 0.78 .405 
N 62 11 62 11 62 11 62 11 62 11 
20-29 
years  
Mean   13.10 16.75 48.07 43.01 3.90 3.42 11.67 12.84 0.39 0.34 
SD 6.69 8.527 9.19 11.624 1.16 1.347 2.44 7.611 0.76 .625 
N 67 122 67 122 67 122 67 122 67 122 
30-39 
years 
Mean 12.16 16.74 48.89 43.28 4.10 3.38 13.05 11.88 0.30 0.49 
SD 7.90 7.966 10.92 11.312 1.25 1.380 8.17 3.426 0.80 .823 
N 63 109 63 109 63 109 63 109 63 109 
40-49 
years  
Mean 12.02 19.95 49.30 38.95 4.21 3.11 12.95 15.89 0.27 0.30 
SD 7.82 9.866 11.18 13.317 1.26 1.410 7.92 14.375 0.60 .520 
N 63 37 63 37 63 37 63 37 63 37 
50-59 
years  
Mean 13.69 19.35 47.37 39.65 3.91 3.06 13.58 12.82 0.30 0.41 
SD 7.70 6.264 10.77 10.295 1.29 1.144 9.37 6.277 0.58 .712 
N 67 17 67 17 67 17 67 17 67 17 
60-64 
years 
Mean 17.64 17.00 41.92 41.00 3.20 3.40 13.00 11.20 0.56 0.00 
SD 9.03 7.810 12.34 11.247 1.47 1.517 5.64 .837 0.92 .000 
N 25 5 25 5 25 5 25 5 25 5 
65-69 
years 
Mean 20.53 31.33 37.84 22.33 2.75 1.67 20.06 18.33 0.50 0.33 
SD 10.96 9.292 15.61 8.083 1.52 .577 16.73 3.055 0.72 .577 
N 32 3 32 3 32 3 32 3 32 3 
75-79 
years  
Mean 26.56 10.00 28.88 51.50 1.81 4.50 18.81 10.00 0.63 0.00 
SD 8.76 4.243 11.37 3.536 0.91 .707 15.14 .000 0.81 .000 
N 16 2 16 2 16 2 16 2 16 2 
*No participants in age group 70-74 in study sample therefore not included in table  
  
      
443 
 
Normative data scores for the WAIS –III (Scaled Scores equivalents for the mean raw score of 
study sample) 
 
 
WAISIII  
Age group categories 
Mental Arithmetic Information Digit Symbol 
Scaled 
 Score 
comparison 
Study 
sample 
score  
Scaled 
Score 
comparison 
Study 
sample 
score 
Scaled 
Score 
comparison 
Study 
sample 
score 
18-19 
years 
Mean 11 14.27 10 14.45 9 74.55 
Std. Deviation  3.771  7.353  23.114 
N  11  11  11 
20-24 
years 
Mean 10 12.69 11 15.89 9 75.33 
Std. Deviation  3.705  5.712  12.921 
N  54  54  54 
25-29 
years  
Mean 10 11.78 11 16.22 9 74.37 
Std. Deviation  4.288  5.843  15.708 
N  68  67  68 
30-34 
years  
Mean 10 12.61 11 17.15 10 75.88 
Std. Deviation  4.034  5.249  16.922 
N  67  67  67 
35-44 
years 
Mean 9 12.34 10 16.57 9 70.28 
Std. Deviation  4.198  4.890  15.081 
N  67  67  67 
45-54 
years  
Mean 9 13.32 10 18.16 10 68.80 
Std. Deviation  4.432  4.810  13.748 
N  25  25  25 
55-64 
years  
Mean 9 12.46 11 17.69 11 68.46 
Std. Deviation  4.719  4.768  17.343 
N  13  13  13 
65-69 
years  
Mean 6 7.67 9 14.67 9 50.67 
Std. Deviation  1.528  4.041  20.648 
N  3  3  3 
70-74 
years 
Mean 12 14.50 13 22.00 18 86.00 
Std. Deviation  3.536  1.414  46.669 
N  2  2  2 
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Normative data for the Controlled Oral Word Association Test 
Age groups Controlled Oral Word Association test  
Normative data Study sample 
16-59 years  Mean  111.94 111.81 
Std. Deviation 0.23 .840 
Education [range/mean 
(SD)] 
16-59 13.52 (2.79) 
N 242 278 
60-79 years 
 
Mean  111.92 111.79 
Std. Deviation 0.27 .774 
Education [range/mean 
(SD)] 
9-12 9.90 (2.13) 
N 292 29 
 
Normative data for the Rey Auditory Verbal Learning Test 
Age groups Rey auditory verbal learning test  
Normative data Study sample 
16-19 years  Mean  53.90 56.81 
Std. Deviation 6.70 11.11 
N 78 11 
20-29 years Mean  56.10 58.96 
Std. Deviation 7.30 6.75 
N 498 123 
30-39 years  Mean  53.60 58.81 
Std. Deviation 8.30 6.75 
N 1,081 109 
40-49 years  Mean  51.10 55.20 
Std. Deviation 8.60 9.48 
N 522 39 
50-59 years  Mean  47.60 54.11 
Std. Deviation 8.10 10.20 
N 161 18 
60-69 years  Mean  43.40 50.55 
Std. Deviation 7.70 10.33 
N 166 9 
70-79 years  Mean  37.10 46.00 
Std. Deviation 7.50 9.73 
N 143 1 
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Appendix N: Univariate Screening for Factors Associated with Cognitive 
Outcomes for the Total Study Sample and the Four Structural Complexity 
Groups  
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Univariate regression (screening) for factors associated with cognitive functioning in the total study sample (all groups combined) 
 TMT-A 
(β) 
TMT-B 
(β) 
COWA 
(β) 
STROO
P-W (β) 
WAIS-
III 
(β) 
 
GP-D 
(β) 
GP-ND 
(β) 
ERRO
R 
(β) 
CLR 
(β) 
NO 
CAT 
(β) 
FTM 
(β) 
 
TTC 
(β) 
SDMT 
W (β) 
 
SDMT-
O 
(β) 
 
RAVLT 
(β) 
Age  -.157** -.194** .169** -.022 -.018 -.041 .045 .092 -.086 -.113* .022 -.019 .075 -.025 .104 
Education 
(yrs) 
-.065 -.175** .286*** .238*** .531*** -.181** -.155** -
.311*** 
.294*** .288*** -.071 -.126* .303*** .257*** .258*** 
Gender  
(Males) 
-.011 -.032 .038 .035 .068 .173** .114* .023 -.050 -.094 .074 -.064 -.081 -.076 -
.232*** 
Employmen
t 
-.062 -
.200*** 
.090 .160** .142* -.017 -.015 -.045 .070 .025 -.012 -.069 
 
.215*** 
 
.103 
 
-.001 
 
ToF vs. 
Simple  
.071 
 
.210** 
 
-.108 
 
-.117* 
 
-.154 
 
.151* 
 
.094 
 
.147 
 
-.147 -.212** 
 
.136 
 
.027 
 
-.150 
 
-.096 
 
.013 
 
TGA vs. 
Simple 
.138 
 
.161* 
 
-.122 
 
-.162* 
 
-.147 
 
.158* 
 
.141 
 
.119 
 
-.130 
 
-.181** 
 
.086 
 
.050 
 
-.125 
 
-.078 
 
-.079 
 
SV vs. 
Simple 
.124 
 
.206** 
 
.028 
 
-.196** 
 
-.101 
 
.172* 
 
.116 
 
.075 
 
-.083 
 
-.120* 
 
.080 
 
.107 
 
-.103 
 
-.030 
 
-.007 
 
Arrhythmia  .023 
 
.055 
 
.059 
 
-.119* 
 
-.081 
 
.001 
 
.045 
 
.072 
 
-.095 
 
-.122* 
 
.044 
 
.030 
 
-.021 
 
-.066 
 
-.001 
 
Hypertensio
n  
-.107 
 
-.078 
 
.007 
 
-.012 
 
-.015 
 
-.070 
 
-.071 
 
.096 
 
-.103 
 
-.065 
 
-.046 
 
.015 
 
.061 
 
.017 
 
-.155** 
 
NYHA .032 
 
.112* 
 
-.058 
 
-.120* -.136* 
 
.033 
 
.097 
 
.087 
 
-.086 
 
-.120* 
 
.132* 
 
.106 
 
-.090 
 
-.093 
 
-.032 
 
Intervention
s total   
.061 
 
.159** 
 
.007 
 
-.042 
 
-.171** 
 
.031 
 
.012 
 
.071 
 
-.080 
 
-.106 
 
.072 
 
.038 
 
-.116* 
 
-.084 
 
.083 
 
Repair total -.009 
 
.024 
 
.016 
 
.002 
 
-.044 
 
-.012 
 
-.045 
 
.102 
 
-.102 
 
-.107 
 
.155*
* 
 
-.019 
 
-.030 
 
-.020 
 
-.008 
 
Palliation 
before 
repair 
.094 
 
.119* -.065 
 
-.144* 
 
-.162** 
 
.111 
 
.107 
 
.144* 
 
-.146* 
 
-.203 
 
.099 
 
.101 
 
-.144* 
 
-.067 
 
-.024 
 
Years since 
last 
operation 
-.043 
 
-.116* 
 
.010 
 
.012 
 
.055 
 
.022 
 
.053 
 
-.015 
 
.011 
 
-.023 
 
.098 
 
-.019 
 
.069 
 
.044 
 
.027 
 
 
  
      
447 
 
Univariate regression (screening) for factors associated with cognitive functioning in the total study sample (all groups combined) 
 TMT-A 
(β) 
TMT-B 
(β) 
COWA 
(β) 
STROO
P-W (β) 
WAIS-
III 
(β) 
 
GP-D 
(β) 
GP-ND 
(β) 
ERRO
R 
(β) 
CLR 
(β) 
NO 
CAT 
(β) 
FTM 
(β) 
 
TTC 
(β) 
SDMT 
W (β) 
 
SDMT-
O 
(β) 
 
RAVLT 
Post-op 
CNS  
.096 .188** 
 
-.135* -.244** -
.284*** 
.096 .127* .245*** -
.273*** 
-
.238*** 
-.057 .293*
* 
-
.224*** 
-.171** -.103 
Post-op 
infection  
.088 
 
.157** 
 
-.091 
 
-.184** 
 
-.188** 
 
.088 
 
.153** 
 
.156** 
 
-.187 
 
-
.204*** 
 
.086 
 
.105 
 
-
.202*** 
 
-.115* 
 
-.099 
 
Post-op VD .022 
 
.087 
 
.049 
 
-.121* 
 
-.047 
 
.022 
 
-.044 
 
.028 
 
-.040 
 
-.082 
 
.055 
 
-.027 
 
-.052 
 
-.069 
 
-.043 
 
HF clinic .076 
 
.098 
 
-.046 
 
-.159** 
 
-.148** 
 
.087 
 
.119* 
 
.093 
 
-.099 
 
-.125* 
 
.071 
 
.031 
 
-.073 
 
-.100 
 
-.096 
 
Pacemaker .138* 
 
.084 
 
.067 
 
-.056 
 
-.097 
 
-.014 
 
.013 
 
.044 
 
-.033 
 
-.027 
 
.031 
 
-.003 
 
-.072 
 
-.067 
 
-.048 
 
ACE 
medication  
.024 
 
.035 
 
-.067 
 
-.109 
 
-.140* 
 
.123* 
 
.186** 
 
.097 
 
-.109 
 
-.127* 
 
.034 
 
.007 
 
.000 
 
-.100 
 
-.186** 
 
Diuretic 
medication  
.101 
 
.001 
 
-.062 
 
-.108 
 
-.162** 
 
.061 
 
.121* 
 
.180** 
 
-.180** 
 
-.179** 
 
.031 
 
.217* 
 
-.098 
 
-.075 
 
-.047 
 
Beta 
blocker 
medication  
.064 
 
-.041 
 
-.009 
 
-.071 
 
-.013 
 
.041 
 
.010 
 
.086 
 
-.070 
 
-.118* 
 
.069 
 
.071 
 
.021 
 
-.014 
 
-.026 
 
Anti-
arrythmia 
medication 
.088 
 
.025 
 
.044 
 
-.049 
 
-.081 
 
.023 
 
 
.090 
 
.110 
 
-.134* 
 
-.162** 
 
.034 
 
.153*
* 
 
-.082 
 
-.064 
 
-.016 
 
Anti-
coagulant 
medication  
.060 
 
.056 
 
.041 
 
-.081 
 
-.097 
 
.012 
 
.026 
 
.089 
 
-.080 
 
-.079 
 
-.032 
 
.140* 
 
-.039 
 
-.065 
 
-.002 
 
RVEF -.030 
 
-.079 
 
.034 
 
.089 
 
.131* 
 
-.035 
 
-.035 
 
-.101 
 
.096 
 
.144* 
 
-.131* 
 
-.099 
 
.062 
 
.071 
 
.055 
 
LVEF -.022 
 
-.107 
 
.019 
 
.108 
 
.107 
 
-.025 
 
-.023 
 
-.154** 
 
.160** 
 
.190** 
 
-.113* 
 
-.140* 
 
.071 
 
.092 
 
.003 
 
Palliation 
total 
.097 .099 .032 -.091 -.095 .094 .111 .078 -.084 -.131* .076 .094 -.044 .017 .061 
Catheter lab 
total  
.000 
 
.083 
 
-.036 
 
-.002 
 
-.133* 
 
-.064 
 
-.046 
 
.069 
 
-.074 
 
-.115* 
 
.007 
 
.025 
 
-.115 
 
-.088 
 
-.101 
 
Medication 
total 
.040 .063 .033 
 
-.122* -.108 .051 .092 .135* -.134* -.175** .024 .140* 
 
-.035 
 
-.101 
 
-.041 
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Univariate regression (screening) for factors associated with cognitive functioning in the total study sample (all groups combined) 
 
 
TMT-A 
(β) 
TMT-B 
(β) 
COWA 
(β) 
STROO
P-W (β) 
WAIS-
III 
(β) 
GP-D 
(β) 
GP-ND 
(β) 
ERRO
R 
(β) 
CLR 
(β) 
NO 
CAT 
(β) 
FTM 
 (β) 
TTC 
 (β) 
SDM
T 
W (β) 
SDMT-
O 
(β) 
RAVLT 
Age at 
repair Q2 
0.058 
 
-0.03 
 
-0.016 
 
0.089 
 
0.129 
 
0.028 
 
0.056 
 
0.07 
 
0.013 
 
0.052 
 
0.146 
 
-0.087 
 
0.224 
 
0.300 
 
0.138 
 
Age at 
repair Q3 
-0.112 
 
-0.187 
 
-0.167* 
 
0.019 
 
-0.088 
 
0.09 
 
0.193 
 
0.103 
 
-0.002 
 
-0.076 
 
0.103 
 
0.213 
 
0.103 
 
0.019 
 
0.109 
 
Age at 
repair Q4 
-0.03 
 
-0.275 
 
0.063* 
 
-0.088 
 
-0.159 
 
0.013 
 
0.077 
 
-0.019 
 
0.058 
 
0.069 
 
0.044 
 
-0.11 
 
0.12 
 
0.149 
 
0.385 
 
Cyanosis 
days Q2 
0.109 
 
-0.057* 
 
-0.007 
 
0.045 
 
0.07 
 
-0.057 
 
-0.011 
 
0.06 
 
-0.068 
 
-0.083 
 
0.095 
 
-0.019 
 
-0.027 
 
0.15 
 
0.056 
 
Cyanosis 
days Q3 
0.006 
 
-
0.234** 
0.118* 
 
0.205 
 
0.028 
 
0.023* 
 
0.094 
 
0.12 
 
-0.056 
 
-0.063* 
 
0.068 
 
0.179 
 
0.021 
 
0.114 
 
0.141 
 
Cyanosis 
days Q4 
-0.101 
 
-0.199 
 
0.047* 
 
0.089 
 
-0.056 
 
0.125* 
 
0.334 
 
0.14 
 
-0.122 
 
-0.123* 
 
-0.034 
 
0.007 
 
-0.01 
 
0.072 
 
0.153 
 
Current 
saturation 
Q1 
0.027* 
 
0.001 
 
0.062 
 
-0.035* 
 
-0.02 
 
0.113 
 
0.029 
 
0.202 
 
-0.2 
 
-0.21 
 
0.05 
 
0.151 
 
-
0.059
* 
-0.04 
 
0.15 
 
Current 
saturation 
Q2 
N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Current 
saturation 
Q3 
-
0.189** 
 
-0.232* 
 
0.157 
 
0.001 
 
0.154 
 
-0.03 
 
-0.129 
 
-0.075 
 
0.082 
 
0.036 
 
0.115 
 
0.042 
 
0.199 
 
0.088 
 
0.121 
 
ICU days 
Q2 
0.08 -0.075 -0.041 0.155 -0.061 0.003 0.195 0.187 -0.107 -0.228 0.135 0.252 -0.041 -0.089 0.136 
ICU days 
Q3 
-0.121 -0.134 -0.135 0.135 -0.195 0.012 0.092 0.142 -0.129 -0.235 0.033 0.159 -0.033 -0.041 0.033 
ICU days 
Q4 
-0.019 0.036 -0.079 0.05 -0.208 0.117 0.248 0.147 -0.132 -0.166 0.086 0.181 -0.129 -0.169 -0.021 
CPB 
minutes Q2 
0.037 
 
-0.18 
 
-0.191 
 
0.143 
 
0.061 
 
0.005** 
 
-0.199 
 
-0.08 
 
0.052 
 
0.057 
 
-0.099 
 
-0.068 
 
0.121 
 
-0.002 
 
0.14 
 
CPB 
minutes Q3 
0.037 
 
-0.21 
 
-0.067 
 
0.313 
 
0.153 
 
-0.063* 
 
-0.158 
 
-0.085 
 
0.066 
 
0.057 
 
-0.156 
 
-0.065 
 
0.177 
 
0.217 
 
0.011 
 
CPB 
minutes Q4 
0.037 
 
-0.21 
 
-0.299 
 
0.085 
 
-0.121 
 
-0.049 
 
-0.086 
 
-0.015 
 
-0.02 
 
-0.134 
 
-0.093 
 
0.201 
 
0.02 
 
0.054 
 
-0.035 
 
HA minutes 
Q2 
0.227 
 
0.013* 
 
0.097 
 
-0.252 
 
0.094 
 
0.122 
 
-0.055 
 
-0.058 
 
0.00 
 
0.056 
 
-0.053 
 
-0.109 
 
0.017 
 
0.074 
 
-0.108 
 
HA minutes 
Q3 
-0.115 
 
-0.121 
 
0.169 
 
-0.053 
 
0.227 
 
-0.093 
 
-0.131 
 
-0.126 
 
0.052 
  
0.078 
 
-0.181 
 
-0.05 
 
0.203 
 
0.214 
 
0.026 
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Univariate regression (screening) for factors associated with cognitive functioning in the total study sample (all groups combined) 
 TMT-A 
(β) 
TMT-B 
(β) 
COWA 
(β) 
STROO
P-W 
(β) 
WAIS-
III 
(β) 
 
GP-D 
(β) 
GP-ND 
(β) 
ERRO
R 
(β) 
CLR 
(β) 
NO 
CAT 
(β) 
 
FTM 
 (β) 
 
TTC 
 (β) 
SDMT 
W (β) 
 
SDMT-
O (β) 
 
RAVLT 
HA minutes 
Q4 
0.031 
 
-0.057* 
 
0.096 
 
-0.149 
 
0.051 
 
-0.035 
 
-0.063 
 
0.078 
 
-0.097 
 
-0.075 
 
-0.121 
 
-0.069 
 
0.017 
 
0.083 
 
0.017 
 
In hospital 
days Q2 
-0.275* 
 
-0.285* 
 
0.014 
 
0.093* 
 
-0.059* 
 
0.012 
 
-0.031 
 
0.348* 
 
-0.35** 
 
-0.261 
 
0.137 
 
-0.087 
 
0.025 
 
-0.058 
 
-0.059 
 
In hospital 
days Q3 
-0.255 
 
-0.293* 
 
-0.052 
 
0.073 
 
0.011** 
 
-0.226 
 
-0.13 
 
0.286* 
 
-0.273* 
 
-0.28* 
 
-0.006 
 
0.133 
 
0.117** 
 
0.123 
 
0.163 
 
In hospital 
days Q4 
-0.123 
 
-0.233 
 
0.01 
 
0.193 
 
-0.016 
 
-0.07 
 
0.015 
 
0.219 
 
-0.217 
 
-0.28* 
 
0.081 
 
0.196 
 
0.083* 
 
0.067 
 
0.025 
 
PANAS PA -.058 
 
-
.217*** 
 
.163** 
 
.165** 
 
.260*** 
 
-.158** 
 
-.141* 
 
-.113* 
 
.109 
 
-.075 
 
.063 
 
.076 
 
.249*** 
 
.266*** 
 
.167* 
 
PANAS 
NA  
-.023 
 
.089 
 
.025 
 
-
.216*** 
 
-.156** 
 
-.053 
 
-.081 
 
.078 
 
-.074 
 
.126 
 
-.033 
 
-.081* 
 
-.086 
 
-.086 
 
-.035 
 
STAI .044 
 
.124* -.071 
 
-
.266*** 
 
-
.204*** 
 
.055 
 
.059 
 
.108 
 
-.092 
 
.057 
 
-.104 
 
-.014 
 
-.088 
 
-.118* 
 
-.046 
 
CESD  .011 
 
.073 
 
-.059 
 
-.183** 
 
-.174** 
 
.022 
 
-.022 
 
.111 
 
-.103 
 
.152 
 
-.062 
 
-.086* 
 
-.120* 
 
-.135* 
 
-.080 
Note - * p<0.05, **p<0.01, ***p<0.001, n/a- in adequate cell count to run analysis 
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Univariate regression (screening) for factors associated with cognitive functioning in the ToF sample  
 TMT-
A (β) 
TMT-B 
(β) 
COWA 
(β) 
STROO
P 
(β) 
WAIS-
III 
GP-D 
(β) 
GP-ND 
(β) 
ERRO
R 
(β) 
CLR 
(β) 
NO 
CAT 
(β) 
TTC 
(β) 
FTM 
(β) 
SDM
T 
W (β) 
SDMT 
O (β) 
RAVLT 
Age  -.103 -.264* .063 -.047 -.122 -.035 .086 .098 -.090 -.170 .061 .179* .119 -.022 .282 
Education 
(years) 
-.020 -.269* .324 .321** .596 -.219 -.102 -.315** .327** .288 -.176 .010* .394*
** 
.310 .264* 
Gender  
(Males) 
.005 -.124 .131 .249* .596 .006 .109 .091 -.130 -.193 -.011* .301*
* 
 
.092 
 
.088 
 
-.255 
 
Employment .011 -.330** 
 
.030 
 
.209 
 
.145 
 
-.070 
 
-.028 
 
-.007 
 
.050 
 
-.010 
 
-.047 
 
.094 
 
.326 
 
.153 
 
-.091* 
 
Arrhythmia  -.074 .084 .067 -.164 -.187 -.028 .149 .161 -.156* -.229 .045 .217 -
.139*
* 
-.239 -.009 
Hypertension  -.045 
 
.000 
 
.141 
 
.024 
 
-.117 
 
.012 
 
.188 
 
-.127 
 
.134 
 
.153 
 
-.024 
 
-.076 
 
.008 
 
-.121 
 
.039 
 
NYHA .035 
 
.162 
 
-.135 
 
.056 
 
-.184 
 
-.015 
 
.031 
 
.231* 
 
-.218* 
 
-.319 
 
.207* 
 
.281 
 
-.212 
 
-.181 
 
-.056 
 
Interventions 
total   
-.034 
 
.040 
 
-.003 
 
.052 
 
-.108 
 
-.118 
 
.006 
 
.174 
 
-.193 
 
-.177 
 
-.019 
 
.054 
 
-.083 
 
-.073 
 
.043 
 
Repair total .025 
 
.116 
 
-.061 
 
.027 
 
-.069 
 
-.031 
 
.030 
 
.128 
 
-.144 
 
-.142 
 
-.040 
 
.081 
 
-.018 
 
-.131 
 
-.130 
 
Palliation 
before repair 
-.004 
 
-.108 
 
.021 
 
.003 
 
-.025 
 
.027 
 
.065 
 
.154 
 
-.157 
 
-.144 
 
.059 
 
.035* 
 
.018 
 
.064 
 
.230 
 
Yrs since last 
intervention 
-.017 
 
-.208 
 
.081 
 
-.048 
 
.111 
 
.018 
 
-.066 
 
-.050 
 
.057 
 
.058 
 
.064 
 
.049 
 
.142 
 
.136 
 
.215 
 
Post-opCNs 
complication  
-.023 
 
.165 
 
.046 
 
-.320** 
 
-.111 
 
-.099 -.129 
 
.023 
 
-.034 
 
-.037 
 
-.077 
 
-.045 
 
-.147 
 
-.093 
 
.025 
 
Post-op 
infection  
-.106 
 
.021 
 
-.048 
 
.055 
 
-.056 
 
-.085 -.031 
 
.108 
 
-.142 
 
-.189 
 
-.019 
 
.095 
 
.025 
 
-.011 
 
-.040 
 
Post-op VD .008 
 
.109 
 
.013 
 
-.245* 
 
.009 
 
-.013 .022 
 
-.007 
 
.003 
 
-.132 
 
-.090* 
 
.241 
 
-.092 
 
-.075 
 
-.096 
 
HF clinic -.069 -.126 .056 .016 .076 -.069 .024 .060 -.078* -.284 .037* .343 .062 .053 .032 
ACE 
medication  
-.065 
 
-.015 
 
-.112 
 
.107 
 
-.111 
 
.077 
 
.223* 
 
.134 
 
-.130* 
 
-.221* 
 
.232 
 
.216 
 
-.075 
 
-.063 
 
-.015 
 
Diuretic 
medication  
-.048 
 
.041 
 
-.207 
 
.108 
 
-.095 
 
-.063 
 
.081 
 
.083 
 
-.094 
 
-.155 
 
.209 
 
.076 
 
-.088 
 
.060 
 
.069 
 
Beta blocker 
medication  
.015 -.055 
 
.146 
 
-.031 
 
-.027 
 
-.077 
 
.033 
 
.035 
 
-.035 
 
-.140 
 
-.095* 
 
.258 
 
-.029 
 
-.165 
 
.009 
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Univariate regression (screening) for factors associated with cognitive functioning in the ToF sample (continued) 
 TMT-
A (β) 
TMT-B 
(β) 
COWA 
(β) 
STROO
P 
(β) 
WAIS-
III 
GP-D 
(β) 
GP-ND 
(β) 
ERRO
R 
(β) 
CLR 
(β) 
NO 
CAT 
(β) 
TTC 
(β) 
FTM 
(β) 
SDM
T 
W (β) 
SDMT 
O (β) 
RAVLT 
Anti-
arrythmia 
medication 
-.043 
 
-.079 
 
.137 
 
.072 
 
.103 
 
-.165 
 
-.036 
 
.015 
 
-.038 
 
-.189 
 
-.092 
 
.211 
 
.007 
 
.010 
 
.071 
 
Anti-
coagulant 
medication  
.074 
 
.082 
 
-.139 
 
.096 
 
-.167 
 
-.020 
 
.036 
 
.095 
 
-.054 
 
-.107* 
 
.233* 
 
.243 
 
-.126 
 
-.099 
 
-.039 
 
RVEF .024 
 
-.029 
 
-.020 
 
-.123 
 
.033 
 
.060 
 
-.002 
 
-.004 
 
-.035 
 
.033 
 
-.007 
 
-.097 
 
.012 
 
.046 
 
.054 
 
LVEF .008 
 
-.094 
 
.011 
 
-.011 
 
.102 
 
.060 
 
-.050 
 
-.123 
 
.162* 
 
.231 
 
-.182 
 
-.151 
 
.129 
 
.127 
 
.014 
 
Palliation 
total 
.025 
 
-.096 
 
.033 
 
-.013 
 
-.016 
 
.046 
 
.078 
 
.179 
 
-.184 
 
-.159 
 
.067 
 
.018*
* 
 
.001 
 
.063 
 
.233 
 
Catheter lab 
total  
-.065 
 
.023 
 
.054 
 
.146 
 
-.062 
 
-.130 
 
-.034 
 
.068 
 
-.092 
 
-.150 
 
-.023 
 
.116 
 
-.084 
 
-.012 
 
-.021 
 
Medication 
total 
-.017 
 
.036 
 
.040 
 
.062 
 
-.169 
 
-.049 
 
.146 
 
.125 
 
-.098* 
 
-.265 
 
.150* 
 
.336 
 
-.114 
 
-.103 
 
.041 
 
Age at 
repairQ2 
.002 
 
-.253 
 
-.242 
 
.287 
 
.233 
 
-.239 
 
-.243 
 
.116 
 
-.006 
 
-.046 
 
-.013 
 
-.014 
 
.165 
 
.302 
 
.149* 
 
Age at 
repairQ3 
-.192 
 
-.282 
 
-.291 
 
.129 
 
-.051 
 
-.108 
 
-.002 
 
.144 
 
-.033 
 
-.125 
 
.044 
 
.140 
 
.111 
 
.144 
 
.225* 
 
Age at 
repairQ4 
.093 
 
-.204 
 
.113 
 
-.016 
 
-.057 
 
-.188 
 
-.087 
 
-.035 
 
.102 
 
.065 
 
-.083 
 
-.053 
 
.061 
 
.110 
 
.319* 
 
Cyanosis 
days Q2 
-.329 
 
-.750 
 
-.025 
 
1.886 
 
.895 
 
.096 
 
-.136* 
 
-.099 
 
.068 
 
.123 
 
.131 
 
.109 
 
1.258 
 
.715 
 
-.270 
 
Cyanosis 
days Q3 
-.393 
 
-1.127 
 
.010 
 
2.383 
 
1.093 
 
.008 
 
-.175* 
 
-.046 
 
.030 
 
.014 
 
.256 
 
.337 
 
1.510 
 
.994 
 
-.194 
 
Cyanosis 
days Q4 
-.549 
 
-1.141 
 
.095 
 
2.242 
 
.986 
 
.171 
 
.059* 
 
.000 
 
.029 
 
.057 
 
.101 
 
.250 
 
1.455 
 
.945 
 
-.026 
 
Current 
saturationQ1 
.089 
 
.232 
 
-.084 
 
-.067 
 
-.188 
 
.204 
 
.086 
 
.304 
 
-.310 
 
-.236 
 
.147 
 
.007 
 
-.286 
 
-.231 
 
.025 
 
Current 
saturationQ2 
-.034 
 
-.182 
 
.152 
 
.005 
 
.122 
 
-.006 
 
-.028 
 
.035 
 
-.029 
 
-.101 
 
-.048 
 
.202 
 
.147 
 
.128 
 
.186 
 
Current 
saturationQ3 
-.189 
 
-.232 
 
.157 
 
.001 
 
.154 
 
-.030 
 
-.129 
 
-.075 
 
.082 
 
.036 
 
.115 
 
.042 
 
.199 
 
.088 
 
.121 
 
ICU days Q2 -.124 
 
-.389 
 
.341 
 
.088 
 
.198 
 
-.221 
 
.030 
 
-.065 
 
.123 
 
.018 
 
.144 
 
.276 
 
.168 
 
.271 
 
.241 
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Univariate regression (screening) for factors associated with cognitive functioning in the ToF sample (continued) 
 TMT-
A (β) 
TMT-B 
(β) 
COWA 
(β) 
STROO
P 
(β) 
WAIS-
III 
GP-D 
(β) 
GP-ND 
(β) 
ERRO
R 
(β) 
CLR 
(β) 
NO 
CAT 
(β) 
TTC 
(β) 
FTM 
(β) 
SDM
T 
W (β) 
SDMT 
O (β) 
RAVLT 
ICU days Q3 -.231 
 
-.360 
 
.103 
 
.135 
 
-.043 
 
-.133 
 
.039 
 
.030 
 
-.009 
 
-.138 
 
.077 
 
.245 
 
.093 
 
.170 
 
.140 
 
ICU days Q4 -.129 
 
-.190 
 
.159 
 
.050 
 
-.056 
 
-.029 
 
.196 
 
.036 
 
-.012 
 
-.069 
 
.130 
 
.267 
 
-.003 
 
.042 
 
.086 
 
 
CPB minutes 
Q2 
.056 
 
.077 
 
.037 
 
.001 
 
.056 
 
.147 
 
.060 
 
-.020 
 
.043 
 
.169 
 
.140 
 
-.295 
 
-.004 
 
-.002 
 
.042 
 
CPB 
minutesQ3 
-.002 
 
-.335 
 
.189 
 
.233 
 
.247 
 
-.086 
 
-.126 
 
-.182 
 
.230 
 
.220 
 
-.014 
 
-.101 
 
.313 
 
.217 
 
.171 
 
CPB minutes 
Q4 
-.032 
 
-.025 
 
.069 
 
.213 
 
.147 
 
-.056 
 
-.526 
 
-.132 
 
.130 
 
.203 
 
-.017 
 
-.103 
 
.013 
 
.054 
 
.134 
 
HA minutes 
Q2 
.277 
 
.433 
 
.035 
 
-.257 
 
-.411 
 
.189 
 
.165 
 
-.105 
 
.030 
 
.160 
 
-.027 
 
-.220 
 
-.447 
 
-.241 
 
-.193 
 
HA minutes 
Q3 
.106 
 
.183 
 
.219 
 
-.160 
 
-.101 
 
-.062 
 
-.060 
 
-.341 
 
.283 
 
.346 
 
-.189 
 
-.195 
 
-.125 
 
.057 
 
.007 
 
HA minutes 
Q4 
.112 
 
.210 
 
.079 
 
-.218 
 
-.272 
 
-.029 
 
.028 
 
-.029 
 
-.004 
 
.061 
 
-.132 
 
-.159 
 
-.273 
 
-.078 
 
-.028 
 
In hospital 
Days Q2 
-.133 
 
.061 
 
.149 
 
-.027 
 
-.150 
 
-.150 
 
.030 
 
.196 
 
-.246 
 
-.141 
 
.071 
 
-.100 
 
-.232 
 
-.387 
 
.024 
 
In hospital 
days Q3 
-.358 
 
-.146 
 
-.096 
 
-.091 
 
-.169 
 
-.206 
 
.064 
 
.426 
 
-.428 
 
-.404 
 
.182 
 
.077 
 
-.102 
 
-.265 
 
.023 
 
In hospital 
days Q4 
-.225 
 
-.130 
 
.155 
 
.108 
 
-.067 
 
-.156 
 
.115 
 
.310 
 
-.339 
 
-.327 
 
.099 
 
.117 
 
-.104 
 
-.160 
 
.075 
 
PANAS PA .057 
 
-.376** 
 
.050 
 
.161 
 
.150 
 
-.227 
 
-.116 
 
-.110 
 
.117 
 
.052 
 
-.085 
 
.106 
 
.241* 
 
.222 
 
.082 
 
PANAS NA  -.068 .089 .008 -.301** -.122 -.227 .004 -.010 -.011 .038 
 
.054 -.140 
 
-.207 
 
-.087 
 
.135 
 
STAI -.044 
 
.157 
 
-.112 
 
-.344** 
 
-.192 
 
.016 
 
.078 
 
-.022 
 
.014 
 
.136 
 
-.034 -.261* 
 
-.098 
 
-.084 
 
.206 
 
CESD  -.003 
 
.109 
 
-.006 
 
-.250* 
 
-.120 
 
.155 
 
-.007 
 
-.024 
 
.032 
 
.061 
 
.017 -.093 
 
-.128 
 
-.129 
 
.071 
 
Note - * p<0.05, **p<0.01, ***p<0.001, n/a- in adequate cell count to run analysis 
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Univariate regression (screening) for factors associated with cognitive functioning in the TGA sample  
 TMT-A 
(β) 
TMT-
B 
(β) 
COWA 
(β) 
STROO
P (β) 
WAIS-
III 
GP-D 
(β) 
GP-ND 
(β) 
ERRO
R (β) 
CLR 
(β) 
NO 
CAT 
 (β) 
TTC 
 (β)  
FTM 
(β) 
 
SDM
T W 
(β) 
SDMT 
O (β) 
RAVLT 
Age  -0.139 
 
-0.191 
 
0.103 
 
-0.06 
 
-.093 
  
-.018 
 
.044 
 
.142 
 
-.139 
 
-.213 
 
-.076 
 
0.128 
 
0.107 
 
0.018 
 
-.097 
 
Education 
(years) 
-0.042 
 
-0.142 
 
0.229* 
 
0.27* 
 
.496*** 
 
-.320** 
 
-.232* 
 
-.219 
 
.171 
 
.262* 
 
-.059 
 
-
0.233
* 
0.291
** 
0.269* 
 
.424*** 
 
Gender  
(Males) 
-0.151 
 
-0.053 
 
0.094 
 
-0.018 
 
.080 
 
.074 
 
.055 
 
.088 
 
-.072 
 
-.130 
 
-.097 
 
0.069 -0.114 -0.132 
 
-.253* 
 
Employment -0.286* -
.303*
* 
0.261* 
 
0.218 
 
.297* 
 
-.182 
 
-.136 
 
-.005 
 
.004 
 
.000 
 
-.012 
 
-0.182 0.226
* 
0.239* 
 
.102 
 
Arrhythmia  -0.078 
 
-0.152 
 
0.1 
 
-0.035 
 
.006 -.021 
 
-.053 
 
-.037 
 
.039 
 
.011 
 
-.041 
 
-0.036 
 
0.121 0.058 
 
.036 
 
Hypertension  -0.096 -0.022 
 
-0.007 
 
-0.055 
 
.086 
 
-.086 
 
-.146 
 
.145 
 
-.179 
 
-.203 
 
.101 
 
0.055 
 
0.104 0.127 
 
-.027 
 
NYHA 0.008 
 
-0.043 
 
-0.058 
 
-0.055 
 
-.066 
 
.087 
 
.165 
 
.086 
 
-.072 
 
-.100 
 
.054 
 
0.201 
 
0.054 -0.005 
 
-.064 
 
Interventions 
total   
0.052 
 
0.015 
 
-0.061 
 
-0.108 
 
-.168 
 
.093 
 
.043 
 
.106 
 
-.077 
 
-.048 
 
-.031 
 
0.009 
 
-0.068 -0.12 
 
-.064 
 
Repair total 0.035 
 
0.041 
 
-0.022 
 
-0.108 
 
-.305** 
 
.033 
 
-.003 
 
.240* 
 
-.222* 
 
-.206 
 
.037 
 
0.158 
 
-0.177 -0.233* 
 
-.044 
 
Palliation 
before repair 
-0.031 0.106 
 
-0.121 
 
-0.125 
 
-.207 
 
.069 
 
.011 
 
.079 
 
.120 
 
-.120 
 
.054 
 
0.008 
 
-0.25* -0.237* 
 
-.255* 
 
Yrs since last 
intervention 
-0.072 0.041 
 
0.038 
 
0.093 
 
.056 
 
-.106 
 
-.015 
 
-.098 .075 .005 -.028 0.066 
 
 
0.072 0.091 
 
-.051 
 
Post-opCNs 
complication  
0.066 
 
0.334
** 
-0.106 
 
-0.299 
 
-.306** 
 
.243* 
 
.267* 
 
.319** 
 
-.344** 
 
-.270* 
 
.334*
* 
 
-0.085 
 
-
0.289
** 
-0.239* 
 
-.079 
 
Post-op 
infection  
0.058 
 
0.16 
 
-0.062 
 
-0.391 
 
-.222* 
 
.147 
 
.227* .187 
 
-.207 
 
-.175 
 
.184 
 
0.039 
 
-
0.277
* 
-0.22 
 
-.132 
 
Post-op VD 0.067 
 
0.028 
 
0.055 
 
-0.05 
 
-.151 
 
-.020 
 
-.092 
 
.065 
 
-.085 
 
-.072 
 
.027 
 
-0.025 -0.079 -0.055 
 
.068 
 
HF clinic 0.034 
 
0.17 
 
-0.148 
 
-0.137 
 
-.262* 
 
.201 
 
.192 
 
.190 
 
-.157 
 
-.157 
 
-.029 
 
0.089 -0.141 -0.205 
 
-.226* 
 
Pacemaker 0.136 0.15 0.049 -0.083 -.164 .044 .021 .226* -.210 -.133 .039 0.124 -0.063 -0.085 -.047 
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Univariate regression (screening) for factors associated with cognitive functioning in the TGA sample (continued) 
 TMT-
A (β) 
TMT-B 
(β) 
COWA 
(β) 
STROO
P 
(β) 
WAIS-
III 
GP-D 
(β) 
GP-ND 
(β) 
ERRO
R (β) 
CLR 
(β) 
NO 
CAT  
(β) 
TTC 
 (β)  
FTM 
(β) 
 
SDM
T W 
(β) 
SDMT 
O (β) 
RAVLT 
ACE 
medication  
0.028 
 
0.038 
 
-0.122 
 
-0.157 
 
-.091 
 
.282* 
 
.284* 
 
.173 
 
-.171 
 
-.256* 
 
-.028 
 
0.15 0.045 -0.027 
 
-.071 
 
Diuretic 
medication  
0.059 
 
-0.108 
 
-0.111 
 
-
0.318** 
 
-.240* 
 
.016 
 
.081 
 
.288** 
 
-.245* 
 
-.216 
 
.033 
 
0.015 -0.013 -0.013 
 
-.054 
 
Beta blocker 
medication  
-0.086 
 
-0.137 
 
-0.042 
 
-0.056 
 
.019 
 
-.055 
 
-.056 
 
.014 
 
.022 
 
-.002 
 
-.002 
 
-0.069 0.197 0.078 
 
.013 
 
Anti-
arrythmia 
medication 
0.094 
 
-0.024 
 
0.002 
 
-0.048 
 
-.147 
 
-.078 
 
.021 
 
.174 
 
-.175 
 
-.157 
 
.046 
 
0.048 0.047 0.013 -.033 
 
Anti-
coagulant 
medication  
0.049 
 
0.018 
 
-0.185 
 
-0.214 
 
-.234* 
 
.099 
 
.117 
 
.096 
 
-.046 
 
-.059 
 
-.075 
 
-0.063 -0.025 -0.082 -.063 
 
RVEF 0.032 
 
-0.109 
 
0.043 
 
0.323** 
 
.264* 
 
-.099 
 
-.072 
 
-.267* 
 
.259* 
 
.335** 
 
-.147 
 
-
0.324
** 
0.151 0.149 .184 
 
LVEF -0.021 -0.123 
 
0.021 
 
0.251* 
 
.175 
 
-.153 
 
-.088 
 
-.300** 
 
.289** 
 
.315** -.094 
 
-0.173 0.183 0.231* .150 
 
Palliation 
total 
0.187 0.019 0.03 -0.002 -.089 .033 .138 -.093 .090 .033 .013 0.002 0.028 0.105 -.187 
Catheter lab 
total  
-0.293 
 
-0.078 
 
-0.026 
 
-0.116 
 
-.073 
 
-.097 
 
-.169 
 
.166 
 
-.150 
 
-.147 
 
.074 
 
0.011 -0.073 -0.103 -.015 
 
Medication 
total 
0.027 0.081 -0.12 -0.181 -.121 .151 .162 .178 
 
-.165 
 
-.182 
 
.134 
 
-0.047 0.028 -0.077 .100 
 
Age at repair 
Q2 
.029 .199* -.165 -.206 -.098 -.009 -.200 .091 
 
-.086 
 
-.114 
 
.191 
 
-.068 
 
-.052 
 
-.033 
 
-.224 
 
Age at repair 
Q3 
.002 
 
.151* 
 
.025 
 
-.191 
 
-.068 
 
-.056 
 
-.032 
 
-.041 
 
.037 
 
.045 
 
-.024 
 
.055 
 
-.116 
 
-.040 
 
-.080 
 
Age at repair 
Q4 
-.174 
 
-.188* 
 
.022 
 
-.204 
 
-.010 
 
-.044 
 
-.125 
 
.101 
 
-.107 
 
-.255 
 
.054 
 
.216 
 
.071 
 
.110 
 
-.141 
 
Cyanosis 
days Q2 
.011 
 
.311* 
 
-.285 
 
-.266 
 
-.220 
 
.228 
 
.058 
 
.080 
 
-.082 
 
-.137 
 
.176 
 
.012 
 
-.221 
 
-.154 
 
-.349** 
 
Cyanosis 
days Q3 
-.093 
 
.175* 
 
.038 
 
-.289 
 
-.096 
 
-.020 
 
.028 
 
.074 
 
-.078 
 
-.091 
 
.028 
 
.083 
 
-.136 
 
-.073 
 
-.090 
 
Cyanosis 
days Q4 
-.092 
 
-.121* 
 
-.117 
 
-.277 
 
-.145 
 
.055 
 
-.074 
 
.149 
 
-.135 
 
-.251 
 
.077 
 
.189 
 
.009 
 
.029 
 
-.306* 
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Univariate regression (screening) for factors associated with cognitive functioning in the TGA sample (contined) 
 TMT-
A (β) 
TMT-B 
(β) 
COWA 
(β) 
STROO
P (β) 
WAIS-
III 
GP-D 
(β) 
GP-ND 
(β) 
ERRO
R (β) 
CLR 
(β) 
NO 
CAT  
(β) 
TTC 
 (β)  
FTM 
(β) 
 
SDM
T W 
(β) 
SDMT 
O (β) 
RAVLT 
Current 
saturation Q1 
.154 
 
.030 
 
-.122 
 
-.141 
 
-.167 
 
.049 
 
-.038 
 
-.074 
 
.056 
 
-.046 
 
.001 
 
.102 
 
-.008 
 
-.046 
 
-.210 
 
Current 
saturation Q2 
-.016 
 
-.003 
 
-.049 
 
.012 
 
.020 
 
.153 
 
.145 
 
.015 
 
-.017 
 
-.098 
 
-.023 
 
.096 
 
-.034 
 
-.010 
 
-.055 
 
Current 
saturation Q3 
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
ICU days Q2 .048 
 
.176 
 
-.170 
 
.063 
 
-.085 
 
.002 
 
-.124 
 
-.086 
 
.104 
 
.172 
 
-.002 
 
-.259 
 
-.173 
 
-.185 
 
.057 
 
ICU days Q3 -.034 
 
.109 
 
-.100 
 
.036 
 
.010 
 
.108 
 
-.061 
 
-.019 
 
.017 
 
.027 
 
.020 
 
-.239 
 
-.031 
 
-.089 
 
.103 
 
ICU days Q4 .071 .115 -.110 -.216 -.196 -.061 -.063 .077 -.098 -.139 .267 -.047 -.213 -.206 -.015 
CPB minutes 
Q2 
.263* 
 
.128 
 
.129 
 
-.058* 
 
-.157* 
 
-.116 
 
-.122 
 
.166 
 
-.190 
 
-.082 
 
.156 
 
.033 
 
-.059 
 
-.263* 
 
.134 
 
CPB minutes 
Q3 
-.092* -.187 .328 .304* .349** -.164 -.144 -.018 .007 -.082 -.038 .051 .257 .001 .216 
CPB minutes 
Q4 
.065*
* 
-.112 
 
.104 
 
.090* 
 
.224* 
 
-.157 
 
-.110 
 
-.073 
 
.050 
 
.113 
 
.018 
 
.096 
 
.198 
 
-.025 
 
.347 
 
HA minutes 
Q 2 
.044 .000 -.046 .163 .189 -.176 -.061 -.182 .194 .259 -.222 -.136 .025 .067 .142 
HA minutes 
Q3 
.079 
 
.000 
 
-.039 
 
.041 
 
.035 
 
-.233 
 
-.185 
 
-.188 
 
.138 
 
.162 
 
-.182 
 
-.057 
 
.025 
 
.142 
 
.107 
 
HA minutes 
Q4 
-.206 
 
-.273 
 
.063 
 
.189 
 
.239 
 
-.313 
 
-.194 
 
-.058 
 
.049 
 
.098 -.202 
 
-.051 
 
.224 
 
.177 
 
.343 
 
In hospital 
days Q2 
.177 
 
.206 
 
-.071 
 
-.094 
 
-.150 
 
.034 
 
.056 
 
.136 
 
-.144 
 
-.108 
 
.026 
 
.089 -.246 
 
-.268 
 
-.053 
 
In hospital 
days Q3 
.169 
 
.206 
 
.026 
 
-.245 -.199 
 
.086 
 
.056 
 
.067 
 
-.025 
 
-.019 
 
.024 -.075 
 
-.230 
 
-.205 
 
-.162 
 
In hospital 
days Q4 
.114 
 
.189 
 
-.116 
 
-.310 
 
-.227 .330 
 
.405** 
 
.317 
 
-.312 
 
-.263 
 
.243 .091 
 
-.265 
 
-.286 
 
-.081 
 
PANAS PA -0.047 
 
-0.147 
 
0.086 
 
0.09 
 
.137 
 
-.168 
 
-.221* 
 
.075 
 
-.071 
 
-.086 
 
.033 
 
0.072 0.128 0.171 -.014 
 
PANAS NA -0.198 -0.119 0.386**
* 
-0.121 .062 -.105 -.162 .111 -.120 -.118 .349*
* 
-0.031 0.259
* 
0.124 .046 
 
STAI 0.025 0.015 0.171 -0.141 -.041 .138 .154 .164 -.142 .034 .044 -0.121 0.037 0.035 -.012 
CESD  -0.059 0.029 0.082 -0.141 -.007 .089 .013 .159 -.164 -.142 .347*
* 
-0.105 
 
0.06 -0.034 .003 
 
Note - * p<0.05, **p<0.01, ***p<0.001, n/a- in adequate cell count to run analysis 
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Univariate regression (screening) for factors associated with cognitive functioning in the SV sample  
 TMT-
A (β) 
TMT-B 
(β) 
COWA 
(β) 
STROOP 
(β) 
WAIS-III GP-D 
(β) 
GP-ND 
(β) 
ERROR 
(β) 
CLR (β) TTC 
(β) 
FTM 
(β) 
NO CAT 
(β) 
SDMT 
W (β) 
SDMT 
O (β) 
RAVLT 
Age  -.149 
 
-.188 
 
.274* 
 
-.031 .183 .100 .044 .142 -.139 -.057 .004 .083 
 
.127 .020 .258* 
 
Education 
(years) 
-.170 
 
-.050 
 
.333** 
 
.211 .497*** 
 
-.129 
 
-.232 
 
-.219* 
 
.171* 
 
-.123 
 
.092 
 
.285* 
 
.255* 
 
.244 
 
.251* 
 
Gender  
(Males) 
.055 
 
.045 
 
.121 
 
.035 .037 
 
.187 
 
.055 
 
.088 
 
-.072 
 
-.083 
 
-.031 
 
.074 
 
-.189 
 
-.110 
 
-.087 
 
Employment .073 
 
-.037 
 
.127 
 
.024 .112 
 
.088 
 
-.136 
 
-.005 
 
.004 
 
-.088 
 
.102 
 
.043 
 
.254* 
 
.028 
 
-.027 
 
Arrhythmia  .067 
 
.047 
 
.120 
 
.049 .040 
 
-.118 
 
-.053 
 
-.037 
 
.039 
 
.050 
 
-.080 
 
-.128 
 
.053 
 
.014 
 
.048 
 
Hypertension  -.052 
 
-.058 .054 .010 -.058 .043 -.146 .145* -.179* -.024 .011 -.181 -.055 .074 -.181 
NYHA .003 .189 -.102 -.079 -.175 -.036 .165 .086 -.072 .056 .028 .036 -.124 -.093 .056 
Interventions 
total   
-.025 
 
.206 
 
.147 
 
.176 -.126 
 
-.153 
 
.043 
 
.106 
 
-.077 
 
.057 
 
.046 
 
-.032 
 
-.043 
 
-.018 
 
-.062 
Repair total .040 -.083 .068 .068 .004 -.147 -.003 .240 -.222 -.015 .180 -.142 .031 .124 -.052 
Palliation 
before repair 
.050 
 
.161 
 
-.119 
 
.015 -.247* 
 
-.084 
 
.011 
 
.079 
 
-.051 
 
.112 
 
.233 
 
-.337** 
 
-.138 
 
-.010 .051 
Yrs since last 
intervention 
-.017 
 
-.095 
 
-.084 
 
-.046 .028 
 
-.064 
 
-.015 
 
-.098 
 
.075 
 
.031 
 
.301* 
 
-.240 
 
.026 
 
.061 
 
.121 
Post-opCNs 
complication  
.198 
 
.043 
 
-.390* 
 
-.082 -.522*** 
 
.085 
 
.267 
 
.319** 
 
-.344** 
 
.452*** 
 
-.117 
 
-.462*** 
 
-.224 
 
-.210 
 
-.322** 
Post-op 
infection  
.322** 
 
.324** 
 
-.168 
 
-.227 -.304* 
 
.168 
 
.227* 
 
.187* 
 
-.207* 
 
.111 
 
.122 
 
-.322** 
 
-.366* 
 
-.127 
 
-.212 
Post-op VD .017 
 
.107 
 
.115 
 
-.035 
 
.012 
 
-.104 
 
-.092 
 
.065 
 
-.085 
 
-.097 
 
-.053 
 
-.037 
 
.020 
 
-.179 
 
-.154 
 
HF clinic .103 
 
.124 
 
.065 
 
-.210 -.160 
 
-.021 
 
.192 
 
.190 
 
-.157 
 
.028 
 
-.139 
 
.025 
 
-.017 
 
-.106 
 
.004 
 
Pacemaker .277* 
 
.095 .175 
 
-.048 
 
-.027 
 
-.063 
 
.021 
 
.226 
 
-.210 
 
-.079 -.014 
 
.052 
 
-.115 
 
-.195 
 
-.059 
ACE 
medication  
.058 
 
.101 -.120 
 
-.137 
 
-.242 
 
.066 
 
.284 
 
.173 
 
-.171 
 
.003 
 
-.088 
 
-.053 
 
.057 
 
-.154 
 
-.233 
Diuretic 
medication  
.298* 
 
-.098 -.117 
 
-.026 
 
-.209 
 
.236 
 
.081 
 
.288* 
 
-.245 
 
.414** 
 
.063 
 
-.202 
 
-.158 
 
-.135 
 
-.098 
Beta blocker 
medication  
.326** 
 
.058 -.155 
 
-.010 -.095 
 
.217 
 
-.056 .014* 
 
.022* 
 
.160 
 
.048 
 
-.329* 
 
-.217 
 
-.144 
 
-.010 
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Univariate regression (screening) for factors associated with cognitive functioning in the SV sample (continued) 
 TMT-
A (β) 
TMT-B 
(β) 
COWA 
(β) 
STROOP 
(β) 
WAIS-III GP-D 
(β) 
GP-ND 
(β) 
ERROR 
(β) 
CLR (β) TTC (β) FTM 
(β) 
NO CAT 
(β) 
SDMT 
W (β) 
SDMT 
O (β) 
RAVLT 
Anti-
arrythmia 
medication 
.121 
 
.029 -.027 
 
-.041 -.117 
 
.098 
 
.021 .174 
 
-.175 
 
.303* 
 
-.133 
 
-.199 
 
-.202 
 
-.187 
 
-.066 
 
Anti-
coagulant 
medication  
-.034 
 
-.127 
 
.198 
 
.036 .070 
 
-.222 
 
.117 .096 
 
-.046 
 
.113 
 
-.281* 
 
.003 
 
.111 
 
-.055 
 
.048 
 
RVEF .003 
 
.041 -.153 
 
-.021 -.033 
 
.119 
 
-.072 -.267 
 
.259 
 
-.123 
 
.113 
 
-.080 
 
-.099 
 
.011 
 
-.009 
 
LVEF .032 
 
-.016 -.101 
 
-.035 -.037 .131 -.088 -.300 
 
.289 -.109 -.006 -.035 -.112 -.007 -.049 
 
Palliation 
total 
-.004 .164 
 
-.019 
 
-.020 
 
-.124 
 
-.041 
 
.138 -.093 
 
.090 
 
.115 
 
.164 
 
-.204 
 
.018 
 
-.049 
 
.177 
 
Catheter lab 
total  
.084 .207 
 
-.013 
 
.079 
 
-.105 
 
-.044 
 
-.169 .166 
 
-.150 
 
.004 
 
-.125 
 
-.018 -.127 
 
-.061 
 
-.133 
Medication 
total 
.071 -.019 .060 -.021 
 
-.057 
 
-.070 
 
.162 .178 
 
-.165 
 
.075 
 
-.244 
 
-.117 -.026 
 
-.183 
 
-.128 
Age at 
repair Q2 
-.107 
 
-.263 
 
.226 
 
.061 
 
.291 
 
-.138 
 
-.138 
 
.069 
 
-.016 
 
.001 
 
.005 
 
-.084 
 
.285 
 
.169 
 
.396 
 
Age at 
repair Q3 
-.116 
 
-.187 
 
.308 
 
.023 
 
.220 
 
-.173 
 
-.180 
 
.090 
 
-.032 
 
.004 
 
-.173 
 
-.094 
 
.094 
 
-.115 
 
.219 
 
Age at 
repair Q4 
-.151 
 
.018 
 
.224 
 
.112 
 
.166 
 
-.030 
 
-.064 
 
-.110 
 
.114 
 
.201 
 
-.125 
 
-.323 
 
.158 
 
-.039 
 
.220 
 
Cyanosis 
days Q2 
.035 
 
-.151 
 
-.202 
 
-.111 
 
-.260 
 
.168 
 
.222 
 
.167 
 
-.136 
 
-.002 
 
.175 
 
-.216 
 
-.115 
 
-.109 
 
-.170 
 
Cyanosis 
days Q3 
-.142 
 
-.184 
 
.101 
 
.106 
 
-.020 
 
.018 
 
.020 
 
.099 
 
-.077 
 
.029 
 
.067 
 
-.211 
 
.016 
 
-.056 
 
-.163 
 
Cyanosis 
days Q4 
.086 
 
.004 
 
.098 
 
-.158 
 
-.203 
 
.163 
 
.202 
 
-.091 
 
.140 
 
.215 
 
.094 
 
-.274 
 
-.262 
 
-.192 
 
-.079 
 
Current 
saturation 
Q1 
.140 
 
.067 
 
-.018 
 
-.150 
 
-.155 
 
.130 
 
.135 
 
-.062* 
 
.145 
 
.109 
 
-.201 
 
.150 
 
-.249 
 
-.304* 
 
.149 
 
Current 
saturation 
Q2 
.190 
 
.030 
 
-.143 
 
-.245 
 
-.224 
 
.128 
 
.150 
 
.356 
 
-.331* 
 
.326 
 
-.228 
 
-.215 
 
-.348 
 
-.360* 
 
.187 
 
Current 
saturation 
Q3 
.143 .025 .079 
 
.011 
 
.097 
 
-.006 
 
-.041 
 
-.047 
 
.097 
 
.029 
 
-.064 
 
.102 
 
-.188 
 
-.068 
 
.358 
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Univariate regression (screening) for factors associated with cognitive functioning in the SV sample (continued) 
 TMT-
A (β) 
TMT-B 
(β) 
COWA 
(β) 
STROOP 
(β) 
WAIS-III GP-D 
(β) 
GP-ND 
(β) 
ERROR 
(β) 
CLR (β) TTC 
(β) 
FTM 
(β) 
NO CAT 
(β) 
SDMT 
W (β) 
SDMT 
O (β) 
RAVLT 
ICU days 
Q2 
-.048 
 
-.070 
 
.155 
 
-.063 
 
.000 
 
-.073 
 
.026 
 
-.035 
 
.019 
 
-.204 
 
.117 
 
.049 
 
-.080 
 
-.061 
 
-.164 
 
ICU days 
Q3 
-.093 
 
.034 
 
.225 
 
-.054 
 
-.083 
 
-.222 
 
-.092 
 
.133 
 
-.222 
 
-.026 
 
.042 
 
-.156 
 
-.069 
 
.005 
 
-.043 
 
ICU days 
Q4 
-.037 
 
.095 
 
.162 
 
.051 
 
-.031 
 
-.193 
 
-.191 
 
.006 
 
-.072 
 
-.150 
 
.254 
 
-.069 
 
.013 
 
.196 
 
-.053 
 
CPB 
minutes Q2 
-.017 
 
-.081 
 
.285 
 
.329* 
 
.331 
 
-.154 
 
-.161 
 
.039 
 
-.131 
 
.043 
 
.059 
 
.046 
 
.183 
 
.059 
 
.261 
 
CPB 
minutes Q3 
.157 
 
-.067 
 
.072 
 
.130 
 
.054* 
 
-.126 
 
-.079 
 
.338 
 
-.397 
 
.188 
 
.249 
 
-.285 
 
.067 
 
.154 
 
.019 
 
CPB 
minutes Q4 
.241 
 
.199 
 
.163 
 
.020 
 
-.060 
 
-.047 
 
.038 
 
.188 
 
-.300 
 
.209 
 
.191 
 
-.229 
 
-.030 
 
.109 
 
.086 
 
HA minutes 
Q2 
-.090 
 
-.008 
 
.171 
 
.170 
 
.278 
 
-.111 
 
-.203 
 
.016 
 
-.074 
 
.073 
 
.166 
 
-.094 
 
.411** 
 
.292 
 
.411** 
 
HA minutes 
Q3 
.129 
 
.193 
 
.060 
 
-.117 
 
.040 
 
-.095 
 
-.074 
 
.030 
 
-.086 
 
.097 
 
.118 
 
-.034 
 
.094 
 
.005 
 
.124 
 
HA minutes 
Q4 
.161 
 
.098 
 
.032 
 
.127 
 
.102 
 
.006 
 
-.078 
 
-.039 
 
-.042 
 
.238 
 
-.035 
 
.074 
 
.331* 
 
.156 
 
.260 
 
In hospital 
days Q2 
-.098 
 
.310 
 
.064 
 
.247 
 
.071 
 
-.233 
 
-.081 
 
-.096 
 
.091 
 
-.109 
 
.283 
 
-.036 
 
.141 
 
.163 
 
.005 
 
In hospital 
days Q3 
.025 
 
.241 
 
-.010 
 
.154 
 
-.063 
 
-.183 
 
-.074 
 
.123 
 
-.171 
 
-.080 
 
.248 
 
-.188 
 
-.016 
 
-.022 
 
-.107 
 
In hospital 
days Q4 
-.080 
 
.315 
 
.067 
 
.127 
 
-.110 
 
-.141 
 
-.201 
 
.027 
 
-.080 
 
-.024 
 
.040 
 
-.044 
 
.168 
 
-.032 
 
-.004 
 
PANAS PA -.223 
 
-.212 .317* .277* .442*** -.004 -.221 
 
.075** -.071 
 
-.131 
 
.196 
 
.111 
 
.364 
 
.440 
 
.418** 
PANAS NA  .081 
 
.231 -.128 -.148 -.228 -.150 
 
-.162 
 
.111 -.071 
 
-.015 
 
-.146 
 
.013 
 
-.273* 
 
-.299* 
 
-.086 
STAI -.006 
 
.111 -.100 -.170 -.185 -.197 
 
.154 
 
.164 -.142 
 
.044 
 
-.039 
 
-.074 
 
.004 
 
-.173 
 
-.176 
CESD  -.042 
 
.147 -.050 -.066 -.228 -.135 
 
.013 
 
.159 -.164 
 
.052 
 
-.206 
 
-.010 
 
-.222 
 
-.299* 
 
-.094 
Note - * p<0.05, **p<0.01, ***p<0.001 
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Univariate regression (screening) for factors associated with cognitive functioning in the SIMPLE group 
 
 
TMT-
A (β) 
TMT-B 
(β) 
COWA 
(β) 
STROOP 
(β) 
WAIS-III GP-D 
(β) 
GP-ND 
(β) 
ERROR 
(β) 
CLR (β) TTC (β) FTM 
(β) 
NO CAT 
(β) 
SDMT 
W (β) 
SDMT 
O (β) 
RAVLT 
Age  -.170 
 
-.038 
 
.289** 
 
-.166 
 
-0.069 -0.029 
 
0.102 
 
0.212 
 
-0.241* 
 
0.119 
 
-0.112 
 
-0.226* 
 
-0.059 
 
-0.1 
 
0.016 
 
Education 
(years) 
-.054 
 
-.181 
 
.256* 
 
.180 
 
0.54*** 
 
-0.091 
 
-0.164 
 
0.311** 
 
0.275* 
 
-
0.297** 
 
-0.126 
 
0.306** 
 
0.299
** 
 
0.204 
 
0.143 
 
Gender  
(Males) 
-.035 
 
-.065 
 
-.142 
 
-.040 
 
-0.025 
 
0.346** 
 
0.163 
 
-0.055 
 
0.01 
 
-0.156 
 
-0.135 
 
-0.005 
 
-0.043 
 
-0.121 
 
-0.274* 
 
Employment -.078 
 
-.136 
 
-.004 
 
.235* 
 
0.067 
 
0.031 
 
0.004 
 
-0.101 
 
0.096 
 
-0.208 
 
-0.112 
 
0.128 
 
0.116 
 
0.01 
 
0.015 
 
Arrhythmia  .029 .110 -.020 -.202 -0.115 0.019 0.134 -0.002 -0.036 -0.041 0.016 -0.055 -0.149 -0.164 -0.008 
Hypertension  -.119 
 
.010 
 
-.082 
 
-.190 
 
-0.172 
 
-0.007 
 
-0.017 
 
0.228* 
 
-0.235* 
 
0.063 
 
-0.035 
 
-0.207 
 
-0.014 
 
-0.098 
 
-
0.315** 
NYHA .022 
 
.077 
 
.113 
 
-.228* 
 
-0.097 
 
-0.008 
 
-0.017 
 
0.085 
 
-0.105 
 
0.063** 
 
-0.058 
 
-0.107 
 
-0.148 
 
-0.205 
 
-0.077 
 
Interventions 
total   
.065 
 
.145 
 
-.013 
 
.061 
 
-0.155 
 
0.061 
 
-0.059 
 
-0.153 
 
0.127 
 
-0.073 
 
0.058 
 
0.117 
 
-0.156 
 
-0.074 
 
-0.039 
 
Repair total -.160 
 
-.176 
 
.189 
 
.128 
 
0.257* 
 
0.048 
 
-0.077 
 
-0.18 
 
0.179 
 
-0.071 
 
0.129 
 
0.200 
 
0.165 
 
0.22* 
 
0.114 
 
Yrs since last 
intervention 
-.112 
 
-.158 
 
.055 
 
.058 
 
0.061 
 
0.212 
 
0.295** 
 
-0.035 
 
0.035 
 
-0.145 
 
0.063 
 
0.027 
 
0.071 
 
-0.062 
 
-0.062 
 
Post-op 
infection  
-.119 
 
-.047 
 
-.021 
 
.067 
 
-0.027 
 
-0.055 
 
-0.093 
 
-0.148 
 
0.133 
 
-0.052 
 
-0.099 
 
0.144 
 
0.078 
 
0.022 
 
-0.01 
 
Post-op VD -.134 
 
-.122 
 
.070 
 
.060 
 
0.171 
 
0.054 
 
-0.065 
 
-0.117 
 
0.092 
 
-0.023 
 
-0.054 
 
0.122 
 
0.123 
 
0.23* 
 
0.01 
 
HF clinic -.061 
 
.020 
 
-.223* 
 
.021 
 
-0.035 
 
-0.127 
 
-0.082 
 
-0.071 
 
0.046 
 
-0.059 
 
0.12 
 
0.03 
 
0.019 
 
0.001 
 
-0.032 
 
Pacemaker -.115 
 
.018 
 
.053 
 
.085 
 
-0.106 
 
-0.174 
 
-0.095 
 
-0.122 
 
0.127 
 
-0.029 
 
-0.05 
 
0.139 
 
-0.043 
 
0.11 
 
0.003 
 
ACE 
medication  
.012 
 
.084 
 
.036 
 
-.216* 
 
-0.172 
 
0.058 
 
0.114 
 
0.001 
 
-0.007 
 
-0.1 
 
-0.065 
 
0.139 
 
-0.115 
 
-0.2 
 
-
0.343** 
Diuretic 
medication  
.051 
 
.125 
 
.167 
 
-.164 
 
-0.091 
 
-0.031 
 
0.06 
 
0.099 
 
-0.159 
 
0.228* 
 
-0.047 
 
-0.138 
 
-0.152 
 
-
0.219
* 
-0.091 
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Univariate regression (screening) for factors associated with cognitive functioning in the SIMPLE group (continued) 
 
 
TMT-
A (β) 
TMT-B 
(β) 
COWA 
(β) 
STROOP 
(β) 
WAIS-III GP-D 
(β) 
GP-ND 
(β) 
ERROR 
(β) 
CLR (β) TTC 
(β) 
FTM 
(β) 
NO CAT 
(β) 
SDMT 
W (β) 
SDMT 
O (β) 
RAVLT 
Beta blocker 
medication  
-.015 
 
.009 
 
.043 
 
-.186 
 
0.023 
 
0.029 
 
-0.091 
 
0.101 
 
-0.065 
 
0.18 
 
0.112 
 
-0.107 
 
0.049 
 
0.077 
 
-0.067 
 
Anti-
arrythmia 
medication 
-.001 
 
.067 
 
.117 
 
.036 
 
-0.08 
 
0.031 
 
0.223* 
 
-0.03 
 
-0.008 
 
-0.005 
 
0.028 
 
-0.018 
 
-0.14 
 
-0.099 
 
0.023 
 
Anti-
coagulant 
medication  
-.002 
 
-.013 
 
.149 
 
.105 
 
-0.05 
 
0.036 
 
-0.028 
 
0.17 
 
-0.18 
 
0.496**
* 
 
-0.085 
 
-0.194 
 
-0.146 
 
-0.118 
 
0.059 
 
RVEF .041 .185 .162 -.135 0.052 0.063 0.113 0.07 -0.047 0.065 -0.133 -0.039 -0.079 -0.081 -0.096 
LVEF .024 
 
.092 
 
.234* 
 
-.016 
 
0.1 
 
0.08 
 
0.085 
 
-0.182 
 
0.175 
 
-0.16 
 
-0.042 
 
0.138 
 
-0.052 
 
-0.014 
 
-0.083 
 
Palliation 
total 
.107 
 
.051 
 
-.128 
 
.060 
 
-0.178 
 
0.169 
 
0.243* 
 
0.169 
 
-0.177 
 
-0.01 
 
-0.035 
 
-0.159 
 
-0.155 
 
-0.037 
 
-0.029 
 
Catheter lab 
total  
.096 
 
.205 
 
-.023 
 
.005 
 
-0.244* 
 
-0.154 
 
-0.083 
 
0.048 
 
-0.074 
 
0.012 
 
0.005 
 
-0.091 
 
-0.179 
 
-0.162 
 
-0.114 
 
Medication 
total 
-.048 
 
.069 
 
.076 
 
-.204 
 
-0.1 
 
0.054 
 
-0.008 
 
0.163 
 
-0.16 
 
0.187 
 
0.011 
 
-0.205 
 
-0.059 
 
-0.139 
 
-0.152 
 
Age at repair 
Q2 
-
.340** 
-.053 
 
.154 
 
-.039 
 
.287 
 
-.127 
 
-.165 
 
-.198 
 
.184 
 
-.051 
 
-.093 
 
.191 
 
-.049 
 
.388 
 
.290 
 
Age at repair 
Q3 
.171 
 
.148 
 
-.018 
 
-.085 
 
.066 
 
-.258 
 
-.255 
 
-.307* 
 
.303* 
 
.006 
 
-.238 
 
.345** 
 
-.157* 
 
.016 
 
.134 
 
Age at repair 
Q4 
-.177 
 
-.054 
 
.158 
 
-.167 
 
.088 
 
-.192 
 
-.216 
 
.133 
 
-.153 
 
.222 
 
-.197 
 
-.156 
 
.081* 
 
.114 
 
.112 
 
Current 
saturation Q1 
-.004 
 
-.015 
 
.103 
 
-.003 
 
-.130 
 
-.016 
 
.084 
 
.265 
 
-.260 
 
.382** 
 
.124 
 
-.268 
 
-.128 
 
-.101 
 
.010 
 
Current 
saturation Q2 
-.181 
 
.003 
 
.170 
 
-.104 
 
-.059 
 
-.034 
 
.167 
 
.088 
 
-.063 
 
-.007 
 
-.118 
 
-.098 
 
-.161 
 
.023 
 
-.172 
 
Current 
saturation Q3 
.119 
 
.154 
 
.193 
 
.029 
 
.069 
 
.000 
 
.106 
 
.055 
 
-.025 
 
.032 
 
.079 
 
-.061 
 
.021 
 
.076 
 
-.026 
 
ICU days Q2 -.207 
 
-.158 
 
-.034 
 
.161 
 
.118 
 
.094 
 
.078 
 
-.042 
 
.005 
 
-.011 
 
.160 
 
-.020 
 
.217 
 
.183 
 
-.041 
 
ICU days Q3 -.289 
 
-.189 
 
-.006 
 
.126 
 
-.050 
 
.017 
 
-.052 
 
-.009 
 
.001 
 
-.063 
 
.061 
 
.012 
 
.046 
 
.089 
 
-.057 
 
ICU days Q4 -.115 
 
-.132 
 
.128 
 
.171 
 
.154 
 
.027 
 
.086 
 
-.006 
 
-.008 
 
-.083 
 
.156 
 
.046 
 
.183 
 
.198 
 
-.089 
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Univariate regression (screening) for factors associated with cognitive functioning in the SIMPLE group (continued) 
 TMT-
A (β) 
TMT-B 
(β) 
COWA 
(β) 
STROOP 
(β) 
WAIS-III GP-D 
(β) 
GP-ND 
(β) 
ERROR 
(β) 
CLR (β) TTC 
(β) 
FTM 
(β) 
NO CAT 
(β) 
SDMT 
W (β) 
SDMT 
O (β) 
RAVLT 
CPB minutes 
Q2 
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a .222 
 
n/a 
CPB minutes 
Q3 
.203 
 
-.047 
 
.076 
 
-.177 
 
-.018 
 
.018 
 
-.047 
 
.022 
 
-.013 
 
.126 
 
-.003 
 
-.056 
 
-.074 
 
.031 
 
.024 
 
CPB minutes 
Q4 
-.093* 
 
-.148 
 
.050 
 
.092 
 
.134 
 
.124 
 
-.025 
 
-.094 
 
.110 
 
.021 
 
.005 
 
.046 
 
.158 
 
.130 
 
-.028 
 
 
HA minutes 
Q2 
 
n/a 
 
n/a 
 
n/a 
 
n/a 
 
n/a 
 
n/a 
 
n/a 
 
n/a 
 
n/a 
 
n/a 
 
n/a 
 
n/a 
 
n/a 
 
n/a 
 
n/a 
 
HA minutes 
Q3 
.186 
 
.105 
 
-.005 
 
-.248* 
 
-.123 
 
.059 
 
.087 
 
.099 
 
-.084 
 
.131 
 
.017 
 
-.119 
 
-.118 
 
.009 
 
.030 
 
HA minutes 
Q4 
.077 
 
.093 
 
.015 
 
.123 
 
-.024 
 
.194 
 
.049 
 
-.141 
 
.142 
 
.020 
 
-.010 
 
.079 
 
.016 
 
.085 
 
.016 
 
In hospital 
days Q2 
-.141 
 
-.023 
 
-.042 
 
.054 
 
-.105 
 
.127 
 
-.024 
 
-.140 
 
.129 
 
-.049 
 
.016 
 
.066 
 
.028 
 
.084 
 
-.132 
 
In hospital 
days Q3 
-.022 
 
-.085 
 
-.019 
 
.037 
 
-.004 
 
.209 
 
.002 
 
-.051 
 
.047 
 
-.108 
 
.070 
 
.076 
 
.112 
 
-.049 
 
-.097 
 
In hospital 
days Q4 
.125 
 
.086 
 
-.060 
 
-.105 
 
-.089 
 
.006 
 
-.059 
 
.058 
 
-.030 
 
-.140 
 
.095 
 
-.028 
 
-.026 
 
.000 
 
-.238 
 
PANAS PA -.067 
-.142 
.276* .222* .407*** -.325** -.167 -.227* .225* -.211 
 
-.143 
 
.317* .367** 
 
.308** 
 
.264* 
 
PANAS NA  .135 
 
.175 
 
-.218* 
 
-.317** 
 
-.371 
 
.037* 
 
-.140 
 
.232* 
 
-.223* 
 
.132 
 
.206 
 
-.293** 
 
-.201 
 
-.147 
 
-.248* 
 
STAI .219* 
 
.196 
 
-.304** 
 
-.429*** 
 
-.423** 
 
.104 
 
.079 
 
.204 
 
-.173 
 
.175 
 
.039 
 
-.210 
 
-
.368** 
 
-
.292** 
 
-.207 
 
CESD  .178 
 
.091 
 
-.291** 
 
-.359** 
 
-.382*** 
 
.113 
 
-.012 
 
.282* 
 
-.273* 
 
.257* 
 
.164 
 
-.338** 
 
-.265* 
 
-.152 
 
-.239* 
 
Note - * p<0.05, **p<0.01, ***p<0.001 
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Appendix O: Univariate Screening for the SF-36 Subscales (MCS & PCS) 
in the Cross-Sectional Study   
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(a) - Univariate screening for the QoL Mental Component Summary (SF 36- MCS) score by total sample and the different 
structural complexity groups 
Independent variables Total group ToF group TGA group SV group Simple group 
Total composite NP score .109 -.139 -.052 .103 .309** 
Age .151 .228* .041 .260* .147 
Education (years) -.020 .083 -.011 -.051 -.031 
Gender (Males) .063 .053 .312** -.014 -.075 
Employment .247*** .335** .187 .384** .099 
Arrhythmia .034 .181 .015 -.074 -.038 
Hypertension -.078 -.034 .081 .011 -.121 
NYHA -.055 .054 -.121 -.107 -.032 
Interventions total .073 .127 -.024 -.048 .207 
Palliation before repair .062 .070 -.067 .008 n/a 
Years since last intervention .053 .100 -.028 .167 -.061 
Post-op CNS complication .022 .141 .051 -.141 .048 
Post-op infection .115* .118 -.008 .193 .048 
Post-op ventricular dysfunction .073 .165 .053 -.016 .106 
HF clinic .049 .108 .066 -.024 .081 
Pacemaker -.028 n/a -.046 -.039 -.055 
ACE medication -.114* .176 -.014 -.319* -.167 
Diuretic medication .031 .135 .029 .048 -.060 
Beta blocker medication -.013 .066 -.117 .238 -.170 
Anti-arrythmia medication .076 .119 .049 .067 .162 
Anti-coagulant medication -.043 .043 .026 -.094 -.009 
RVEF -.072 -.237* .031 .194 -.081 
LVEF .003 -.120 -.160 .151 .079 
Palliation total .023 .071 .107 -.058 .122 
Catheter lab total .033 -.041 -.102 -.006 .076 
Medication total -.113* .130 -.273* -.105 -.121 
Age at repair Q2 .134 .107 -.00 -.103 .255 
Age at repair Q3 .099 .035 .098 -.269 .001 
Age at repair Q4 -.025 .241 .168 -.194 .207 
      
*p0.05, **p<0.01,  ***p<0.001, n/a- in adequate cell count to run analysis 
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Univariate screening for the QoL Mental Component Summary (MCS) score by total sample and the different structural 
complexity groups (Continued) 
Independent variables Total group ToF group TGA group SV group Simple group 
Cyanosis days Q2 .101 .119 .077 .054 n/a 
Cyanosis days Q3 .205** .144 .140 .040 n/a 
Cyanosis days Q4 .079 .202 .173 -.079 .093 
Current saturationQ1 -.106 -.049 .102 -.253** -.060 
Current saturationQ2 .076 -.248* .216 -.417 -.155 
Current saturationQ3 -.068 n/a n/a -.246 -.186 
ICU days Q2 -.040 .078 -.210 -.119 -.092 
ICU days Q3 -.008 .200 -.066 -.280 -.097 
ICU days Q4 .055 .356** -.149 .141 -.045 
CPB minutes Q2 .147* -.012 .005 .000 n/a 
CPB minutes Q3 .112 .081 .007 -.021 -.068 
CPB minutes Q4 .144* .049 .020 -.041 .074 
HA minutes Q2 .056 .007 -.024 .170 n/a 
HA minutes Q3 .170* .305* .076 .267 -.065 
HA minutes Q4 .069 .014 -.094 .176 -.059 
In hospital days Q2 .041 -.272* -.186 .200 -.062 
In hospital days Q3 .034 -.061 -.104 .013 .136 
In hospital days Q4 .035 .101 -.172 -.027 -.059 
PANAS PA .502*** .453*** .437*** .525*** .561*** 
PANAS NA -.617*** -.425*** -.568*** -.747*** -.720*** 
STAI -.496*** -.417*** -.306** -.609*** -.591*** 
CESD -.748*** -.690*** -.306*** -.794*** -.768*** 
*p0.05, **p<0.01,  ***p<0.001, n/a- in adequate cell count to run analysis 
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(b) - Univariate screening for the QoL Physical Component Summary (PCS) score by total sample and the different structural 
complexity groups 
Independent variables Total group ToF group TGA group SV group Simple group 
Total composite NP score .109 .031 .234 .133 .161 
Age -.164** -.119 -.145 -.116 -.369** 
Education (years) .185** .152 .194 .129 .305** 
Gender (Males) .107 .077 .087 .327** .053 
Employment .174** .344** .112 .219 .057 
Arrhythmia -.138* -.284* -.065 -.020 -.124 
Hypertension .018 .022 .168 .126 -.096 
NYHA -.460*** -.560*** -.341** -.529** -.555*** 
Interventions total -.113* -.232* -.094 -.004 -.298** 
Palliation before repair -.083 -.110 -.047 .101 -.009 
Years since last intervention .163** .254* .105 .161 .115 
Post-op CNS complication -.050 -.012 -.083 -.048 -.083 
Post-op infection -.108 -.306** -.046 -.049 .023 
Post-op ventricular dysfunction .054 .038 .204 .018 .048 
HF clinic -.135* -.113 -.148 -.081 -.088 
Pacemaker -.055 n/a -.010 -.090 -.031 
ACE medication -.156** -.287** -.018 -.030 -.258* 
Diuretic medication -.295*** -.360** -.214 -.202 -.395*** 
Beta blocker medication -.174** -.276* -.170 -.108 -.151 
Anti-arrythmia medication -.117* -.301** -.084 -.045 .107 
Anti-coagulant medication -.186** -.276* -.161 -.005 -.119 
RVEF .089 .165 .100 .053 .021 
LVEF .127* .195 .012 .091 .081 
Palliation total -.055 -.125 .085 .136 .043 
Catheter lab total -.163** -.132 -.174 -.159 -.208 
*p0.05, **p<0.01,  ***p<0.001, n/a- in adequate cell count to run analysis 
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Univariate screening for the QoL Physical Component Summary (PCS) score by total sample and the different structural complexity 
groups (Continued) 
Independent variables Total group ToF group TGA group SV group Simple group 
Medication total -.229*** -.390*** -.086 -.001 -.242* 
Age at repair Q2 .038 .081 -.051 .094 .098 
Age at repair Q3 -.035 -.020 .038 -.021 -.111 
Age at repair Q4 -.228** -.145 -.029 -.194 -.262* 
Cyanosis days Q2 .042 -.207 -.131 -.244 n/a 
Cyanosis days Q3 -.011 -.135 -.102 -.347* n/a 
Cyanosis days Q4 -.154 -.072 -.118 -.516*** n/a 
Current saturationQ1 -.297*** -.265* -.061 -.406** -.203 
Current saturationQ2 -.064 -.154 -.085 -.071 .057 
Current saturationQ3 -.071 n/a n/a .058 .228 
ICU days Q2 .058 -.144 .111 .063 .067 
ICU days Q3 .013 -.226 .013 -.008 .024 
ICU days Q4 -.059 -.088 -.023 -.043 .027 
CPB minutes Q2 .134 .056 -.058 .302 n/a 
CPB minutes Q3 .079 -.144 .087 .179 -.199 
CPB minutes Q4 .033 -.252 .122 .130 -.018 
HA minutes Q2 -.020 .187 -.079 .216 n/a 
HA minutes Q3 .026 -.008 .059 .127 -.189 
HA minutes Q4 -.003 .147 -.198 .255 -.028 
In hospital days Q2 .039 -.130 .100 .055 .210 
In hospital days Q3 .001 -.185 .031 -.074** .280* 
In hospital days Q4 -.203** -.360** -.051 -.326* -.018 
PANAS PA .272*** .215 .260* .394** .240* 
PANAS NA -.279*** -.157 -.212 -.393** -.337** 
STAI -.218*** .020 -.145 -.228 -.416*** 
CESD -.312*** -.147 -.249* -.408** -.341** 
*p0.05, **p<0.01,  ***p<0.001,  n/a- in adequate cell count to run analysis 
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Appendix P: Cross-Sectional Study Clinical Variables Descriptive Data 
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Variable (Median, 
Interquartile range) 
ToF TGA SV Simple Total H r (ES) df p-value 
Age at repair 48.0 
a
 
(20-71.50) 
8.0 
b
 
(5-14) 
111.0 
c
 
(63-226) 
88.50 
a, c
 
(16-327) 
48.00 
(9.75-121) 
88.298 -0.72 - 0.36 3 <0.001 
Interventions total 2.0
 a, b
 
(1-3) 
2.0
 a, b
 
(2-3) 
3.0
 b
 
(2-4) 
1.0
 c
 
(1-2) 
2.0 
(1-3) 
74.01 -0.22 - 0.64 3 <0.001 
Repairs total 1.0
 a
 
(1-2) 
1.0
 b,c,d
 
(1-1) 
1.0
 b,c,d
 
(1-1) 
1
 b,c,d
 
(1-1) 
1.0 
(1-1) 
41.46 0.35 – 0.43 3 <0.001 
Palliations total 0.0
a
 
(0-1) 
0.0
 b,d
 
(0-0) 
1.0
 c
 
(1-2) 
0.0
 b,d
 
(0-0) 
0.0 
(0-1) 
130.17 -0.49 – 0.88 3             <0.001 
Catheter labs total 0.0
 a,c,d
 
(0-1) 
1.0
 b
 
(1-2) 
0.0
 a,c,d
 
(0-1) 
0.0
 a,c,d
 
(0-1) 
0.0 
(0-1) 
65.13 -0.57 – 0.52 3 <0.001 
Years since last 
intervention 
10.0
 a, b, c, d
 
(3-27) 
25.0
 b, d
 
(7.25-30) 
15.0
 c, d
 
(4-21) 
10.0
 a,b,c,d
 
(3.25-24) 
17.0 
(4-26) 
12.73 0.27 3 <0.001 
Cyanosis days total 900
 a,c
 
(390-1747.50) 
242.0
 b
 
(150-420) 
1825.0
 a,c
 
(900-4310) 
0.0
 d
 
(0-0) 
322.50 
(0-1095) 
218.11 -0.51 – 1.01 3 <0.001 
Current saturation 97.0
 a
 
(96-98) 
96.50
 b
 
(96-97) 
93.0
 c
 
(88-97) 
98.0
 d
 
(97-100) 
97.0 
(96-98) 
101.06 -0.22 – 0.56 3 <0.001 
CPB minutes Total 115.0
 a,b,c
 
(77.5-160.5) 
100.0
 a,b,c
 
(75.25-160) 
109.0
 a,b,c
 
(80.50-143) 
0.0
 d
 
(0-58.75) 
90.0 
(53-134) 
109.98 0.05 – 0.70 3 <0.001 
HA minutes total 30
 a,b,c
 
(24.50-39) 
34.50
 a,b,c
 
(27.5-48.75) 
30.0
 a,b,c
 
(15-55.50) 
0.0
 d
 
(0-19.50) 
28.0 
(10-40) 
81.12 0.04 – 0.64 3 <0.001 
In hospital days 35
 a,b,c
 
(24.50-60) 
25.50
 a,b
 
(20-48) 
50.0
 a,c
 
(30-90) 
12.0
 d
 
(8.25-20) 
26.50 
(15.75-50) 
120.31 -0.35 – 0.83 3 <0.001 
Co-morbidities total 1
 a
 
(0-1) 
1.0
 b
 
(0-2) 
1.0
 c
 
(0-1) 
1.0
 d
 
(0-1) 
1.0 
(0-1) 
4.14 n/a   3 0.247 
Medication total 0.0
 a,d
 
(0-0.50) 
1.0
b,c,d
 
(0-1) 
1.0
c
 
(1-2) 
0.0
 a, b,d
 
(0-1) 
0.0 
(0-2) 
36.64 -0.23 – 0.25 3 <0.001 
RVEF 58.0
 a,b,c
 
(49.50-61.50) 
55.0
 a,b,c
 
(50.25-60) 
60.0
 a,b,c
 
(50-62) 
65.0
 d
 
(60-65) 
50.0 
(53-64) 
71.82 -0.46 - -0.61 3 <0.001 
LVEF 60.0 a 
(56.50-65) 
64.0 a,b,d 
(58-67.75) 
57.0a,c 
(50-61) 
65.0 b,d 
(60-70) 
61.0 
(57-65) 
50.36 -0.32 – 0.42 3 <0.001 
Note: H= Kruskal-Wallis test statistic, ES= Effect Size, SD=Standard Deviation, RVEF = Right Ventricle Ejection Fraction, LVEF=Left Ventricle Ejection Fraction, HA = Hypothermic 
arrest, CPB= Cardio Pulmonary Bypass.  
 
Interpretation key- the pair wise comparisons between the groups are indicated in the table with the help of superscripts. Groups sharing a common alphabet indicate the absence of any 
significant differences on that variable. The range of the effect sizes across all pairwise comparisons is presented (‘r’). 
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Appendix Q: Correlation Matrix for the WCST-64 Scores  
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 WCST- total 
number of error 
WCST-
Conceptual level 
response (CLR) 
WCST- NO of 
categories 
completed 
WCST- Trials to 
complete 1
st
 
category (TTC) 
WCST- failure 
to maintain set 
(FTM) 
WCST- total number of error -     
WCST-Conceptual level response  -.973** -    
WCST- NO of categories completed -.863** .869** -   
WCST- Trials to complete 1
st
 category  .345** -.353** -.404** -  
WCST- failure to maintain set  .085 -.066 -.408** -.019 - 
Note- **p<0.01 
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Appendix R: Multiple Hierarchical Regression Analysis to Identify Factors 
Associated with Cognitive Functioning (Sub-Group Analysis)  
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Multivariate regression models for the ToF group  
Regression model for TMT-B test in ToF 
Block Predictor Variables R
2
 
 
Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
 
1  .229 .199 .229 7.618  .000** 
 Age      -.257 .014 
 Education (Yrs)     -.271 .009 
 Employment     -.267 .010 
2  .225 .216 .026 2.651  .108 
 Age      -.225 .031 
 Education (Yrs)     -.253 .014 
 Employment     -.155 .206 
 Positive affect      -.203 .108 
**p<0.01 
 
Regression model for SDMT- Written scores in ToF 
Block Predictor 
Variables 
R
2 
 Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
 
1  .155 .145 .155 14.533  <0.001 
 Education (Yrs.)     .394 <0.001 
2  .177 .156 .021 2.028  .158 
 Education (Yrs.)     .397 <0.001 
 Arrhythmias     -.146 .158 
3  .209 .178 .032 3.086  .083 
 Education (Yrs.)     .373 <0.001 
 Arrhythmias     -.128 .212 
 Positive affect      .181 .083 
 
Regression model for Stroop test in ToF 
Block Predictor Variables R
2
 
 
Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
 
1  .146 .124 .146 6.687  .002** 
 Education (Yrs)     .293 .007** 
 Gender (Males)     .210 .050 
2  .269 .230 .122 6.367  .003** 
 Education (Yrs)     .312 .003** 
 Gender (Males)     .221 .030 
 Post-op CNS complication     -.183 .110 
 Post-op Ventricular 
dysfunction 
    -.226 .051 
3  .321 .256 .052 1.872  .142 
 Education (Yrs)     .267 .010 
 Gender (Males)     .159 .130 
 Post-op CNS complication     -.167 .138 
 Post-op Ventricular 
dysfunction 
    -.229 .047 
 Depression     -.025 .848 
 Anxiety      -.141 .269 
 Negative affect     -.122 .324 
**p<0.01 
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Regression model for WCST-Error in ToF   
Block Predictor 
Variables 
R
2 
 Adjusted R
2
 ΔR2  ΔF β Sig. 
 
1  .099 .088 .099 8.672  .004** 
 Education (Yrs)     -.315 .004** 
2  .139 .117 .040 3.652  .060 
 Education (Yrs)     -.294 .007** 
 NYHA     .202 .060 
**p<0.01 
 
Regression model for WCST-Conceptual level responses in ToF   
Block Predictor Variables R
2
 
 
Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
 
1  .107 .096 .107 9.472  .003** 
 Education (Yrs)     .327 .003** 
2  .152 .107 .045 1.336  .269 
 Education (Yrs)     .324 .004** 
 NYHA     -.127 .308 
 Arrhythmias      -.061 .596 
 HF clinic     -.085 .484 
3  .164 .084 .012 .361  .781 
 Education (Yrs)     .316 .006** 
 NYHA     -.158 .234 
 Arrhythmias      -.056 .666 
 HF clinic     -.100 .466 
 ACE medication      -.067 .616 
 LVEF     .066 .582 
 Medication total 0 vs. all     .134 .385 
**p<0.01 
 
Regression model for WCST-Failure To Maintain score in ToF   
Block Predictor Variables R
2
 
 
Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
 
1  .144 .111 .144 4.327  .007** 
 Education (Yrs)     -.008 .938 
 Gender (Males)     .341 .002** 
 Age      .234 .032 
2  .163 .107 .019 .851  .431 
 Education (Yrs)     .005 .960 
 Gender (Males)     .372 .001*** 
 Age      .227 .038 
 Palliation total 0 vs. all      -.440 .359 
 Palliation before repair     .533 .270 
3  .198 .133 .035 3.245  .076 
 Education (Yrs)     -.038 .727 
 Gender (Males)     .302 .011 
 Age      .234 .031 
 Palliation total 0 vs. all      -.567 .236 
 Palliation before repair     .627 .191 
 Anxiety      -.208 .076 
**p<0.01 
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Regression model for WCST-No. of categories completed in ToF  
Block Predictor 
Variables 
R
2 
 Adjusted R
2
 ΔR2  ΔF β Sig. 
 
1  .049 .025 .049 2.020  .140 
 ACE medication     -.214 .082 
 Anti-coagulant 
medication 
    -.017 .889 
 
 
Regression model for WCST- Trials to complete first set in ToF  
Block Predictor Variables R
2
 
 
Adjus
ted R
2
 
ΔR2  ΔF β Sig. 
 
1  .000 -.013 .000 .009  .923 
 Gender (Males)     -.011 .923 
2  .045 .007 .044 1.789  .174 
 Gender (Males)     -.030 .789 
 NYHA     .217 .067 
 HF clinic     -.023 .844 
3  .069 .020 .025 2.034  .158 
 Gender (Males)     -.026 .819 
 NYHA     .223 .058 
 HF clinic     .110 .464 
 Post-operative ventricular dysfunction     -.208 .158 
4  .146 .064 .076 2.167  .099 
 Gender (Males)     -.039 .727 
 NYHA     .222 .099 
 HF clinic     .208 .215 
 Post-operative ventricular dysfunction     -.167 .255 
 Medication total 0 vs. all     -.006 .972 
 Anti-coagulant medication     .216 .174 
 Beta-blocker medication     -.284 .046 
 
 
Regression model for GP- Non dominant in ToF  
Block Predictor Variables R
2 
 Adjusted R
2
 ΔR2  ΔF β Sig. 
 
1  .103 .068 .103 2.948  .038 
 Cyanotic days Q2      -.011 .934 
 Cyanotic days Q3     .094 .482 
 Cyanotic days Q4     .334 .014 
2  .132 .087 .029 2.576  .113 
 Cyanotic days Q2     -.024 .855 
 Cyanotic days Q3     .053 .693 
 Cyanotic days Q4     .293 .031 
 ACE medication      .176 .113 
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Regression model for RAVLT scores in ToF 
Block Predictor 
Variables 
R
2
 
 
Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
 
1  .083 .060 .083 3.550 .033* .033 
 Education (Yrs.)     .275 .013** 
 Employment      -.118 .281 
2  .243 .192 .159 5.266 .002** .002** 
 Education (Yrs.)     .367 0.001 
 Employment      -.128 .216 
 Age at repair Q2     .188 .125 
 Age at repair Q3     .175 .156 
 Age at repair Q4     .486 <0.001 
**p<0.01 
 
Multivariate regression models for the TGA group  
Regression model for TMT-A in TGA 
Block Predictor Variables R
2
 
 
Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
1  .082 .070 .082 6.933  .010 
 Employment      -.286 .010 
2  .161 .116 .079 2.360  .078 
 Employment      -.272 .014 
 CPB minutes Q2      .274 .040 
 CPB minutes Q 3     -.044 .738 
 CPB minutes Q 4      .048 .714 
 
Regression model for TMT-B in TGA 
Block Predictor Variables R
2
 
 
Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
 
1  .092 .080 .092 7.859  .006** 
 Employment      -.303 .006** 
2  .289 .241 .197 5.130  .001** 
 Employment      -.293 .004** 
 CNS complication     .278 .008** 
 Age at repair Q2     .237 .040 
 Age at repair Q3     .208 .070 
 Age at repair Q4     -.088 .446 
3  .352 .279 .063 2.311  .084 
 Employment      -.327 .002** 
 CNS complication     .284 .008** 
 Age at repair Q2     .128 .537 
 Age at repair Q3     .367 .147 
 Age at repair Q4     .090 .738 
 Cyanosis days Q2     .224 .281 
 Cyanosis days Q3     -.140 .598 
 Cyanosis days Q4     -.196 .475 
**p<0.01 
 
 
  
      
476 
 
Regression model for COWA in TGA 
Block Predictor Variables R
2
 
 
Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
 
1  .112 .089 .112 4.875  .010 
 Employment      .210 .054 
 Education (Yrs)     .246 .025 
2  .291 .263 .179 19.174  <0.001 
 Employment      .238 .016 
 Education(Yrs)     .278 .005** 
 Negative affect     .425 <0.001 
**p<0.01 
 
Regression model for STROOP in TGA 
Block Predictor Variables R
2
 Adjusted R
2
 ΔR2  ΔF β Sig. 
1  .073 .061 .073 6.122  .016 
 Education (Yrs)     .270 .016 
2  .161 .116 .088 2.634  .056 
 Education (Yrs)     .241 .026 
 CPB minutes Q2     -.057 .664 
 CPB minutes Q3     .281 .032 
 CPB minutes Q4     .081 .530 
3  .277 .207 .116 3.860  .013 
 Education (Yrs)     .152 .151 
 CPB minutes Q2     -.057 .650 
 CPB minutes Q3     .311 .014 
 CPB minutes Q4     .110 .388 
 RVEF     .206 .119 
 LVEF     .117 .332 
 Diuretic medication     -.111 .373 
 
Regression model for WAIS-III in TGA 
Block Predictor Variables R
2
 Adjusted R
2
 ΔR2  ΔF β Sig. 
1  .314 .296 .314 17.608  <0.001 
 Education (Yrs)      .476 <0.001 
 Employment      .261 .007** 
2  .316 .289 .002 .219  .641 
 Education (Yrs)     .459 <0.001 
 Employment      .254 .010 
 Heart failure clinic     -.048 .641 
3  .535 .475 .219 5.485  <0.001 
 Education (Yrs)      .353 <0.001 
 Employment      .191 .029 
 Heart failure clinic     -.055 .565 
 CPB minutes Q2     -.156 .133 
 CPB minutes Q3     .241 .026 
 CPB minutes Q4     .254 .017 
 Repair surgeries total     -.168 .074 
 Post-op CNS complication     -.131 .160 
 Post-op infection     -.074 .414 
4  .584 .510 .050 2.678  .054 
 Education (Yrs)     .322 .001** 
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Block Predictor Variables R
2
 Adjusted R
2
 ΔR2  ΔF β Sig. 
 Employment      .192 .027 
 Heart failure clinic     .048 .629 
 CPB minutes Q2     -.143 .154 
 CPB minutes Q3     .281 .009** 
 CPB minutes Q4     .307 .004** 
 Repair surgeries total     -.142 .124 
 Post-op CNS complication      -.153 .094 
 Post-op infection     -.063 .473 
 Diuretic medication     .115 .311 
 Anti–coagulant medication     -.215 .043 
 RVEF     .209 .046 
**p<0.01 
 
Regression model for GP dominant hand in TGA 
Block Predictor Variables R
2
 
 
Adjuste
d R
2
 
ΔR2  ΔF β Sig. 
 
1  .102 .091 .102 8.890  .004** 
 Education (Yrs)     -.320 <0.001 
2  .146 .124 .044 3.943  .051 
 Education (Yrs)     -.297 .006** 
 Post-op CNS complication     .210 .051 
3  .206 ..175 .060 5.789  .019 
 Education (Yrs)     -.229 .035 
 Post-op CNS complication     .251 .019 
 ACE medication     .257 .019 
**p<0.01 
 
Regression model for GP non-dominant hand in TGA 
Block Predictor Variables R
2
 
 
Adjuste
d R
2
 
ΔR2  ΔF β Sig. 
 
1  .054 .042 .054 4.434  .038 
 Education (Yrs)     -.232 .038 
2  .189 .122 .135 2.437  .042 
 Education (Yrs)     -.122 .276 
 In hospital days Q2     .050 .681 
 In hospital days Q3  .   .048 .701 
  In hospital days Q4     .302 .029 
 Post-op CNS complication      .181 .117 
 Post-op infection      .046 .701 
3  .237 .163 .048 4.556  .036 
 Education (Yrs)     -.074 .504 
 In hospital days Q2     .07 .538 
 In hospital days Q3     .030 .806 
  In hospital days Q4     .238 .083 
 Post-op CNS complication      .234 .043 
 Post-op infection      .047 .688 
 ACE medication     .240 .036 
4  .258 .174 .020 1.944  .168 
 Education (Yrs)     -.050 .654 
 In hospital days Q2     .071 .548 
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Block Predictor Variables R
2
 
 
Adjuste
d R
2
 
ΔR2  ΔF β Sig. 
 
 In hospital days Q3     .014 .911 
  In hospital days Q4     .205 .137 
 Post-op CNS complication      .222 .054 
 Post-op infection      .078 .509 
 ACE medication     .239 .036 
 Positive affect      -.150 .168 
 
 
Regression model for SDMT-Oral in TGA 
Block Predictor Variables R
2
 
 
Adjus
ted R
2
 
ΔR2  ΔF β Sig. 
 
1  .120 .097 .120 5.261  .007** 
 Education (Yrs)     .252 .021 
 Employment  .    .220 .044 
2  .288 .207 .167 2.780  .017 
 Education (Yrs)     .105 .348 
 Employment   .   .162 .126 
 CPB minutes Q2     -.046 .717 
 CPB minutes Q3     .246 .052 
 CPB minutes Q4     .237 .065 
 Post – op CNS complication     -.122 .245 
 Repair surgeries total      -.174 .123 
 Palliation before repair     -.201 .063 
3  .359 .276 .071 7.754  .007** 
 Education (Yrs)     .055 .613 
 Employment      .184 .071 
 CPB minutes Q2     -.059 .624 
 CPB minutes Q3     .267 .029 
 CPB minutes Q4     .201 .102 
 Post – op CNS complication     -.115 .251 
 Repair surgeries total      -.173 .110 
 Palliation before repair     -.253 .017 
 LVEF     .279 .007 
**p<0.01 
 
 
Regression model for SDMT-Written in TGA 
Block Predictor Variables R
2
 
 
Adjus
ted R
2
 
ΔR2  ΔF β Sig. 
 
1  .127 .104 .127 5.579  .005** 
 Education (Yrs)     .275 .012 
 Employment .    .205 .058 
2  .237 .185 .110 3.570  .018 
 Education (Yrs)     .172 .116 
 Employment  .   .178 .087 
  Palliation before repair      -.184 .089 
 Post-op CNS complication     -.201 .067 
 Post-op infection     -.154 .161 
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3  .340 .286 .103 11.395  .001** 
 Education (Yrs)     .184 .074 
 Employment     .201 .040 
  Palliation before repair      -.205 .044 
 Post-op CNS complication     -.205 .046 
 Post-op infection     -.168 .105 
 Negative affect     .324 .001** 
**p<0.01 
 
 
Regression model for RAVLT in TGA 
Block Predictor Variables R
2
 
 
Adjus
ted R
2
 
ΔR2  ΔF β Sig. 
 
1  .248 .229 .248 12.727  <0.001 
 Education (Yrs)     .429 <0.001 
 Gender (Males) .    -.263 .010 
2  .251 .221 .002 .210  .648 
 Education (Yrs)     .411 <0.001 
 Gender (Males)  .   -.258 .012 
 HF clinic      -.049 .648 
3  .268 .229 .018 1.803  .183 
 Education (Yrs)     .375 .001** 
 Gender (Males)     -.262 .010 
 HF clinic      -.030 .780 
 Palliation before repair     -.140 .183 
4  .322 .256 .054 1.910  .136 
 Education (Yrs)     .326 .004** 
 Gender (Males)     -.271 .007** 
 HF clinic      -.006 .957 
 Palliation before repair     -.111 .300 
 Cyanotic days Q2      -.244 .044 
 Cyanotic days Q3     -.057 .641 
 Cyanotic days Q4     -.210 .088 
5  .347 .273 .025 2.701  .105 
 Education (Yrs)     .322 .004** 
 Gender (Males)     -.257 .010 
 HF clinic      .003 .980 
 Palliation before repair     -.114 .282 
 Cyanotic days Q2      -1.507 .136 
 Cyanotic days Q3     -.053 .958 
 Cyanotic days Q4     -1.203 .233 
**p<0.01 
 
Regression model for WCST-Error in TGA 
Block Predictor Variables R
2
 
 
Adjus
ted R
2
 
ΔR2  ΔF β Sig. 
 
1  .147 .125 .147 6.649  <0.001 
 Post-op CNS complication     .301 .006** 
 Repair surgeries      .215 .045 
2  .264 .204 .117 2.901  .028 
 Post-op CNS complication     .310 .004** 
 Repair surgeries   .   .150 .179 
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  RVEF     -.076 .579 
 LVEF     -.20 .089 
 Diuretic medication     .096 .452 
 Pacemaker      .088 .435 
**p<0.01 
 
Regression model for WCST-Conceptual level responses in TGA 
Block Predictor Variables R
2
 
 
Adjus
ted R
2
 
ΔR2  ΔF β Sig. 
1  .156 .134 .156 7.119  .001** 
 Repair surgeries     -.194 .068 
 Post-op CNS complications      -.328 .003** 
2  .255 .205 .099 3.283  .025 
 Repair surgeries     -.138 .213 
 Post-op CNS complications      -.342 .001** 
 Diuretic medication  .   -.072 .555 
 RVEF     .123 .364 
 LVEF     .197 .102 
**p<0.01 
 
Regression model for WCST-No of Categories completed in TGA  
Block Predictor Variables R
2
 
 
Adjuste
d R
2
 
ΔR2  ΔF β Sig. 
 
1  .069 .057 .069 5.762  .019 
 Education (Yrs)     .262 .019 
2  .128 .105 .059 5.201  .025 
 Education (Yrs)     .235 .031 
 Post-op CNS complication     -.244 .025 
3  .314 .257 .186 4.951  .001** 
 Education (Yrs)     .119 .257 
 Post-op CNS complication     -.301 .004** 
 RVEF     .222 .060 
 LVEF     .128 .260 
 ACE Medication      -.180 .089 
**p<0.01 
 
 
 
Regression model for WCST- Failure to maintain set score in TGA  
Block Predictor Variables R
2
 
 
Adjuste
d R
2
 
ΔR2  ΔF β Sig. 
 
1  .054 .042 .054 4.467  .038 
 Education (Yrs)     -.233 .038 
2  .131 .109 .077 6.849  .011 
 Education (Yrs)     -.168 .129 
 RVEF     -.285 .001** 
**p<0.01 
 
 
 
  
      
481 
 
Regression model for WCST-Trials to complete first category score in TGA 
Block Predictor Variables R
2
 
 
Adjuste
d R
2
 
ΔR2  ΔF β Sig. 
 
1  .112 .100 .112 9.806  .002** 
 Post-op CNS complication     .334 .002** 
2  .231 .200 .119 5.876  .004** 
 Post-op CNS complication     .299 .005** 
 Negative affect      .271 .043 
 Depression      .104 .446 
**p<0.01 
 
 
Multivariate regression models for the SV group  
Regression model for WAIS-III in SV 
Block Predictor Variables R
2 
 Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
 
1  .247 .235 .247 20.680  .009** 
 Education (Yrs)     .497 .012 
2  .524 .465 .277 5.523  <0.001 
 Education (Yrs)     .344 .001 
 Post-op CNS complication     -.351 .001 
 Post-op infection     -.152 .125 
 Palliation before repair     -.221 .023 
 CPB minutes Q2     .222 .061 
 CPB minutes Q3     .118 .314 
 CPB minutes Q4     .000 1.000 
3  .589 .530 .065 8.805  .004** 
 Education (Yrs)     .290 .003** 
 Post-op CNS complication     -.293 .003** 
 Post-op infection     -.201 .035 
 Palliation before repair     -.209 .023 
 CPB minutes Q2     .177 .112 
 CPB minutes Q3     .201 .081 
 CPB minutes Q4     .009 .933 
 Positive affect     .293 .004** 
**<0.01 
 
Regression model for TMT-A in SV 
Block Predictor Variables R
2 
 Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
 
1  .103 .089 .103 7.271  .009** 
 Post-op infection     .322 .009** 
2  .253 .203 .149 3.994  .012 
 Post-op infection     .296 .014 
 Pacemaker     .235 .051 
 Diuretic medication     .260 .052 
 Beta-blocker medication     .045 .754 
**p<0.01 
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Regression model for TMT-B in SV 
Block Predictor Variables R
2 
 Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
 
1  .105 .091 .015 7.395  .008** 
 Post-operative infection     .324 .008** 
**p<0.01 
 
Regression model for COWA in SV 
Block Predictor Variables R
2 
 Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
 
1  .165 .138 .165 6.112  .004** 
 Education (Yrs)     .302 .012 
 Age      .233 .051 
2  .238 .200 .073 5.864  .018 
 Education (Yrs)     .237 .045 
 Age      .172 .141 
 Post-op CNS complications      -.287 .018 
3  .267 .218 .029 2.377  .128 
 Education (Yrs)     .203 .082 
 Age      .167 .149 
 Post-op CNS complications      -.247 .044 
 Positive affect     .181 .128 
**P<0.01 
 
Regression model for Stroop-word score in SV 
Block Predictor Variables R
2 
 Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
 
1  .090 .045 .090 2.016  .121 
 CPB minutes Q2     .329 .032 
 CPB minutes Q3     .130 .393 
 CPB minutes Q4     .020 .893 
2  .147 .090 .056 3.966  .051 
 CPB minutes Q2     .271 .074 
 CPB minutes Q3     .193 .206 
 CPB minutes Q4     .017 .909 
 Positive affect     .257 .051 
 
Regression model for Grooved pegboard-non dominant hand score in SV 
Block Predictor Variables R
2 
 Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
 
1  .068 .053 .068 4.611  .036 
 Post-operative infection     .261 .036 
 
Regression model for WCST-Error score in SV 
Block Predictor Variables R
2
 Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
 
1  .167 .154 .167 12.622  .001** 
 Education (Yrs)     -.409 .001** 
2  .225 .200 .058 4.621  .035 
 Education (Yrs)     -.379 .001** 
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Block Predictor Variables R
2
 Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
 
 Hypertension     .242 .035 
3  .362 .320 .138 6.470  .003** 
 Education (Yrs)     -.272 .015 
 Hypertension     .158 .144 
 Post-op CNS complication     .344 .003 
 Post-op infection     .164 .125 
4  .443 .374 .080 2.738  .052 
 Education (Yrs)     -.221 .045 
 Hypertension     .135 .198 
 Post-op CNS complication     .352 .002** 
 Post-op infection     .175 .093 
 Current saturation Q1     .046 .708 
 Current saturation Q2     .323 .009** 
 Current saturation Q3     .128 .314 
5  .458 .370 .016 .796  .456 
 Education (Yrs)     -.234 .036 
 Hypertension     .117 .272 
 Post-op CNS complication     .308 .009** 
 Post-op infection     .153 .159 
 Current saturation Q1     .012 .924 
 Current saturation Q2     .320 .010 
 Current saturation Q3     .136 .289 
 Diuretic medication     .086 .513 
 Beta-blocker medication     .077 .530 
6  .468 .369 .009 .953  .333 
 Education (Yrs)     -.214 .059 
 Hypertension     .116 .275 
 Post-op CNS complication     .281 .020 
 Post-op infection     .156 .151 
 Current saturation Q1     -.024 .862 
 Current saturation Q2     .305 .015 
 Current saturation Q3     .115 .376 
 Diuretic medication     .067 .615 
 Beta-blocker medication     .090 .465 
 Positive affect      -.111 .333 
**p<0.01  
 
 
Regression model for WCST-Conceptual level responses score in SV 
Block Predictor Variables R
2
 Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
 
1  .173 .160 .173 13.170  .001** 
 Education (Yrs)      .416 .001** 
2  .231 .206 .058 4.66  .035 
 Education (Yrs)     .387 .001** 
 Hypertension      -.242 .035 
3  .410 .371 .180 9.143  .029 
 Education (Yrs)     .263 .014 
 Hypertension      -.147 .156 
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 Post-op CNS complication      -.383 .001** 
 Post-op infection      -.203 .049 
4  .496 .434 .086 3.225  <0.001 
 Education (Yrs)     .213 .042 
 Hypertension      -.117 .239 
 Post-op CNS complication      -.384 <0.001 
 Post-op infection      -.205 .039 
 Current saturation Q1     .030 .800 
 Current saturation Q2     -.303 .010 
 Current saturation Q3     -.085 .479 
5  .505 .434 .009 .964  .330 
 Education (Yrs)     .222 .035 
 Hypertension      -.108 .278 
 Post-op CNS complication      -.361 .001** 
 Post-op infection      -.179 .081 
 Current saturation Q1     .036 .761 
 Current saturation Q2     -.306 .009** 
 Current saturation Q3     -.088 .465 
 Beta-blocker medication     -.100 .330 
**P<0.01 
 
Regression model for WCST-Trials to complete first category score in SV 
Block  Predictor Variables R
2
 Adjusted R
2
 ΔR2  ΔF β Sig. 
 
1  .205 .192 .205 16.203  <0.001 
 Post-op CNS complication             .452 <0.001 
2  .321 .287 .116 5.220  .008** 
 Post-op CNS complication     .327 .005** 
 Diuretic medication      .271 .019 
 Anti-arrhythmic medication      .201 .067 
**P<0.001 
 
Regression model for WCST-Failure to maintain set score in SV 
Block  Predictor Variables R
2
 Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
 
1  .091 .076 .091 6.228  .015 
 Yrs. Since last operation     .301 .015 
2  .159 .132 .068 5.031  .028 
 Yrs. Since last operation     .284 .018 
 Anti-coagulant medication     -.262 .028 
 
Regression model for WCST-No categories completed score in SV 
Block  Predictor Variables R
2
 Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
 
1  .081 .067 .081 5.560  .021 
 Education (Yrs)      .021 
2  .372 .331 .291 9.283  <0.001 
 Education (Yrs)     .161 .138 
 Palliation before repair      -.269 .012 
 Post-op CNS complication      -.357 .001** 
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 Post-op infection     -.220 .040 
3  .398 .347 .026 2.514  .118 
 Education (Yrs)     .176 .104 
 Palliation before repair      -.264 .013 
 Post-op CNS complication      -.315 .006** 
 Post-op infection     -.177 .103 
 Beta-blocker medication     -.172 .118 
**p<0.01 
 
 
 
 
Regression model for RAVLT in SV 
Block  Predictor Variables R
2
 Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
 
1  .115 .086 .115 4.011  .023 
 Age     .229 .062 
 Education (Yrs)     .221 .072 
2  .288 .214 .174 3.534  .012 
 Age     .217 .065 
 Education (Yrs)      .140 .238 
 Post-op CNS infection      -.229 .059 
 HA minutes Q2     .429 .003 
 HA minutes Q3     .149 .283 
 HA minutes Q4     .248 .077 
3  .360 .281 .072 6.398  .014 
 Age     .207 .066 
 Education (Yrs)     .089 .437 
 Post-op CNS infection      -.161 .172 
 HA minutes Q2     .384 .006** 
 HA minutes Q3     .157 .237 
 HA minutes Q4     .262 .051 
 Positive affect     .290 .014 
**p<0.01 
 
Regression model for SDMT-written score in SV 
Block  Predictor Variables R
2
 Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
 
1  .109 .080 .109 3.784  .028 
 Education (Yrs)      .214 .084 
 Employment     .213 .087 
2  .312 .241 .203 4.289  .028 
 Education (Yrs)     .140 .227 
 Employment     .172 .131 
 HA minutes Q2     .361 .011 
 HA minutes Q3     .141 .302 
 HA minutes Q4     .282 .041 
 Post-op infection     -.315 .007** 
3  .358 .279 .046 4.047  .004** 
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 Education (Yrs)      .172 .133 
 Employment     .104 .368 
 HA minutes Q2     .322 .020 
 HA minutes Q3     .078 .566 
 HA minutes Q4     .236 .081 
 Post-op infection     -.312 .006 
 Negative affect     -.233 .049 
**p<0.01 
 
Regression model for SDMT-Oral score in SV 
Block  Predictor Variables R
2
 Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
 
1  .138 .096 .138 3.259  .027 
 Current saturation Q1     -.304 .037 
 Current saturation Q2     -.360 .013 
 Current saturation Q3     -.068 .645 
2  .184 .115 .046 1.653  .200 
 Current saturation Q1     -.194 .212 
 Current saturation Q2     -.286 .057 
 Current saturation Q3     -.006 .967 
 Negative affect     -.105 .565 
 Depression      -.146 .416 
 
 
Multivariate regression models for the Simple group  
Regression model for TMT-A in Simple group 
Block  Predictor Variables R
2
 Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
 
1  .222 .172 .222 4.442  .001** 
 Age at repair Q2      -.300 .019 
 Age at repair Q3     .177 .147 
 Age at repair Q4     -.171 .163 
 CPB minutes Q3     .165 .122 
 CPB minutes Q4     -.004 .973 
2  .233 .173 .011 1.135  .290 
 Age at repair Q2      -.268 .040 
 Age at repair Q3     .179 .144 
 Age at repair Q4     -.172 .159 
 CPB minutes Q3     .150 .162 
 CPB minutes Q4     -.005 .966 
 Anxiety      .113 .290 
**p<0.01 
 
 
Regression model for COWA in Simple group 
Bloc
k  
Predictor Variables R
2
 Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
 
1  .227 .207 .227 11.862  <0.001 
 Age      .427 <0.001 
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 Education (Yrs)     .403 <0.001 
2  .276 .249 .050 5.489  .022 
 Age      .414 <0.001 
 Education (Yrs)     .417 <0.001 
 HF clinic     -.224 .022 
3  .298 .263 .022 2.483  .119 
 Age      .419 <0.001 
 Education (Yrs)     .395 <0.001 
 HF clinic     -.175 .084 
 LVEF     .158 .119 
4  .374 .307 ,076 2.267  .070 
 Age      .400 <0.001 
 Education (Yrs)     .343 .001** 
 HF clinic     -.237 .023 
 LVEF     .117 .238 
 Positive affect     .027 .844 
 Negative affect     .157 .309 
 Anxiety     -.218 .139 
 Depression     -.175 .332 
**p<0.01 
 
Regression model for Stroop-Colour Word in Simple group 
Block  Predictor Variables R
2
 Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
 
1  .055 .044 .055 4.776  .032 
 Employment      .235 .032 
2  .081 .058 .025 2.245  .138 
 Employment      .179 .117 
 NYHA     -.169 .138 
3  .144 .101 .064 2.950  .058 
 Employment      .126 .266 
 NYHA     -.156 .163 
 HA minutes Q3     -.206 .066 
 HA minutes Q4     .111 .313 
4  .190 .138 .045 4.376  .040 
 Employment      .131 .239 
 NYHA     -.069 .554 
 HA minutes Q3     -.236 .033 
 HA minutes Q4     .138 .202 
 ACE medication     -.233 .040 
5  .319 .237 .130 3.523  .011 
 Employment      .063 .553 
 NYHA     -.003 .978 
 HA minutes Q3     -.184 .083 
 HA minutes Q4     .185 .076 
 ACE medication     -.195 .069 
 Positive affect     -.148 .301 
 Negative affect      -.025 .872 
 Anxiety      -.371 .019 
 Depression      -.111 .556 
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Regression model for WAIS-III in Simple group 
Block  Predictor Variables R
2
 Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
 
1  .291 .283 .291 33.708  <0.001 
 Education (Yrs)     .540 <0.001 
2  .317 .292 .026 1.517  .226 
 Education (Yrs)     .506 <0.001 
 Cathlab intervention total     -.015 .891 
 Repairs total     .158 .123 
3  .423 .378 .106 4.720  .004** 
 Education (Yrs)     .440 <0.001 
 Cathlab intervention total     -.011 .909 
 Repairs total     .115 .235 
 Positive affect     .098 .448 
 Anxiety      -.185 .171 
 Depression      -.092 .514 
**p<0.01 
 
 
 
 
Regression model for GP dominant hand score in Simple group 
Block  Predictor Variables R
2
 Adjusted R
2
 ΔR2  ΔF β Sig. 
 
1  .120 .109 .120 11.182  .001** 
 Gender (Males)     .346 .003** 
2  .222 .193 .102 5.272  .007** 
 Gender (Males)     .300 .063 
 Positive affect     -.387 .002** 
 Negative affect      -.188 .116 
**p<0.01 
 
Regression model for GP non-dominant hand score in Simple group 
Block  Predictor Variables R
2
 Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
 
1  .133 .111 .133 6.204  .003** 
 Yrs since last operation     .273 .010 
 Total no. of palliations     .216 .041 
2  .206 .176 .073 7.334  .008** 
 Yrs since last operation     .313 .003** 
 Total no. of palliations     .216 .034 
 Anti-arrythmia 
medication 
    .273 .008** 
**p<0.01  
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Regression model for WCST-error score in Simple group 
Block  Predictor Variables R
2
 Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
 
1  .097 .086 .097 8.793  .004** 
 Education      -.311  
2  .143 .122 .046 4.238  .039 
 Education      -.302 .004** 
 Hypertension      .216 .039 
3  .285 .239 .141 5.136  .003** 
 Education      -.260 .011 
 Hypertension      .253 .011 
 Age at repair Q2     -.226 .055 
 Age at repair Q3     -.367 .002 
 Age at repair Q4     .029 .807 
4  .332 .261 .048   .155 
 Education      -.227 .027 
 Hypertension      .253 .011 
 Age at repair Q2     -.171 .153 
 Age at repair Q3     -.362 .002 
 Age at repair Q4     .044 .715 
 Positive affect     .025 .854 
 Negative affect     -.024 .875 
 Depression      .262 .140 
**p<0.01  
 
 
 
 
 
Regression model for WCST-conceptual level response score in Simple group 
Block  Predictor Variables R
2
 Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
 
1   .100 .078 .100 4.493  .014 
 Age      -.166 .144 
 Education (Yrs)     .218 .055 
2  .138 .106 .039 3.582  .062 
 Age      -.122 .284 
 Education (Yrs)     .225 .045 
 Hypertension      -.201 .062 
3  .275 .219 .137 4.855  .004** 
 Age      .024 .857 
 Education (Yrs)     .221 .037 
 Hypertension      -.265 .010 
 Age at repair Q2     .210 .081 
 Age at repair Q3     .359 .003** 
 Age at repair Q4     -.077 .603 
4  .322 .240 .047 1.709  .172 
 Age      -.002 .989 
 Education (Yrs)     .181 .091 
 Hypertension      -.260 .013 
 Age at repair Q2     .156 .200 
 Age at repair Q3     .355 .003** 
 Age at repair Q4     -.077 .599 
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Block  Predictor Variables R
2
 Adjusted 
R
2
 
ΔR2  ΔF β Sig. 
 
 Positive affect     -.006 .966 
 Negative affect     .029 .852 
 Depression      -.252 .161 
**p<0.01 
 
Regression model for WCST-No. of categories completed score in Simple group 
Block  Predictor Variables R
2
 Adjusted R
2
 ΔR2  ΔF β Sig. 
1  .110 .088 .110 5.011  .009** 
 Age      -.138 .221 
 Education (Yrs)     .258 .023 
2  .252 .204 .142 4.935  .003** 
 Age      -.008 .951 
 Education (Yrs)     .254 .018 
 Age at repair Q2     .191 .113 
 Age at repair Q3     .368 .003** 
 Age at repair Q4     -.074 .621 
3  .347 .277 .095 3.624  .017 
 Age      -.043 .730 
 Education (Yrs)     .182 .081 
 Age at repair Q2     .103 .381 
 Age at repair Q3     .365 .002** 
 Age at repair Q4     -.084 .555 
 Positive affect     .128 .339 
 Negative affect     -.093 .531 
 Depression      -.147 .393 
**p<0.01 
 
 
 
 
 
 
Regression model for WCST-trials to complete first category score in Simple group 
Block  Predictor Variables R
2
 Adjusted R
2
 ΔR2  ΔF β Sig. 
1  .088 .077 .088 7.909  .006** 
 Education (Yrs)     -.297 .006** 
2  .138 .117 .050 4.724  .033 
 Education (Yrs)     -.223 .043 
 NYHA     .236 .033 
3  .217 .167 .079 2.631  .056 
 Education (Yrs)     -.143 .199 
 NYHA     .211 .055 
 Current saturation Q1      .302 .010 
 Current saturation Q2     -.011 .929 
 Current saturation Q3     .056 .631 
4  .364 .306 .147 8.771  <0.001 
 Education (Yrs)     .423 .423 
 NYHA     .019 .019 
 Current saturation Q1      .108 .108 
 Current saturation Q2     .900 .900 
 Current saturation Q3     .329 .329 
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Block  Predictor Variables R
2
 Adjusted R
2
 ΔR2  ΔF β Sig. 
 Diuretic medication      .219 .219 
 Anti-coagulant medication     .000 <0.001 
5  .380 .314 .016 1.886  .174 
 Education (Yrs)     -.071 .487 
 NYHA     .326 .035 
 Current saturation Q1      .169 .127 
 Current saturation Q2     -.025 .815 
 Current saturation Q3     .101 .350 
 Diuretic medication      -.178 .232 
 Anti-coagulant medication     .416 <0.001 
 Depression      .131 .174 
**p<0.01 
 
 
Regression model for RAVLT score in Simple group 
Block  Predictor Variables R
2
 Adjusted R
2
 ΔR
2 
 ΔF β Sig. 
1  .075 .064 .075 6.641  .012 
 Gender (Males)     -.247 .012 
2  .159 .138 .084 8.055  .006** 
 Gender (Males)     -.224 .019 
 Hypertension      -.291 .006** 
3  .190 .160 .032 3.121  .081 
 Gender (Males)     -.237 .021 
 Hypertension      -.149 .252 
 ACE medication      -.228 .081 
4  .245 .186 .055 1.869  .142 
 Gender (Males)     -.229 .028 
 Hypertension      -.148 .260 
 ACE medication     -.204 .116 
 Positive affect     .077 .589 
 Negative affect     -.070 .662 
 Depression     -.117 .537 
**p<0.01 
 
 
 
Regression model for SDMT written score in Simple group 
Block  Predictor Variables R
2
 Adjusted R
2
 ΔR
2 
 ΔF β Sig. 
1  .089 .078 .089 8.042  .006** 
 Education (Yrs)     .299 .006** 
2  .215 .175 .126 4.225  .008** 
 Education (Yrs)     .304 .004** 
 Age at repair Q2     .387 .002** 
 Age at repair Q3     .043 .724 
 Age at repair Q4     .206 .103 
3  .285 .220 .070 2.490  .067 
 Education (Yrs)     .244 .022 
 Age at repair Q2     .299 .016 
 Age at repair Q3     .030 .798 
 Age at repair Q4     .180 .146 
 Positive affect      .192 .186 
 Anxiety      -.220 .152 
 Depression      .131 .404 
**p<0.01 
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Regression model for SDMT oral score in Simple group 
Block  Predictor Variables R
2
 Adjusted R
2
 ΔR
2 
 ΔF β Sig. 
1  .069 .046 .069 2.983  .056 
 Repairs surgery total      .143 .246 
 Post-op ventricular dysfunction      .162 .188 
2  .108 .074 .039 3.524  .064 
 Repairs surgery total      .117 .338 
 Post-op ventricular dysfunction     .167 .168 
 Diuretic medication      -.200 .064 
3  .176 .124 .068 3.243  .044 
 Repairs surgery total      .071 .554 
 Post-op ventricular dysfunction      .166 .162 
 Diuretic medication      -.153 .151 
 Positive affect     .192 .168 
 Anxiety     -.103 .485 
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Appendix S: Visual Representation of the Irregular Distribution of 
Residuals in Regression Analysis 
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Figure 1 - Scatter plot of the distribution of the residuals on the RAVLT multivariate regression 
analysis for the total sample  
 
 
 
Figure 2- Scatter plot of the distribution of the residuals on the SDMT-Oral subtest multivariate 
regression analysis for the total sample  
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Appendix T: Follow-Up Study Information Sheet 
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Appendix U: Follow-Up Study Consent Form 
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Appendix V: NP Test Battery Follow-Up Study  
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BOOK BOOK BOOK BOOK BOOK BOWL BOOK 
FLOWER FLOWER FLOWER FLOWER FLOWER DAWN FLOWER 
TRAIN TRAIN TRAIN TRAIN TRAIN JUDGE TRAIN 
RUG RUG RUG RUG RUG GRANT RUG 
MEADOW MEADOW MEADOW MEADOW MEADOW INSECT MEADOW 
HARP HARP HARP HARP HARP PLANE HARP 
SALT SALT SALT SALT SALT COUNT SALT 
FINGER FINGER FINGER FINGER FINGER POOL FINGER 
APPLE APPLE APPLE APPLE APPLE SEED APPLE 
CHIMNEY CHIMNEY CHIMNEY CHIMNEY CHIMNEY SHEEP CHIMNEY 
BUTTON BUTTON BUTTON BUTTON BUTTON MEAL BUTTON 
LOG LOG LOG LOG LOG COAT LOG 
KEY KEY KEY KEY KEY BOTTLE KEY 
RATTLE RATTLE RATTLE RATTLE RATTLE PEACH  RATTLE 
GOLD GOLD GOLD GOLD GOLD CHAIR GOLD 
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Appendix W: Follow-Up Study Missing Data 
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Variables  % of missing data 
Demographic variables 
Employment 2.7 
Age 2.7 
Marital Status 2.7 
Living Status 2.7 
Psychosocial variables 
PANAS_PA_1 2.7 
PANAS_NA_1 2.7 
PANAS_PA_2 3.4 
PANAS_NA_2 2.7 
PANAS_PA_3 2.7 
PANAS_NA_3 2.7 
PANAS_NA_4 2.7 
PANAS_NA_5 2.7 
PANAS_PA_4 2.7 
PANAS_PA_5 2.7 
PANAS_NA_6 2.7 
PANAS_PA_6 2.7 
PANAS_NA_7 2.7 
PANAS_PA_7 2.7 
PANAS_NA_8 2.7 
PANAS_PA_8 2.7 
PANAS_PA_9 2.7 
PANAS_NA_9 2.7 
PANAS_PA_10 2.7 
PANAS_NA_10 2.7 
STAI_1 2.7 
STAI_2 2.7 
STAI_3 2.7 
STAI_4 2.7 
STAI_5 2.7 
STAI_6 2.7 
CESD10_1 2.7 
CESD10_2 2.7 
CESD10_3 3.4 
CESD10_4 2.7 
CESD10_5 2.7 
CESD10_6 2.7 
CESD10_7 2.7 
CESD10_8 2.7 
CESD10_9 2.7 
CESD10_10 2.7 
NP variables 
TMT C 0 
TMT D 0 
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Variables  % of missing data 
COWA B 0 
COWA D 0 
COWA T 0 
Stroop C Correct 0 
Stroop W Correct 0 
GP Dominant Time 0 
GP Non Dominant Time 0 
RAVLT TRIAL 1 0 
RAVLT TRIAL 2 0 
RAVLT TRIAL 3 0 
RAVLT TRIAL 4 0 
RAVLT TRIAL 5 0 
RAVLT TRIAL 6 0 
RAVLT TRIAL 7 0 
Symbol Digit Written 0 
Symbol Digit Oral 0 
WCST Errors 0 
WCST Conceptual Level 0 
WCST No. Categories 0 
WCST Trials1stCategory 0 
WCST Failure to Maintain Set 0 
Clinical variables 
HF Clinic 2.7 
Arrhythmias 2.7 
Hypertension 2.7 
ACE medication 2.7 
Diuretic medication 2.7 
Beta-Blocker medication  2.7 
Anti-arrhythmia medication  2.7 
Anticoagulant medication  2.7 
Interventions Total 2.7 
Current Saturation 2.7 
In Hospital Days 2.7 
Co Morbidities Total 2.7 
Medication Total 2.7 
Note- PANAS- Positive And Negative Affect Scale, STAI- State and Trait Anxiety Inventory, CESD- Centre 
for Epidemiologic Study Depression Scale, TMT- Trail Making Test, COWA- Controlled Oral Word 
Association Test, RAVLT- Rey Auditory Verbal Learning Test, WCST- Wisconsin Card Sorting Test, HF- 
Heart Failure, ACE- angiotensin-converting-enzyme 
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Appendix X: Follow-Up Study Kolmogorov-Smirnov Test Results 
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Kolmogorov-Smirnov for demographic variables (Follow-up data)  
Variables Kolmogorov-Smirnov test 
statistic 
Statistic  p value 
Age  .146 <0.001 
Marital Status .443 <0.001 
Living Status .402 <0.001 
Total Years in Education .205 <0.001 
Employment  .491 <0.001 
Occupation Category .205 <0.001 
Interpretation key- A significant (p<0.001) Kolmogorov-Smirnov statistic is indicative of a non-normal 
distribution.  
 
Kolmogorov-Smirnov for the Neuropsychological test scores (raw scores) (Follow-up data)  
Variables Kolmogorov-Smirnov 
test statistic 
Statistic  p value 
Trail making C .148 <0.001 
Trail making D .218 <0.001 
Controlled Oral Word Association letter B .083 .011 
Controlled Oral Word Association letter D .066 .096 
Controlled Oral Word Association letter T .070 .063 
Stroop word no correct .250 <0.001 
Peg dominant hand time .225 <0.001 
Peg Non-dominant hand time .222 <0.001 
RAVLT Trial 1 .147 <0.001 
RAVLT Trial 2 .110 <0.001 
RAVLT Trial 3 .114 <0.001 
RAVLT Trial 4 .158 <0.001 
RAVLT Trial 5 .136 <0.001 
RAVLT Trial 6 .163 <0.001 
RAVLT Trial 7 .135 <0.001 
Symbol digit written .075 .035 
Symbol digit oral .057 .200 
Wisconsin card sort Errors .188 <0.001 
Wisconsin card sort Conceptual Level .176 <0.001 
Wisconsin card sort No. Categories .233 <0.001 
Wisconsin card sort Trials1stCategory .397 <0.001 
Wisconsin card sort Failure Maintain .376 <0.001 
Interpretation key- A significant (p<0.001) Kolmogorov-Smirnov statistic is indicative of a non-normal 
distribution; RAVLT- Rey Auditory Verbal Learning Test 
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Kolmogorov-Smirnov results for the psychosocial variables (Scaled scores) (Follow-up data)  
Variables Kolmogorov-Smirnov 
test statistic 
Statistic  p value 
Physical component summary .184 <0.001 
Mental component summary  .135 <0.001 
PANAS- Positive affect .090 .004 
PANAS- Negative affect .182 <0.001 
Sum STAI .123 <0.001 
Sum CESD-10 .129 <0.001 
Interpretation key- A significant (p<0.001) Kolmogorov-Smirnov statistic is indicative of a non-normal 
distribution. PANAS- Positive and Negative Affect Scale, STAI- State and Trait Anxiety Inventory, CESD-Center 
for Epidemiological Studies Depression Scale.   
 
 
Kolmogorov-Smirnov for NP and mood change scores (Follow-up data-used in the multiple 
hierarchical regression analysis in follow-up study)  
Variables Kolmogorov-Smirnov test statistic 
Statistic p value 
NP variables change scores  
TMT-A .129 <0.001 
COWA .076 .031 
GP-DOMINANT .128 <0.001 
GP-NON-DOMINANT .221 <0.001 
RAVLT .064 .200 
SDMT-ORAL .088 .006 
Mood variables change scores 
PANAS-PA .052 .200 
PANAS-NA .110 <0.001 
STAI .112 <0.001 
CESD-10 .131 <0.001 
Interpretation key- A significant (p<0.001) Kolmogorov-Smirnov statistic is indicative of a non-normal distribution; 
TMT- Trail Making Test, COWA- Controlled Oral Word Association test, GP- Grooved Pegboard, RAVLT- Rey 
Auditory Verbal Learning Test, SDMT- Symbol Digit Modalities Test, PANAS- Positive and Negative Affect Scale, 
STAI- State and Trait Anxiety Inventory, CESD-Center for Epidemiological Studies Depression Scale.   
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Appendix Y: Differences between Responders and Non-Responders on 
Follow-Up Study 
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Sample characteristics  Responders Non-responders Test statistic  Sig.  
Demographic variables 
 
Age (mean, SD) 
 
33.78 (11.38) 32.73(10.01) f(1,308)=1.851 0.391 
Total years of  
education (mean, SD) 
 
13.56(2.98) 13.26(2.72) f(1,308)=2.620 0.365 
Gender (N %)   X2(1)=.185 0.731 
Males  84(54.9%) 90(57.3%)   
Females  69(45.1%) 67(42.7%)   
 
Marital status (N %) 
  X2(1)=4.165 
 
0.053 
 
Married/in a relationship  69(45.1%) 89(56.7%)   
Single/divorced/widowed  84(54.9%) 68(43.3%)   
Ethnicity (N %)   X2(1)=2.169 0.159 
White-British  134(87.6%) 128(81.5%)   
Others 19(12.4%) 29(18.5%)   
Living status (N %)   X2(1)=.320 0.053 
Cohabiting  127(83.0%) 89(56.7%)   
Alone  26(17.0%) 68(43.3%)   
Employment status (N %)   X2(1)=1.139 
 
0.329 
 
Employed 109(71.2%) 103(65.6%)   
Unemployed/studying 44(28.8%) 54(34.4%)   
Clinical variables 
 
Post-op CNS complication 
(N%) 
  X2(1)=1.26 0.345 
No 146(95.4%) 145(92.4%)   
Yes 7(4.6%) 12(7.6%)   
Post-op infection (N%)   X2(1)=.277 0.602 
No 117(76.5%) 116(73.9%)   
Yes 36(23.5%) 41(26.1%)   
HF clinic (N%)   X2(1)=.065 0.882 
No 125(81.7%) 130(82.8%)   
Yes 28(18.3%) 27(17.2%)   
Arrhythmia (N%)   X2(1)=.155 0.701 
No 111(72.5%) 117(74.5%)   
Yes 42(27.5%) 40(25.5%)   
Hypertension (N%)   X2(1)=.088 0.853 
No 138(90.2%) 140(89.2%)   
Yes 15(9.8%) 17(10.8%)   
Pacemaker (N%)   X2(1)=.645 0.463 
No 143(93.5%) 150(95.5%)   
Yes 10(6.5%) 7(4.5%)   
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Sample characteristics  Responders Non-responders Test statistic  Sig.  
ACE (N%)   X2(1)=.025 0.891 
No 121(79.1%) 123(78.3%)   
Yes 32(20.9%) 34(21.7%)   
Diuretic medication (N%)   X2(1)=3.584 0.072 
No 141(92.2%) 134(85.4%)   
Yes 12(7.8%) 23(14.6%)   
Beta-blockers (N%)   X2(1)=.041 0.88 
No 128(83.7%) 130(82.8%)   
Yes 25(16.3% 27(17.2%)   
Anti-arrhythmia 
medication (N%) 
    
No 134(87.6%) 140(89.2%) X2(1)=.191 0.724 
Yes 19(12.4%) 17(10.8%)   
Anti-coagulant medication 
(N%) 
  X2(1)=.069 0.895 
No 114(74.5%) 119(75.8%)   
Yes 39(25.5%) 38(24.2%)   
NYHA   X2(1)=2.713 0.12 
Class 1 139(90.8%) 133(84.7%)   
Class 2+3+4 14(9.2%) 24(15.3%)   
Repair age in months 
(Mean, SD) 
122.84(187.58
7) 
 
112.9(167.972) 
 
f(1,308)=0.159 
 
0.624 
 
Interventions total  
(Mean, SD) 
2.29(1.376) 
 
2.39(1.334) 
 
f(1,308)=0.216 
 
0.513 
 
Repair total  
(Mean, SD) 
1.16(0.73) 
 
1.2(0.696) 
 
f(1,308)=0.004 
 
0.618 
 
Palliations total (Mean, 
SD) 
0.46(0.787) 
 
0.48(0.852) 
 
f(1,308)=0.967 
 
0.884 
 
Catheter lab total (Mean, 
SD) 
0.67(1.039) 0.71(0.968) f(1,308)=0.038 0.682 
Yrs. Since last operation 
(Mean, SD) 
15.82(12.625) 
 
16.51(11.998) 
 
f(1,308)=0.635 
 
0.621 
 
Cyanotic days (Mean, SD) 1249.93(2621.
231) 
 
1317.94(2745.12) f(1,308)=0.742 
 
0.824 
 
Current saturation  
(Mean, SD) 
95.97(4.253) 
 
95.83(5.424) 
 
f(1,308)=0.399 
 
0.811 
 
ICU days (Mean, SD) 5.73(5.667) 5.71(6.167) f(1,308)=0.106 0.97 
CPB minutes (Mean, SD) 96.05(77.762) 96.22(74.137) f(1,308)=0.023 0.985 
HA minutes (Mean, SD) 31.73(26.952) 29.31(25.36) f(1,308)=0.949 0.416 
Hospital days (Mean, SD) 38.43(32.288) 
 
42.87(67.578) 
 
f(1,308)=0.732 
 
0.463 
 
Co-morbidities (Mean, SD) 0.967(1.05) 
 
0.955(1.10) 
 
f(1,308)=0.146 
 
0.923 
 
Medications total (Mean, 0.94(1.26) 0.97(1.34) f(1,308)=0.479 0.856 
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Sample characteristics  Responders Non-responders Test statistic  Sig.  
SD)     
LVEF (Mean, SD) 61.1(8.51) 60.96(8.469) f(1,308)=0.402 0.882 
RVEF (Mean, SD) 57.93(7.41) 57.11(9.511) f(1,308)=4.672 0.402 
 
Cognition measures 
TMT-A (Mean, SD) 0.62(1.42) 0.81(1.72) f(1,308)=5.642 0.463 
TMT-B (Mean, SD) 0.63(1.41) 0.80(1.92) f(1,308)=5.472 0.363 
COWA (Mean, SD) -0.61(1.02) 
 
-0.73(1.06) 
 
f(1,308)=0.502 
 
0.291 
 
Stroop-CW (Mean, SD) -0.09(1.30) -0.49(1.62) f(1,308)=6.824 0.019 
GP-Dominant (Mean, SD) 0.92(1.84) 1.03(1.65) f(1,308)=0.145 0.583 
GP-Non-dominant (Mean, 
SD) 
0.74(1.35) 
 
0.73(1.35) 
 
f(1,308)=0.311 
 
0.973 
 
WCST-error (Mean, SD) 0.50(1.08) 
 
0.68(1.22) 
 
f(1,308)=4.168 
 
0.18 
 
WCST-Conceptual level 
(Mean, SD) 
-0.48(1.07) 
 
-0.65(1.22) 
 
f(1,308)=4.421 
 
0.181 
 
WCST- no. Categories 
(Mean, SD) 
-0.44(1.09) 
 
-0.61(1.19) 
 
f(1,308)=1.724 
 
0.178 
 
Trial to complete 1
st
 
(Mean, SD) 
0.23(2.62) 
 
0.16(1.57) 
 
f(1,308)=0.175 
 
0.77 
 
Failure to maintain (Mean, 
SD) 
-0.02(0.83) 
 
0.13(1.02) 
 
 
f(1,308)=5.111 
 
0.132 
 
RAVLT (Mean, SD) 0.58(0.92) 
 
0.47(1.03) 
 
f(1,308)=1.222 
 
0.292 
 
SDMT-Written (Mean, SD) 0.26(1.50) 
 
-0.02(1.58) 
 
f(1,308)=0.019 
 
0.099 
 
SDMT-Oral (Mean, SD) 0.45(1.55) 
 
0.38(1.52) 
 
f(1,308)=0.138 
 
0.678 
 
WAIS-III 98.38(15.02) 95.44(15.76) f(1,308)=0.66 0.095 
Note- NYHA- New York Health Association, CPB-Cardo pulmonary bypass, HA-Hypothermic Arrest, ICU- 
intensive Care Unit, CNS- Central Nervous System, LVEF-Left Ventricle Ejection Fraction, RVEF- Right Ventricle 
Ejection Fraction, TMT- Trail Making Test, COWA- Controlled Oral Word Association test, GP- Grooved Pegboard, 
WCST- Wisconsin Card Sorting Test, RAVLT- Rey Auditory Verbal Learning Test, SDMT- Symbol Digit Modalities 
Test 
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Appendix Z: Univariate Screening for Factors Associated with Cognitive 
Change Scores in the Follow-Up Study 
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 COWA 
Change score 
TMT-A 
Change score 
GP-Dom  
Change score 
GP Non-Dom 
Change score 
RAVLT 
Change score 
SDMT-O 
Change score 
Age  -0.06 -0.077 0.015 -0.089 0.095 0.068 
Education (years) 0.189* 
 
-0.223** 
 
0.017 
 
-0.006 
 
0.227** 
 
0.127 
 
Gender  
(Males) 
0.02 0.033 0.013 0.051 -0.028 0.064 
Employment -0.046 0.016 -0.007 0.13 0.083 0.174* 
Arrhythmia  0.02 
 
0.098 
 
0.07 
 
-0.108 
 
0.044 
 
-0.046 
 
Hypertension  -0.032 0.023 0.074 -0.015 0.079 0.021 
NYHA -0.022 
 
0.178* 
 
0.241** 
 
-0.038 
 
0.103 
 
-0.071 
 
Interventions total  -0.046 0.269** 0.187* -0.087 -0.154 -0.134 
Repair total -0.104 
 
0.08 
 
0.156 
 
0.003 
 
-0.121 
 
0.01 
 
Palliation before repair 0.008 0.144 0.066 0.057 -0.033 -0.139 
Years since last intervention 0.113 
 
-0.161* 
 
-0.006 
 
0.191* 
 
0.115 
 
0.09 
 
Post-op CNS complication  0.125 0.09 0.006 0.104 -0.134 -0.039 
Post-op infection  0.077 0.155 0.054 -0.072 0.024 0.048 
 
Post-op ventricular 
dysfunction 
-0.103 0.079 0.131 
 
-0.031 
 
-0.01 
 
-0.037 
 
HF clinic 0.004 0.188* 0.089 -0.196* -0.043 -0.041 
Pacemaker -0.118 
 
0.205* 0.052 -0.089 -0.09 -0.087 
ACE medication  -0.037 0.055 0.211** 0.044 -0.045 -0.099 
Diuretic medication  -0.172* 0.092 0.031 0.095 -0.13 -0.115 
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 COWA 
Change score 
TMT-A 
Change score 
GP-Dom  
Change score 
GP Non-Dom 
Change score 
RAVLT 
Change score 
SDMT-O 
Change score 
 
Beta blocker medication  -0.011 0.177* 0.01 -0.019 -0.008 0.007 
Anti-arrythmia medication -0.04 0.205* 0.098 0.034 -0.018 -0.036 
Anti-coagulant medication  -0.046 
 
0.246** 
 
-0.019 
 
-0.028 
 
0.017 
 
-0.167* 
 
RVEF 0.014 -0.106 -0.196* 0.029 -0.013 0.054 
LVEF -0.019 
 
-0.228** 
 
-0.17* 
 
0.018 
 
0.137 
 
-0.013 
 
Palliation total 0.015 0.108 0.048 -0.008 -0.113 -0.172* 
Catheter lab total  -0.024 
 
0.156 
 
0.092 
 
-0.042 
 
0.009 
 
-0.067 
 
Medication total -0.005 0.21* 0.043 0.048 -0.012 -0.035 
Age at repair Q3 -0.157 
 
0.039* 
 
-0.026 
 
0.074 
 
-0.031 
 
-0.034 
 
Age at repair Q4 -0.193 -0.055 -0.162 -0.061 0.067 0.014 
Cyanosis days Q2 0.065 
 
-0.065 
 
0.039 
 
0.159 
 
0.07 
 
-0.027 
 
Cyanosis days Q3 0.035 0.083 -0.041 -0.002 0.063 -0.05 
Cyanosis days Q4 0.067 
 
0.195 
 
0.049 
 
0.048 
 
0.06 
 
-0.158 
 
Current saturationQ1 0.075 0.223* -0.009 0.06 0.028 -0.01 
Current saturationQ2 0.035 
 
-0.053 
 
0.049 
 
0.091 
 
0.198* 
 
0.056 
 
Current saturationQ3 -0.002 0.014 0.053 -0.025 -0.077 0.089 
ICU days Q2 0.163 
 
0.111 
 
-0.163 
 
-0.179 
 
0.018 
 
-0.046 
 
ICU days Q3 0.054 0.154 -0.017 -0.01 0.007 -0.14 
ICU days Q4 0.154 
 
0.2 
 
0.1 
 
-0.082 
 
0.144 
 
-0.069 
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 COWA 
Change score 
TMT-A 
Change score 
GP-Dom  
Change score 
GP Non-Dom 
Change score 
RAVLT 
Change score 
SDMT-O 
Change score 
CPB minutes Q2 0.028 0.052 -0.109 -0.019 -0.011 0.034 
CPB minutes Q4 0.116 
 
0.234 
 
0.079 
 
0.093 
 
-0.05 
 
-0.061 
 
HA minutes Q2 -0.112 0.03 
 
-0.109 -0.111 -0.063 0.128 
HA minutes Q3 -0.12 
 
0.116 
 
-0.09 
 
-0.057 
 
-0.061 
 
0.142 
 
HA minutes Q4 -0.068 0.207 0.015 0.062 0.008 0.059 
In hospital days Q2 0.083 
 
-0.048 
 
0.006 
 
-0.066 
 
0.063 
 
0.045 
 
In hospital days Q3 0.05 -0.074 -0.087 -0.166 -0.001 -0.033 
In hospital days Q4 -0.058 
 
0.236* 
 
0.138 
 
-0.188 
 
0.01 
 
-0.071 
 
PANAS PA -0.076 -0.055 0.06 0.014 0.068 0.016 
PANAS NA  0.01 
 
-0.055 
 
-0.008 
 
-0.051 
 
-0.091 
 
-0.01 
 
STAI -0.049 -0.066 0.101 -0.041 -0.033 0.021 
CESD  0.083 
 
-0.121 
 
-0.075 
 
-0.033 
 
-0.092 
 
-0.09 
 
*P<0.05, **P<0.01;   NYHA- New York Health Association, CNS- Central Nervous System, HF-Heart Failure, ACE-angiotensin converting enzyme, , LVEF- Left 
Ventricular Ejection Fraction, RVEF- Right Ventricular Ejection Fraction, ICU-Intensive Care Unit, HA-Hypothermic Arrest, ACE-Angiotensin Converting Enzyme,;  
PANAS= Positive and Negative Scale, STAI= State and Trait Anxiety Inventory, CESD= Centre for Epidemiology Short Depression Scale, 
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Appendix AA: Published Study Paper 
 
 
